---
document_datetime: 2025-05-20 14:52:22
document_pages: 121
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/tevimbra-h-c-005919-ii-0016-epar-assessment-report-variation_en.pdf
document_name: tevimbra-h-c-005919-ii-0016-epar-assessment-report-variation_en.pdf
version: success
processing_time: 210.0356789
conversion_datetime: 2025-12-20 08:56:45.951219
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

27 March 2025 EMA/CHMP/136727/2025 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Tevimbra

International non-proprietary name: Tislelizumab

Procedure No. EMEA/H/C/005919/II/0016

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................7                                  |                                                                                                         |
|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................7  |                                                                                                         |
| 1.2. Steps taken for the assessment of the product.........................................................8                |                                                                                                         |
| 2. Scientific discussion                                                                                                    | ................................................................................8                       |
| 2.1. Introduction.........................................................................................................8 |                                                                                                         |
| 2.1.1. Problem statement                                                                                                    | ............................................................................................8           |
| 2.1.2. About the product..............................................................................................9     |                                                                                                         |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                            | ......10                                                                                                |
| 2.1.4. General comments on compliance with                                                                                  | GCP........................................................10                                           |
| 2.2. Non-clinical aspects                                                                                                   | ............................................................................................10          |
| 2.2.1. Introduction....................................................................................................10   |                                                                                                         |
| 2.2.2. Ecotoxicity/environmental risk assessment                                                                            | .........................................................10                                             |
| 2.2.3. Conclusion on the non-clinical aspects................................................................10             |                                                                                                         |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................10    |
| 2.3.1. Introduction....................................................................................................10   |                                                                                                         |
| 2.3.2. Pharmacokinetics.............................................................................................11      |                                                                                                         |
| 2.3.3. Pharmacodynamics..........................................................................................14         |                                                                                                         |
| 2.3.4. Discussion on clinical pharmacology...................................................................31             |                                                                                                         |
| 2.3.5. Conclusions on clinical pharmacology.................................................................33              |                                                                                                         |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................33    |
| 2.4.1. Dose response study........................................................................................33        |                                                                                                         |
| 2.4.2. Main study......................................................................................................34   |                                                                                                         |
| 2.4.3. Discussion on clinical efficacy............................................................................74        |                                                                                                         |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................78          |                                                                                                         |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................79  |
| 2.5.1. Discussion on clinical safety ............................................................................           | 110                                                                                                     |
| 2.5.2. Conclusions on clinical safety ..........................................................................            | 114                                                                                                     |
| 2.5.3. PSUR cycle                                                                                                           | ................................................................................................... 114 |
| 2.6. Risk management plan......................................................................................             | 114                                                                                                     |
| 2.7. Update of the Product information ......................................................................               | 115                                                                                                     |
| 2.7.1. User consultation...........................................................................................         | 116                                                                                                     |
| 3. Benefit-Risk Balance............................................................................116                      |                                                                                                         |
| 3.1. Therapeutic Context .........................................................................................          | 116                                                                                                     |
| 3.1.1. Disease or condition.......................................................................................          | 116                                                                                                     |
| 3.1.2. Available therapies and unmet medical need.....................................................                      | 116                                                                                                     |
| 3.1.3. Main clinical studies                                                                                                | ....................................................................................... 117             |
| 3.2. Favourable effects                                                                                                     | ............................................................................................ 117        |
| 3.3. Uncertainties and limitations about favourable effects...........................................                      | 117                                                                                                     |
| 3.4. Unfavourable effects.........................................................................................          | 117                                                                                                     |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | ....................................... 118                                                             |
| 3.6. Effects Table....................................................................................................      | 118                                                                                                     |
| 3.7. Benefit-risk assessment and discussion...............................................................                  | 119                                                                                                     |
| 3.7.1. Importance of favourable and unfavourable effects............................................                        | 119                                                                                                     |

<div style=\"page-break-after: always\"></div>

| 3.7.2. Balance of benefits and risks........................................................................... 119        |
|----------------------------------------------------------------------------------------------------------------------------|
| 3.7.3. Additional considerations on the benefit-risk balance ......................................... 119                 |
| 3.8. Conclusions ..................................................................................................... 119 |

4. Recommendations ...............................................................................  120

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation or Specialist Term   | Definition                                                                                                                          |
|-----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|
| ∆                                 | difference (delta)                                                                                                                  |
| 1L                                | First-line                                                                                                                          |
| ADA                               | antidrug antibody                                                                                                                   |
| ADR                               | adverse drug reaction                                                                                                               |
| AE                                | adverse event                                                                                                                       |
| AESI                              | adverse event of special interest                                                                                                   |
| AJCC                              | American Joint Committee on Cancer                                                                                                  |
| ALT                               | alanine aminotransferase                                                                                                            |
| AST                               | aspartate aminotransferase                                                                                                          |
| BGB-A317                          | tislelizumab                                                                                                                        |
| C max,ss                          | maximum serum concentration at steady state                                                                                         |
| C avg,ss                          | average serum concentration at steady state                                                                                         |
| CBR                               | clinical benefit rate                                                                                                               |
| CDE                               | Centre for Drug Evaluation                                                                                                          |
| C max,ss                          | maximum serum concentration at steady state                                                                                         |
| CR                                | complete response                                                                                                                   |
| CSCO                              | Chinese Society of Clinical Oncology                                                                                                |
| CSR                               | clinical study report                                                                                                               |
| CTCAE                             | Common Terminology Criteria for Adverse Events                                                                                      |
| DCR                               | disease control rate                                                                                                                |
| DOR                               | duration of response                                                                                                                |
| EAER                              | exposure-adjusted event rate                                                                                                        |
| ECG                               | electrocardiogram                                                                                                                   |
| eGFR                              | estimated glomerular filtration rate                                                                                                |
| EM                                | effect modifier                                                                                                                     |
| EMA                               | European Medicines Agency                                                                                                           |
| EORTC QLQ-C30                     | European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30                                    |
| EORTC QLQ-LC13                    | European Organization Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Supplement Lung Cancer Module |
| ER                                | Exposure-response                                                                                                                   |
| ESMO                              | European Society for Medical Oncology                                                                                               |
| ES-SCLC                           | extensive-stage small cell lung cancer                                                                                              |
| EU                                | European Union                                                                                                                      |
| EURD                              | European Union reference dates                                                                                                      |

<div style=\"page-break-after: always\"></div>

| Abbreviation or Specialist Term   | Definition                                             |
|-----------------------------------|--------------------------------------------------------|
| FA                                | final analysis                                         |
| Fc γ R                            | Fc gamma receptors                                     |
| FDA                               | US Food and Drug Administration                        |
| G/GEJ                             | gastric or gastroesophageal junction                   |
| GHS                               | global health status                                   |
| HR                                | hazard ratio                                           |
| HRQoL                             | health-related quality of life                         |
| HTA                               | health technology assessment                           |
| ICI                               | immune checkpoint inhibitor                            |
| IgG4                              | immunoglobulin G4                                      |
| imADR                             | immune-mediated adverse drug reaction                  |
| imAE                              | immune-mediated adverse event                          |
| imTEAE                            | immune-mediated treatment-emergent adverse event       |
| IRRs                              | infusion-related reactions                             |
| ITT                               | intent-to-treat                                        |
| LDH                               | lactate dehydrogenase                                  |
| LLN                               | lower limit of normal                                  |
| LS                                | least square                                           |
| MAIC                              | matching-adjusted indirect comparison                  |
| MedDRA                            | Medical Dictionary for Regulatory Activities           |
| NAb                               | neutralizing antibodies                                |
| NCCN                              | National Comprehensive Cancer Network                  |
| NEC                               | not elsewhere classified                               |
| NMPA                              | National Medical Products Administration               |
| NSCLC                             | non-small cell lung cancer                             |
| ORR                               | overall response rate                                  |
| OS                                | overall survival                                       |
| OSCC                              | oesophageal squamous cell carcinoma                    |
| PBRER                             | Periodic Benefit-Risk Evaluation Report                |
| PD-1                              | programmed cell death protein-1                        |
| PD-L1                             | programmed cell death protein ligand-1                 |
| PD-L2                             | programmed cell death protein ligand-2                 |
| PFS                               | progression-free survival                              |
| PFS2                              | Progression free survival after next-line of treatment |
| PK                                | pharmacokinetic(s)                                     |
| popPK                             | population pharmacokinetic                             |

<div style=\"page-break-after: always\"></div>

| Abbreviation or Specialist Term   | Definition                                    |
|-----------------------------------|-----------------------------------------------|
| PRO                               | patient-reported outcome                      |
| PS                                | performance status                            |
| PT                                | preferred term                                |
| RCT                               | randomised controlled trial                   |
| RDI                               | relative dose intensity                       |
| RECIST                            | Response Evaluation Criteria in Solid Tumours |
| RMST                              | Restricted Mean Survival Time                 |
| RWE                               | real-world evidence                           |
| SCLC                              | small cell lung cancer                        |
| SCS                               | Summary of Clinical Safety (Module 2.7.4)     |
| SD                                | standard deviation                            |
| SJS                               | Stevens Johnson Syndrome                      |
| SmPC                              | Summary of Product Characteristics            |
| SMQ                               | Standardised MedDRA Queries                   |
| SOC                               | system organ class                            |
| STC                               | simulated treatment comparisons               |
| T4                                | thyroxine                                     |
| TEAE                              | treatment-emergent adverse event              |
| TEN                               | toxic epidermal necrolysis                    |
| TLR                               | targeted literature review                    |
| TSH                               | thyroid-stimulating hormone                   |
| ULN                               | upper limit of normal                         |
| US                                | United States                                 |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Beigene Ireland Limited submitted to the European Medicines Agency on 3 October 2024 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of indication to include first-line treatment of adult patients with extensive-stage Small Cell Lung Cancer (SCLC) for Tevimbra in combination with etoposide and platinum chemotherapy based on final results from study BGB-A317-312; a phase 3, randomized, double-blind, placebo-controlled study of platinum plus etoposide with or without tislelizumab in patients with untreated extensive-stage small cell lung cancer. As a consequence, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The MAH also took the opportunity to make editorial changes to the SmPC, Annex II and Package Leaflet.

The supportive studies BGB-A317-309 and BGB-A317-315 are provided for the purpose of updating the safety data package as well as updated data (latest CSR versions with new data cut-off) from the monotherapy pool (tislelizumab used at 200mg Q3W) consisting of the studies 001, 102, 203, 204, 208, 209, 301, 302, and 303 and from the combination with chemotherapy pool consisting of the studies 205, 206, 304, 305, 306, 307 and 312. Version 2.4 of the RMP has also been submitted.

The variation requested amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0142/2019 on the granting of a product-specific waiver for tislelizumab for the treatment of all conditions included in the category of malignant neoplasms (except central nervous system, haematopoietic and lymphoid tissue).

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with an authorised orphan medicinal product.

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Jan Mueller-Berghaus

Co-Rapporteur:

N/A

| Timetable                                                                   | Actual dates     |
|-----------------------------------------------------------------------------|------------------|
| Submission date                                                             | 3 October 2024   |
| Start of procedure:                                                         | 2 November 2024  |
| CHMP Rapporteur Assessment Report                                           | 17 December 2024 |
| PRAC Rapporteur Assessment Report                                           | 2 January 2025   |
| PRAC Outcome                                                                | 16 January 2025  |
| CHMP members comments                                                       | 20 January 2025  |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report                        | 23 January 2025  |
| Request for supplementary information (RSI)                                 | 30 January 2025  |
| CHMP Rapporteur Assessment Report                                           | 12 March 2025    |
| CHMP members comments                                                       | 17 March 2025    |
| Updated CHMP Rapporteur Assessment Report                                   | n/a              |
| Opinion                                                                     | 27 March 2025    |
| The CHMP adopted a report on similarity of Tevimbra with Hetronifly on date | 27 March 2025    |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

This type II variation application concerns an extension of indication for tislelizumab (Tevimbra) to include the 1L treatment of extensive-stage small cell lung cancer (ES-SCLC).

## State the claimed the therapeutic indication

The proposed new indication for tislelizumab in this procedure is:

'Tevimbra, in combination with etoposide and platinum chemotherapy, is indicated for the first-line treatment of adult patients with extensive-stage SCLC.'

## Epidemiology and risk factors

In the EU in 2022, lung cancer was the leading cause of cancer mortality, and 11.6% of newly diagnosed cancer cases and 19.5% of cancer-related deaths were from lung cancer (ECIS 2022) . SCLC, one subtype of lung cancer, accounts for approximately 13% of all lung cancer cases. It is strongly associated with exposure to tobacco carcinogens (Rudin et al 2021).

<div style=\"page-break-after: always\"></div>

## Comparison between Chinese and European Population

The incidence of SCLC varies across different geographical regions. The number of new SCLC cases in Europe, standing at 68,840 is comparable to that in China, which totalled 63,246 cases. However, the magnitude of the male-to-female ratio differs, with age standardized incidence rates of 6.0 per 100,000 for males and 3.1 per 100,000 for females in Europe, and rates of 4.9 and 0.6 per 100,000 for males and females in China, respectively (Sung et al 2021; Zhang et al 2023) .

The prevalence rates of current tobacco users are generally comparable between Europe (25.3%) and China (25.6%); however, there is a strong contrast in female tobacco users with a prevalence rate of only 1.7% in China and 17.7% in Europe (WHO 2021; WHO 2023) .

## Clinical presentation, diagnosis and prognosis

SCLC is an aggressive, poorly differentiated, and high-grade neuroendocrine carcinoma. It is typically classified as limited-stage or extensive-stage disease depending on the extent of involvement. The majority of patients (approximately 70%) are diagnosed with extensive-stage disease and have a poor prognosis, with a median OS of approximately 8 to 13 months and an expected 2-year survival rate of only 5% (Johal et al 2021; Socinski et al 2009).

## Management

Standard of care 1L treatment for patients with untreated ES-SCLC was platinum plus etoposide for decades. Despite the high initial response rates after chemotherapy, almost all patients with ES-SCLC would relapse or experience disease progression with a PFS of 5-6 months. Recently, the addition of PD-L1 inhibitors to a standard platinum-etoposide backbone, with continuation of immunotherapy as maintenance, has become the new standard of care in first-line therapy (ESMO 2021). Atezolizumab was the first checkpoint inhibitor that received an approval for the 1L treatment of ES-SCLC in the EU in September 2019 (based on Study IMpower133), followed by durvalumab in August 2020 (based on the CASPIAN study). In February 2025, serplulimab received a marketing authorisation in 1L ES-SCLC.

## 2.1.2. About the product

Tislelizumab (BGB-A317) is a humanized immunoglobulin (Ig) G4 variant monoclonal antibody against programmed cell death protein-1 (PD-1), that competitively blocks the binding of both programmed cell death protein ligand-1 (PD-L1) and PD-L2, thereby inhibiting PD-1-mediated negative signalling and enhancing the functional activity of T cells in in-vitro cell-based assays.

Tislelizumab was approved for the treatment of 2L ESCC on 15-September-2023 under the tradename Tevimbra. In February 2024, CHMP recommended an approval for tislelizumab (tradename Tizveni) for the 1L and 2L treatment of NSCLC. Both approvals have been reconciled under the tradename Tevimbra. In October 2024, CHMP adopted a positive opinion for the 1L treatment of HER-2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma and for the 1L treatment of unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma (OSCC); both indications were restricted to patients whose tumours express PD-L1 with a tumour area positivity (TAP) score ≥ 5%.

The approved dosing regimen of tislelizumab as monotherapy or in combination treatment with chemotherapy is 200 mg IV Q3W.

<div style=\"page-break-after: always\"></div>

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

The MAH did not seek EMA SA regarding the clinical development in this indication.

## 2.1.4. General comments on compliance with GCP

The assessment of the clinical study data did not raise any specific concerns questioning GCP compliance.

## 2.2. Non-clinical aspects

## 2.2.1. Introduction

No new non-clinical data have been submitted in this application.

## 2.2.2. Ecotoxicity/environmental risk assessment

According to the Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00) proteins are exempted from the submission of ERA studies because they are unlikely to result in significant risk to the environment. Tislelizumab is a protein, therefore an ERA has not been submitted by the MAH which is acceptable.

## 2.2.3. Conclusion on the non-clinical aspects

No new non-clinical data have been submitted in this application which is acceptable.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Table 1 Summary of Tislelizumab Clinical Studies in Patients With ES-SCLC

| Study number Status    | Phase, Design                                                   | Number of Patients Enrolled                                                                          | Patient populatio n                    | Treatment arms                                                                                                                                                                                                                                                                                                                                                                                                                                    | Efficacy endpoints                                                                                                 | Data cutoff date                                              |
|------------------------|-----------------------------------------------------------------|------------------------------------------------------------------------------------------------------|----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|
| Study 312 Complet ed   | Phase 3, double- blind, ↓ placebo- controlled, randomised study | Total: 457 Tislelizumab + Chemotherapy arm (Arm T+C): 227 Placebo + Che motherapy arm (Arm P+C): 230 | ES-SCLC without prior systemic therapy | Tislelizumab + Chemotherapy arm (Arm T+C): Tislelizumab 200 mg IV, Day 1 + cisplatin 75 mg/m² (or carboplatin AUC 5)IV,Day 1 + etoposide 100 mg/m2 IV, mg repeated every 3weeks Days 1, 2, and 3 for 4 cycles, followed by tislelizumab 200 Placebo+ Chemotherapy arm (Arm P+C): Placebo IV, Day 1, + cisplatin 75 mg/m² (or carboplatin AUC 5) IV,Day 1 + etoposide 100 mg/m2 IV, Days 1,2,and 3 for 4cyclesfollowedbyplaceborepeatedevery3weeks | Primary: ·OS in the ITT Analysis Set Secondary: ·PFS, ORR, and DOR by investigator ·HRQoLa ·DCR Exploratory: ·PFS2 | 19 April 2023 (FA); 29December2023 (LPLV, study end analysis) |
| Study 206 6 Complet ed | Phase 2, open-label, multicohort study                          | Total: 54 17 with SCLC                                                                               | ES-SCLC without prior systemic therapy | SCLC cohort: Tislelizumab 200 mg IV, Day 1+ cisplatin 75 mg/m2 (or carboplatin AUC 5) IV,Day 1 + etoposide 100 mg/m² IV, Days1,2,and 3for 4 to6cycles,followed by tislelizumab 200 mg repeated every 3 weeks                                                                                                                                                                                                                                      | Primary: · ORR by investigator Secondary: ·PFS, DOR, and DCR by investigator Exploratory: ·Os                      | 31December2019 (LPLV, study end analysis)                     |

Abbreviations: 206, BGB-A317-206; 312, BGB-A317-312; AUC, area under the plasma or serum concentration-time curve; CSR, Clinical Study Report; DCR, disease control rate; DOR, duration of response; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; EQ-5D-5L, EuroQol Five Dimensions Questionnaire-5 level version; ES-SCLC, extensive-stage small cell lung cancer; FA, final analysis; HRQoL, health-related quality of life; ITT, Intent-to-Treat; IV, intravenous(ly); LPLV, last patient last visit; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PFS2, progression-free survival after next line of treatment; QLQ-LC13, Quality of Life Questionnaire Supplement Lung Cancer Module; SCLC, small cell lung cancer.

a HRQoL outcomes were assessed using the EORTC QLQ-C30, EQ-5D-5L, and the QLQ-LC13.

b Study 206 included 4 cohorts: 1 nonsquamous NSCLC cohort, 2 squamous NSCLC cohorts, and 1 SCLC cohort. Only the information of the SCLC cohort is presented in this table.

## 2.3.2. Pharmacokinetics

With this application for extension of indication, the Applicant is seeking approval of tislelizumab, a humanized IgG4 variant mAb against programmed cell death protein-1 (PD-1), for the first-line treatment of ES-SCLC.

Pharmacokinetics of tislelizumab have been adequately characterized throughout the initial marketing authorization procedure (EMEA/H/C/005919). Therefore, in this variation assessment report, only summarized data on tislelizumab ADME, dose proportionality, special populations and interaction studies are presented.

The recommended dose of tislelizumab is equal to the previously approved posology in several indications (200 mg IV Q3W, until disease progression or unacceptable toxicity).

The PopPK analysis was performed based on pooled data (PK, dosing information, demographics, and patient or disease characteristics) across 12 clinical studies (Studies 001, 102, 203, 204, 205, 206, 208, 209, 302, 303, 304, and 307) (EMEA/H/C/005919/II/0008).

In the pivotal Study 312, only sparse PK samples were collected.

PK data from Study 312 were not included in the development of the original PopPK model but were used for external validation to assess the predictive performance and robustness of the population PK model for Study 312.

<div style=\"page-break-after: always\"></div>

The full information on pharmacokinetics data can be found in the Tevimbra public assessment report (EPAR) for the initial marketing authorisation (EMEA/H/C/005919).

## Pharmacokinetics in target population

## Study BGB-A317-312 (Study 312)

A total of 457 patients were enrolled in this ongoing, global study, 227 of whom received 200 mg tislelizumab administered intravenously Q3W in combination with cisplatin or carboplatin plus etoposide. Patients continued tislelizumab until loss of clinical benefit as assessed by the investigator, withdrawal of consent, study completion by the sponsor, start of a new anticancer therapy, or death, whichever occurred first.

## Pharmacokinetic results:

The mean (± SD) predose and postdose serum concentrations after the intravenous doses of tislelizumab 200 mg Q3W, as of the PK data cutoff date (22-December-2022), are presented in Table 2.

Table 2 Summary of tislelizumab serum concentrations (AM ± SD) in Study 312 (PK Analysis Set)

|          | Tislelizumab Concentrations (μg/mL)   | Tislelizumab Concentrations (μg/mL)   |
|----------|---------------------------------------|---------------------------------------|
| Visit    | Predose                               | Postdose                              |
| Cycle 1  | NCa (n = 222)                         | 68.2 ± 14.65 (n = 223)                |
| Cycle 2  | 16.8 ± 4.49 (n =211)                  | NA                                    |
| Cycle 5  | 37.0 ± 10.24 (n = 160)                | 101.7 ± 19.74 (n = 163)               |
| Cycle 9  | 46.6 ± 13.52 (n = 73)                 | NA                                    |
| Cycle 17 | 51.0 ± 13.05 (n = 37)                 | NA                                    |

Source: ADPC.Data cutoff: 22Dec2022.Data extraction: 07Sep2023.

## External validation of the final PopPK model for Study 312

Since Study 312 was not incorporated in the original PopPK dataset and only sparse samples were collected in this study, an external validation was performed to verify the predictive performance of the final PopPK model using Study 312 data. The ability of the existing PopPK model to reproduce the distribution of tislelizumab concentration data over time was evaluated using pcVPC based on 1000 simulated replicates of the Study 312 dataset.

The pcVPC plots showed that the observed median, 2.5 th  and 97.5 th  percentiles of the concentrationtime profiles were generally contained within the simulation-based 95% confidence intervals for the corresponding model-predicted median and 2.5 th  and 97.5 th  percentiles in all validation patients. The pcVPC plot of tislelizumab serum concentration-time profiles is shown in Figure 1.

The pcVPC plot showed that the observed 5 th , 50 th  and 95 th  percentiles of the concentration-time profiles were generally contained within the simulation-based 90% confidence intervals for the corresponding model predicted 5 th , 50 th  and 95 th  percentiles.

<div style=\"page-break-after: always\"></div>

Figure 1 Prediction-corrected concentration (µg/ml) vs. time after previous dose (days)

## All patients (n=226)

<!-- image -->

Time after last dose = time elapsed since previous dose. Black dots represent observed concentrations, the two dashed lines represent the 5th and 95th percentiles of the observed concentrations, while the solid black line represents the 50th percentile of the observations. The blue shaded areas are model predicted percentiles and represent 90% confidence interval for 5th and 95th percentile, while red shaded area represent 90% confidence interval for 50th percentile.

A summary of simulated steady state exposure of tislelizumab used for the exposure-response analyses, including Cavg,ss (AUCss is equal to Cavg,ss*21 days, the dosing interval), Cmax,ss, Cycle 1 Cavg, and Cmin,ss is presented in the table below.

Table 3 Geometric Mean (GCV%) for simulated steady state exposure of tislelizumab (Cavg,ss, (AUCss is equal to Cavg,ss*21 days), Cmax,ss, Cmin,ss, Cavg,Cycle 1) for Study 312

|           | C avg,ss (μg/mL)   | C max,ss (μg/mL)   | C avg, Cycle 1 (μg/mL)   | C min,ss (μg/mL)   |
|-----------|--------------------|--------------------|--------------------------|--------------------|
| Study 312 | 63.9               | 112                | 28.9                     | 44.5               |
| (n=226)   | (21.4)             | (17.0)             | (12.8)                   | (28.7)             |

## PK in Special populations

Information on PK in special populations can be found in the Tevimbra public assessment report (EPAR) for the initial marketing authorisation.

The original popPK analysis showed that race was not a significant covariate on the PK parameters (CL and Vc) of tislelizumab. The simulated geometric mean exposures (AUCss, Cmax,ss, and Cmin,ss) of the Asian patient population (the majority of Asian patients are Chinese) from 12 studies were approximately 12% to 21% higher than those of white patients. The overall range of tislelizumab

<div style=\"page-break-after: always\"></div>

exposure after administration of 200 mg once every 3 weeks largely overlapped between the Asian and White patients.

Figure 2 Steady state exposure of tislelizumab by Asian; White and Other following 200 mg Q3W dosing

<!-- image -->

Source: Module 5.3.3.5 PopPK Report (March, 2021), Figure 22.

Abbreviations: AUCss, area under the serum concentration-time curve at steady state; CL, clearance; Cmin,ss minimum serum concentration at steady state.

Note: The steady-state exposures (Cmin,ss, AUCss) of tislelizumab were computed for each patient. AUCs was calculated as dose/CL. Cminss was calculated as the minimum concentration at 21 days after 10 consecutive doses of tislelizumab 200 mg once every 3 weeks.

The dashed red horizontal line represents the mean of the overall population

## Pharmacokinetic interaction studies

No formal drug-drug interaction studies have been conducted with tislelizumab. Information on pharmacokinetic interaction studies can be found in the Tevimbra public assessment report (EPAR) for the initial marketing authorisation.

## 2.3.3. Pharmacodynamics

No specific pharmacodynamic endpoint were investigated in Study BGB-A317-312 (Study 312).

An exposure-response analysis was conducted to evaluate the relationship between the exposure of tislelizumab and selected efficacy and safety endpoints, based on data from the pivotal study BGBA317-312.

Immunogenicity of tislelizumab in combination with chemotherapy was assessed as exploratory objective in Study 312.

## Mechanism of action

Tislelizumab is a humanized IgG4 variant monoclonal antibody against PD-1, binding to the extracellular domain of human PD-1 with high specificity and affinity (KD = 0.15 nM). It competitively blocks the binding of both PD-L1 and PD-L2, inhibiting PD-1-mediated negative signalling, and enhancing the functional activity in T-cells in in vitro cell-based assays. Tislelizumab does not bind to

<div style=\"page-break-after: always\"></div>

Fc gamma receptors and C1q and therefore does not induce antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity.

## Primary and secondary pharmacology

## Immunogenicity

The immunogenicity profile of tislelizumab has been characterized in clinical studies using validated assays. Serum samples from 2810 tislelizumab-treated patients in 11 Phase I to III clinical studies (monotherapy: studies 001, 102, 203, 204, 208, 302, and 303; in combination with chemotherapy: studies 206, 304, 307 and 306) and 220 patients form Study 312 were assessed for treatmentemergent ADA and Nab. Analyses of ADA and its potential impact on PK, efficacy, and safety were performed for 2577 evaluable patients. Study 312 immunogenicity analyses and integrated analyses are presented below.

## Immunogenicity in Study 312

The immunogenicity data for ES-SCLC patients treated with tislelizumab 200 mg Q3W in combination with chemotherapy in the first-line setting is presented below.

Table 4 Summary of immunogenicity results for Study 312 (ADA analysis set)

|                        | Tislelizumab (N = 220) (%)N   |
|------------------------|-------------------------------|
| Treatment-Emergent ADA | 55 (25.0)                     |
| Treatiment-Boosted ADA | 4 (1.8)                       |
| Treatiment-Induced ADA | 51 (23.2)                     |
| Persistent ADA         | 26 (11.8)                     |
| Transient ADA          | 25 (11.4)                     |
| NAb Positive           | 0 (0.0)                       |

Source: Study 312 CSR

Abbreviations: ADA, anti-drug antibodies; NAb, neutralising antibodies.

No patients were found to be positive for NAb. ADA incidence was comparable across expand smoking status but slightly elevated in patients with ECOG Performance Status score II and patients older than age 65.

<div style=\"page-break-after: always\"></div>

Figure 3: Median and range of ADA titers over time for tislelizumab in combination with chemotherapy - Study 312 (ADA evaluable patients)

<!-- image -->

Impact of ADA on PK (Study 312)

In the ADA evaluable analysis set, the serum concentrations of tislelizumab were slightly numerically lower in treatment-emergent ADA positive patients until Cycle 9 compared to ADA-negative patients, and numerically lower in patients with maximum titers ≥ 320 (8 patients) after Cycle 9.

Figure 4 ADA Impact on Mean (± SD) Trough Tislelizumab Serum Concentrations (ADA Evaluable Analysis Set)

<!-- image -->

Impact of ADA on efficacy (Study 312)

<div style=\"page-break-after: always\"></div>

Table 5 Clinical response endpoints for tislelizumab-treated patients by ADA status (Study 312)

|                         | ClinicalResponse                                                                  | ClinicalResponse   | ClinicalResponse   | ClinicalResponse   | ClinicalResponse   | ClinicalResponse   |
|-------------------------|-----------------------------------------------------------------------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
|                         | ObjectiveResponse                                                                 | ObjectiveResponse  | Disease Control    | Disease Control    | Clinical Benefit   | Clinical Benefit   |
| Treatment- emergent ADA | Yes % (n/N)                                                                       | No % (n/N)         | Yes % (n/N)        | No % (n/N)         | Yes % (n/N)        | No % (n/N)         |
| Yes                     | 61.8 (34/55)                                                                      | 38.2 (21/55)       | 89.1 (49/55)       | 10.9 (6/55)        | 63.6 (35/55)       | 36.4 (20/55)       |
| No                      | 73.3 (121/165)26.7 (44/165)92.1 (152/165)7.9 (13/165)73.9 (122/165)26.1 (43/165)  |                    |                    |                    |                    |                    |
| Total                   | 70.5 (155/220)29.5 (65/220)91.4 (201/220)|8.6 (19/220)71.4 (157/220)28.6 (63/220) |                    |                    |                    |                    |                    |

Source:ADSL,ADIS,ADRS

ADA, anti-drug antibody; n, number of patients with observed endpoints; N, total number of patients in the subgroups (Yes, Treatment EmergentYes,No,Treatment Emergent No,Total, ADA EvaluablePatients). unblind/bgb\\_a317/filing\\_sclc312/sclc312\\_2024\\_iar\\_eu/dev/pgm/tlfs/t-eff-ada.sas26JUL2024 02:11t-9-eff-ada-i.rtf

Figure 5 Overall survival by ADA status for tislelizumab in combination with chemotherapy Study 312 (ADA evaluable patients)

<!-- image -->

The principal stratum strategy was used to evaluate the impact of ADA on clinical efficacy. OS results using the principal stratum strategy are showed in Table 6.

Table 6 Analyses of Overall Survival Using the Principal Stratum Strategy in Patients (Intent-to-Treat Analysis Set)

| Landmark a,b   | Variable Selection c   | Baseline Covariates Selected d   | ADA-positive HR (95% CI)   | ADA-negative HR (95% CI)   |
|----------------|------------------------|----------------------------------|----------------------------|----------------------------|
| No             | No                     | All covariates                   | 0.85 (0.61, 1.19)          | 0.71 (0.57, 0.89)          |
| No             | Yes                    | Body weight                      | 0.87 (0.62, 1.21)          | 0.71 (0.56, 0.88)          |
| Yes            | No                     | All covariates                   | 0.85 (0.58, 1.25)          | 0.72 (0.57, 0.89)          |

<div style=\"page-break-after: always\"></div>

| Landmark a,b   | Variable Selection c   | Baseline Covariates Selected d   | ADA-positive HR (95% CI)   | ADA-negative HR (95% CI)   |
|----------------|------------------------|----------------------------------|----------------------------|----------------------------|
| Yes            | Yes                    | Body weight                      | 0.84 (0.57, 1.24)          | 0.72 (0.58, 0.89)          |

Source: ADSL, ADIS, ADTTE.

ADA, anti-drug antibody; ECOG PS, Eastern Cooperative Oncology Group Performance Status.

Baseline covariates include: Age, Sex, ECOG PS, Liver metastasis, LDH, Smoking status, Investigator chosen platinum, AJCC staging at study entry, Body weight.

a No: ADA status was not defined by landmark; Yes: ADA status was defined by landmark.

b The landmark time point of 4 weeks was chosen to reflect the approximate median time to ADA onset, and a small proportion of patients who experienced OS event/censored prior to the landmark time point were excluded. c No: no variable selection, used all the baseline covariates in the logistic regression; Yes: implemented stepwise variable selection.

d All the baseline covariates listed are applied to the variable selection \"Yes\" models.

Figure 6 Progression-free survival by ADA status for tislelizumab in combination with chemotherapy - Study 312 (ADA evaluable patients)

<!-- image -->

Impact of ADA on safety (Study 312)

In Study 312, the rates of Grade ≥ 3 AEs, im munological AEs and AEs causing dose modification were comparable between the ADA groups, while the rate of SAEs, IRRs and AEs causing treatment discontinuation was higher in the ADA-positive group. (Table 7).

<div style=\"page-break-after: always\"></div>

Table 7 Treatment-emergent adverse events by ADA status in Study 312

| Treatment- emergent ADA   | imAE % (n/N)   | IRR % (n/N)   | AE Grade>=3 % (n/N)   | SAE % (n/N)   | AE Discontinuationlodification % (n/N)   | AE % (n/N)     | AESI % (n/N)   |
|---------------------------|----------------|---------------|-----------------------|---------------|------------------------------------------|----------------|----------------|
| Yes                       | 41.8 (23/55)   | 14.5 (8/55)   | 87.3 (48/55)          | 47.3 (26/55)  | 16.4 (9/55)                              | 47.3 (26/55)   | 47.3 (26/55)   |
| No                        | 41.2 (68/165)  | 4.2 (7/165)   | 90.9 (150/165)        | 40.0 (66/165) | 10.3 (17/165)                            | 50.3 (83/165)  | 43.6 (72/165)  |
| Total                     | 41.4 (91/220)  | 6.8 (15/220)  | 90.0 (198/220)        | 41.8 (92/220) | 11.8 (26/220)                            | 49.5 (109/220) | 44.5 (98/220)  |

Source:ADSL,ADIS,ADAE

There was no correlation between AE onset and ADA onset in both the ADA groups.

Integrated immunogenicity analysis

Analyses of ADA and its potential impact on PK, efficacy, and safety were performed for 3270 evaluable patients.

ADA incidence

Table 8 ADA incidence by dose regimen (ADA evaluable patients) (Studies 001, 102, 203, 204, 206, 208, 302, 303, 304, 307 and 312)

| Dose Regimen   |   Stud Y |   Evaluable Patients N | Treatment- Emergent ADA n (%)   | Boosted ADA n (%)   | Treatment-Treatment- Induced ADA n (%)   | PersistentTransien ADA n (%)   | tADA n (%)   | NAb- Positive (%)   |
|----------------|----------|------------------------|---------------------------------|---------------------|------------------------------------------|--------------------------------|--------------|---------------------|
| 0.5 mg/kg Q2W  |      001 |                      3 | 1 (33.3)                        | 0 (0.0)             | 1 (33.3)                                 | 0 (0.0)                        | 1 (33.3)     | 0 (0.0)             |
| 2.0 mg/kgQ2W   |      001 |                     21 | 6 (28.6)                        | 0 (0.0)             | 6 (28.6)                                 | 2 (9.5)                        | 4 (19.0)     | 0 (0.0)             |
| 5.0 mg/kgQ2W   |      001 |                     25 | 5 (20.0)                        | 0 (0.0)             | 5 (20.0)                                 | 4 (16.0)                       | (4.0)        | 0 (0.0)             |
| 10.0mg/kgQ2W   |      001 |                      6 | 1 (16.7)                        | 0 (0.0)             | 1 (16.7)                                 | 1 (16.7)                       | 0 (0.0)      | 0 (0.0)             |
| 2.0 mg/kg Q3W  |      001 |                     19 | 6 (31.6)                        | 0 (0.0)             | 6 (31.6)                                 | (15.8)                         | 3 (15.8)     | 0 (0.0)             |

<div style=\"page-break-after: always\"></div>

| 5.0 mg/kg Q3W                                 | 001   |   287 | 44 (15.3)   | 1 (0.3)   | 43 (15.0)                             | 21 (7.3)                    | 22 (7.7)   | 0 (0.0)   |
|-----------------------------------------------|-------|-------|-------------|-----------|---------------------------------------|-----------------------------|------------|-----------|
| Subtotal of Weight-Based Regimen in Study 001 |       |   361 | 63 (17.5)   | 1 (0.3)   | 62 (17.2)                             | 31 (8.6)                    | 31 (8.6)   | 0 (0.0)   |
| 200 mgQ3W                                     | 001   |    11 | 3 (27.3)    | 0 (0.0)   | 3 (27.3)                              | 1 (9.1)                     | 2 (18.2)   | 1 (9.1)   |
| 200 mgQ3W                                     | 102   |   280 | 43 (15.4)   | 2 (0.7)   | 41 (14.6)                             | 26 (9.3)                    | 15 (5.4)   | 2 (0.7)   |
| 200 mgQ3W                                     | 203   |    70 | 6 (8.6)     | 0 (0.0)   | 6 (8.6)                               | 4 (5.7)                     | 2 (2.9)    | 1 (1.4)   |
| 200mgQ3W                                      | 204   |   104 | 18 (17.3)   | 1 (1.0)   | 17 (16.3)                             | 13 (12.5)                   | 4 (3.8)    | 0 (0.0)   |
| 200 mgQ3W                                     | 208   |   231 | 51 (22.1)   | 0 (0.0)   | 51 (22.1)                             | 34 (14.7)                   | 17 (7.4)   | 4 (1.7)   |
| 200 mg Q3W                                    | 302   |   223 | 32 (14.3)   | 2 (0.9)   | 30 (13.5)                             | 19 (8.5)                    | 11 (4.9)   | 1 (0.4)   |
| 200 mg Q3W                                    | 303   |   508 | 83 (16.3)   | 3 (0.6)   | 80 (15.7)                             | 42 (8.3)                    | 38 (7.5)   | 2 (0.4)   |
| Subtotal of Tislelizumab Monotherapy at       |       |  1427 | 236 (16.5)  | 8 (0.6)   | 228 (16.0)                            | 139 (9.7)                   | 89 (6.2)   | 11 (0.8)  |
| Subtotal of Tislelizumab Monotherapy          |       |  1788 | 299 (16.7)  | 9 (0.5)   | 290 (16.2)                            | 170 (9.5) 120 (6.7)11 (0.6) |            |           |
| 200 mg Q3W                                    | 206   |    51 | 7 (13.7)    | 0 (0.0)   | 7 (13.7)                              | 1 (2.0)                     | 6 (11.8)   | 0 (0.0)   |
| 200 mg Q3W                                    | 304   |   213 | 48 (22.5)   | 2 (0.9)   | 46 (21.6)                             | 12 (5.6)                    | 34 (16.0)  | 2 (0.9)   |
| 200 mgQ3W                                     | 305   |   470 | 107 (22.8)  | 1 (0.2)   | 106 (22.6)                            | 65 (13.8)                   | 41 (8.7)   | 8 (1.7)   |
| 200 mgQ3W                                     | 306   |   300 | 66 (22.0)   | 0 (0.0)   | 66 (22.0)                             | 29 (9.7)                    | 37 (12.3)  | 1 (0.3)   |
| 200 mgQ3W                                     | 307   |   228 | 63 (27.6)   | 2 (0.9)   | 61 (26.8)                             | 28 (12.3)                   | 33 (14.5)  | 5 (2.2)   |
| 200mgQ3W                                      | 312   |   220 | 55 (25.0)   | 4 (1.8)   | 51 (23.2)                             | 26 (11.8)                   | 25 (11.4)  | 0 (0.0)   |
| Subtotal of Tislelizumab Combination          |       |  1482 | 346 (23.3)  | 9 (0.6)   | 337 (22.7)                            | 161 (10.9)                  | 176 (11.9) | 16 (1.1)  |
| Therapy Subtotal of 200 mg Q3W                |       |  2909 | 582 (20.0)  | 17 (0.6)  | 565 (19.4)300 (10.3)265 (9.1)27 (0.9) |                             |            |           |
| Total                                         |       |  3270 | 645 (19.7)  | 18 (0.6)  | 627 (19.2)                            | 331 (10.1)296 (9.1)27 (0.8) |            |           |

Table 9 Table Summary of ADA Incidence by Race (Asian vs White) for Patients Treated With Tislelizumab 200 mg Q3W (ADA Evaluable Analysis Set)

| Dose Regimen/ Race                     | Evaluable Patients N   | Treatment -Emergent ADA n (%)   | Treatment -Boosted ADA n (%)   | Treatment -Induced ADA n (%)   | Persistent ADA n (%)   | Transient ADA n (%)   | NAb- Positive n (%)   |
|----------------------------------------|------------------------|---------------------------------|--------------------------------|--------------------------------|------------------------|-----------------------|-----------------------|
| Tislelizumab Monotherapy at 200 mg Q3W |                        |                                 |                                |                                |                        |                       |                       |
| Asian                                  | 1156                   | 167 (14.4)                      | 6 (0.5)                        | 161 (13.9)                     | 97 (8.4)               | 64 (5.5)              | 5 (0.4)               |
| White                                  | 162                    | 38 (23.5)                       | 2 (1.2)                        | 36 (22.2)                      | 21 (13.0)              | 15 (9.3)              | 2 (1.2)               |
| Tislelizumab Combination Therapy       |                        |                                 |                                |                                |                        |                       |                       |
| Asian                                  | 1641                   | 425 (25.9)                      | 12 (0.7)                       | 413 (25.2)                     | 200 (12.2)             | 213 (13.0)            | 20 (1.2)              |
| White                                  | 163                    | 33 (20.2)                       | 0 (0.0)                        | 33 (20.2)                      | 19 (11.7)              | 14 (8.6)              | 2 (1.2)               |
| Total of 200 mg Q3W b                  |                        |                                 |                                |                                |                        |                       |                       |
| Asian                                  | 2797                   | 592 (21.2)                      | 18 (0.6)                       | 574 (20.5)                     | 297 (10.6)             | 277 (9.9)             | 25 (0.9)              |
| White                                  | 325                    | 71 (21.8)                       | 2 (0.6)                        | 69 (21.2)                      | 40 (12.3)              | 29 (8.9)              | 4 (1.2)               |

<div style=\"page-break-after: always\"></div>

## Impact of ADA on Efficacy

Table 10 Clinical response endpoints after tislelizumab treatment by ADA status in all patients Studies 001, 102, 203, 204, 208, 302, 303, 304, 307 and 312 (ADA evaluable patients)

|                         | Treatment-Emergent ADAPositive n/N (%)   | Treatment-Emergent ADA Negative m/N (%)   |
|-------------------------|------------------------------------------|-------------------------------------------|
| TislelizumabMonotherapy |                                          |                                           |
| Study001-SolidTumors    |                                          |                                           |
| Objective Response      | 11/66 (16.7)                             | 48/306 (15.7)                             |
| Disease Control         | 34/66 (51.5)                             | 159/306 (52.0)                            |
| Clinical Benefit        | 20/66 (30.3)                             | 93/306 (30.4)                             |

| Objective Response               | 5/43 (11.6)    | 46/237 (19.4)   |
|----------------------------------|----------------|-----------------|
| Disease Control                  | 14/43 (32.6)   | 120/237 (50.6)  |
| Clinical Benefit                 | 8/43 (18.6)    | 88/237 (37.1)   |
| Study 203 -cHL                   |                |                 |
| Objective Response               | 5/6 (83.3)     | 56/64 (87.5)    |
| Disease Control                  | 5/6 (83.3)     | 58/64 (90.6)    |
| Study 204 -UC                    |                |                 |
| Objective Response               | 4/18 (22.2)    | 21/86 (24.4)    |
| Disease Control                  | 8/18 (44.4)    | 35/86 (40.7)    |
| Clinical Benefit                 | 6/18 (33.3)    | 27/86 (31.4)    |
| Study208-HCC                     |                |                 |
| Objective Response               | 12/51 (23.5)   | 20/180 (11.1)   |
| Disease Control                  | 33/51 (64.7)   | 96/180 (53.3)   |
| Clinical Benefit                 | 16/51 (31.4)   | 40/180 (22.2)   |
| Study 302-0SCC                   |                |                 |
| Objective Response               | 6/32 (18.8)    | 32/191 (16.8)   |
| Disease Control                  | 18/32 (56.3)   | 98/191 (51.3)   |
| Study 303-NSCLC                  |                |                 |
| Objective Response               | 22/83 (26.5)   | 88/425 (20.7)   |
| Disease Control                  | 51/83 (61.4)   | 244/425 (57.4)  |
| Clinical Benefit                 | 41/83 (49.4)   | 191/425 (44.9)  |
| Tislelizumab Combination Therapy |                |                 |
| Study 304 -NSCLC                 |                |                 |
| Objective Response               | 28/48 (58.3)   | 86/165 (52.1)   |
| Disease Control                  | 46/48 (95.8)   | 151/165 (91.5)  |
| Clinical Benefit                 | 34/48 (70.8)   | 114/165 (69.1)  |
| Study 305 - G/GEJC               |                |                 |
| Objective Response               | 53/107 (49.5)  | 182/363 (50.1)  |
| Disease Control                  | 100/107 (93.5) | 344/363 (94.8)  |
| Clinical Benefit                 | 69/107 (64.5)  | 245/363 (67.5)  |
| Study 306-0SCC                   |                |                 |
| Objective Response               | 38/66 (57.6)   | 139/234 (59.4)  |
| Disease Control                  | 57/66 (86.4)   | 219/234 (93.6)  |
| Clinical Benefit                 | 43/66 (65.2)   | 174/234 (74.4)  |
| Study 307-NSCLC: T+PC            |                |                 |
| Objective Response               | 24/43 (55.8)   | 50/72 (69.4)    |
| Disease Control                  | 35/43 (81.4)   | 68/72 (94.4)    |
| Clinical Benefit                 | 27/43 (62.8)   | 58/72 (80.6)    |
| Stidy 307-NSCLC:T+nPC            |                |                 |
| Objective Response               | 10/20 (50.0)   | 64/93 (68.8)    |
| Disease Control                  | 20/20 (100.0)  | 88/93 (94.6)    |
| Clinical Benefit                 | 14/20 (70.0)   | 72/93 (77.4)    |
| Study 312- SCLC                  |                |                 |
| Objective Response               | 34/55 (61.8)   | 121/165 (73.3)  |
| Disease Control                  | 49/55 (89.1)   | 152/165 (92.1)  |
| Clinical Benefit                 | 35/55 (63.6)   | 122/165 (73.9)  |

<div style=\"page-break-after: always\"></div>

## Impact of ADA on Safety

Table 11 Treatment-emergent adverse events by ADA status - Studies 001, 102, 203, 204, 208, 302, 303, 304, 307 and 312 (ADA evaluable patients)

|                                                                                       | Treatment-Emergent ADA Positive   | Treatment-Emergent ADA Negative   |
|---------------------------------------------------------------------------------------|-----------------------------------|-----------------------------------|
| Tislelizumab Monotherapy                                                              |                                   |                                   |
| Monotherapy Studies (001,102,203,204,208,302,236                                      |                                   | 1191                              |
| and 303), N                                                                           |                                   |                                   |
| Immune-Mediated Adverse Events, n (%)                                                 | 80 (33.9)                         | 412 (34.6)                        |
| Infusion-Related Reactions, n (%)                                                     | 4 (1.7)                           | 42 (3.5)                          |
| TEAEs >= Grade 3, n (%)                                                               | 124 (52.5)                        | 502 (42.1)                        |
| Serious TEAEs, n (%)                                                                  | 92 (39.0)                         | 379 (31.8)                        |
| TEAEs Leading to Tislelizumab Discontinuation, n (%)                                  | 29 (12.3)                         | 136 (11.4)                        |
| TEAEs Leading to Treatment Modification of Tislelizumab, n (%)                        | 71 (30.1)                         | 334 (28.0)                        |
| Tislelizumab Combination Therapy                                                      |                                   |                                   |
| Combination Therapy Studies (304, 305, 306, 307, 312), N                              | 339                               | 1092                              |
| Immune-Mediated Adverse Events, n (%)                                                 | 139 (41.0)                        | 430 (39.4)                        |
| Infusion-Related Reactions, n (%)                                                     | 30 (8.8)                          | 67 (6.1)                          |
| TEAEs = Grade 3, n (%)                                                                | 271 (79.9)                        | 851 (77.9)                        |
| Serious TEAEs, n (%)                                                                  | 157 (46.3)                        | 470 (43.0)                        |
| TEAEs Leading to Tislelizumab Discontinuation, n (%)                                  | 52 (15.3)                         | 157 (14.4)                        |
| TEAEs Leading to Treatment Modification of Tislelizumab, n (9)                        | 185 (54.6)                        | 615 (56.3)                        |
| Study 304 - NSCLC, N                                                                  | 48                                | 165                               |
| Immune-Mediated Adverse Events, n (%)                                                 | 23 (47.9)                         | 79 (47.9)                         |
| Infusion-Related Reactions, n (%)                                                     | 1 (2.1)                           | 4 (2.4)                           |
| TEAEs >=Grade 3, n (%)                                                                | 39 (81.3)                         | 117 (70.9)                        |
| Serious TEAEs, n (%)                                                                  | 23 (47.9)                         | 69 (41.8)                         |
| TEAEs Leading to Tislelizumab                                                         | 7 (14.6)                          | 33 (20.0)                         |
| Discontimuation, n (%) TEAEs Leading to Treatment Modification of Tislelizumab, n (%) | 34 (70.8)                         | 110 (66.7)                        |
| Study 305 - G/GEJC, N                                                                 | 107                               | 363                               |
| Immune-Mediated Adverse Events, n (%)                                                 | 35 (32.7)                         | 115 (31.7)                        |
| Infusion-Related Reactions, n (%)                                                     | 8 (7.5)                           | 24 (6.6)                          |
| TEAEs >= Grade 3, n (%)                                                               | 75 (70.1)                         | 248 (68.3)                        |
| Serious TEAEs, n (%)                                                                  | 41 (38.3)                         | 151 (41.6)                        |
| TEAEs Leading to Tislelizumab                                                         | 18 (16.8)                         | 51 (14.0)                         |
| Discontimuation, n (%) TEAEs Leading to Treatment Modification of Tislelizumab, n (%) | 55 (51.4)                         | 182 (50.1)                        |
| Study 306 -0SCC,N                                                                     | 66                                | 234                               |
| Immune-Mediated Adverse Events, n (%)                                                 | 23 (34.8)                         | 87 (37.2)                         |
| Infusion-Related Reactions, n (%)                                                     | 8 (12.1)                          | 17 (7.3)                          |
| TEAEs >= Grade 3, n (%)                                                               | 53 (80.3)                         | 185 (79.1)                        |
| Serious TEAEs, n (%)                                                                  | 35 (53.0)                         | 110 (47.0)                        |
| TEAEs Leading to Tislelizumab Discontimuation, n (%)                                  | 8 (12.1)                          | 33 (14.1)                         |
| TEAEs Leading to Treatment Modification of Tislelizumab, n (%)                        | 34 (51.5)                         | 124 (53.0)                        |
| Study 307 -NSCLC,N                                                                    | 63                                | 165                               |
| Immune-Mediated Adverse Events, n (%)                                                 | 35 (55.6)                         | 81 (49.1)                         |
| Infusion-Related Reactions, n (%)                                                     | 5 (7.9)                           | 15 (9.1)                          |
| TEAEs >= Grade 3, n (%)                                                               | 56 (88.9)                         | 151 (91.5)                        |
| Serious TEAEs, n (%)                                                                  | 32 (50.8)                         | 74 (44.8)                         |
| TEAEs Leading to Tislelizumab Discontinuation, n (%)                                  | 10 (15.9)                         | 23 (13.9)                         |

<div style=\"page-break-after: always\"></div>

|                                                                | Treatment-Emergent ADA Positive   | Ireatment-Emergent ADA Negative   |
|----------------------------------------------------------------|-----------------------------------|-----------------------------------|
| TEAEs Leading to Treatment Modification of Tislelizumab, n (%) | B6 (57.1)                         | 116 (70.3)                        |
| Study 312 -SCLC,N                                              | 55                                | 165                               |
| Immune-Mediated Adverse Events, n (%)                          | 23 (41.8)                         | 68 (41.2)                         |
| Infusion-Related Reactions, n (%)                              | 8 (14.5)                          | 7 (4.2)                           |
| TEAEs = Grade 3, n (%)                                         | 48 (87.3)                         | 150 (90.9)                        |
| Serious TEAEs, n (%)                                           | 26 (47.3)                         | 66 (40.0)                         |
| TEAEs Leading to Tislelizumab Discontimuation, n (%)           | p (16.4)                          | 17 (10.3)                         |
| TEAEs Leading to Treatment Modification of Tislelizumab, n (%) | 26 (47.3)                         | 83 (50.3)                         |

Sowrce: ADSL, ADIS, ADAE

Abbreviations: ADA, Antidug Antibody; OSCC, Oesophageal Squamous Cell Carcinoma; G/GEIC, Gashic

Cancer/Gastroesophageal Junction Cancer; NPC, Nasopharyngeal Cancer; NSCLC, Non-Small Cell Lumg Cancer; SCLC, Small

Cell Lung Cancer; TEAE, Treatment-Emergent Adverse Event.

Patients in Study 00l with weight-based dosing Q2W/Q3W were excluded from this table.

Immune-mediated AEs were identified based on BeiGene standard process as defined in Immune-Mediated Adverse Event Identification Charter vl.2, imAE CCQ v2.4.

Dose modification for Tislelizumab includes dose intemuption, dose delay and infusion rate decrease.

Adverse events were graded for severity using CICAE (v5.0 for shudies 304, 305, 307, and 312, v4.03 for studies 001, 102, 203, 204, 208, 302, 303, and 306).

Treatment-emergent adverse events were further analysed by ADA status in race or region subgroups (see tables below).

Table 12 Summary of Treatment-Emergent Adverse Events by ADA Status and Race for Patients Treated With Tislelizumab 200 mg Q3W (ADA Evaluable Analysis Set)

|                                                                                 | Treatment-Emergent ADA Positive   | Treatment-Emergent ADA Positive   | Treatment-Emergent ADA Negative   | Treatment-Emergent ADA Negative   |
|---------------------------------------------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|                                                                                 | White                             | Asian                             | White                             | Asian                             |
| Tislelizumab Monotherapy Studies (001, 102, 203, 204, 208, 302, 303), N         | 38                                | 167                               | 124                               | 989                               |
| Immune-Mediated Adverse Events, n (%)                                           | 14 (36.8)                         | 56 (33.5)                         | 40 (32.3)                         | 352 (35.6)                        |
| Infusion-Related Reactions, n (%)                                               | 0 (0.0)                           | 2 (1.2)                           | 6 (4.8)                           | 31 (3.1)                          |
| TEAEs ≥ Grade 3, n (%)                                                          | 19 (50.0)                         | 86 (51.5)                         | 55 (44.4)                         | 405 (41.0)                        |
| Serious TEAEs, n (%)                                                            | 9 (23.7)                          | 70 (41.9)                         | 37 (29.8)                         | 311 (31.4)                        |
| TEAEs Leading to Tislelizumab Discontinuation, n (%)                            | 6 (15.8)                          | 19 (11.4)                         | 15 (12.1)                         | 112 (11.3)                        |
| TEAEs Leading to Treatment Modification of Tislelizumab, n (%)                  | 14 (36.8)                         | 52 (31.1)                         | 46 (37.1)                         | 268 (27.1)                        |
| Tislelizumab Combination Therapy Studies (304, 305, 306, 307, 309, 312, 315), N | 33                                | 418                               | 130                               | 1172                              |
| Immune-Mediated Adverse Events, n (%)                                           | 9 (27.3)                          | 179 (42.8)                        | 32 (24.6)                         | 498 (42.5)                        |
| Infusion-Related Reactions, n (%)                                               | 1 (3.0)                           | 34 (8.1)                          | 4 (3.1)                           | 71 (6.1)                          |
| TEAEs ≥ Grade 3, n (%)                                                          | 26 (78.8)                         | 335 (80.1)                        | 89 (68.5)                         | 936 (79.9)                        |
| Serious TEAEs, n (%)                                                            | 17 (51.5)                         | 177 (42.3)                        | 52 (40.0)                         | 479 (40.9)                        |
| TEAEs Leading to Tislelizumab Discontinuation, n (%)                            | 6 (18.2)                          | 55 (13.2)                         | 25 (19.2)                         | 148 (12.6)                        |
| TEAEs Leading to Treatment Modification of Tislelizumab, n (%)                  | 16 (48.5)                         | 207 (49.5)                        | 62 (47.7)                         | 646 (55.1)                        |

<div style=\"page-break-after: always\"></div>

|                                                                | Treatment-Emergent ADA Positive   | Treatment-Emergent ADA Positive   | Treatment-Emergent ADA Negative   | Treatment-Emergent ADA Negative   |
|----------------------------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|                                                                | White                             | Asian                             | White                             | Asian                             |
| Total, N                                                       | 71                                | 585                               | 254                               | 2161                              |
| Immune-Mediated Adverse Events, n (%)                          | 23 (32.4)                         | 235 (40.2)                        | 72 (28.3)                         | 850 (39.3)                        |
| Infusion-Related Reactions, n (%)                              | 1 (1.4)                           | 36 (6.2)                          | 10 (3.9)                          | 102 (4.7)                         |
| TEAEs ≥ Grade 3, n (%)                                         | 45 (63.4)                         | 421 (72.0)                        | 144 (56.7)                        | 1341 (62.1)                       |
| Serious TEAEs, n (%)                                           | 26 (36.6)                         | 247 (42.2)                        | 89 (35.0)                         | 790 (36.6)                        |
| TEAEs Leading to Tislelizumab Discontinuation, n (%)           | 12 (16.9)                         | 74 (12.6)                         | 40 (15.7)                         | 260 (12.0)                        |
| TEAEs Leading to Treatment Modification of Tislelizumab, n (%) | 30 (42.3)                         | 259 (44.3)                        | 108 (42.5)                        | 914 (42.3)                        |

## Table 13 Summary of Treatment-Emergent Adverse Events by ADA Status and Region for Patients Treated With Tislelizumab 200 mg Q3W (ADA Evaluable Analysis Set)

|                                                                                 | Treatment-Emergent ADA Positive   | Treatment-Emergent ADA Positive   | Treatment-Emergent ADA Negative   | Treatment-Emergent ADA Negative   |
|---------------------------------------------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|                                                                                 | Europe/Nor th America             | Asia                              | Europe/Nor th America             | Asia                              |
| Tislelizumab Monotherapy Studies (001, 102, 203, 204, 208, 302, 303), N         | 61                                | 167                               | 177                               | 987                               |
| Immune-Mediated Adverse Events, n (%)                                           | 20 (32.8)                         | 56 (33.5)                         | 45 (25.4)                         | 352 (35.7)                        |
| Infusion-Related Reactions, n (%)                                               | 2 (3.3)                           | 2 (1.2)                           | 10 (5.6)                          | 31 (3.1)                          |
| TEAEs ≥ Grade 3, n (%)                                                          | 34 (55.7)                         | 86 (51.5)                         | 86 (48.6)                         | 405 (41.0)                        |
| Serious TEAEs, n (%)                                                            | 18 (29.5)                         | 70 (41.9)                         | 58 (32.8)                         | 311 (31.5)                        |
| TEAEs Leading to Tislelizumab Discontinuation, n (%)                            | 9 (14.8)                          | 19 (11.4)                         | 22 (12.4)                         | 112 (11.3)                        |
| TEAEs Leading to Treatment Modification of Tislelizumab, n (%)                  | 15 (24.6)                         | 52 (31.1)                         | 57 (32.2)                         | 268 (27.2)                        |
| Tislelizumab Combination Therapy Studies (304, 305, 306, 307, 309, 312, 315), N | 37                                | 418                               | 146                               | 1172                              |
| Immune-Mediated Adverse Events, n (%)                                           | 12 (32.4)                         | 179 (42.8)                        | 36 (24.7)                         | 498 (42.5)                        |
| Infusion-Related Reactions, n (%)                                               | 1 (2.7)                           | 34 (8.1)                          | 6 (4.1)                           | 71 (6.1)                          |
| TEAEs ≥ Grade 3, n (%)                                                          | 29 (78.4)                         | 335 (80.1)                        | 99 (67.8)                         | 936 (79.9)                        |
| Serious TEAEs, n (%)                                                            | 20 (54.1)                         | 177 (42.3)                        | 62 (42.5)                         | 479 (40.9)                        |
| TEAEs Leading to Tislelizumab Discontinuation, n (%)                            | 7 (18.9)                          | 55 (13.2)                         | 30 (20.5)                         | 148 (12.6)                        |
| TEAEs Leading to Treatment Modification of Tislelizumab, n (%)                  | 18 (48.6)                         | 207 (49.5)                        | 70 (47.9)                         | 646 (55.1)                        |
| Total, N                                                                        | 98                                | 585                               | 323                               | 2159                              |
| Immune-Mediated Adverse Events, n (%)                                           | 32 (32.7)                         | 235 (40.2)                        | 81 (25.1)                         | 850 (39.4)                        |
| Infusion-Related Reactions, n (%)                                               | 3 (3.1)                           | 36 (6.2)                          | 16 (5.0)                          | 102 (4.7)                         |
| TEAEs ≥ Grade 3, n (%)                                                          | 63 (64.3)                         | 421 (72.0)                        | 185 (57.3)                        | 1341 (62.1)                       |
| Serious TEAEs, n (%)                                                            | 38 (38.8)                         | 247 (42.2)                        | 120 (37.2)                        | 790 (36.6)                        |

<div style=\"page-break-after: always\"></div>

|                                                                | Treatment-Emergent ADA Positive   | Treatment-Emergent ADA Positive   | Treatment-Emergent ADA Negative   | Treatment-Emergent ADA Negative   |
|----------------------------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|                                                                | Europe/Nor th America             | Asia                              | Europe/Nor th America             | Asia                              |
| TEAEs Leading to Tislelizumab Discontinuation, n (%)           | 16 (16.3)                         | 74 (12.6)                         | 52 (16.1)                         | 260 (12.0)                        |
| TEAEs Leading to Treatment Modification of Tislelizumab, n (%) | 33 (33.7)                         | 259 (44.3)                        | 127 (39.3)                        | 914 (42.3)                        |

## Exposure-response analyses

## Exposure-efficacy analysis in Study 312

The exposure-efficacy relationship for tislelizumab was explored using efficacy datasets from 226 patients who received at least one dose of tislelizumab and had PopPK model predicted Cavg, dose1 for exposure - efficacy. The efficacy endpoints analyzed were OS (primary endpoint), PFS, and responders/non-responders status based on OOR (secondary endpoints).

## Exposure versus OS and PFS

There is no monotonic relationship between Cavg,dose1 and OS or PFS. There is limited separation between the Kaplan-Meier curves when stratified by quartiles Cavg,dose1.

Figure 7 Kaplan-Meier curves of OS stratified by Cavg,dose1

<!-- image -->

Abbreviations: Cavg,dose1, average concentration after the first dose; OS, overall survival.

<div style=\"page-break-after: always\"></div>

Figure 8 Kaplan-Meier curves of PFS stratified by quartiles of Cavg,dose1 -

<!-- image -->

Source: Figure 4-3 Exposure-Response Report

The Kaplan-Meier curves showed that no clinically relevant E-R relationship was observed between tislelizumab exposure and PFS.

Cox regression models were also used to evaluate the relationship between the PopPK predicted Cavg,dose1 and OS. The slopes (coefficient of log of Cavg,dose1) were negative and the 95% CI includes zero.

Table 14 Summary of Cox model parameters for OS

|     |                 | Parameter Estimates   | Parameter Estimates   | Wald    | 95% CI for β   | 95% CI for β   |
|-----|-----------------|-----------------------|-----------------------|---------|----------------|----------------|
| Run | Predictor       | B                     | exp(β)                | p-value | Lower          | Upper          |
| 2   | Log(C avg.dose1 | -0.5221               | 0.5933                | 0.3811  | -1.6904        | 0.6461         |

## Exposure versus ORR

The E-R relationship for objective response rate (ORR) was explored based on patients with untreated extensive-stage SCLC enrolled in study BGB-A317-312.

The boxplot in the Figure below shows the distribution of Cavg,dose1 in tislelizumab treated patients with or without ORR. The median Cavg,dose1 values were similar between responders (N=155) and nonresponders (N=71). The probability of response plot showed a slightly increasing trend between tislelizumab Cavg,dose1 and ORR.

<div style=\"page-break-after: always\"></div>

Figure 9 The relationship between tislelizumab exposure and ORR

<!-- image -->

The E-R logistic regression model for ORR with Cavg,dose1 and covariates were developed based on tislelizumab treated patients in study BGB-A317-312).

Figure 10 Logistic regression of probability of ORR versus exposure

<!-- image -->

## Exposure-safety analysis in Study 312:

Exposure-safety analyses explored the relationship between predicted tislelizumab exposure and clinically relevant safety endpoints in Study 312: CTCAE ≥ Grade 3 TEAEs, TEAEs leading to tislelizumab discontinuation, TEAEs leading to tislelizumab dose modification (ie, dose interruption, dose delay, and infusion rate decrease), AESIs, and serious TEAEs. The AESI safety endpoints were imAEs and IRRs. The predicted exposures of patients with and without a given safety endpoint were described using summary statistics. Box-plots display PopPK-predicted Cavg,ss and Cmax,ss for patients with and without the safety event of interest. For each safety endpoint, the predicted

<div style=\"page-break-after: always\"></div>

exposures of patients who experience the event and patients who did not experience the event could be regarded as comparable.

## TEAE with CTCAE grade ≥ 3

The median Cavg,ss and Cmax,ss values of tislelizumab were comparable between patients with and without any TEAE grade ≥ 3. The probability of any TEAE grade ≥ 3 by quantiles of tislelizumab exposures is shown below.

Figure 11 The relationship between exposure and any TEAE grade ≥ 3 for tislelizumab treated patients

## AnyTEAEgrade3andabove

<!-- image -->

The probability of any TEAE grade ≥ 3 by quantiles of tislelizumab exposures is shown below.

Figure 12 Probability of any TEAE grade ≥ 3 versus exposure for tislelizumab treated patients

<!-- image -->

Cmax.ss (μg/mL)

Open blue circles reflect the observed events. The filled black symbols are the observed probability of events and the error bars are SE [sqit (P*(1-P)/N)] for quantiles (at 100x(1/4)th percentiles, vertical dotted lines) of exposures (plotted at the median value within each quantile), where P is the probability of event and N is the number of patients in each quantile bin. The red lines are smooth curves to show the relationship between two variables.

Immune-mediated TEAEs

<div style=\"page-break-after: always\"></div>

Figure 13 The relationship between exposure and immune-mediated AEs for tislelizumab treated patients

## Immune-mediatedAE

<!-- image -->

Open blue circles are the model-predicted exposure. The median is represented by the horizontal black line in the middle of each box. The lower and upper ends of the box plot represent the 25th and 75th percentile (the lower and upper quartiles, respectively). The bars extend to the most extreme data point which is no more than 1.5xIQR from the box. The dashed red horizontal line represents the median value in study BGB-A317-312.

The probability of immune-mediat ed AEs by quantiles of tislelizumab exposure is shown in the Figure below.

Figure 14 Probability of immune-mediated AEs versus exposure for tislelizumab treated patients

<!-- image -->

Open blue circles reflect the observed events. The filled black symbols are the observed probability of events and the error bars are SE [sqrt (P*(1-P)/N)] for quantiles (at 100x(1/4)th percentiles, vertical dotted lines) of exposures (plotted at the median value within each quantile), where P is the probability of event and N is the number of patients in each quantile bin. The red lines are smooth curves to show the relationship between two variables.

## Infusion-related reactions

The median Cavg,ss and Cmax,ss values of tislelizumab were slightly higher in patients without infusion related reactions than with infusion related reactions.

<div style=\"page-break-after: always\"></div>

Figure 15 The relationship between exposure and infusion related reactions

<!-- image -->

Open blue circles are the model-predicted exposure. The median is represented by the horizontal black line in the middle of each box. The lower and upper ends of the box plot represent the 25th and 75th percentile (the lower and upper quartiles, respectively). The bars extend to the most extreme data point which is no more than 1.5xIQR from the box. The dashed red horizontal line represents the median value in study BGB-A317-312.

The probability of infusion related reactions by quantiles of tislelizumab exposure is shown in the Figure below.

Figure 16 Probability of infusion related reactions versus tislelizumab exposure

<!-- image -->

Open blue circles reflect the observed events. The filled black symbols are the observed probability of events and the error bars are SE [sqrt (P*(1-P)/N)] for quantiles (at 100x(1/4)th percentiles, vertical dotted lines) of exposures (plotted at the median value within each quantile), where P is the probability of event and N is the number of patients in each quantile bin. The red lines are smooth curves to show the relationship between two variables.

## TEAE leading to treatment discontinuation or dose modification of tislelizumab

Tislelizumab exposure was similar between patients with or without any TEAEs leading to tislelizumab discontinuation or TEAEs leading to tislelizumab dose modification (data not shown).

## Serious TEAE

Overall, the tislelizumab exposure was comparable between subjects with or without any serious TEAEs.

<div style=\"page-break-after: always\"></div>

Figure 17 The relationship between exposure and serious TEAEs

<!-- image -->

Open blue circles are the model-predicted exposure. The median is represented by the horizontal black line in the middle of each box. The lower and upper ends of the box plot represent the 25th and 75th percentile (the lower and upper quartiles, respectively). The bars extend to the most extreme data point which is no more than 1.5xIQR from the box. The dashed red horizontal line represents the median value in study BGB-A317-312.

The probability of serious TEAEs by quantiles of tislelizumab exposures is shown in Figure 18 .

Figure 18 Probability of serious TEAEs versus tislelizumab exposure

<!-- image -->

Open blue circles reflect the observed events. The filled black symbols are the observed probability of events and the error bars are SE [sqrt (P*(1-P)/N)] for quantiles (at 100x(1/4)th percentiles, vertical dotted lines) of exposures (plotted at the median value within each quantile), where P is the probability of event and N is the number of patients in each quantile bin. The red lines are smooth curves to show the relationship between two variables.

## 2.3.4. Discussion on clinical pharmacology

## Pharmacokinetics

Pharmacokinetics of tislelizumab at the proposed dosing regimen of 200 mg Q3W had already been extensively characterized in previous applications.

In the pivotal study BGB-A317-312 supporting the current application for extension of indication of tislelizumab for 1L treatment of ES-SCLC, only sparse PK samples were collected. These data were used for external validation of the predictive performance and robustness of the previously developed population PK model for Study 312.

<div style=\"page-break-after: always\"></div>

In Study 312, pre- and post-dose concentrations of tislelizumab were similar to the concentrations reported in previous studies in which tislelizumab was either administered as monotherapy or in combination with chemotherapy.

External validation using data from Study 312 confirmed that the final PopPK model accurately described the observed pharmacokinetic data. The simulated steady state exposure of tislelizumab (Cmaxss, Cminss, AUCss [derived by Cavg,ss*21 days]) in Study 312 was comparable to that in previous studies. Therefore, the final PopPK model is deemed adequate for generating exposure metrics for future exposure-response analyses.

## PK in special populations

In the population PK model, baseline body weight, albumin level, tumour size of solid tumours, ADA status (treatment-emergent ADA), and tumour type were identified as significant covariates on clearance. Baseline body weight, sex, and age were identified as significant covariates on Vc. However, simulated mean exposure differences observed in patients with impaired renal or hepatic function, different gender, different race (Asian vs. White), different body weight, and in the elderly were rather small compared to the overall variability of tislelizumab exposure.

## Pharmacodynamics

## Immunogenicity

In Study 312, the incidence of treatment-emergent ADA was 25.0%. Of those, 11.4% presented with a persistent ADA response. Neutralizing ADA were not detected. ADA rates reported in Study 312 were within the range seen in other Phase III combination therapy studies 304, 306 and 307 (17.7% to 37.4%).

The analysis of impact of ADA-positive status on PK in tislelizumab monotherapy studies revealed reduced exposure of tislelizumab in ADA-positive patients. Similar, but less pronounced tendencies have been observed in other tislelizumab combination therapy studies. Given the generally high variability of tislelizumab exposure and considering that lower concentrations reported for ADA-positive patients were still within the range of overall variability, the clinical relevance of this finding is considered not significant.

However, regarding the analysis of ADA status on efficacy, ADA-positive patients showed less benefit in terms of response rates and overall survival (OS), with a median OS of 13.4 months compared to 16.5 months in ADA-negative patients. The hazard ratio (HR) was 1.26 (95% CI: 0.90, 1.78). As ADA positivity could be associated to other negative prognostic factors, an adjusted analysis using the principal stratum strategy was conducted to assess ADA's impact on clinical efficacy. The 95% confidence intervals (CIs) for OS HR estimates largely overlapped between the two ADA groups, indicating a likely comparable OS benefit for both groups.

The impact of ADA on safety based on cumulative data from 3270 evaluable patients showed that the safety profile of tislelizumab was not impacted by the development of treatment-emergent ADA. The incidence rates of Grade ≥ 3 TEAEs and serious TEAEs were higher in ADA-positive patients treated with tislelizumab. However, a review of the Preferred Terms for Grade ≥ 3 and serious TEAEs did not indicate that ADA positivity resulted in higher frequencies of particular diagnoses. The incidence rates of imAEs, IRRs, TEAEs leading to tislelizumab discontinuation, and TEAEs leading to treatment modification of tislelizumab were comparable between patients who developed ADA and those who tested negative for ADA.

In line with findings from previous tislelizumab studies, in Study 312 the rate of serious adverse events was higher in the ADA-positive population as compared to the ADA-negative population (47.3% vs.

<div style=\"page-break-after: always\"></div>

40%) and IRR (14.5 % vs. 4.2%). No meaningful differences were seen in the frequency of imAEs, TEAEs with CTCAE grade ≥ 3 and TEAEs leading to dose modification .

During the initial MAA procedure, higher ADA incidence rates were observed in White vs. Asian patients and in patients from Europe/North America vs. Asia however, no conclusions could be drawn due to the limited size of the database presented and the imbalances in the number of patients included in different subgroups. Further data were provided by ADA status, divided by subgroups of ethnicity (White vs. Asian) and region (Europe/North America vs. Asia) during the current procedure. In the tislelizumab combination therapy studies, the rates of TEAEs Grade ≥ 3 and serious TEAEs are similar between ADA-positive and ADA-negative patients in the Asian population (Asian: TEAEs Grade ≥ 3: 80.1% vs. 79.9%, serious TEAEs: 42.3% vs. 40.9%; Asia: TEAEs Grade ≥ 3: 80.1% vs. 79.9%, serious TEAEs: 42.3% vs. 40.9), while TEAE rates were different in ADA-positive vs. ADA-negative patients in the White/European population (White: TEAEs Grade ≥ 3: 78.8% vs. 68.5%, serious TEAEs: 51.5% vs. 40.0%; Europe/NA: TEAEs Grade ≥ 3: 78.4% vs. 67.8%, serious TEAEs: 54.1% vs. 42.5%). While the differences initially observed are less pronounced in the overall population of tislelizumab combination therapy studies, the sample size of the subgroups by ADA status in the White/European population is too low to draw reliable conclusions on a potential differential impact of ADA positivity in race or region subgroups.

## Exposure-response analyses

The final PopPK model was used as basis for analyses of the exposure-efficacy and exposure-safety relationship for tislelizumab. Data from 226 patients who received at least one dose of tislelizumab in Study 312 and had PopPK model predicted Cavg,dose1 and Cmax,dose1 were utilized.

OS, PFS and responder status based on ORR were investigated as efficacy parameters. Safety endpoints included IRRs, imAEs, TEAEs with CTCAE grade ≥ 3, TEAEs leading to tislelizumab treatment discontinuation or dose modification and serious TEAEs.

In the exposure-efficacy analysis, KM plots for OS and PFS stratified by Cavg,dose1 quartiles did not show any consistent trend and predicted exposures of patients were similar between responders vs nonresponders. These results suggest the absence of a relationship between exposure and efficacy within the exposure range evaluated. Further Cox regression model of OS suggested no statistically significant relationship between exposure and OS.

No clinically relevant E-R relationship was observed between tislelizumab exposure and the safety endpoints of the probability of any TEAE grade ≥ 3, immune-mediated AEs, TEAEs leading to treatment discontinuation, TEAEs leading to dose modification, AESI, and serious TEAEs.

## 2.3.5. Conclusions on clinical pharmacology

Pharmacokinetics and pharmacodynamics of tislelizumab have been sufficiently characterized. Results from the pivotal study BGB-A317-312 supporting this application for extension of indication are consistent with the analyses provided in preceding applications.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

The approved fixed dose regimen of 200 mg IV Q3W was used for tislelizumab in the pivotal study. No additional dose selection studies were performed for this submission.

<div style=\"page-break-after: always\"></div>

## 2.4.2. Main study

## BGB-A317-312 study

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Etoposide With or Without Tislelizumab (BGB-A317) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

## Methods

## Figure 19 BGB-A317-312 - Study Design

<!-- image -->

Cross-over was not allowed.

Regular safety monitoring and the planned interim analysis was performed by an IDMC.

Tumour response was investigator assessed, per RECIST v1.1. Tumour imaging was performed within 28 days before randomization, every 6 weeks (± 7 days) during the first 48 weeks, and every 9 weeks (± 7 days) thereafter. Tumour assessment continued until radiographic disease progression was confirmed by investigator per RECIST v1.1. Baseline brain imaging was mandatory for all screened patients.

During the maintenance treatment period, prophylactic cranial irradiation was permitted as per local standard of care.

## Study participants

## Key inclusion criteria:

1. Age ≥ 18 years on the day of signing informed consent
2. Histologically or cytologically confirmed ES-SCLC (defined by the AJCC, 7 th  Ed, as Stage IV [T any, N any, M 1a/b] or T3-4 due to multiple lung nodules that were too extensive or had tumor/nodal volume that was too large to be encompassed in a tolerable radiation plan)
3. No prior systemic treatment for ES-SCLC
- Patients who received prior chemoradiotherapy for LS-SCLC must have been treated with curative intent and experienced a treatmentfree interval of ≥ 6 months between the completion of chemotherapy, radiotherapy, or chemoradiotherapy and diagnosis of ES-SCLC.
4. ECOG Performance Status score ≥ 1
5. Adequate organ function as indicated by the following laboratory values obtained ≤ 7 days before randomization:
7. -Absolute neutrophil count ≥ 1. 5 x 10 9 /L
8. -Platelets ≥ 100 x 10 9 /L

<div style=\"page-break-after: always\"></div>

- -Hemoglobin ≥ 90 g/L.
- -INR or PT ≤ 1.5 x ULN, aPTT ≤ 1.5 x ULN
- -Serum total bilirubin ≤ 1.5 x ULN (total bilirubin must be &lt; 3 x ULN for patients with Gilberts syndrome)
- -AST and ALT ≤ 2.5 x ULN or AST and ALT ≤ 5 x ULN for patients with liver metastases
- -Creatinine clearance ≥ 60 mL/min for cisplatin or ≥ 45 mL/min for carboplatin
6. Willing to use highly effective method of birth control through ≥ 120 days after the last dose of study treatment
7. Life expectancy ≥ 12 weeks

## Key exclusion criteria:

1. Received prior therapy with an antibody or drug against immune checkpoint pathways including but not limited to anti-PD-1, anti-PD-L1, or anti-CTLA
2. Treatment with systemic immune-stimulating agents within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to randomization
3. Any condition that requires systemic treatment with either corticosteroids (&gt; 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before randomization
4. Was administered a live vaccine ≤ 4 weeks before randomization
5. Active leptomeningeal disease or uncontrolled, untreated brain metastasis

Note : Patients with new asymptomatic CNS metastases detected at the screening scan must have received radiation therapy and/or surgery for CNS metastases

6. Active autoimmune diseases or history of autoimmune diseases that might have relapsed
7. With a history of interstitial lung disease, noninfectious pneumonitis, or uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, acute lung diseases, etc.
8. Severe chronic or active infections requiring systemic antibacterial, antifungal, or antiviral therapy within 2 weeks before randomization
9. Clinically significant pericardial effusion
10. Clinically uncontrolled pleural effusion or ascites that requires pleurocentesis or abdominal tapping for drainage within 2 weeks before randomization
11. With significant cardiovascular risk factors

<div style=\"page-break-after: always\"></div>

## Treatments

## Table 15 Selection and Timing of Dose for Each Patient

| Study drug              | Dose      | Frequency of administration                                           | Route of administration   |
|-------------------------|-----------|-----------------------------------------------------------------------|---------------------------|
| Tislelizumab or placebo | 200 mg    | Day 1 of each 21-day cycle                                            | Intravenous infusion      |
| Carboplatin             | AUC 5     | Day 1 of each 21-day cycle during induction treatment period          | Intravenous infusion      |
| Cisplatin               | 75 mg/m²  | Day 1 of each 21-day cycle during induction treatment period          | Intravenous infusion      |
| Etoposide               | 100 mg/m² | Day 1 to Day 3 of each 21-day cycle during induction treatment period | Intravenous infusion      |

Chemotherapy was given for 4 cycles (i.e., induction treatment period).

The choice of platinum (cisplatin or carboplatin) was at the investigator's discretion and determined prior to randomization.

Administration of cisplatin, carboplatin, and etoposide was to be in accordance with relevant local guidelines, package insert/summary of product characteristics (SmPC).

The initial infusion of tislelizumab (Cycle 1, Day 1) was delivered over 60 minutes; if this was well tolerated, then the subsequent infusions could be administered over 30 minutes.

Treatment continued until disease progression as assessed by the investigator per RECIST v1.1, loss of clinical benefit, unacceptable toxicity, or withdrawal of informed consent, whichever occurred first.

Treatment beyond investigator assessed disease progression was permitted until progressive disease was confirmed by repeated imaging ≥ 4 weeks if the patient was expected to benefit from continued treatment in the investigator's judgement and with agreement by the medical monitor.

## Objectives

## Primary Objective

To evaluate the efficacy of tislelizumab + cisplatin or carboplatin + etoposide compared with placebo + cisplatin or carboplatin + etoposide in the Intent-to-Treat (ITT) Analysis Set as measured by overall survival (OS)

## Secondary Objectives

- To evaluate investigator-assessed progression-free survival ( PFS ) according to RECIST v1.1 in the ITT Analysis Set
- To evaluate investigator-assessed overall response rate ( ORR ), duration of response ( DOR ) and disease control rate ( DCR) according to RECIST 1.1
- To evaluate patients' health-related quality of life (HRQoL) according to the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life (QoL) Questionnaire - Core 30 (QLQ-C30) and the supplemental lung cancer module (QLQ-LC13)
- To evaluate the safety and tolerability profile of tislelizumab in combination with cisplatin or carboplatin and etoposide compared with cisplatin or carboplatin and etoposide or placebo plus chemotherapy

<div style=\"page-break-after: always\"></div>

## Exploratory efficacy Objectives

- To assess PFS after next line of treatment ( PFS2 )
- To explore potential predictive biomarkers in archival and/or fresh tumor tissue and/or blood (or blood derivatives), including but not limited to PD-L1 expression

## Outcomes/endpoints

## Primary endpoint

The primary efficacy endpoints for this study was OS in the ITT Analysis Sets, defined as the time from randomization to death from any cause.

## Secondary endpoints

- PFS was defined as the time from the randomization date to the first occurrence of disease progression as determined by the investigators using RECIST Version 1.1 or death from any cause, whichever occurred first.
- ORR was defined as the number of patients whose best overall response (BOR) was confirmed complete response (CR) or partial response (PR) divided by the number of randomized patients in each arm. Confirmation of response was required.
- The disease control rate (DCR) was defined as the proportion of patients whose BOR was CR, PR, or stable disease including non-CR/nonPD ≥ 6 weeks.
- The duration of response (DOR) for responders only was defined as progression/death-event-free time counted from the first objective response date to the first documented radiological disease progression date/or death date, whichever occurred first.
- Health-Related Quality of Life was assessed based on descriptive analyses using EORTC QLQ-C30 and EORTC QLQ-LC13:

## Score changes from baseline

Clinically meaningful changes from baseline in the following PRO endpoints to key clinical cycles of Cycle 4 and Cycle 6:

- -GHS and physical functioning as measured by the QLQ-C30
- -Coughing, dysphagia, and chest pain as measured by the QLQ-LC13

## Time to deterioration

Time to deterioration was defined as the time from randomisation to the first occurrence of a worsening score confirmed at the subsequent visit or death from any cause.

The minimum important clinically meaningful worsening was defined as ≥ 10-point change toward worsening in:

- -GHS and physical functioning per the QLQ-C30
- -Coughing and chest pain measured by the QLQ-LC13

## Exploratory endpoints

<div style=\"page-break-after: always\"></div>

PFS2 was defined as the time from the randomisation date to the first documented disease progression on next-line therapy or death from any cause, whichever occurred first. Next-line therapy was defined as the first subsequent treatment initiated after the discontinuation of the study treatment.

## Biomarker Assessments

Per protocol, archival tumor tissue was required to be collected for the purpose of biomarker analysis. If no archival samples were available, a fresh tumor biopsy at screening (within 28 days before randomization) was required, if feasible.

PD-L1 expression levels were evaluated by a central laboratory (Q Squared Solutions, China) using the validated SP263 IHC assay (Ventana Medical Systems, Inc) and the algorithm of TC, IC, and TAP.

## Sample size

The sample size calculation was based on the number of events required to demonstrate the OS superiority of Arm A to Arm B in the ITT Analysis Set. The number of events required to demonstrate efficacy with regard to OS was estimated based on the following assumptions (protocol amendment 1):

Overall survival:

- -Median OS of 12 months in Arm B.
- -At a one-sided α of 0.025, 80% power to detect an OS HR of 0.74 in the ITT Analysis Set.
- -One OS interim analysis was planned in the ITT Analysis Set when approximately 80% of total OS events occurred, with Lan-DeMets approximation to O'Brien-Fleming boundary.
- -Exponential survival distribution is assumed for both Arm A and Arm B.

In addition, the MAH assumed a randomization ratio of 1:1. Assuming approximately 455 patients were planned to be enrolled over a 22-month period at a steady-state enrolment rate of 26 patients per month with enrolment ramp-up duration of 9 months, and assuming a dropout rate of 5% per year for OS endpoints, a total of 353 OS events were considered required for the ITT Analysis Set for the final OS analysis.

Initially, it was planned to enrol 364 patients to observe a total of 266 OS events, the expected median survival in the control arm and Hazard Ratio were updated in amendment 1 (median OS updated from 10.5 months to 12 months, HR changed from 0.7 to 0.74), and the significance level was increased from 0.02 to 0.025 when PFS was no longer considered primary.

## Randomisation

Patients were planned to be randomized in a 1:1 ratio using the IRT system for this study by permuted block stratified randomization with stratification factors of ECOG Performance Status (0 versus 1), investigator-chosen chemotherapy (carboplatin versus cisplatin), and brain metastasis (yes versus no).

## Blinding (masking)

In this double-blinded, placebo-controlled study, all patients and personnel involved in the conduct and interpretation of the study, including the investigators, BeiGene study team, and site personnel, were planned to be blinded to the treatment assignment. Randomization data was planned to be kept strictly confidential; filed securely by the appropriate groups for BeiGene, the IRT and the IDMC; and was planned to be accessible only to authorized persons per SOPs until the time of unblinding.

<div style=\"page-break-after: always\"></div>

## Statistical methods

## Analysis Set

The ITT Analysis Set was planned to include all randomized patients. Patients were planned to be analyzed according to their randomized treatment arms. This was planned to be the primary Analysis Set for all efficacy analysis.

## Significance level and multiplicity considerations

The primary endpoint OS was planned to be tested at the one-sided significance level α=0.025. Initially PFS and OS were planned as dual primary endpoints with an alpha-split to control for multiplicity. This was amended in Amendment 1, 02 Sept 2020, OS was made the single primary endpoint and PFS was moved to secondary.

Type-I-error control across secondary endpoints was not defined in the study protocol. In a separate SAP, it was specified to test PFS hierarchically after OS, at full one-sided level α=0.025.

## Primary efficacy analyses

OS was defined as the time from randomization until death from any cause. OS was planned to be analyzed in the ITT Analysis Set. Data for patients who are not reported as having died at the time of analysis was planned to be censored at the date last known to be alive. Data for patients who do not have postbaseline information was planned to be censored at the date of randomization.

OS was planned to be compared between tislelizumab + cisplatin or carboplatin + etoposide (Arm A) and placebo + cisplatin or carboplatin + etoposide (Arm B) in a stratified log-rank test using a onesided significance level of 0.025:

The null hypothesis to be tested was:

## H0: OS in Arm A ≤ OS in Arm B

against the alternative hypothesis:

Ha: OS in Arm A &gt; OS in Arm B

The p-value from a stratified log-rank tests was planned to be presented using stratification factors with actual values as recorded in the electronic data capture (EDC) system at randomization. The HR for OS between the 2 arms and its 95% CI was planned to be estimated using a stratified Cox regression model with treatment arm as a factor and stratified by the actual value of the stratification factors. The median OS and the cumulative probability of OS at 1 year and 2 years, if estimable, were planned to be calculated for each treatment arm and presented with two-sided 95% CI using KaplanMeier methodology. A Kaplan-Meier curve was planned to be constructed to provide a visual description of the difference among arms.

## Secondary efficacy analyses

PFS was defined as the time from randomization until the first documented disease progression as assessed by the investigator with the use of RECIST v1.1, or death from any cause, whichever occurs first. PFS was planned to be analyzed in the ITT Analysis Set. The actual tumor assessment visit date was planned to be used to calculate PFS. Data for patients without disease progression or death at the time of analysis was planned to be censored at the time of the last valid tumor assessment. Data for patients without postbaseline tumor assessment was planned to be censored at the time of randomization. Data for patients who start to receive new anticancer therapy or are lost to follow-up was planned to be censored at the last valid tumor assessment date prior to the introduction of new therapy or loss to follow-up.

<div style=\"page-break-after: always\"></div>

Patients who have a clinical determination of progression were expected to undergo radiographic imaging as required by RECIST v1.1, if possible, to correlate radiographic findings with the clinical findings. If a clinical determination of progression for a patient is confirmed, the date of the radiographic imaging scan was planned to be considered as the progression date for that patient.

The HR for PFS was planned to be estimated using a stratified Cox regression model with treatment arm as a factor and stratified by the actual value of the stratification factors. The 95% CI for the HR was planned to be provided. Kaplan-Meier methodology was planned to be used to estimate the median PFS and cumulative probabilities of PFS at 6 months and 1 year, and a Kaplan-Meier curve was planned to be constructed to provide a visual description of the difference among arms.

## Interim analyses

An interim efficacy analysis of OS was planned to be performed in the ITT Analysis Set. The interim efficacy analysis of OS was planned be performed with at least 282 OS events observed in the ITT Analysis Set. The primary OS analysis was planned to be conducted with 353 OS events.

The interim boundary for OS was based on the Lan-DeMets approximation to O'Brien-Fleming boundary. The interim and final analysis timing, and stopping boundaries are summarized in Table below. As the exact timing of the analysis depends on when at least 282 OS events have occurred, the stopping boundaries were expected to be updated based on the actual OS events observed in the ITT Analysis Set at the time of interim analysis.

Table 16 Analysis Timing and Stopping Boundaries for OS in the ITT Analysis Set

|                  |               |          | One-Sided Testing Boundary   | One-Sided Testing Boundary   |
|------------------|---------------|----------|------------------------------|------------------------------|
| Type of Analysis | Time (Months) | # Events | p-Value Boundary             | Approx. HR Threshold         |
| Interim Analysis | 36            | 282      | 0.0122                       | 0.765                        |
| Final analysis   | 51            | 353      | 0.0214                       | 0.806                        |

Abbreviations: HR, hazard ratio; ITT, Intent-to-Treat; OS, overall survival

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

## Figure 20 Disposition of patients (Final Analysis, 19 April 2023 Cutoff)

<!-- image -->

A total of 215 patients (32%) did not meet the screening criteria. The most common reason for screening failures was not meeting the eligibility criteria (n=165; 77% of screen failures) and withdrawal by subject (n=47; 22% of screen failures).

Table 17 Patient Disposition and Reasons for Discontinuation (ITT Analysis Set) - Study 312 (Final Analysis, 19 April 2023 Cutoff)

|                                                | Tislelizumab + Chemotherapy (N = 227) n (%)   | Placebo + Chemotherapy (N = 230) n (%)   | Total (N = 457) n (%)   |
|------------------------------------------------|-----------------------------------------------|------------------------------------------|-------------------------|
| Number of Patients Randomized                  | 227 (100.0)                                   | 230 (100.0)                              | 457 (100.0)             |
| Number of Patients Randomized, but Not Treated | 0 (0.0)                                       | 1 (0.4)                                  | 1 (0.2)                 |
| Number of Patients Treated                     | 227 (100.0)                                   | 229 (99.6)                               | 456 (99.8)              |
| Number of Patients Discontinued from Treatment | 203 (89.4)                                    | 224 (97.4)                               | 427 (93.4)              |
| Reason for Discontinuation a                   |                                               |                                          |                         |
| Progressive Disease                            | 126 (55.5)                                    | 166 (72.2)                               | 292 (63.9)              |

<div style=\"page-break-after: always\"></div>

|                                            | Tislelizumab + Chemotherapy (N = 227) n (%)   | Placebo + Chemotherapy (N = 230) n (%)   | Total (N = 457) n (%)   |
|--------------------------------------------|-----------------------------------------------|------------------------------------------|-------------------------|
| Physician Decision                         | 30 (13.2)                                     | 38 (16.5)                                | 68 (14.9)               |
| Loss of Clinical Benefit                   | 27 (11.9)                                     | 35 (15.2)                                | 62 (13.6)               |
| Other                                      | 3 (1.3)                                       | 3 (1.3)                                  | 6 (1.3)                 |
| Adverse Event                              | 28 (12.3)                                     | 5 (2.2)                                  | 33 (7.2)                |
| Withdrawal by Subject                      | 17 (7.5)                                      | 15 (6.5)                                 | 32 (7.0)                |
| Other                                      | 2 (0.9)                                       | 0 (0.0)                                  | 2 (0.4)                 |
| Number of Patients Remained on Treatment   | 24 (10.6)                                     | 5 (2.2)                                  | 29 (6.3)                |
| Number of Patients Discontinued from Study | 168 (74.0)                                    | 198 (86.1)                               | 366 (80.1)              |
| Reason for Discontinuation                 |                                               |                                          |                         |
| Death                                      | 165 (72.7)                                    | 192 (83.5)                               | 357 (78.1)              |
| Withdrawal by Subject                      | 1 (0.4)                                       | 4 (1.7)                                  | 5 (1.1)                 |
| Lost to Follow-up                          | 2 (0.9)                                       | 2 (0.9)                                  | 4 (0.9)                 |
| Number of Patients Remained in Study       | 59 (26.0)                                     | 32 (13.9)                                | 91 (19.9)               |
| Study Follow-up Time (Months) b            |                                               |                                          |                         |
| N                                          | 227                                           | 230                                      | 457                     |
| Mean (SD)                                  | 17.65 (10.699)                                | 15.48 (9.272)                            | 16.56 (10.054)          |
| Median                                     | 15.44                                         | 13.22                                    | 14.16                   |
| Q1, Q3                                     | 8.87, 26.05                                   | 8.15, 22.51                              | 8.57, 25.30             |
| Min, Max                                   | 0.2, 44.9                                     | 0.1, 40.8                                | 0.1, 44.9               |

Data cutoff: 19Apr2023. Data extraction: 07Sep2023.

Percentages are based on number of patients randomized.

a  Reason for treatment discontinuation is the reason for discontinuation from the last component.

b  Study follow-up time is defined as the time from the randomization date to the death date or end of study date (whichever occurs first) for patients discontinued from the study, or the database cutoff date for ongoing patients.

As of the study end date (29 December 2023):

- -All treated patients discontinued all study treatment. The most frequent reason for discontinuation of treatment was due to progressive disease, which occurred in a higher proportion of patients in Arm P+C (72.2%) than Arm T+C (55.9%).

Treatment discontinuation due to adverse events occurred in a higher proportion of patients in Arm T+C (12.3%) than Arm P+C (2.2%).

- -All patients discontinued from study, and death was the most common primary reason for study discontinuation, with a lower incidence in Arm T+C (77.1% versus 85.2% in Arm P+C).

## Recruitment

The study enrolled 457 subjects across 51 sites in China.

The first patient was randomized on 22 July 2019; the last patient was randomized on 21 April 2021.

The data cutoff date of the final analysis (FA) is 19 April 2023 (database lock: 07 September 2023).

The study was unblinded on 17 May 2023. The database was unlocked and relocked for the study FA (data cutoff date of 19 April 2023) update on 07 September 2023 because of the logistics challenges in

<div style=\"page-break-after: always\"></div>

death certificate collection, further verification of death dates was conducted and corrected as required.

The clinical trial is completed, the clinical trial end date is 29 December 2023.

## Conduct of the study

## Protocol amendments

The original global protocol for this study was dated 28 Jan 2019. The protocol was amended once before the data cutoff date.

At the time of this protocol amendment, 252 patients had been randomized.

Amendment Version 1.0 (02 Sept 2020) (excerpt)

- Changed investigator-assessed PFS from a primary endpoint to a secondary endpoint because PFS was not proven to be a convincing surrogate endpoint for OS in ES-SCLC after consultation with the local health authority and taking competitor's data as a reference
- Updated the statistical assumptions for OS and sample size consideration and increased the sample size from N= 364 to N=455 patients

Rationale : The analyses of external data drove the updates in HR and median OS. Considering the delayed treatment effect and updated HR assumption, the OS events number at both interim and final analysis were updated.

- o One-sided α=0.025 was allocated to OS (instead of 0.02, with 0.005 allocated to PFS);
- o Median OS of Arm B was updated from 10.5 months to 12 months;
- o HR assumption was adjusted from 0.7 to 0.74;
- o Increased the number and timing for the interim analysis and the final analysis:

For the IA, the required OS events changed from 189 to 282 events, the expected time of analysis changed from 23 to 36 months.

For the FA, the required OS events changed from 266 to 353, the expected time of analysis changed from 36 months to 51 months;

- o Enrolment period was updated to 22 months with steady enrolment rate being 26 patients per month, and the enrolment ramp-up period was updated to 9 months
- Added patients' QoL as measured by EQ-5D-5L to exploratory analyses
- Revised inclusion criterion to allow the enrolment of patients who received local palliative therapy for metastasis lesion; new: 'no prior systemic treatment for ES-SCLC'
- Shortened the duration between receiving systemic immune-stimulating treatment and randomization in the exclusion criterion to read 'Treatment with systemic immune-stimulating agents … within 4 weeks or 5 half-lives of the drug, whichever is shorter' instead of 'whichever is longer'
- Removed the requirement of measurable disease outside of the CNS
- Updated the protocol with new data from IMpower133, CASPIAN, and Keynote-604 to further support the rationale of combining immune checkpoint inhibitors to chemotherapy as treatment option for SCLC

<div style=\"page-break-after: always\"></div>

## Protocol deviations

Table 18 Summary of Important Protocol Deviations (ITT Analysis Set)

| Category Subcategory                            | Tislelizumab + Chemotherapy (N = 227) n (%)   | Placebo + Chemotherapy (N = 230) n (%)   | Total (N = 457) n (%)   |
|-------------------------------------------------|-----------------------------------------------|------------------------------------------|-------------------------|
| Patients With Any Important Protocol Deviations | 47 (20.7)                                     | 30 (13.0)                                | 77 (16.8)               |
| Protocol Compliance                             | 30 (13.2)                                     | 22 (9.6)                                 | 52 (11.4)               |
| Study assessments & procedures                  | 19 (8.4)                                      | 11 (4.8)                                 | 30 (6.6)                |
| Prohibitive medication or treatment             | 4 (1.8)                                       | 4 (1.7)                                  | 8 (1.8)                 |
| Inclusion / exclusion                           | 2 (0.9)                                       | 3 (1.3)                                  | 5 (1.1)                 |
| Maintaining study blind                         | 2 (0.9)                                       | 3 (1.3)                                  | 5 (1.1)                 |
| Visit compliance                                | 2 (0.9)                                       | 2 (0.9)                                  | 4 (0.9)                 |
| Randomization/ stratification                   | 3 (1.3)                                       | 0 (0.0)                                  | 3 (0.7)                 |
| Safety                                          | 8 (3.5)                                       | 5 (2.2)                                  | 13 (2.8)                |
| Safety reporting (sponsor, IRB/IEC)             | 7 (3.1)                                       | 5 (2.2)                                  | 12 (2.6)                |
| AE/SAE follow-up                                | 2 (0.9)                                       | 0 (0.0)                                  | 2 (0.4)                 |
| Investigational Product                         | 9 (4.0)                                       | 2 (0.9)                                  | 11 (2.4)                |
| Dosing & administration                         | 7 (3.1)                                       | 2 (0.9)                                  | 9 (2.0)                 |
| Dosing compliance                               | 2 (0.9)                                       | 0 (0.0)                                  | 2 (0.4)                 |
| Informed Consent                                | 5 (2.2)                                       | 3 (1.3)                                  | 8 (1.8)                 |
| Timing of consent                               | 4 (1.8)                                       | 3 (1.3)                                  | 7 (1.5)                 |
| Version                                         | 1 (0.4)                                       | 0 (0.0)                                  | 1 (0.2)                 |

Data cutoff: 19Apr2023. Data extraction: 07Sep2023.

Patients with multiple important protocol deviations in each category/subcategory were counted only once at the category/subcategory level.

Events were sorted by decreasing frequency of category and subcategory in the 'Total' column.

In the ITT Analysis Set, 3 patients (0.7%) were identified as having 1 critical protocol deviation each (1 patient in Arm A and 2 patients in Arm B). Critical protocol deviations are a subset of important protocol deviations that significantly impact efficacy and safety analyses. All critical protocol deviations identified were related to key inclusion/exclusion criteria including baseline brain metastasis status, creatinine clearance limits, and disease stage, which were judged to have significant impact to the analyses.

## Changes in the planned analyses due to the COVID-19 Pandemic

The conduct of Study 312 continued during the COVID-19 pandemic, from the end of January 2020 throughout the data cutoff date of 19 April 2023, where a total of 364 patients were enrolled as of 21 April 2021. Contingency measures were developed in line with local and global regulatory guidance to maintain patient safety and study integrity.

Two patients (0.4%; 1 patient in each arm) discontinued from treatment and two patients (1 patient in each arm) discontinued from study due to death or other reasons related to COVID-19.

In Arm A, 45 patients (19.8%), 4 patients (1.8%), 4 patients (1.8%), and 9 patients (4.0%) had a delayed dose of tislelizumab, carboplatin, cisplatin, and etoposide, respectively, because of COVID-19; In Arm B, 26 patients (11.4%), 6 patients (2.6%), 5 patients (2.2%), and 11 patients (4.8%) had a delayed dose of placebo, carboplatin, cisplatin, and etoposide, respectively, because of COVID-19; no patients had dose interruption of tislelizumab/placebo or dose interruption or reduction of any chemotherapy agents, because of COVID-19 in Arm A or Arm B.

<div style=\"page-break-after: always\"></div>

Due to COVID19 related restrictions, ≥ 1 missed tumour assessment were reported in 12 patients (5.3%) in Arm A and 8 patients (3.5%) in Arm B, which were reported as protocol deviations for the study.

Important protocol deviations caused by COVID-19 related restrictions were identified in 12 patients (5.3%) in Arm A and 3 patients (1.3%) in Arm B (mostly due to delayed study assessments and procedures). None were deemed critical.

No delayed SAE reporting was identified to be due to the COVID-19 pandemic.

A total of 14 patients (11 patients [4.8%] in Arm A and 3 patients [1.3%] in Arm B]) experienced ≥ 1 AE related to COVID-19. Among these 14 patients, 1 patient in Arm A experienced a serious adverse event of COVID-19 pneumonia.

Overall, the COVID-19 pandemic did not significantly impact the safety and efficacy results of the study and did not significantly impact the ability of investigational sites to monitor and manage patient safety during the conduct of the study.

## Baseline data

## Table 19 Summary of Demographics and Baseline Characteristics (ITT Analysis Set) - Study 312 (Final Analysis, 19 April 2023 Cutoff)

|                        | Tislelizumab + Chemotherapy (N = 227) n (%)   | Placebo + Chemotherapy (N = 230) n (%)   | Total (N = 457) n (%)   |
|------------------------|-----------------------------------------------|------------------------------------------|-------------------------|
| Age (Years)            |                                               |                                          |                         |
| n                      | 227                                           | 230                                      | 457                     |
| Mean (SD)              | 61.5 (7.75)                                   | 60.7 (8.25)                              | 61.1 (8.01)             |
| Median                 | 63.0                                          | 62.0                                     | 62.0                    |
| Q1, Q3                 | 56.0, 66.0                                    | 55.0, 67.0                               | 56.0, 67.0              |
| Min, Max               | 31, 78                                        | 34, 78                                   | 31, 78                  |
| Age Group, n (%)       |                                               |                                          |                         |
| < 65 Years             | 138 (60.8)                                    | 149 (64.8)                               | 287 (62.8)              |
| >= 65 Years            | 89 (39.2)                                     | 81 (35.2)                                | 170 (37.2)              |
| 65 - 74 Years          | 81 (35.7)                                     | 78 (33.9)                                | 159 (34.8)              |
| >= 75 Years            | 8 (3.5)                                       | 3 (1.3)                                  | 11 (2.4)                |
| Sex, n (%)             |                                               |                                          |                         |
| Male                   | 186 (81.9)                                    | 186 (80.9)                               | 372 (81.4)              |
| Female                 | 41 (18.1)                                     | 44 (19.1)                                | 85 (18.6)               |
| Race, n (%)            |                                               |                                          |                         |
| Asian                  | 227 (100.0)                                   | 230 (100.0)                              | 457 (100.0)             |
| Ethnicity, n (%)       |                                               |                                          |                         |
| Not Hispanic or Latino | 227 (100.0)                                   | 230 (100.0)                              | 457 (100.0)             |
| Weight (kg)            |                                               |                                          |                         |
| n                      | 227                                           | 230                                      | 457                     |
| Mean (SD)              | 64.58 (10.043)                                | 63.98 (10.702)                           | 64.28 (10.373)          |
| Median                 | 64.00                                         | 63.00                                    | 63.00                   |
| Q1, Q3                 | 57.50, 70.00                                  | 56.00, 70.00                             | 57.00, 70.00            |
| Min, Max               | 43.0, 96.0                                    | 43.0, 109.0                              | 43.0, 109.0             |
| Height (m)             |                                               |                                          |                         |
| n                      | 227                                           | 230                                      | 457                     |
| Mean (SD)              | 1.65 (0.073)                                  | 1.65 (0.074)                             | 1.65 (0.073)            |

<div style=\"page-break-after: always\"></div>

|                       | Tislelizumab + Chemotherapy (N = 227) n (%)   | Placebo + Chemotherapy (N = 230) n (%)   | Total (N = 457) n (%)   |
|-----------------------|-----------------------------------------------|------------------------------------------|-------------------------|
| Median                | 1.66                                          | 1.66                                     | 1.66                    |
| Q1, Q3                | 1.61, 1.70                                    | 1.61, 1.70                               | 1.61, 1.70              |
| Min, Max              | 1.4, 1.8                                      | 1.5, 1.8                                 | 1.4, 1.8                |
| BMI (kg/m^2)          |                                               |                                          |                         |
| n                     | 227                                           | 230                                      | 457                     |
| Mean (SD)             | 23.56 (3.139)                                 | 23.34 (3.219)                            | 23.45 (3.178)           |
| Median                | 23.63                                         | 23.19                                    | 23.44                   |
| Q1, Q3                | 21.11, 25.39                                  | 20.96, 25.10                             | 21.08, 25.32            |
| Min, Max              | 16.7, 36.6                                    | 16.1, 33.6                               | 16.1, 36.6              |
| Smoking Status, n (%) |                                               |                                          |                         |
| Never                 | 53 (23.3)                                     | 59 (25.7)                                | 112 (24.5)              |
| Current               | 151 (66.5)                                    | 135 (58.7)                               | 286 (62.6)              |
| Former                | 23 (10.1)                                     | 36 (15.7)                                | 59 (12.9)               |
| Baseline LDH, n (%)   |                                               |                                          |                         |
| <= ULN                | 114 (50.2)                                    | 109 (47.4)                               | 223 (48.8)              |
| > ULN                 | 113 (49.8)                                    | 121 (52.6)                               | 234 (51.2)              |

Data cutoff: 19Apr2023. Data extraction: 07Sep2023.

Abbreviations: BMI, body mass index.

Baseline is defined as the last non-missing value collected before or on randomization.

Table 20 Summary of Randomization Stratification Factors per Electronic Case Report Form (ITT Analysis Set) - Study 312 (Final Analysis, 19 April 2023 Cutoff)

| Randomization Stratum   | Tislelizumab + Chemotherapy (N = 227) n (%)   | Placebo + Chemotherapy (N = 230) n (%)   | Total (N = 457) n (%)   |
|-------------------------|-----------------------------------------------|------------------------------------------|-------------------------|
| ECOG Performance        |                                               |                                          |                         |
| 0                       | 35 (15.4)                                     | 34 (14.8)                                | 69 (15.1)               |
| 1                       | 192 (84.6)                                    | 196 (85.2)                               | 388 (84.9)              |
| Brain Metastases        |                                               |                                          |                         |
| Yes                     | 1 (0.4)                                       | 4 (1.7)                                  | 5 (1.1)                 |
| No                      | 226 (99.6)                                    | 226 (98.3)                               | 452 (98.9)              |
| Chemotherapy            |                                               |                                          |                         |
| Cisplatin               | 47 (20.7)                                     | 49 (21.3)                                | 96 (21.0)               |
| Carboplatin             | 180 (79.3)                                    | 181 (78.7)                               | 361 (79.0)              |

## Table 21 Disease History (ITT Analysis Set) - Study 312 (Final Analysis, 19 April 2023 Cutoff)

|                                                       | Tislelizumab + Chemotherapy (N = 227) n (%)   | Placebo + Chemotherapy (N = 230) n (%)   | Total (N = 457) n (%)   |
|-------------------------------------------------------|-----------------------------------------------|------------------------------------------|-------------------------|
| Time from Initial Diagnosis to Study Entry (Months) a |                                               |                                          |                         |
| N                                                     | 227                                           | 230                                      | 457                     |
| Mean (SD)                                             | 1.08 (3.064)                                  | 2.02 (6.284)                             | 1.55 (4.970)            |
| Median                                                | 0.59                                          | 0.59                                     | 0.59                    |
| Q1, Q3                                                | 0.43, 0.85                                    | 0.39, 0.82                               | 0.39, 0.82              |

<div style=\"page-break-after: always\"></div>

|                                                               | Tislelizumab + Chemotherapy (N = 227) n (%)   | Placebo + Chemotherapy (N = 230) n (%)   | Total (N = 457) n (%)   |
|---------------------------------------------------------------|-----------------------------------------------|------------------------------------------|-------------------------|
| Min, Max                                                      | 0.1, 34.9                                     | 0.1, 56.7                                | 0.1, 56.7               |
| Time from Extensive-Stage Diagnosis to Study Entry (Months) a |                                               |                                          |                         |
| N                                                             | 227                                           | 230                                      | 457                     |
| Mean (SD)                                                     | 0.67 (0.471)                                  | 0.71 (1.162)                             | 0.69 (0.888)            |
| Median                                                        | 0.59                                          | 0.56                                     | 0.56                    |
| Q1, Q3                                                        | 0.39, 0.85                                    | 0.39, 0.76                               | 0.39, 0.79              |
| Min, Max                                                      | 0.1, 5.1                                      | 0.1, 16.8                                | 0.1, 16.8               |
| Stage at Initial Diagnosis, n (%)                             |                                               |                                          |                         |
| Limited-Stage Disease                                         | 5 (2.2)                                       | 12 (5.2)                                 | 17 (3.7)                |
| Extensive-Stage Disease                                       | 222 (97.8)                                    | 218 (94.8)                               | 440 (96.3)              |
| AJCC Staging at Study Entry, n (%) a                          |                                               |                                          |                         |
| IIIA                                                          | 4 (1.8)                                       | 2 (0.9)                                  | 6 (1.3)                 |
| IIIB                                                          | 16 (7.0)                                      | 27 (11.7)                                | 43 (9.4)                |
| IV                                                            | 207 (91.2)                                    | 201 (87.4)                               | 408 (89.3)              |
| Distant Metastatic Site(s), n (%) b                           |                                               |                                          |                         |
| Liver                                                         | 64 (28.2)                                     | 59 (25.7)                                | 123 (26.9)              |
| Lung                                                          | 32 (14.1)                                     | 59 (25.7)                                | 91 (19.9)               |
| Brain                                                         | 1 (0.4)                                       | 4 (1.7)                                  | 5 (1.1)                 |
| Lymph nodes                                                   | 48 (21.1)                                     | 45 (19.6)                                | 93 (20.4)               |
| Number of Metastatic Sites, n (%)                             |                                               |                                          |                         |
| 1                                                             | 2 (0.9)                                       | 2 (0.9)                                  | 4 (0.9)                 |
| 2                                                             | 42 (18.5)                                     | 64 (27.8)                                | 106 (23.2)              |
| >= 3                                                          | 183 (80.6)                                    | 164 (71.3)                               | 347 (75.9)              |
| Target Lesion Sum of Diameter (mm)                            |                                               |                                          |                         |
| N                                                             | 227                                           | 228                                      | 455                     |
| Mean (SD)                                                     | 110.27 (49.417)                               | 101.70 (47.121)                          | 105.98 (48.417)         |
| Median                                                        | 104.30                                        | 94.00                                    | 99.40                   |
| Q1, Q3                                                        | 78.70, 137.00                                 | 66.00, 133.90                            | 69.00, 135.20           |
| Min, Max                                                      | 16.9, 293.0                                   | 12.0, 243.3                              | 12.0, 293.0             |

Data cutoff: 19Apr2023. Data extraction: 07Sep2023. AJCC staging was based on 7th version.

a Study entry date is randomization date. b A patient could have multiple metastatic sites.

## Prior anti-cancer therapies

All of the 17 patients with initial diagnosis of LS-SCLC received ≥ 1 prior anticancer drug therapy. Of these, 2 patients received surgery with curative intent and 3 patients with palliative intent. 15 patients also received prior radiotherapy with curative intent. Nine patients received prophylactic cranial irradiation.

<div style=\"page-break-after: always\"></div>

## Numbers analysed

## Table 22 Analysis Sets (ITT Analysis Set) - Study 312 (Final Analysis, 19 April 2023 Cutoff)

| Analysis Set                   | Tislelizumab + Chemotherapy (N = 227) n (%)   | Placebo + Chemotherapy (N = 230) n (%)   | Total (N = 457) n (%)   |
|--------------------------------|-----------------------------------------------|------------------------------------------|-------------------------|
| Intent-to-Treat Analysis Set a | 227 (100.0)                                   | 230 (100.0)                              | 457 (100.0)             |
| HRQoL Analysis Set b           | 227 (100.0)                                   | 229 (99.6)                               | 456 (99.8)              |
| PD-L1 Analysis Set c           | 60 (26.4)                                     | 65 (28.3)                                | 125 (27.4)              |

a  The Intent-to-Treat Analysis Set includes all randomized patients.

b  The HRQoL analysis set includes all randomized patients who received any dose of study drug and completed at least one HRQoL assessment.

c  The PD-L1 analysis set includes all randomized patients whose baseline PD-L1 expression was assessed and evaluable.

## Outcomes and estimation

## Primary endpoint OS

One prespecified interim analysis of OS was performed after 292 OS events occurred (data cutoff date: 05 May 2022); the study continued without modifications in a double-blinded manner as recommended by the Independent Data Monitoring Committee.

## OS at final analysis

The primary efficacy evaluation is based on the final analysis (DCO 19 April 2023) with a minimum study follow-up time of 23.9 months (defined as time from last patient randomized to the data cutoff date).

Study 312 met its primary endpoint of OS in favour of tislelizumab plus chemotherapy over placebo plus chemotherapy; the stratified OS HR was 0.75 (95% CI: 0.61 to 0.93, 1 sided p value from log rank test = 0.0040). The one-sided p-value boundary was 0.0211 for the FA.

<div style=\"page-break-after: always\"></div>

Table 23 Overall Survival (Efficacy Analysis Set) - Study 312 (Final Analysis, 19 April 2023 Cutoff)

|                                              | Tislelizumab + Chemotherapy (N = 227)   | Placebo + Chemotherapy (N = 230)   |
|----------------------------------------------|-----------------------------------------|------------------------------------|
| Overall Survival                             |                                         |                                    |
| Death, n (%)                                 | 165 (72.7)                              | 191 (83.0)                         |
| Censored, n (%)                              | 62 (27.3)                               | 39 (17.0)                          |
| Lost to Follow-up                            | 2 (0.9)                                 | 2 (0.9)                            |
| Withdrew Consent                             | 1 (0.4)                                 | 4 (1.7)                            |
| Ongoing Without Events                       | 59 (26.0)                               | 32 (13.9)                          |
| Other Reason                                 | 0 (0.0)                                 | 1 (0.4)                            |
| One-Sided Stratified Log-rank Test p-Value a | 0.0040                                  | --                                 |
| Stratified Hazard Ratio (95% CI) ab          | 0.75 (0.61, 0.93)                       | --                                 |
| Unstratified Hazard Ratio (95% CI) b         | 0.75 (0.61, 0.93)                       | --                                 |
| Overall Survival (Months) c                  |                                         |                                    |
| Median (95% CI)                              | 15.5 (13.5, 17.1)                       | 13.5 (12.1, 14.9)                  |
| Overall Survival Rate at, %(95% CI) d        |                                         |                                    |
| 3 Months                                     | 93.4 (89.2, 95.9)                       | 97.4 (94.2, 98.8)                  |
| 6 Months                                     | 87.6 (82.6, 91.3)                       | 87.2 (82.1, 90.9)                  |
| 9 Months                                     | 73.8 (67.6, 79.1)                       | 73.0 (66.7, 78.3)                  |
| 12 Months                                    | 62.7 (56.1, 68.7)                       | 58.4 (51.7, 64.5)                  |
| 18 Months                                    | 43.1 (36.6, 49.5)                       | 34.5 (28.4, 40.7)                  |
| 24 Months                                    | 33.2 (27.1, 39.4)                       | 22.4 (17.2, 28.0)                  |
| Follow-up Time (Months) e                    |                                         |                                    |
| Median (95% CI)                              | 31.2 (28.6, 32.3)                       | 31.9 (27.8, 32.9)                  |

Data cutoff: 19Apr2023. Data extraction: 07Sep2023.

Abbreviations: NE, not estimable. CI, confidence interval. Percentages were based on N.

a Stratified by ECOG performance (1 vs 0) and platinum (Carboplatin vs Cisplatin).

b Hazard ratio and 95% CIs were estimated using a Cox regression model with placebo + chemotherapy as the reference group.

c Medians and other quartiles were estimated by the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method with log-log transformation.

d Overall survival rates were estimated using the Kaplan-Meier method with 95% CIs estimated using the Greenwood formula.

e Median was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method. Patient was with unknown death date and censored at last known alive date for overall survival analysis.

Figure 21 KM Plot for Overall Survival (ITT Analysis Set) - Study 312 (Final Analysis, 19 April 2023 Cutoff)

<!-- image -->

Abbreviations: ARM A, Tislelizumab + Chemotherapy; ARM B, Placebo + Chemotherapy.

<div style=\"page-break-after: always\"></div>

Both log-rank and Cox regression model were stratified by ECOG performance (1 vs 0) and platinum (Carboplatin vs Cisplatin). P-value is one sided and is based on the stratified log rank test.

## Updated OS results

Updated efficacy data with an additional 8.3 months of follow-up, using the data cutoff of 29 December 2023 (database lock: 06 February 2024), were provided as additional efficacy data (minimum study follow-up time of 32.3 months).

Table 24 Overall Survival (Efficacy Analysis Set) - Study 312 (Updated Analysis, 29 Dec 2023 Cutoff)

|                                       | Tislelizumab + Chemotherapy (N = 227)   | Placebo + Chemotherapy (N = 230)   |
|---------------------------------------|-----------------------------------------|------------------------------------|
| Overall Survival                      |                                         |                                    |
| Death, n (%)                          | 175 (77.1)                              | 195 (84.8)                         |
| Censored, n (%)                       | 52 (22.9)                               | 35 (15.2)                          |
| Lost to Follow-up                     | 2 (0.9)                                 | 2 (0.9)                            |
| Withdrew Consent                      | 1 (0.4)                                 | 6 (2.6)                            |
| Ongoing Without Events                | 49 (21.6)                               | 26 (11.3)                          |
| Other Reason                          | 0 (0.0)                                 | 1 (0.4)                            |
| Stratified Hazard Ratio (95% CI) ab   | 0.78 (0.63, 0.95)                       | --                                 |
| Unstratified Hazard Ratio (95% CI) b  | 0.78 (0.63, 0.95)                       | --                                 |
| Overall Survival (Months) c           |                                         |                                    |
| Median (95% CI)                       | 15.5 (13.5, 17.1)                       | 13.5 (12.1, 14.9)                  |
| Overall Survival Rate at, %(95% CI) d |                                         |                                    |
| 36 Months                             | 22.1 (16.8, 27.9)                       | 13.1 (9.0, 18.1)                   |
| Follow-up Time (Months) e             |                                         |                                    |
| Median (95% CI)                       | 39.8 (36.2, 41.4)                       | 36.4 (35.0, 40.9)                  |

Abbreviations: NE, not estimable. CI, confidence interval.

Percentages were based on N.

a Stratified by ECOG performance (1 vs 0) and platinum (Carboplatin vs Cisplatin).

b Hazard ratio and 95% CIs were estimated using a Cox regression model with placebo + chemotherapy as the reference group.

c Medians and other quartiles were estimated by the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method with log-log transformation.

d Overall survival rates were estimated using the Kaplan-Meier method with 95% CIs estimated using the Greenwood formula.

e Median was estimated by the reverse Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method.

Source: Table 14.2.1.1.1; Data extraction: 06Feb2024

<div style=\"page-break-after: always\"></div>

Figure 22 KM Plot for Overall Survival (ITT) - Study 312 (updated Analysis, 29 Dec 2023 Cutoff)

<!-- image -->

## Secondary endpoints

- PFS (INV-assessed)

## PFS at final analysis

Since OS met statistical significance at the FA, the full 1-sided α of 0.025 was passed to the hypothesis testing of PFS in the ITT Analysis Set. The PFS in Arm T+C was statistically significant improved compared to Arm P+C, with a 1-sided stratified log-r ank test p value &lt; 0.0001; the one -sided p-value boundary was 0.025 (as specified in the SAP).

<div style=\"page-break-after: always\"></div>

Table 25 Progression-Free Survival (ITT Analysis Set) - Study 312 (Final Analysis, 19 April 2023 Cutoff)

|                                              | Tislelizumab + Chemotherapy (N = 227)   | Placebo + Chemotherapy (N = 230)   |
|----------------------------------------------|-----------------------------------------|------------------------------------|
| Events, n (%)                                | 176 (77.5)                              | 207 (90.0)                         |
| Progressive Disease                          | 162 (71.4)                              | 201 (87.4)                         |
| Death                                        | 14 (6.2)                                | 6 (2.6)                            |
| Censored, n (%)                              | 51 (22.5)                               | 23 (10.0)                          |
| No Post-baseline                             | 5 (2.2)                                 | 9 (3.9)                            |
| New Anticancer Therapy                       | 8 (3.5)                                 | 4 (1.7)                            |
| Missed >= 2 Consecutive Assessments          | 11 (4.8)                                | 4 (1.7)                            |
| Withdrew Consent                             | 0 (0.0)                                 | 1 (0.4)                            |
| Ongoing Without Events                       | 27 (11.9)                               | 5 (2.2)                            |
| One-Sided Stratified Log-rank Test p-Value a | <0.0001                                 | --                                 |
| Stratified Hazard Ratio (95% CI) ab          | 0.64 (0.52, 0.78)                       | --                                 |
| Unstratified Hazard Ratio (95% CI) b         | 0.63 (0.52, 0.78)                       | --                                 |
| Progression-Free Survival (Months) c         |                                         |                                    |
| Median (95% CI)                              | 4.7 (4.3, 5.5)                          | 4.3 (4.2, 4.4)                     |
| Q1 (95% CI)                                  | 4.0 (3.1, 4.1)                          | 4.0 (3.8, 4.1)                     |
| Q3 (95% CI)                                  | 8.5 (7.0, 13.7)                         | 5.7 (5.6, 5.7)                     |
| Event-Free Rate at, %(95% CI) d              |                                         |                                    |
| 3 Months                                     | 81.4 (75.6, 86.0)                       | 86.7 (81.5, 90.6)                  |
| 6 Months                                     | 35.3 (28.8, 41.8)                       | 17.7 (12.9, 23.1)                  |
| 9 Months                                     | 24.2 (18.6, 30.3)                       | 6.5 (3.7, 10.4)                    |
| 12 Months                                    | 20.6 (15.3, 26.4)                       | 4.5 (2.2, 8.0)                     |
| 18 Months                                    | 16.1 (11.4, 21.6)                       | 2.5 (0.9, 5.4)                     |

a Stratified by ECOG performance (1 vs 0) and platinum (Carboplatin vs Cisplatin).

b Hazard ratio and 95% CIs were estimated using a Cox regression model with placebo + chemotherapy as the reference group.

c Medians and other quartiles were estimated by the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method with log-log transformation.

d Event free rates were estimated using the Kaplan-Meier method with 95% CIs estimated using the Greenwood formula.

Figure 23 Kaplan-Meier Plot for PFS (ITT Analysis Set) - Study 312 (Final Analysis, 19 April 2023 Cutoff)

<!-- image -->

Abbreviations: ARM A, Tislelizumab + Chemotherapy; ARM B, Placebo + Chemotherapy. Both log-rank and Cox regression model were stratified by ECOG performance (1 vs 0) and platinum (Carboplatin vs Cisplatin). P-value is one sided and is based on the stratified log rank test.

<div style=\"page-break-after: always\"></div>

## Updated PFS results

Table 26 Progression-Free Survival (ITT Analysis Set) - Study 312 (Updated Analysis, 29 Dec 2023 Cutoff)

|                                     | Tislelizumab + Chemotherapy (N = 227)   | Placebo + Chemotherapy (N = 230)   |
|-------------------------------------|-----------------------------------------|------------------------------------|
| Progression - Free Survival         |                                         |                                    |
| Events, n (%)                       | 178 (78.4)                              | 207 (90.0)                         |
| Progressive Disease                 | 164 (72.2)                              | 201 (87.4)                         |
| Death                               | 14 (6.2)                                | 6 (2.6)                            |
| Stratified Hazard Ratio (95% CI) ab | 0.65 (0.53, 0.80)                       | --                                 |
| Median (months) (95% CI)            | 4.7 (4.3, 5.5)                          | 4.3 (4.2, 4.4)                     |

a Stratified by ECOG performance (1 vs 0) and platinum (Carboplatin vs Cisplatin).

b Hazard ratio and 95% CIs were estimated using a Cox regression model with placebo + chemotherapy as the reference group.

c Medians and other quartiles were estimated by the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method with log-log transformation.

Source: Excerpt from Table 14.2.2.1 SCE Appendix 1

Figure 24 KM for PFS (ITT) (Updated Analysis, 29 Dec 2023 Cutoff)

<!-- image -->

Both log-rank and Cox regression model were stratified by ECOG performance (1 vs 0) and platinum (Carboplatin vs Cisplatin). P-value is one sided and is based on the stratified log rank test. Source: Figure 14.2.2.1.1 SCE-Appendix 1

- Disease response, DOR (INV-assessed)

Table 27 Analysis of Disease Response with Confirmation (ITT) (FA)

|                              | Tislelizumab + Chemotherapy (N = 227)   | Placebo + Chemotherapy (N = 230)   |
|------------------------------|-----------------------------------------|------------------------------------|
| Best Overall Response, n (%) |                                         |                                    |
| Complete Response            | 1 (0.4)                                 | 0 (0.0)                            |
| Partial Response             | 154 (67.8)                              | 142 (61.7)                         |
| Stable Disease               | 46 (20.3)                               | 60 (26.1)                          |
| Non-CR/Non-PD                | 0 (0.0)                                 | 1 (0.4)                            |
| Progressive Disease          | 11 (4.8)                                | 15 (6.5)                           |
| Could Not Be Determined      | 15 (6.6)                                | 12 (5.2)                           |
| Not Evaluable a              | 1 (0.4)                                 | 0 (0.0)                            |
| Not Assessable b             | 14 (6.2)                                | 12 (5.2)                           |
| Overall Response Rate, n (%) | 155 (68.3)                              | 142 (61.7)                         |
| 95% CI (%) c                 | 61.8, 74.3                              | 55.1, 68.0                         |
| Odds Ratio (95% CI) d        | 1.33 (0.90, 1.96)                       | --                                 |
| Risk Difference, %(95% CI)   | 6.3 (-2.4, 15.0)                        | --                                 |

<div style=\"page-break-after: always\"></div>

|                                | Tislelizumab + Chemotherapy (N = 227)   | Placebo + Chemotherapy (N = 230)   |
|--------------------------------|-----------------------------------------|------------------------------------|
| Disease Control Rate, n (%)    | 201 (88.5)                              | 203 (88.3)                         |
| 95% CI (%) c                   | 83.7, 92.4                              | 83.4, 92.1                         |
| Clinical Benefit Rate, n (%) e | 157 (69.2)                              | 150 (65.2)                         |
| 95% CI (%) c                   | 62.7, 75.1                              | 58.7, 71.4                         |

Abbreviations: CR, complete response; PD, progressive disease; SD, stable disease; CI, confidence interval. Complete response and partial response were confirmed per RECIST v1.1.

a Patients who had &gt;=1 post-baseline tumour assessment, none of which were evaluable for response determination (e.g., not all target lesions captured). Not evaluable is based on RECIST 1.1.

b Patients with no post-baseline tumour assessment by the data cutoff, including those who discontinued study (any reason) or died without having any post-baseline tumour assessment.

c The 95% CI was estimated using the Clopper-Pearson method.

d Odds ratio was calculated using Cochran-Mantel-Haenszel estimates and stratified by ECOG performance (1 vs 0) and platinum (Carboplatin vs Cisplatin).

e Durable SD (SD with duration &gt;=24 weeks) was included.

At the updated DCO (29 Dec 2023), 2 more patients in Arm T+C had complete response compared with FA; other results were the same.

Table 28 Duration of Response with Confirmation (ITT) (FA)

|                                     | Tislelizumab + Chemotherapy (N = 227)   | Placebo + Chemotherapy (N = 230)   |
|-------------------------------------|-----------------------------------------|------------------------------------|
| Number of Responders                | 155                                     | 142                                |
| Duration of Response                |                                         |                                    |
| Events, n (%)                       | 118 (76.1)                              | 134 (94.4)                         |
| Progressive Disease                 | 116 (74.8)                              | 134 (94.4)                         |
| Death                               | 2 (1.3)                                 | 0 (0.0)                            |
| Censored, n (%)                     | 37 (23.9)                               | 8 (5.6)                            |
| New Anticancer Therapy              | 5 (3.2)                                 | 3 (2.1)                            |
| Missed >= 2 Consecutive Assessments | 5 (3.2)                                 | 0 (0.0)                            |
| Ongoing Without Events              | 27 (17.4)                               | 5 (3.5)                            |
| Duration of Response (Months) a     |                                         |                                    |
| Median (95% CI)                     | 4.3 (4.1, 5.6)                          | 3.7 (3.0, 4.1)                     |

Only patients with best overall response of complete response or partial response confirmed per RECIST v1.1 were included in the analysis, and percentages were based on the number of responders.

a Medians and other quartiles were estimated using the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method with log-log transformation.

<div style=\"page-break-after: always\"></div>

Figure 25 Kaplan-Meier Plot for Duration of Response with Confirmation (ITT Analysis Set) Study 312 (Final Analysis, 19 April 2023 Cutoff)

45

<!-- image -->

Median DOR remained unchanged with the updated DCO (29 Dec 2023).

## · Health-Related Quality of Life

Health-Related Quality of Life was assessed based on descriptive analyses using EORTC QLQ-C30 and EORTC QLQ-LC13.

Adjusted compliance rates (defined as the proportion of questionnaires actually received divided by the patients still in treatment) were 100% in both treatment arms at baseline and key clinical cycles (ie, Cycle 4 and Cycle 6).

Baseline scores in EORTC QLQ-C30 and QLQ-LC13 domains were similar in both arms.

## Changes from baseline

Descriptive analysis was performed for all the scales and single items of the PRO questionnaires in all cycles.

A mixed effect model analysis for measuring the magnitude of differences in changes between the two arms postbaseline was performed on the selected prespecified PRO endpoints (global health status [GHS] and physical function in QLQ-C30, coughing, dysphagia, and chest pain in QLQ-LC13) at the key preselected clinical cycles of 4 and 6 to assess the changes from baseline to the key clinical cycles and to assess the differences in change between the arms. The model included baseline score, stratification factors, treatment arm, visit, and treatment arm by visit interaction as fixed effects and visit as a repeated measure with an unstructured covariance structure.

- Score change from baseline by Cycle 6

<div style=\"page-break-after: always\"></div>

Table 29 Summary of the mean changes in scores from baseline to Cycle 6 (assessor's table):

| Questionnaire/ Parameter - Mean change (standard deviation)   | Tislelizumab + Chemotherapy   | Placebo + Chemotherapy   |
|---------------------------------------------------------------|-------------------------------|--------------------------|
| EORTC QLQ-C30                                                 |                               |                          |
| GHS (Global Health Status)/QoL                                | 11.3 [21.30]                  | 4.2 [19.04]              |
| Physical functioning                                          | 1.9 [15.18]                   | 1.8 [12.36]              |
| EORTC QLQ-LC13                                                |                               |                          |
| Coughing                                                      | -18.6 [27.86]                 | -16.7 [25.08]            |
| Dysphagia                                                     | -2.9 [11.47]                  | -3.5 [15.23]             |
| Chest pain                                                    | -7.0 [25.34]                  | -6.9 [21.51]             |

· Least square mean changes from baseline by cycle 6 (based on the mixed-effects model analysis)

## Table 30 Summary of Least Square (LS) Mean Changes From Baseline (95% CI) from baseline to Cycle 6 (assessor's table):

| Questionnaire/ Parameter - LS Mean Score change from baseline (95% CI)   | Tislelizumab + Chemotherapy   | Placebo + Chemotherapy   |
|--------------------------------------------------------------------------|-------------------------------|--------------------------|
| EORTC QLQ-C30                                                            |                               |                          |
| GHS (Global Health Status)/QoL                                           | 8.92 (6.10, 11.73)            | 4.71 (1.92, 7.51)        |
| Physical functioning                                                     | 1.33 (-0.56, 3.21)            | 1.75 (-0.13, 3.62)       |
| EORTC QLQ-LC13                                                           |                               |                          |
| Coughing                                                                 | -17.39 (-20.84, -13.95)       | -17.18 (-20.57, -13.79)  |
| Dysphagia                                                                | -3.54 (-5.05, -2.04)          | -3.01 (-4.49, -1.54)     |
| Chest pain                                                               | -8.14 (-10.89, -5.39)         | -5.33 (-8.04, -2.63)     |
| Haemoptysis                                                              | -6.42 (-7.44, -5.41)          | -5.85 (-6.86, -4.85)     |
| Dyspnoea                                                                 | -6.23 (-8.57, -3.89)          | -5.94 (-8.25, -3.63)     |

## Time to Deterioration

The minimum important clinically meaningful worsening was defined as a ≥ 10-point change toward worsening, i.e., decrease of ≥ 10 points in GHS and physical functioning scales and increase of ≥ 10 points in the symptom scales from baseline. The median time to deterioration of the selected PRO endpoints (physical function in QLQ-C30; coughing and chest pain in QLQ-LC13) were calculated using Kaplan-Meier estimates and presented with 2-sided 95% CIs. A relatively low proportion (approximately 16% to 26%) of the patients experienced a deterioration event (i.e., ≥ 10 -point change from baseline), and the median time to deterioration was not reached for all the prespecified HRQoL parameters.

The results showed that patients in both arms were at similar risk of worsening of

- physical functioning:

HR of 0.92 [95% CI: 0.642 to 1.330],

- coughing:

HR of 0.73 [95% CI: 0.473 to 1.123], or

- chest pain:

HR of 0.72 [95% CI: 0.485 to 1.057].

<div style=\"page-break-after: always\"></div>

## Exploratory endpoint

## · PFS2

Table 31 Analysis of PFS after Next-Line of Treatment (PFS2) (ITT) (FA)

|                                                           | Tislelizumab + Chemotherapy (N = 227)   | Placebo + Chemotherapy (N = 230)   |
|-----------------------------------------------------------|-----------------------------------------|------------------------------------|
| Events, n (%)                                             | 155 (68.3)                              | 169 (73.5)                         |
| Second Progressive Disease                                | 58 (25.6)                               | 65 (28.3)                          |
| Death                                                     | 97 (42.7)                               | 104 (45.2)                         |
| Censored, n (%)                                           | 72 (31.7)                               | 61 (26.5)                          |
| Second New Anticancer Therapy Without PD on the First One | 24 (10.6)                               | 39 (17.0)                          |
| Lost to Follow-up                                         | 2 (0.9)                                 | 0 (0.0)                            |
| Withdrew Consent                                          | 1 (0.4)                                 | 4 (1.7)                            |
| Ongoing Without Events                                    | 45 (19.8)                               | 18 (7.8)                           |
| Stratified Hazard Ratio (95% CI) ab                       | 0.71 (0.57, 0.89)                       | --                                 |
| Unstratified Hazard Ratio (95% CI) b                      | 0.72 (0.57, 0.89)                       | --                                 |
| PFS2 (Months) c                                           |                                         |                                    |
| Median (95% CI)                                           | 13.1 (11.1, 15.1)                       | 11.0 (10.0, 12.2)                  |
| Q1 (95% CI)                                               | 8.0 (6.5, 8.8)                          | 7.3 (6.5, 7.9)                     |
| Q3 (95% CI)                                               | 25.6 (20.9, NE)                         | 17.0 (14.7, 20.1)                  |
| PFS2 Rate at, %(95% CI) d                                 |                                         |                                    |
| 12 Months                                                 | 54.0 (46.9, 60.5)                       | 45.0 (38.0, 51.8)                  |
| 18 Months                                                 | 36.3 (29.7, 43.0)                       | 23.1 (17.3, 29.4)                  |
| 24 Months                                                 | 29.5 (23.2, 35.9)                       | 15.0 (10.1, 20.7)                  |

Abbreviations: NE, not estimable. CI, confidence interval.

Percentages were based on N.

a Stratified by ECOG performance (1 vs 0) and platinum (Carboplatin vs Cisplatin).

b Hazard ratio and its 95% CI were estimated from Cox model with placebo + chemotherapy as the reference group.

c Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

d Event-free rates were estimated using the Kaplan-Meier method with 95% CIs estimated using the Greenwood formula.

Figure 26 Kaplan-Meier Plot for Progression-Free Survival after Next-Line of Treatment (PFS2) (ITT Analysis Set) - Study 312 (Final Analysis, 19 April 2023 Cutoff)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

## · OS additional analyses

Subgroup analysis

Figure 27 Forest Plot for Overall Survival (ITT) (FA)

| Subgroup                     | Event/Total ARMA           | Event/Total ARMB   | Median (95% CI) ARMA   | Median (95% CI) ARMB   | Hazard Ratio for Death (95% CI)   | Hazard Ratio (95% CI)   |
|------------------------------|----------------------------|--------------------|------------------------|------------------------|-----------------------------------|-------------------------|
|                              |                            |                    |                        |                        | 1                                 |                         |
| Overall                      | 165/227                    | 191/230            | 15.5 (13.5, 17.1)      | 13.5 (12.1, 14.9)      |                                   | 0.75 (0.61, 0.93)       |
| Age Group                    |                            |                    |                        |                        |                                   |                         |
| <65 years                    | 98/138                     | 122/149            | 15.6 (12.8, 19.4)      | 14.3 (12.4, 15.7)      |                                   | 0.76 (0.58, 0.99)       |
| >= 65 years                  | 67/89                      | 69/81              | 15.4 (12.2, 20.5)      | 12.4 (10.9, 14.0)      |                                   | 0.74 (0.53, 1.03)       |
| Sex                          |                            |                    |                        |                        |                                   |                         |
| Male                         | 136/186                    | 153/186            | 15.4 (13.4, 17.1)      | 13.2 (12.1, 14.7)      |                                   | 0.76 (0.61, 0.96)       |
| Female                       | 29/41                      | 38/44              | 16.5 (11.0, 24.2)      | 15.4 (9.4, 18.8)       |                                   | 0.69 (0.42, 1.12)       |
| ECOGPerformanceStatus        |                            |                    |                        |                        |                                   |                         |
| 0                            | 23/35                      | 27/34              | 17.1 (13.4, 24.2)      | 15.3 (11.0, 26.2)      |                                   | 0.74 (0.42, 1.29)       |
| 1                            | 142/192                    | 164/196            | 15.2 (12.6, 17.0)      | 13.3 (12.0, 14.9)      |                                   | 0.76 (0.60, 0.95)       |
| BrainMetastasis              |                            |                    |                        |                        |                                   |                         |
| No                           | 164/226                    | 187/226            | 15.5 (13.4, 17.1)      | 13.5 (12.1, 14.9)      |                                   | 0.76 (0.61, 0.94)       |
| ChoiceofPlatinum             |                            |                    |                        |                        |                                   |                         |
| Cisplatin                    | 35/47                      | 42/49              | 15.2 (12.3, 17.1)      | 13.7 (11.4, 18.0)      |                                   | 0.81 (0.51, 1.26)       |
| Carboplatin                  | 130/180                    | 149/181            | 15.6 (13.2, 19.4)      | 13.3 (12.0, 15.2)      |                                   | 0.74 (0.59, 0.94)       |
| Liver Metastases at Baseline |                            |                    |                        |                        |                                   |                         |
| Yes                          | 54/64                      | 56/59              | 11.9 (9.7, 13.6)       | 10.6 (7.9, 11.3)       |                                   | 0.65 (0.44,0.95)        |
| No                           | 111/163                    | 135/171            | 18.2 (15.6, 22.8)      | 14.9 (13.3, 17.2)      |                                   | 0.76 (0.59, 0.98)       |
| Baseline LDH                 |                            |                    |                        |                        |                                   |                         |
| <= ULN                       | 79/114                     | 88/109             | 18.2 (15.4, 21.3)      | 15.7 (14.0, 18.4)      |                                   | 0.73 (0.54, 0.99)       |
| >ULN                         | 86/113                     | 103/121            | 12.2 (10.3, 15.5)      | 11.8 (10.5, 13.2)      |                                   | 0.80 (0.60, 1.06)       |
| Smoking Status               |                            |                    |                        |                        |                                   |                         |
| Never                        | 36/53                      | 48/59              | 19.7 (12.5, 24.2)      | 15.4 (11.4, 17.7)      |                                   | 0.70 (0.45, 1.08)       |
| Smoker                       | 129/174                    | 143/171            | 15.2 (12.8, 17.0)      | 13.0 (11.8, 14.7)      |                                   | 0.77 (0.60, 0.97)       |
| AJCC Staging at StudyEntry   | AJCC Staging at StudyEntry |                    |                        |                        |                                   |                         |
| Ⅲ                            | 11/20                      | 21/29              | 26.7 (15.4, NE)        | 15.4 (13.2, 26.2)      |                                   | 0.62 (0.30,1.29)        |
| IV                           | 154/207                    | 170/201            | 15.1 (12.6, 17.0)      | 12.8 (11.4, 14.3)      |                                   | 0.75 (0.60, 0.93)       |

0.0

0.5

1.0

1.5

2.0

←ARMAARMB→

## Abbreviations: ARM A, Tislelizumab + Chemotherapy; ARM B, Placebo + Chemotherapy.

Hazard ratio and its 95% CIs were estimated using an unstratified Cox regression model.

Medians in months were estimated by the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method with log-log transformation.

Number of metastatic sites at baseline was added as a post hoc subgroup considering the observed imbalance between arms at baseline. Results showed unstratified HRs of 0.58 (95% CI: 0.36 to 0.95) and 0.75 (95% CI: 0.60 to 0.95) for subgroups of &lt; 3 metasta tic sites and ≥ 3 metastatic sites, respectively.

Sensitivity and Supplementary Analyses of OS

Table 32 Overview of Sensitivity and Supplementary Analyses for OS (ITT Analysis Set) Study 312 (Final Analysis, 19 April 2023 Cutoff)

| Analysis                                                           | Summary statistics               |
|--------------------------------------------------------------------|----------------------------------|
| Primary analysis                                                   | HR = 0.75 (95% CI: 0.61 to 0.93) |
| Sensitivity analyses                                               | Sensitivity analyses             |
| 1. Unstratified OS analysis a                                      | HR = 0.75 (95% CI: 0.61 to 0.93) |
| 2. OS analysis with stratification factors recorded from the IRT b | HR = 0.75 (95% CI: 0.61 to 0.93) |

<div style=\"page-break-after: always\"></div>

| Analysis                                                                                                                    | Summary statistics                                                                   |
|-----------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| Supplementary analyses                                                                                                      | Supplementary analyses                                                               |
| 1. OS analysis accounting for possible nonproportional HR effect based on the restricted mean survival time (RMST) method c | 3.2-month difference in OS restricted mean survival time (95% CI: 0.9 to 5.5 months) |
| 2. OS analysis adjusted for baseline covariates (liver metastasis, LDH, and smoking status)                                 | HR = 0.72 (95% CI: 0.58 to 0.89)                                                     |
| 3. OS analysis adjusted for baseline covariates (post hoc, includes number of metastatic sites besides prespecified ones)   | HR = 0.71 (95% CI: 0.57 to 0.87)                                                     |

Abbreviations: IRT, interactive response technology; HR, hazard ratio; LDH, lactate dehydrogenase; OS, overall survival; RMST, restricted mean survival time.

a Unstratified OS sensitivity analysis: Hazard ratio was estimated from unstratified Cox model

b Stratified by ECOG performance (1 vs 0) and platinum (carboplatin vs cisplatin) per IRT

c Difference in RMST is calculated as difference of area under the curve from baseline to the minimum of the largest observed time on each of the 2 treatment groups. Source: SCE Table 10

Note regarding sensitivity analysis 2: In the 2 systems (EDC and IRT), a total of 2 patients had different records of ECOG PS, and 1 patient had different records of brain metastasis. These differences were due to data entry errors in the IRT.

Note regarding supplementary analysis 3: Between-arms imbalance was observed for number of metastatic sites at study entry (see disease characteristics). Therefore, the number of metastatic sites, categorized by &lt; 3 and ≥ 3, was added as another covariate to be adjusted upon the predefined baseline covariates (liver metastasis, LDH, and smoking status).

Exploratory analyses of early OS data

Table 33 Summary of Deaths by Time Interval (Safety Analysis Set)

| Category                     | Tislelizumab + Chemotherapy (N = 227) n (%)   | Placebo + Chemotherapy (N = 229) n (%)   |
|------------------------------|-----------------------------------------------|------------------------------------------|
| Total Number of Deaths       | 165 (72.7)                                    | 192 (83.8)                               |
| Primary Cause of Death       |                                               |                                          |
| Disease Under Study          | 150 (66.1)                                    | 183 (79.9)                               |
| Adverse Event                | 8 (3.5)                                       | 0 (0.0)                                  |
| Other                        | 7 (3.1)                                       | 9 (3.9)                                  |
| Death Within 3 Months        | 15 (6.6)                                      | 6 (2.6)                                  |
| Primary Cause of Death       |                                               |                                          |
| Disease Under Study          | 9 (4.0)                                       | 6 (2.6)                                  |
| Adverse Event                | 6 (2.6)                                       | 0 (0.0)                                  |
| Other                        | 0 (0.0)                                       | 0 (0.0)                                  |
| Death Between 3 and 6 Months | 13 (5.7)                                      | 23 (10.0)                                |
| Primary Cause of Death       |                                               |                                          |
| Disease Under Study          | 12 (5.3)                                      | 21 (9.2)                                 |
| Adverse Event                | 0 (0.0)                                       | 0 (0.0)                                  |
| Other                        | 1 (0.4)                                       | 2 (0.9)                                  |

Data cutoff: 19Apr2023. Data extraction: 07Sep2023

<div style=\"page-break-after: always\"></div>

Table 34 Baseline Disease Characteristics for Patients who Died within 3 Months vs All Population ITT Analysis Set

|                                      | Tislelizumab + Chemotherapy for death<3months (N =15) n (%)   | Tislelizumab + Chemotherapy (N = 227) n (%)   | Placebo + Chemotherapy for death<3months (N=6) n (%)   | Placebo + Chemotherapy (N = 230) n (%)   |
|--------------------------------------|---------------------------------------------------------------|-----------------------------------------------|--------------------------------------------------------|------------------------------------------|
| ECOG Performance, n (%)              |                                                               |                                               |                                                        |                                          |
| 0                                    | 1 (6.7)                                                       | 35 (15.4)                                     | 1 (16.7)                                               | 34 (14.8)                                |
| 1                                    | 14 (93.3)                                                     | 192 (84.6)                                    | 5 (83.3)                                               | 196 (85.2)                               |
| Stage at Initial Diagnosis, n (%)    |                                                               |                                               |                                                        |                                          |
| Limited-Stage Disease                | 0 (0.0)                                                       | 5 (2.2)                                       | 0 (0.0)                                                | 12 (5.2)                                 |
| Extensive-Stage Disease              | 15 (100.0)                                                    | 222 (97.8)                                    | 6 (100.0)                                              | 218 (94.8)                               |
| AJCC Staging at Study Entry, n (%) a |                                                               |                                               |                                                        |                                          |
| IIIA                                 | 0 (0.0)                                                       | 4 (1.8)                                       | 0 (0.0)                                                | 2 (0.9)                                  |
| IIB                                  | 0 (0.0)                                                       | 16 (7.0)                                      | 0 (0.0)                                                | 27 (11.7)                                |
| IV                                   | 15 (100.0)                                                    | 207 (91.2)                                    | 6 (100.0)                                              | 201 (87.4)                               |
| Number of Metastatic Sites, n (%)    |                                                               |                                               |                                                        |                                          |
| 1                                    | 0 (0.0)                                                       | 2 (0.9)                                       | 0 (0.0)                                                | 2 (0.9)                                  |
| 2                                    | 1 (6.7)                                                       | 42 (18.5)                                     | 1 (16.7)                                               | 64 (27.8)                                |
| >=3                                  | 14 (93.3)                                                     | 183 (80.6)                                    | 5 (83.3)                                               | 164 (71.3)                               |
| Target Lesion Sum of Diameter (mm)   |                                                               |                                               |                                                        |                                          |
| n                                    | 15                                                            | 227                                           | 6                                                      | 228                                      |
| Mean (SD)                            | 109.61 (52.942)                                               | 110.27 (49.417)                               | 140.98 (52.398)                                        | 101.70 (47.121)                          |
| Median                               | 103.80                                                        | 104.30                                        | 121.85                                                 | 94.00                                    |
| Q1, Q3                               | 73.20, 128.30                                                 | 78.70, 137.00                                 | 109.20, 200.00                                         | 66.00, 133.90                            |
| Min, Max                             | 29.7, 226.0                                                   | 16.9,293.0                                    | 81.6, 211.4                                            | 12.0, 243.3                              |
| Baseline LDH, n (%)                  |                                                               |                                               |                                                        |                                          |
| <=ULN                                | 4 (26.7)                                                      | 114 (50.2)                                    | 0 (0.0)                                                | 109 (47.4)                               |
| >ULN                                 | 11 (73.3)                                                     | 113 (49.8)                                    | 6 (100.0)                                              | 121 (52.6)                               |

Source: ADSL, ADBASE. Data cutoff: 19Apr2023. Data extraction: 07Sep2023.

a Study entry date is randomization date.

AJCC staging was based on 7th version.

Posttreatment Subsequent Systemic Anticancer Therapy

Table 35 Summary of Subsequent Systemic Anticancer Therapies (ITT Analysis Set) - Study 312 (Final Analysis, 19 April 2023 Cutoff)

|                                                          | Tislelizumab + Chemotherapy (N = 227) n (%)   | Placebo + Chemotherapy (N = 230) n (%)   | Total (N = 457) n (%)   |
|----------------------------------------------------------|-----------------------------------------------|------------------------------------------|-------------------------|
| Patients with Any Subsequent Systemic Anticancer Therapy | 148 (65.2)                                    | 180 (78.3)                               | 328 (71.8)              |
| Chemotherapy                                             | 124 (54.6)                                    | 155 (67.4)                               | 279 (61.1)              |
| Immunotherapy (PD-(L)1 inhibitors)                       | 43 (18.9)                                     | 53 (23.0)                                | 96 (21.0)               |
| Targeted Therapy                                         | 69 (30.4)                                     | 73 (31.7)                                | 142 (31.1)              |
| Catequentinib                                            | 65 (28.6)                                     | 70 (30.4)                                | 135 (29.5)              |
| Other Therapies                                          | 45 (19.8)                                     | 45 (19.6)                                | 90 (19.7)               |
| Line of Treatment                                        |                                               |                                          |                         |
| Second Line                                              | 148 (65.2)                                    | 180 (78.3)                               | 328 (71.8)              |
| Third Line                                               | 67 (29.5)                                     | 83 (36.1)                                | 150 (32.8)              |
| >Third Line                                              | 21 (9.3)                                      | 34 (14.8)                                | 55 (12.0)               |

Source extract from SCE Table 11

Note : Anlotinib (coded as Catequentinib) is an approved tyrosine kinase inhibitor for treating relapsed SCLC in China.

<div style=\"page-break-after: always\"></div>

Most commonly used drugs among 'other therapies' were traditional Chinese medicines including the Chinese herbal medicines or patent medicines, which were commonly used for auxiliary or supportive treatment for multiple malignant tumours.

## · PFS additional analyses

## Subgroup analysis

Figure 28 Forest Plot for PFS (ITT) (FA)

| Subgroup                     | Event/Total ARMA             | Event/Total ARMB   | Median (95% CI) ARMA   | Median (95% CI) ARMB   | Hazard Ratio for PD (95% CI)   | Hazard Ratio (95% CI)   |
|------------------------------|------------------------------|--------------------|------------------------|------------------------|--------------------------------|-------------------------|
| Overall                      | 176/227                      | 207/230            | 4.7 (4.3, 5.5)         | 4.3 (4.2, 4.4)         | = =                            | 0.63 (0.52, 0.78)       |
| Age Group                    |                              |                    |                        |                        |                                |                         |
| <65years                     | 106/138                      | 138/149            | 4.7 (4.3, 5.6)         | 4.3 (4.2, 4.4)         |                                | 0.59 (0.45, 0.77)       |
| >=65 years                   | 70/89                        | 69/81              | 5.2 (4.3, 5.7)         | 4.4 (4.2, 5.5)         |                                | 0.74 (0.53, 1.05)       |
| Sex                          |                              |                    |                        |                        |                                |                         |
| Male                         | 144/186                      | 165/186            | 4.5 (4.3, 5.5)         | 4.4 (4.3, 4.5)         |                                | 0.70 (0.56, 0.88)       |
| Female                       | 32/41                        | 42/44              | 5.5 (4.3, 6.9)         | 4.2 (4.1, 4.4)         |                                | 0.38 (0.23,0.63)        |
| ECOGPerformanceStatus        |                              |                    |                        |                        |                                |                         |
| 0                            | 28/35                        | 29/34              | 5.2 (4.2, 5.8)         | 4.3 (4.1, 5.7)         |                                | 0.65 (0.39, 1.10)       |
| 1                            | 148/192                      | 178/196            | 4.7 (4.3, 5.5)         | 4.3 (4.2, 4.4)         |                                | 0.63 (0.50, 0.79)       |
| BrainMetastasis No           | 175/226                      | 204/226            | 4.8 (4.3, 5.5)         | 4.3 (4.2, 4.4)         |                                | 0.63 (0.51,0.78)        |
| Choice ofPlatinum            |                              |                    |                        |                        |                                |                         |
| Cisplatin                    | 38/47                        | 43/49              | 4.3 (4.0, 5.2)         | 4.3 (4.1, 4.5)         |                                | 0.75 (0.48, 1.18)       |
| Carboplatin                  | 138/180                      | 164/181            | 5.4 (4.3, 5.6)         | 4.3 (4.2, 4.4)         |                                | 0.61 (0.48, 0.77)       |
| Liver Metastases at Baseline | Liver Metastases at Baseline |                    |                        |                        |                                |                         |
| Yes                          | 52/64                        | 56/59              | 4.2 (4.0, 4.6)         | 4.2 (4.2, 4.4)         |                                | 0.71 (0.48, 1.05)       |
| No                           | 124/163                      | 151/171            | 5.5 (4.4, 5.7)         | 4.4 (4.2, 4.5)         |                                | 0.60 (0.47, 0.77)       |
| Baseline LDH                 |                              |                    |                        |                        |                                |                         |
| <=ULN                        | 91/114                       | 97/109             | 5.2 (4.3, 5.7)         | 4.4 (4.2, 5.0)         |                                | 0.63 (0.47,0.84)        |
| >ULN                         | 85/113                       | 110/121            | 4.4 (4.2, 5.5)         | 4.3 (4.2, 4.4)         |                                | 0.65 (0.48,0.87)        |
| Smoking Status               |                              |                    |                        |                        |                                |                         |
| Never                        | 41/53                        | 55/59              | 5.4 (4.3, 5.7)         | 4.2 (4.2, 4.7)         |                                | 0.50 (0.32, 0.77)       |
| Smoker                       | 135/174                      | 152/171            | 4.7 (4.3, 5.6)         | 4.3 (4.2, 4.5)         |                                | 0.68 (0.53, 0.86)       |
| AJCCStaging at StudyEntry    | AJCCStaging at StudyEntry    |                    |                        |                        |                                |                         |
| Ⅲ                            | 14/20                        | 25/29              | 8.5 (4.3, 14.3)        | 5.7 (4.5, 5.7)         |                                | 0.50 (0.25, 1.00)       |
| IV                           | 162/207                      | 182/201            | 4.6 (4.3, 5.5)         | 4.3 (4.2, 4.4)         |                                | 0.63 (0.50,0.78)        |

0.0

0.5

1.0

1.5

52.0

←ARMAARMB→

Abbreviations: ARM A, Tislelizumab + Chemotherapy; ARM B, Placebo + Chemotherapy.

Hazard ratio and its 95% CIs were estimated using an unstratified Cox regression model.

Medians in months were estimated by the Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method with log-log transformation.

## Supplementary Analyses of PFS (following EMA guideline)

| Analysis                                                                                                                                                                                 | Summary statistics                                                                        |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| Primary analysis                                                                                                                                                                         | strat. HR = 0.64 (95% CI 0.52 to 0.78) median PFS 4.7 (4.3, 5.5) vs 4.3 (4.2, 4.4) months |
| Supplementary analyses                                                                                                                                                                   |                                                                                           |
| 1. Same as primary analysis except that it used actual reported date of progression or death to define PFS regardless of PFS event occurred after more than one missed tumour assessment | strat. HR = 0.64 (95% CI 0.52 to 0.78) median PFS 5.2 (4.4, 5.6) vs 4.3 (4.2, 4.4) months |
| 2. Same as primary analysis except that it used actual reported date of progression or death to define PFS regardless of PFS event occurred after initiation of new anti-cancer therapy. | strat. HR = 0.65 (95% CI 0.53 to 0.80) median PFS 4.7 (4.3, 5.5) vs 4.3 (4.2, 4.4) months |

<div style=\"page-break-after: always\"></div>

## · Meta-Analysis of efficacy by 75 years of age in tislelizumab RCT

All tislelizumab RCTs (RATIONALE 301, 302, 303, 304, 305, 306, 307, 309, 312 and 315) were identified. A meta-analysis was then conducted on the interaction terms for treatment*age, each, derived from unstratified Cox-regression, with inclusion of treatment, age group ( ≥75 vs &lt;75 years old), and treatment by age group interaction term as covariates, in each study.

Table 36 Number of patients and events in tislelizumab RCTs in several indications in different age groups

| Study ID   | Disease Setting   | Treatment Arm               | Enrolled Patients   | Enrolled Patients   | # OS Events   | # OS Events   | #PFS Events   | #PFS Events   |
|------------|-------------------|-----------------------------|---------------------|---------------------|---------------|---------------|---------------|---------------|
| Study ID   | Disease Setting   | Treatment Arm               | <75 years old       | ≥75 years old       | <75 years old | ≥75 years old | <75 years old | ≥75 years old |
|            |                   | Tislelizumab                | 297                 | 45                  | 227           | 32            | 263           | 38            |
|            |                   | Sorafenib                   | 287                 | 45                  | 232           | 40            | 226           | 40            |
| 302        |                   | Tislelizumab                | 242                 | 14                  | 219           | 14            | 216           | 13            |
| 302        |                   | ICC                         | 242                 | 14                  | 219           | 14            | 172           | 9             |
| 303        |                   | Tislelizumab                | 518                 | 17                  | 394           | 15            | 448           | 15            |
| 303        |                   | Docetaxel                   | 258                 | 12                  | 212           | 10            | 200           | 10            |
|            |                   | Tislelizumab +Pem/Plat      | 220                 | 3                   | 143           | 1             | 164           | 1             |
|            |                   | Pem/Plat                    | 108                 | 3                   | 67            | 2             | 87            | 1             |
|            |                   | Tislelizumab + Chemotherapy | 473                 | 28                  | 349           | 21            | 338           | 23            |
|            |                   | Placebo + Chemotherapy      | 467                 | 29                  | 385           | 21            | 374           | 17            |
|            |                   | Tislelizumab + Chemotherapy | 313                 | 13                  | 189           | 7             | 213           | 7             |
|            |                   | Placebo + Chemotherapy      | 298                 | 25                  | 212           | 14            | 236           | 18            |
|            |                   | Tislelizumab + Pac + Carbo  | 119                 | 1                   | 78            | 0             | 89            | 0             |
|            |                   | Pac + Carbo                 | 120                 | 1                   | 86            | 1             | 93            | 1             |
|            |                   | Tislelizumab + Chemotherapy | 219                 | 8                   | 158           | 7             | 171           | 5             |
|            |                   | Placebo + Chemotherapy      | 227                 | 3                   | 188           | 3             | 204           | 3             |
|            |                   | Tislelizumab                | 220                 | 6                   | 30            | 1             | -             | -             |
|            |                   | Placebo                     | 218                 | 9                   | 42            | 3             | -             | -             |

Study RATIONALE 307 was excluded as convergency issue occurred when including the interaction term. All other studies were included for meta-analysis of OS. For meta-analysis of PFS additionally Study RATIONALE 315 was excluded, since analysis of PFS was not an endpoint in this study.

<div style=\"page-break-after: always\"></div>

Figure 29 Results of meta-analysis for assessment of difference in OS benefit between age groups

<!-- image -->

Figure 30 Results of meta-analysis for assessment of difference in PFS benefit between age groups

<!-- image -->

## · PD-L1-subgroup analyses (exploratory endpoint)

PD-L1 expression levels in Study 312 were evaluated centrally using the Ventana SP263 IHC assay and the algorithm of Tumour cells (TC), Immune Cell (IC), and Tumour Area Positivity (TAP). The exploratory PD-L1 subgroup analysis in Study 312 utilized different algorithms since there was no consensus of the optimal PD-L1 scoring algorithm and cutoff for anti-PD-(L)1 therapy in ES-SCLC. The cutoff of 1% explored was selected based on prevalence and commonly used cutoffs from competitor's data (Paz-Ares et al 2024 - durvalumab; Cheng et al 2022 - serplulimab; Liu et al 2021- atezolizumab) .

As of the FA data cutoff date (19 April 2023), a total of 125 patients ( 27.4% of the ITT Analysis Set) were included in the PD-L1 Analysis Set , for whom baseline PD-L1 expression was assessed and evaluable (60 patients in Arm T+C and 65 patients in Arm P+C).

## PD-L1 expression prevalence

Table 37 Summary of PD-L1 Immune Cell (IC), Tumour Cell (TC) and Tumour Area Positivity (TAP) (ITT Analysis Set) - Study 312 (Final Analysis, 19 April 2023 Cutoff)

|                       |           | Number (%) of Patients      | Number (%) of Patients   | Number (%) of Patients   |
|-----------------------|-----------|-----------------------------|--------------------------|--------------------------|
| Subgroup              | Category  | Tislelizumab + Chemotherapy | Placebo + Chemotherapy   | Total                    |
| ITT Analysis Set      |           | 227                         | 230                      | 457                      |
| PD-L1 Analysis Set a  |           | 60 ( 26.4 )                 | 65 ( 28.3 )              | 125 ( 27.4 )             |
| Immune Cells ( IC ) b | 0         | 20 (33.3)                   | 9 (13.8)                 | 29 (23.2)                |
|                       | >0 to <1% | 6 (10.0)                    | 2 (3.1)                  | 8 (6.4)                  |

<div style=\"page-break-after: always\"></div>

|                                 |              | Number (%) of Patients      | Number (%) of Patients   | Number (%) of Patients   |
|---------------------------------|--------------|-----------------------------|--------------------------|--------------------------|
| Subgroup                        | Category     | Tislelizumab + Chemotherapy | Placebo + Chemotherapy   | Total                    |
|                                 | >=1% to <5%  | 9 (15.0)                    | 11 (16.9)                | 20 (16.0)                |
|                                 | >=5% to <50% | 17 (28.3)                   | 26 (40.0)                | 43 (34.4)                |
|                                 | >=50%        | 8 (13.3)                    | 17 (26.2)                | 25 (20.0)                |
|                                 | IC <1%       | 26 (43.3)                   | 11 (16.9)                | 37 ( 29.6 )              |
|                                 | IC >=1%      | 34 (56.7)                   | 54 (83.1)                | 88 ( 70.4 )              |
| Tumor Cells ( TC ) b            | 0            | 44 (73.3)                   | 42 (64.6)                | 86 (68.8)                |
|                                 | >0 to <1%    | 12 (20.0)                   | 15 (23.1)                | 27 (21.6)                |
|                                 | >=1% to <5%  | 3 (5.0)                     | 4 (6.2)                  | 7 (5.6)                  |
|                                 | >=5% to <50% | 0 (0.0)                     | 1 (1.5)                  | 1 (0.8)                  |
|                                 | >=50%        | 1 (1.7)                     | 3 (4.6)                  | 4 (3.2)                  |
|                                 | TC <1%       | 56 (93.3)                   | 57 (87.7)                | 113 ( 90.4 )             |
|                                 | TC >=1%      | 4 (6.7)                     | 8 (12.3)                 | 12 ( 9.6 )               |
| Tumor Area Positivity ( TAP ) b | 0            | 35 (58.3)                   | 31 (47.7)                | 66 (52.8)                |
|                                 | >0 to <1%    | 2 (3.3)                     | 0 (0.0)                  | 2 (1.6)                  |
|                                 | >=1% to <5%  | 15 (25.0)                   | 21 (32.3)                | 36 (28.8)                |
|                                 | >=5% to <50% | 7 (11.7)                    | 10 (15.4)                | 17 (13.6)                |
|                                 | >=50%        | 1 (1.7)                     | 3 (4.6)                  | 4 (3.2)                  |
|                                 | TAP <1%      | 37 (61.7)                   | 31 (47.7)                | 68 ( 54.4 )              |
|                                 | TAP >=1%     | 23 (38.3)                   | 34 (52.3)                | 57 ( 45.6 )              |

## Efficacy outcomes by PD-L1 subgroups

Figure 31 Forest Plot for Overall Survival by PD-L1 Expression at Baseline Using Different PD-L1 Cut-offs (ITT Analysis Set) - Study 312 (Final Analysis, 19 April 2023 Cutoff)

<!-- image -->

| Subgroup           | Event/Total ARMA   | Event/Total ARMB   | Median (95% CI) ARMA   | ARMB              | Median (95% CI)Hazard Ratio for Death Hazard Ratio (95% CI) (95% CI)   |                   |
|--------------------|--------------------|--------------------|------------------------|-------------------|------------------------------------------------------------------------|-------------------|
| ITT Analysis Set   | 165/227            | 191/230            | 15.5 (13.5, 17.1)      | 13.5 (12.1, 14.9) |                                                                        | 0.75 (0.61, 0.93) |
| PD-L1 Analysis Set | 43/60              | 50/65              | 20.7 (12.6, 26.3)      | 13.5 (10.4, 19.4) |                                                                        | 0.71 (0.47, 1.08) |
| IC 1%              |                    |                    |                        |                   |                                                                        |                   |
| <1%                | 18/26              | 8/11               | 18.8 (11.9, 29.8)      | 13.2 (5.5, NE)    |                                                                        | 0.77 (0.33, 1.78) |
| >=1%               | 25/34              | 42/54              | 21.0 (11.0, 27.2)      | 13.5 (9.9, 20.0)  |                                                                        | 0.70 (0.42, 1.15) |
| TC 1%              |                    |                    |                        |                   |                                                                        |                   |
| <1%                | 41/56              | 46/57              | 19.9 (12.6, 23.8)      | 12.9 (9.4, 15.7)  |                                                                        | 0.68 (0.45, 1.05) |
| TAP 1%             |                    |                    |                        |                   |                                                                        |                   |
| <1%                | 28/37              | 27/31              | 16.2 (10.1, 22.8)      | 12.9 (9.1, 14.4)  |                                                                        | 0.72 (0.43, 1.23) |
| >= 1%              | 15/23              | 23/34              | 27.2 (17.0, 29.8)      | 15.7 (10.0, 23.3) |                                                                        | 0.61 (0.32, 1.19) |
|                    |                    |                    |                        |                   | 0 1 2                                                                  |                   |

←ARMAARMB→

Abbreviations: ARM A, Tislelizumab + Chemotherapy; ARM B, Placebo + Chemotherapy. Hazard ratio and its 95% CIs were estimated using an unstratified Cox regression model.

Note: results for the TC ≥ 1% subgroup are not included due to the small sample size (n = 4 in Arm T+C, n = 8 in Arm P+C)

<div style=\"page-break-after: always\"></div>

Figure 32 Forest Plot for Progression-Free Survival by PD-L1 Expression at Baseline Using Different PD-L1 Cut-offs (ITT Analysis Set) - Study 312 (Final Analysis, 19 April 2023 Cutoff)

<!-- image -->

| Subgroup           | Event/Total ARMA   | Event/Total ARMB   | Median (95% CI) ARMA   | Median (95% CI) ARMB   | Hazard Ratio forPD (95% CI)   | Hazard Ratio (95% CI)   |
|--------------------|--------------------|--------------------|------------------------|------------------------|-------------------------------|-------------------------|
| ITT Analysis Set   | 176/227            | 207/230            | 4.7 (4.3, 5.5)         | 4.3 (4.2, 4.4)         |                               | 0.63 (0.52, 0.78)       |
| PD-L1 Analysis Set | 51/60              | 57/65              | 5.6 (4.4, 6.8)         | 4.2 (4.1, 4.3)         |                               | 0.59 (0.40, 0.87)       |
| IC 1%              |                    |                    |                        |                        |                               |                         |
| <1%                | 23/26              | 10/11              | 5.4 (4.1, 6.8)         | 4.3 (4.0, 4.5)         |                               | 0.52 (0.24, 1.13)       |
| >= 1%              | 28/34              | 47/54              | 5.7 (4.3, 7.0)         | 4.2 (4.1, 4.4)         |                               | 0.55 (0.34, 0.90)       |
| TC 1%              |                    |                    |                        |                        |                               |                         |
| <1%                | 47/56              | 50/57              | 5.6 (4.4, 6.1)         | 4.2 (4.1, 4.3)         |                               | 0.58 (0.39, 0.87)       |
| TAP 1%             |                    |                    |                        |                        |                               |                         |
| <1%                | 34/37              | 27/31              | 4.6 (4.1, 5.5)         | 4.3 (4.2, 4.5)         |                               | 0.75 (0.45, 1.26)       |
| >= 1%              | 17/23              | 30/34              | 6.9 (5.6, 14.4)        | 4.2 (4.1, 5.0)         |                               | 0.41 (0.22, 0.77)       |
|                    |                    |                    |                        |                        | 0 1                           |                         |
|                    |                    |                    |                        |                        | ←ARMAARMB→                    | ←ARMAARMB→              |

Hazard ratio and its 95% CIs were estimated using an unstratified Cox regression model. Note: results for the TC ≥

1% subgroup are not included due to the small sample size (n = 4 in Arm T+C, n = 8 in Arm P+C)

## · Applicability of Study 312 Data to the EU Patient Population

Comparison of Disease Characteristics between Study 312 and European ES-SCLC Patient Population

A comparison of baseline characteristics and disease status of patients with untreated ES-SCLC was provided by region based on a pooled literature analysis and real-world data from IQVIA's Onclology Dynamics database (Reguart et al 2023).

Table 38 Comparison of Baseline and Disease Characteristics Between Study 312 and the EU Treatment-Naïve ES-SCLC Patient Population

| Characteristics          | BGB-A317-312 (N = 457)   | EU Patients a (Literature Search)   | EU Patients (ONC-D database, N = 5832)   |
|--------------------------|--------------------------|-------------------------------------|------------------------------------------|
| Age (years), median      | 62.0                     | 64-69                               | 66.0                                     |
| Gender (%)               |                          |                                     |                                          |
| Male                     | 81.4                     | 65.9                                | 65.9                                     |
| Female                   | 18.6                     | 33.4                                | 34.1                                     |
| Smoking status (%)       |                          |                                     |                                          |
| Never                    | 24.5                     | 3.4                                 | 8.2                                      |
| Current/Former           | 75.5                     | 90.7                                | 90.4                                     |
| ECOG 0-1 (%) b           | 100                      | 82.0                                | 74.6                                     |
| Clinical TNM Stage (%)   |                          |                                     |                                          |
| Stage III                | 10.7                     | 7.1                                 | 5.2                                      |
| Stage IV                 | 89.3                     | 89.6                                | 88.4                                     |
| Distant metastatic sites |                          |                                     |                                          |
| Liver                    | 26.9                     | 43.0                                | 55.4                                     |
| Brain                    | 1.1                      | 23.6                                | -                                        |

<div style=\"page-break-after: always\"></div>

| Characteristics   | BGB-A317-312 (N = 457)   | EU Patients a (Literature Search)   | EU Patients (ONC-D database, N = 5832)   |
|-------------------|--------------------------|-------------------------------------|------------------------------------------|
| Baseline LDH      |                          |                                     |                                          |
| ≤ ULN             | 48.8                     | 44.4                                | -                                        |
| > ULN             | 51.2                     | 48.3                                | -                                        |

Abbreviations: ES-SCLC, extensive-stage small cell lung cancer; EU, European Union; LDH, lactate dehydrogenase; ONC-D, Oncology Dynamics; ULN, upper limit of normal.

- a) Literature search criteria of 'extensive-stage small-cell lung cancer (ES-SCLC), European, no prior systemic treatment or treatment naïve,' excluding 'NSCLC and US or China only studies' were used. The value of each baseline parameter in 'EU patients (literature search)' was determined through a weighted average calculation, except for the median age which was represented by a range across multiple studies.
- b) In Study 312, only patients with ECOG 0-1 were enrolled, which inherently led to the differences in ECOG distribution compared to the EU real-world data and literature evaluation.

Sources : Bria et al 2024; Garcia Campelo et al 2022; Debieuvre et al 2022; Falchero et al 2023; Franco et al 2021; Gomez Mugarza et al 2023; Grambow-Velilla et al 2023; Longo et al 2024; Moliner et al 2022a; Moliner et al 2022b; Porte et al 2024; Steffens et al 2019; Valette et al 2023.

## Quantification of Transferability of Treatment Effects Observed in Study 312 to European ES-SCLC Patient Population

Protocol-driven targeted literature review (TLRs) and statistical analyses were conducted to evaluate the transferability of treatment effects observed in Study 312 to the European ES-SCLC patient population. A total of 9 RWE studies representing European target populations were selected for the statistical analysis. A set of potential effect modifiers was considered and included in the outcome regression models based on data availability from each target population. The individual predicted outcomes were then pooled in a meta-analysis to estimate the overall treatment effect in a Europeanlike population.

Figure 33 Treatment Effect (TIS + CT vs Placebo + CT) for OS and PFS Observed in Study 312 and Predicted in Target European Populations

<!-- image -->

## Population-Adjusted Treatment Comparisons

Indirect treatment comparisons based on OS HRs were performed to evaluate how the benefit of tislelizumab plus chemotherapy in untreated ES-SCLC patients compares to other ICI combination approaches used in global trials conducted in this setting. The publicly available summary-level (aggregate) data from studies with similar designs to Study 312 were used, including IMpower133 (atezolizumab), CASPIAN (durvalumab), ASTRUM-005 (serplulimab), and Keynote-604 (pembrolizumab) ( Cheng et al 2022a; Horn et al 2018; Paz-Ares et al 2019; Rudin et al 2020 ). Considering Study 312 had a minimum follow-up of 28 months at FA, the reported updated results for these trials were used for primary comparisons ( Cheng et al 2022b; Liu et al 2021; Paz-Ares et al 2022; Rudin et al 2022 ).

<div style=\"page-break-after: always\"></div>

The OS HR in Study 312 was re-estimated after adjusting for key baseline characteristics to account for differences in baseline characteristics between the tislelizumab study and other ICI trials.

The objective of this analysis included:

- Direct comparison: evaluate the treatment benefit of tislelizumab arm compared with internal control arm after adjusting the baseline characteristics according to selected ICI trials.
- Indirect comparison: evaluate the treatment benefit of tislelizumab arm versus respective ICI arms after adjusting the baseline characteristics according to selected ICI trials.

The following covariates were selected for adjustment as main analysis: sex (male versus female), ECOG Performance Status score (0 versus 1), and age (&lt; 65 versus ≥ 65), since they are known prognostic factors based on ESMO guidance [ESMO 2021].

Liver metastasis was selected as another covariate for sensitivity analysis upon main analysis, since it was identified as prognostic factor using Study 312 data based on univariate and inclusion of interaction term modelling (sensitivity analysis 2: add liver metastasis). Additional sensitivity analyses were conducted including or excluding smoking status as a covariate, based on its potential prognostic effect in SCLC (sensitivity analysis 1: add liver metastasis (yes versus no) and smoking status (never versus smoker, with smoker including current and former smokers)).

The subgroup analysis results across prespecified key factors from Study 312 were listed and compared with those from other similar ICI trials in first-line ES-SCLC, subject to data availability. No conclusive treatment effect modifier was identified in this disease setting based on this analysis. For patients with brain metastasis results were inconsistent, a long-term improvement from anti-PD-(L)1 treatment was observed in the studies of CASPIAN and ASTRUM-005, but not in IMpower133 and Keynote 604, with point estimates of HRs of 0.79, 0.73, 0.96, and 1.07, respectively.

<div style=\"page-break-after: always\"></div>

Table 39 OS Subgroup Analysis Results of Phase 3 Studies With Publicly Available Data Evaluating Anti-PD-1/PD-L1 Antibodies in 1L ES SCLC

| Key Factors Comparison-OS     | Key Factors Comparison-OS   | Study 312 (Primary CSR) (N=457)   | Study 312 (Primary CSR) (N=457)   | IMpower133 (Liu et al 2021; Tecentriq assessment report 2019) (N=403)   | IMpower133 (Liu et al 2021; Tecentriq assessment report 2019) (N=403)   | CASPIAN (Paz-Aresetal2022; Imfinzi assessment report 2020) (N=537)   | CASPIAN (Paz-Aresetal2022; Imfinzi assessment report 2020) (N=537)   | Keynote-604 (Rudin et al 2022; WCLC News [2022]) (N=453)   | Keynote-604 (Rudin et al 2022; WCLC News [2022]) (N=453)   | ASTRUM-005 (Cheng et al 2022b; Cheng 2022) (N=585)   | ASTRUM-005 (Cheng et al 2022b; Cheng 2022) (N=585)   |
|-------------------------------|-----------------------------|-----------------------------------|-----------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| Subgroup Population           | Subgroup Population         | %                                 | HR (95% CI)                       | %                                                                       | HR (95% CI)                                                             | %                                                                    | HR (95% CI)                                                          | %                                                          | HR (95% CI)                                                | %                                                    | HR (95% CI)                                          |
| ITT                           | ITT                         | 100%                              | 0.75 (0.61, 0.93)                 | 100%                                                                    | 0.76 (0.60, 0.95)                                                       | 100%                                                                 | 0.75 (0.62, 0.91)                                                    | 100%                                                       | 0.76 (0.63, 0.93)                                          | 100%                                                 | 0.62 (0.50, 0.76)                                    |
|                               | < 65 years                  | 62.8%                             | 0.76 (0.58, 0.99)                 | 54%                                                                     | 0.94 (0.68, 1.28)                                                       | 60%                                                                  | 0.68 (0.54, 0.87)                                                    | 48%                                                        | 0.88 (0.66, 1.17)                                          | 61%                                                  | 0.56 (0.42, 0.73)                                    |
|                               | ≥ 65 years                  | 37.2%                             | 0.74 (0.53, 1.03)                 | 46%                                                                     | 0.59 (0.42, 0.82)                                                       | 40%                                                                  | 0.78 (0.59, 1.04)                                                    | 52%                                                        | 0.70 (0.53, 0.91)                                          | 39%                                                  | 0.69 (0.50, 0.97)                                    |
|                               | Male                        | 81.4%                             | 0.76 (0.61, 0.96)                 | 65%                                                                     | 0.83 (0.63, 1.10)                                                       | 70%                                                                  | 0.79 (0.63,0.99)                                                     | 65%                                                        | 0.77 (0.61, 0.98)                                          | 82%                                                  | 0.61 (0.49, 0.77)                                    |
|                               | Female                      | 18.6%                             | 0.69 (0.42, 1.12)                 | 35%                                                                     | 0.64 (0.43, 0.94)                                                       | 30%                                                                  | 0.65 (0.45, 0.93)                                                    | 35%                                                        | 0.78 (0.55, 1.10)                                          | 18%                                                  | 0.65 (0.38, 1.10)                                    |
| Region                        | Asian                       | 100%                              | 0.75 (0.61,0.93)                  | NR                                                                      | NR                                                                      | 14%                                                                  | 0.86 (0.52, 1.40)                                                    | 19%                                                        | 0.61 (0.44, 1.19)                                          | 68%                                                  | 0.63 (0.49, 0.81)                                    |
| Region                        | Non-Asian                   | NA                                | NA                                | NR                                                                      | NR                                                                      | 86%                                                                  | 0.75 (0.61, 0.92)                                                    | 81%                                                        | 0.82 (0.66, 1.02)                                          | 32%                                                  | 0.56 (0.37,0.83)                                     |
| ECOG Performance Status score | 1                           | 84.9%                             | 0.76 (0.60, 0.95)                 | 65%                                                                     | 0.78 (0.60, 1.03)                                                       | 65% a                                                                | 0.76 (0.60, 0.96) a                                                  | 74%                                                        | 0.80 (0.64, 1.00)                                          | 82%                                                  | 0.63 (0.50, 0.79)                                    |
| ECOG Performance Status score | 0                           | 15.1%                             | 0.74 (0.42, 1.29)                 | 35%                                                                     | 0.73 (0.48, 1.10)                                                       | 35% a                                                                | 0.77 (0.56, 1.06) a                                                  | 26%                                                        | 0.74 (0.50, 1.10)                                          | 18%                                                  | 0.60 (0.33, 1.09)                                    |
|                               | Current                     | 62.6%                             | 0.77 (0.60, 0.97)                 | NR                                                                      | 0.76 (0.52, 1.11)                                                       | 93%                                                                  | 0.75 (0.62,0.91)                                                     | 62%                                                        | 0.81 (0.63, 1.04)                                          | 25%                                                  | 0.49 (0.32,0.75)                                     |
|                               | Former                      | 12.9%                             |                                   | NR                                                                      | 0.79 (0.59, 1.05)                                                       |                                                                      |                                                                      | 34%                                                        | 0.71 (0.50, 0.99)                                          | 55%                                                  | 0.61 (0.46, 0.82)                                    |
|                               | Never                       | 24.5%                             | 0.70 (0.45, 1.08)                 | NR                                                                      | 0.40 (0.05, 2.98)                                                       | 7%                                                                   | 0.83 (0.41, 1.71)                                                    | 4%                                                         | NR                                                         | 20%                                                  | 0.79 (0.48, 1.30)                                    |
| Brain metastases              | Yes                         | 1.1%                              | NR                                | 9%                                                                      | 0.96 (0.44, 2.01)                                                       | 10%                                                                  | 0.79 (0.44, 1.41)                                                    | 12%                                                        | 1.07 (0.61, 1.88)                                          | 13%                                                  | 0.73 (0.42, 1.25)                                    |
| Brain metastases              | No                          | 98.9%                             | 0.76 (0.61, 0.94)                 | %16                                                                     | 0.74 (0.58,0.94)                                                        | 90%                                                                  | 0.76 (0.62, 0.92)                                                    | 88%                                                        | 0.74 (0.60,0.91)                                           | 87%                                                  | 0.60 (0.48, 0.75)                                    |

<div style=\"page-break-after: always\"></div>

| Key Factors Comparison-Os   | Key Factors Comparison-Os   | Study 312 (Primary CSR) (N=457)   | Study 312 (Primary CSR) (N=457)   | IMpower133 (Liu et al 2021; Tecentriq assessment report 2019) (N=403)   | IMpower133 (Liu et al 2021; Tecentriq assessment report 2019) (N=403)   | CASPIAN (Paz-Aresetal2022; Imfinzi assessment report 2020) (N=537)   | CASPIAN (Paz-Aresetal2022; Imfinzi assessment report 2020) (N=537)   | Keynote-604 (Rudin et al 2022; WCLCNews[2022]) (N=453)   | Keynote-604 (Rudin et al 2022; WCLCNews[2022]) (N=453)   | ASTRUM-005 (Cheng et al 2022b; Cheng 2022) (N=585)   | ASTRUM-005 (Cheng et al 2022b; Cheng 2022) (N=585)   |
|-----------------------------|-----------------------------|-----------------------------------|-----------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| Subgroup Population         | Subgroup Population         | %                                 | HR (95% CI)                       | %                                                                       | HR (95% CI)                                                             | %                                                                    | HR (95% CI)                                                          | %                                                        | HR (95% CI)                                              | %                                                    | HR (95% CI)                                          |
| Liver metastases            | Yes                         | 26.9%                             | 0.65 (0.44, 0.95)                 | 37%                                                                     | 0.75 (0.52,1.07)                                                        | 40%                                                                  | 0.87 (0.66, 1.16)                                                    | 42%                                                      | 0.77 (0.57,1.03)                                         | 26%                                                  | 0.58 (0.40, 0.84)                                    |
| Liver metastases            | No                          | 73.1%                             | 0.76 (0.59,0.98)                  | 63%                                                                     | 0.76 (0.56, 1.01)                                                       | 60%                                                                  | 0.68 (0.53,0.88)                                                     | 58%                                                      | 0.75 (0.58,0.98)                                         | 74%                                                  | 0.62 (0.48, 0.80)                                    |
|                             | >ULN                        | 51.2%                             | 0.80 (0.60, 1.06)                 | NR                                                                      | NR                                                                      | NR                                                                   | NR                                                                   | 57%                                                      | 0.79 (0.61, 1.02)                                        | NR                                                   | NR                                                   |
|                             | ≤ULN                        | 48.8%                             | 0.73 (0.54,0.99)                  | NR                                                                      | NR                                                                      | NR                                                                   | NR                                                                   | 43%                                                      | 0.73 (0.53, 0.99)                                        | NR                                                   | NR                                                   |
| AJCC stage                  | III                         | 10.7%                             | 0.62 (0.30, 1.29)                 | NR                                                                      | NR                                                                      | 10%                                                                  | 0.83 (0.44, 1.54)                                                    | NR                                                       | NR                                                       | NR                                                   | NR                                                   |
| AJCC stage                  | IV                          | 89.3%                             | 0.75 (0.60,0.93)                  | NR                                                                      | NR                                                                      | 90%                                                                  | 0.75 (0.62,0.92)                                                     | NR                                                       | NR                                                       | NR                                                   | NR                                                   |
| Platinum                    | Carboplati n                | 79%                               | 0.74 (0.59,0.94)                  | NA                                                                      | NA                                                                      | 75%                                                                  | 0.79 (0.63,0.98)                                                     | 70%                                                      | 0.80 (0.63, 1.01)                                        | NA                                                   | NA                                                   |
| Platinum                    | Cisplatin                   | 21%                               | 0.81 (0.51, 1.26)                 | NA                                                                      | NA                                                                      | 25%                                                                  | 0.67 (0.46, 0.97)                                                    | 30%                                                      | 0.71 (0.49, 1.02)                                        | NA                                                   | NA                                                   |

Abbreviations: AJCC, American Joint Committee on Cancer; HR, hazard ratio; LDH, lactate dehydrogenase; NA, not applicable; NR, not reported; OS, overall survival; WCLC, World Conference on Lung Cancer.

aTheWHOPSscorewasusedinCASPIANStudy.

<div style=\"page-break-after: always\"></div>

To address potential bias arising from indirect comparison of heterogeneous study populations, 2 wellestablished population-adjustment methods were used: (1) MAIC - matching-adjusted indirect comparison (Signorovitch et al 2012) and (2) STC - simulated treatment comparisons (Ishak et al 2015) . These methods were utilised to adjust the estimated treatment effects and construct anchored indirect comparisons against other ICI combinations.

## · Results of main analysis

Figure 34 Population-Adjusted Hazard Ratios for OS and Indirect Treatment Comparisons with Other ICI Combinations in 1L ES-SCLC - Study 312 (ITT Analysis Set) - Main analysis

<!-- image -->

The upper panel depicting OS HRs and corresponding 95% CIs presented in red shows the comparison between the tislelizumab experimental arm and the internal control arm, before (unadjusted) and after adjustment for baseline characteristics using MAIC (left) or STC (right) for each of the selected ICI studies (direct comparison).

Additional analyses presented show the OS HRs and 95% CIs in green, blue, and violet corresponding to the indirect population-adjusted comparisons of tislelizumab experimental arms relative to other ICI combinations.

Results from sensitivity analysis 2 were generally comparable with the main analysis from both methods for population adjustment (data not shown).

Results from sensitivity analysis 1 showed wider confidence intervals and estimates are less consistent.

<div style=\"page-break-after: always\"></div>

Figure 35 Population-Adjusted Hazard Ratios for OS and Indirect Treatment Comparisons With Other ICI Combinations in 1L ES-SCLC - Study 312 (ITT Analysis Set) - Sensitivity Analysis 1

<!-- image -->

## PK by Race

The original popPK analysis showed that race was not a significant covariate on the PK parameters (CL and Vc) of tislelizumab. The simulated geometric mean exposures (AUCss, Cmax,ss, and Cmin,ss) of the Asian patient population (the majority of Asian patients are Chinese) from 12 studies were approximately 12% to 21% higher than those of white patients. The overall range of tislelizumab exposure after administration of 200 mg once every 3 weeks largely overlapped between the Asian and White patients.

<div style=\"page-break-after: always\"></div>

Figure 36 Steady state exposure of tislelizumab by Asian; White and Other following 200 mg Q3W dosing

<!-- image -->

Source: Module 5.3.3.5 PopPK Report (March, 2021), Figure 22.

Abbreviations: AUCs, area under the serum concentration-time curve at steady state; CL, clearance; Cmin,ss,. minimum serum concentration at steady state.

Note: The steady-state exposures (Cmin,ss, AUCss) of tislelizumab were computed for each patient. AUCs was calculated as dose/CL. Cminss was calculated as the minimum concentration at 21 days after 10 consecutive doses of tislelizumab 200 mg once every 3 weeks.

The dashed red horizontal line represents the mean of the overall population

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 40 Summary of efficacy for trial RATIONALE 312

| Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Etoposide With or Without Tislelizumab (BGB-A317) in Patients With Untreated Extensive Stage Small Cell Lung Cancer   | Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Etoposide With or Without Tislelizumab (BGB-A317) in Patients With Untreated Extensive Stage Small Cell Lung Cancer   | Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Etoposide With or Without Tislelizumab (BGB-A317) in Patients With Untreated Extensive Stage Small Cell Lung Cancer   | Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Etoposide With or Without Tislelizumab (BGB-A317) in Patients With Untreated Extensive Stage Small Cell Lung Cancer   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                            | BGB-A317-312                                                                                                                                                                                                | BGB-A317-312                                                                                                                                                                                                | BGB-A317-312                                                                                                                                                                                                |
| Design                                                                                                                                                                                                      | Phase 3, Randomized, Double-Blind, Placebo-Controlled                                                                                                                                                       | Phase 3, Randomized, Double-Blind, Placebo-Controlled                                                                                                                                                       | Phase 3, Randomized, Double-Blind, Placebo-Controlled                                                                                                                                                       |
|                                                                                                                                                                                                             | Duration of main phase: Duration of Run-in phase: Duration of                                                                                                                                               | Extension phase:                                                                                                                                                                                            | Not applicable, event driven. Not applicable Not applicable                                                                                                                                                 |
| Hypothesis                                                                                                                                                                                                  | Superiority                                                                                                                                                                                                 | Superiority                                                                                                                                                                                                 | Superiority                                                                                                                                                                                                 |
| Treatments groups                                                                                                                                                                                           | Arm T+C (Tislelizumab + Chemotherapy arm)                                                                                                                                                                   | Arm T+C (Tislelizumab + Chemotherapy arm)                                                                                                                                                                   | Tislelizumab + cisplatin or carboplatin + etoposide for 4 cycles, followed by tislelizumab, until PD or loss of clinical benefit, n=227                                                                     |
|                                                                                                                                                                                                             | Arm P+C (Placebo + Chemotherapy arm)                                                                                                                                                                        | Arm P+C (Placebo + Chemotherapy arm)                                                                                                                                                                        | Placebo + cisplatin or carboplatin + etoposide for 4 cycles, followed by placebo, until PD or loss of clinical benefit, n=230                                                                               |
| Endpoints and definitions                                                                                                                                                                                   | Primary endpoint                                                                                                                                                                                            | OS                                                                                                                                                                                                          | OS in the ITT Analysis Set                                                                                                                                                                                  |
|                                                                                                                                                                                                             | Secondary endpoint                                                                                                                                                                                          | PFS                                                                                                                                                                                                         | Investigator-assessed PFS according to RECIST v1.1 in the ITT Analysis Set                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                                                 | Secondary endpoint                                                     | ORR, DOR, DCR                                                          | Investigator-assessed confirmed ORR, DOR, and DCR according to RECIST v1.1 in the ITT Analysis Set   | Investigator-assessed confirmed ORR, DOR, and DCR according to RECIST v1.1 in the ITT Analysis Set   |
|-------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| Data cut-off                                    | 19 Apr 2023 final analysis; 29 December 2023 study end analysis (LPLV) | 19 Apr 2023 final analysis; 29 December 2023 study end analysis (LPLV) | 19 Apr 2023 final analysis; 29 December 2023 study end analysis (LPLV)                               | 19 Apr 2023 final analysis; 29 December 2023 study end analysis (LPLV)                               |
| Database lock                                   | 07 Sep 2023 final analysis; 06 February 2024 study end analysis (LPLV) | 07 Sep 2023 final analysis; 06 February 2024 study end analysis (LPLV) | 07 Sep 2023 final analysis; 06 February 2024 study end analysis (LPLV)                               | 07 Sep 2023 final analysis; 06 February 2024 study end analysis (LPLV)                               |
| Results and Analysis                            | Results and Analysis                                                   | Results and Analysis                                                   | Results and Analysis                                                                                 | Results and Analysis                                                                                 |
| Analysis description                            | Final analysis of study                                                | Final analysis of study                                                | Final analysis of study                                                                              | Final analysis of study                                                                              |
| Analysis population and time point description  | Intent to treat=457, when 356 (77.9%) OS events were observed          | Intent to treat=457, when 356 (77.9%) OS events were observed          | Intent to treat=457, when 356 (77.9%) OS events were observed                                        | Intent to treat=457, when 356 (77.9%) OS events were observed                                        |
| Descriptive statistics and estimate variability | Treatment group                                                        | Treatment group                                                        | Arm T+C                                                                                              | Arm P+C                                                                                              |
| Descriptive statistics and estimate variability | Number of subject                                                      | Number of subject                                                      | 227                                                                                                  | 230                                                                                                  |
| Descriptive statistics and estimate variability | Median OS, months                                                      | Median OS, months                                                      | 15.5                                                                                                 | 13.5                                                                                                 |
| Descriptive statistics and estimate variability | 95% CI                                                                 | 95% CI                                                                 | 13.5, 17.1                                                                                           | 12.1, 14.9                                                                                           |
| Descriptive statistics and estimate variability | Median INV-PFS, months                                                 | Median INV-PFS, months                                                 | 4.7                                                                                                  | 4.3                                                                                                  |
| Descriptive statistics and estimate variability | 95% CI                                                                 | 95% CI                                                                 | 4.3, 5.5                                                                                             | 4.2, 4.4                                                                                             |
| Descriptive statistics and estimate variability | Confirmed INV-ORR,%                                                    | Confirmed INV-ORR,%                                                    | 68.3                                                                                                 | 61.7                                                                                                 |
| Descriptive statistics and estimate variability | 95% CI                                                                 | 95% CI                                                                 | 61.8, 74.3                                                                                           | 55.1, 68.0                                                                                           |
| Descriptive statistics and estimate variability | Confirmed INV-DOR, months                                              | Confirmed INV-DOR, months                                              | 4.3                                                                                                  | 3.7                                                                                                  |
| Descriptive statistics and estimate variability | 95% CI                                                                 | 95% CI                                                                 | 4.1, 5.6                                                                                             | 3.0, 4.1                                                                                             |
| Descriptive statistics and estimate variability | Confirmed INV-DCR,%                                                    | Confirmed INV-DCR,%                                                    | 88.5                                                                                                 | 88.3                                                                                                 |
| Descriptive statistics and estimate variability | 95% CI                                                                 | 95% CI                                                                 | 83.7, 92.4                                                                                           | 83.4, 92.1                                                                                           |
| Effect estimate per comparison                  | OS                                                                     | OS                                                                     | Comparison groups                                                                                    | Arm T+C vs Arm P+C                                                                                   |
| Effect estimate per comparison                  |                                                                        |                                                                        | Stratified Hazard Ratio                                                                              | 0.75                                                                                                 |
| Effect estimate per comparison                  |                                                                        |                                                                        | 95% CI                                                                                               | 0.61, 0.93                                                                                           |
| Effect estimate per comparison                  |                                                                        |                                                                        | P-value (log-rank)                                                                                   | 0.0040                                                                                               |
| Effect estimate per comparison                  | INV-PFS                                                                | INV-PFS                                                                | Comparison groups                                                                                    | Arm T+C vs Arm P+C                                                                                   |
| Effect estimate per comparison                  |                                                                        |                                                                        | Stratified Hazard Ratio                                                                              | 0.64                                                                                                 |
| Effect estimate per comparison                  |                                                                        |                                                                        | 95% CI                                                                                               | 0.52, 0.78                                                                                           |
| Effect estimate per comparison                  |                                                                        |                                                                        | P-value (log-rank)                                                                                   | <0.0001                                                                                              |
| Effect estimate per comparison                  | Confirmed INV-ORR                                                      | Confirmed INV-ORR                                                      | Comparison groups                                                                                    | Arm T+C vs Arm P+C                                                                                   |
| Effect estimate per comparison                  |                                                                        |                                                                        | Odds ratio                                                                                           | 1.33                                                                                                 |
| Effect estimate per comparison                  |                                                                        |                                                                        | 95% CI                                                                                               | 0.90, 1.96                                                                                           |
| Notes                                           | The primary endpoint has been met.                                     | The primary endpoint has been met.                                     | The primary endpoint has been met.                                                                   | The primary endpoint has been met.                                                                   |

<div style=\"page-break-after: always\"></div>

## Analysis performed across trials (pooled analyses and meta-analysis)

Considering differences in the study design (eg, up to 6 cycles of chemotherapy in Study 206 and fixed 4 cycles in Study 312) and the small sample size of the ES-SCLC cohort in the supportive Study 206 (N = 17), no pooled analyses on efficacy were conducted.

## Supportive Study 206

In the Phase 2, open-label, multicohort Study 206 17 participants with ES-SCLC without prior systemic therapy were treated with ≥ 1 dose of tislelizumab. Tislelizumab (200 mg IV Q3W) was given in addition to 4-6 cycles of chemotherapy (cisplatin or carboplatin + etoposide) and following chemotherapy as maintenance.

Efficacy data were provided from the study end analysis with the data cutoff date of 31 December 2019 (median study follow-up duration of 15.51 months).

Table 41 Summary of Efficacy in Patients with ES-SCLC in Study 206

| Efficacy Variable               | Results in ES-SCLC Patients (N = 17)                |
|---------------------------------|-----------------------------------------------------|
| ORR a                           | 76.5% (95% CI: 50.1% to 93.2%)                      |
| Median DOR                      | 6.5 months (95% CI: 2.69 months to not estimable)   |
| Patients with PFS events, n (%) | 13 (76.5%)                                          |
| Median PFS                      | 6.9 months (95% CI: 4.90 to 10.09 months)           |
| Event free rate at,%            |                                                     |
| 3-month                         | 94.1%                                               |
| 6-month                         | 63.3%                                               |
| 9-month                         | 38.0%                                               |
| 12-month                        | 25.3%                                               |
| Patients with death, n (%)      | 10 (58.8)                                           |
| Median OS                       | 15.5 months (95% CI: 11.79 months to not estimable) |
| Survival rate at,%              |                                                     |
| 12-month                        | 75%                                                 |
| 18-month                        | 38%                                                 |

a Responses were assessed by the investigator and confirmed per RECIST v1.1.

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The double-blinded, randomized Study 312 evaluated the addition of tislelizumab to four cycles of standard first-line chemotherapy (platinum plus etoposide) for extensive-stage small cell lung cancer (ES-SCLC). Tislelizumab (200 mg/kg IV Q3W) or placebo were continued as maintenance treatment until disease progression or unacceptable toxicity.

The study enrolled 457 patients solely in China. At the start of recruitment in July 2019, immunotherapy had not yet been approved in this setting, neither in China nor in the EU (with atezolizumab as the first checkpoint inhibitor being approved in the EU in September 2019 and in China in February 2020). The investigator's choice of platinum (cisplatin or carboplatin) was in line with international guideline recommendations and was included as stratification factor, besides ECOG PS (0 versus 1) and brain metastasis (yes versus no). Thus, the control arm can be considered

<div style=\"page-break-after: always\"></div>

acceptable from a regulatory perspective. The trial did not integrate the option to receive consolidation thoracic radiotherapy to the residual primary tumour and lymph nodes for patients with a response to chemotherapy, which is discussed by ESMO guidance 2021 (II, C recommendation); however, this approach was also not permitted in other pivotal immunotherapy studies in this setting. Prophylactic cranial irradiation (PCI) was permitted during the maintenance treatment period; however, only 3 (1%) patients in the tislelizumab group and 1 (0.4%) patient in the placebo group received PCI which aligns with medical practices in China, where patients with ES-SCLC rarely receive PCI during maintenance treatment.

The eligibility criteria were overall considered adequate to select a patient population without prior systemic treatment for ES-SCLC; however, as common in pivotal oncology studies, only patients with a good clinical condition were enrolled with ECOG PS of 0 or 1, adequate organ function and a life expectancy of ≥ 12 weeks. The median age of enrolled patients was relatively low (median age 62 years with 63% of patients below 65 years and only 11 patients [2.4%] with ≥ 75 years).

Baseline  and  disease  characteristics  were  generally  balanced  between  treatment  arms  apart  from  a slightly higher baseline tumour burden in patients in the tislelizumab + chemotherapy arm (Arm T+C) than in patients in the placebo arm (Arm P+C), evidenced by a numerically higher percentage of patients initially diagnosed with extensive and stage IV disease, liver metastasis, ≥ 3 distant metastasis site, and greater sum of target lesions diameters.

Study 312 enrolled 18.6% female participants, which is a lower rate than would be expected for a European SCLC population and lower compared to other global immunotherapy studies that enrolled about 30%-35% of female patients. The lower proportion of females is however in line with the different male-to-female ratio for SCLC in China. Likewise, Study 312 had a higher proportion of neversmokers (24.5%) compared to the reported worldwide epidemiology data of 2.5% (or a pooled literature analysis and real-world data for EU SCLC patients with 3.4% and 8.2%). The high rate of never-smokers in Study 312 is consistent with the incidence of never-smoker reported in Asian SCLC patients. Notably, the majority of never-smokers in Study 312 were females (89.4%). Information of additional exposures like indoor radon exposure, air pollution or second-hand smoke to further evaluate the primary risk factors for never-smokers was not collected.

The number of patients with brain metastasis was extremely low in Study 312 (n=5, 1.1% of study population). Baseline brain imaging was mandatory for all screened patients and per protocol patients with brain metastasis were eligible only after prior treatment, even if asymptomatic. The MAH explained that radiotherapy or radiosurgery for asymptomatic brain metastasis in ES-SCLC is relatively uncommon in China in accordance with CSCO guidelines and due to logistic challenges from a clinical practice perspective. Overall, 58 patients (8.6% of screened patients) were not enrolled due to untreated brain metastasis. Based on a literature search, about 24% would be expected to have brain metastasis in an unselected ES-SCLC population in the EU; global immunotherapy studies recruited about 9-13% of participants with CNS metastases (see ancillary analyses - Applicability of Study 312 Data to the EU Patient Population).

Study 312 enrolled also a relatively low number of participants with liver metastasis (26%) compared to about 40% in most multinational reference studies. This might be partly due to concurrent occurrence of brain and liver metastases and the exclusion of patients with untreated brain metastases.

Randomization was stratified by ECOG Performance Status (0 versus 1), investigator-chosen chemotherapy (carboplatin versus cisplatin), and brain metastasis (yes versus no) which is considered acceptable

<div style=\"page-break-after: always\"></div>

In the original protocol (dated Jan 2019), primary efficacy endpoints were PFS and OS in the ITT Analysis Set, secondary endpoints included ORR, DOR, and patients' HRQoL; PFS2 was evaluated as an exploratory endpoint. On 02 September 2020, the study was revised with protocol amendment V1.0 when already 252 participants (out of the originally planned 364 participants) had been randomized. Investigator-assessed PFS was changed to a secondary endpoint. The superiority of PFS was to be tested sequentially only after the hypothesis testing on the primary endpoint OS demonstrated significant improvement, however this was not specified in the study protocol, but only in a separate SAP. The statistical assumptions for OS were revised and the sample size was increased from 364 to 455 participants along with an increase in the required number of OS events for the interim and the final analyses. The rationale for these changes were based on published external data from immunotherapy studies with a similar design (such as IMpower133, CASPIAN, and Keynote-604), the interim readout of the supportive phase II Study 206 and the approval of anlotinib for 3L+ treatment of SCLC in China. Emerging data from competitor trials demonstrated a delayed treatment effect and indicated that a PFS endpoint may not be an optimal predictor of benefit. It was emphasized that the study maintained double-blinded throughout the amendment process and the data cutoff date for the planned IA was set much later in May 2022.

Such critical and late changes in the design and the statistical analysis of pivotal studies are not supported from a regulatory point, even if considering the double-blinded study conduct and even though the provided rationale appears plausible. Retrospectively, in the final analysis dataset, only 28 OS events in total occurred before or on 02 Sep 2020, corresponding to a very low event-to-patient ratio relative to the enrolled patients at that time (11.1%, 28/252), indicating that the changes in Amendment 1 were not opportunistic and results are robust despite the rather late change. In addition, sensitivity analyses suggest that downgrading of PFS from primary to secondary endpoint was not decisive of study success.

PFS as well as other secondary endpoints ORR, DOR and DCR were solely based on investigatorassessment. Although the lack of an independent review is considered a methodological limitation, this can be considered acceptable given the clinical relevance of the primary endpoint OS and the doubleblinded study design.

There is minor uncertainty on the statistical stringency of the PFS analysis. In the study protocol, no strategy to ensure type-I-error control across secondary endpoints was specified. However, since PFS was originally planned as one of the primary endpoints, it appears plausible to test PFS as first secondary endpoint in hierarchy and this was also specified in the separate SAP. PFS was tested at full one-sided α=0.025, without accounting for multiplicity of the two possible analysis timepoints. While this may in principle increase type-I-error for PFS, no concern is raised in light of the small p-value for PFS (p&lt;0.0001, see below).

Censoring rules for PFS may suffer from informative censoring. Most notably, new anticancer therapy may indicate that the patient progressed or that the treatment was no longer a viable option for other reasons (e.g. tolerability). The MAH provided sensitivity analyses for PFS to address uncertainties with potential informative censoring. A tipping point analysis including worst case scenarios (in which observation time is artificially prolonged in the control arm and non-administrative censoring is imputed by an event in the experimental arm) suggested that the overall results for PFS were robust against informative censoring.

The conduct of Study 312 continued during the COVID-19 pandemic, while contingency measures needed to be developed. The rate of important protocol deviations (16.8%) and the provided analyses that evaluated the impact of the COVID-19 pandemic on the efficacy and safety results did not raise serious concerns regarding the integrity of efficacy or safety results. A numerical higher rate of important protocol deviations in the tislelizumab + chemotherapy arm (20.7%) compared to the

<div style=\"page-break-after: always\"></div>

placebo + chemotherapy arm (13%) and a higher rate of delayed dose of tislelizumab vs placebo due to COVID-19 (19.8% vs 11.4%) were primarily attributed to the longer follow-up and treatment duration in the tislelizumab arm.

## Efficacy data and additional analyses

The study met its primary endpoint of OS at the final analysis (DCO 19 April 2023) with a two-months improvement in median OS in favour of tislelizumab + Chemotherapy over Placebo + Chemotherapy (median OS 15.5 vs 13.5 months; stratified OS HR 0.75 [95% CI: 0.61, 0.93]). The OS data were mature at the FA (with 73% and 83% event/patient rates in the T+C and P+C arms) and the OS benefit was sustained with further follow-up at the study end date (DCO 29 Dec 2023 with a median follow-up time of 40 months in the T+P arm). Sensitivity and supplementary analyses of OS including post-hoc analyses adjusting for imbalances in disease characteristics supported the primary outcome.

The OS benefit of additional tislelizumab to standard 1L chemotherapy can be considered clinically relevant for patients with ES-SCLC.

However, OS KM curves showed a late separation and an early crossing at 6 months after randomization. While the late separation of KM curves is consistent with results of similar immunotherapy studies in 1L ES-SCLC, no crossing was observed for checkpoint inhibitors that have been approved in the EU (crossing similar only in study KEYNOTE-604). Exploratory analyses showed a higher number of deaths within 3 months of randomisation in Arm T+C (n=15 [6.6%]) than in Arm P+C (n=6 [2.6%]). This imbalance was due to a higher rate of death due to AEs and death due to disease under study (difference 2.6% and 1.4% between treatment arms, respectively). A comparison of baseline disease characteristics for patients who died within 3 months vs the ITT Analysis Set indicated a higher tumour burden and worse performance status as risk factors similarly in both treatment arms. In view of the small numbers of early death, further analyses were not considered likely to provide deeper insights in the reasons for the higher rate of early deaths in the tislelizumab treatment arm.

Investigator-assessed PFS was statistically significantly improved in Arm T+C compared to Arm P+C (median PFS 4.7 versus 4.3 months; stratified PFS HR 0.64 [95% CI 0.53, 0.78]). The late separation of the PFS KM curves was maintained with longer follow-up (DCO Dec 2023). Results of other secondary endpoints were descriptive and showed only slightly improved results for ORR (68% vs 62%), CBR (69% vs 65%) and DOR (median 4.3 vs 3.7 months for Arm T+C vs P+C, respectively). HRQoL results were comparable between the two treatment arms. The results for the exploratory endpoint PFS2 supported the OS benefit (median PFS2 was 13.1 versus 11.0 months for T+C versus P+C; stratified HR 0.71 [95% CI: 0.57, 0.89]).

As the pivotal study was conducted in China only, exploratory analyses were provided to support the applicability of Chinese Study 312 data to the EU patient population. A comparison of measured baseline and disease characteristics indicated differences regarding gender, smoking status, liver and brain metastases (as discussed above). The MAH conducted re-analyses of Study 312 in an approach to weigh the estimates according to patient characteristics in other (European) studies. In addition, the MAH provided indirect comparisons to compare survival in the tislelizumab arm against experimental arms from studies with other products conducted with European patients. Different methods to account for measured imbalances (MAIC, STC) were used. These analyses require the assumption that all relevant differences between the populations are measured and that they can be accounted for, thus they should be interpreted with caution, but are considered useful for signal generation. Most analyses did not raise any concerns, a signal of potentially reduced efficacy when accounting for liver metastases and smoking status was not considered plausible. Study 312 itself did not suggest major

<div style=\"page-break-after: always\"></div>

inconsistencies of the treatment effect across subgroups. In the absence of plausible signals, the effects of tislelizumab demonstrated in Study 312 can also apply to European patients.

Evaluation of efficacy in subgroups

Overall, OS and PFS results in pre-specified subgroups were overall consistent with the ITT analyses.

The vast majority of study participants received carboplatin (79%) without collecting the reason for the platinum choice. Subgroup results showed a trend towards a slightly larger treatment effect of tislelizumab in the carboplatin-treated subpopulation (OS HR 0.74; 95% CI 0.59, 0.94), but the confidence interval in the smaller cisplatin-treated subgroup (OS HR 0.81; 95% CI 0.51, 1.26) was notably wider and a benefit of tislelizumab can be acknowledged for both platinum backbone agents. The proposed wording of the indication 'in combination with etoposide and platinum chemotherapy' can be therefore considered acceptable.

Tumour PD-L1 expression status was not a stratification factor. Per protocol, archival tumour tissue was required to be collected for the purpose of biomarker analysis (defined as an exploratory objective) and collection of fresh tumour biopsy at screening was recommended, if feasible. PD-L1 status was evaluated centrally using the Ventana SP263 IHC assay. However, the requirement to provide tumour tissue was not reflected in the inclusion criteria and results were available from only 125 patients (27.4% of the ITT population). Although point estimates of OS and PFS HRs were largely consistent between the PD-L1 and the ITT Analysis Sets, median OS in the tislelizumab arm was considerably longer in the PD-L1 Analysis Set compared with the ITT (20.7 months vs 15.5 months, respectively) and representativeness of the PD-L1 Analysis Set cannot be ascertained given its small size. Exploratory PD-L1 analyses using different scoring algorithms (IC, TC and TAP) indicated a numerical trend towards a slightly improved OS and PFS benefit in the PD-L1 positive subgroup with a TAP score ≥1%; however, no reliabl e conclusions can be drawn based on these data. Also considering previous studies with PD-(L)1 inhibitors, data appear overall inconclusive regarding the predictive potential of PD-L1 expression in this disease setting.

The results of subgroup analyses by age showed a consistent treatment effect for patients below and above 65 years. But the number of elderly patients with ≥ 75 years are too limited to draw conclusions on a potentially different treatment effect in these subgroups (n=11 [2.4%] with 8 patients in Arm T+C and 3 patients in Arm P+C). Given the extremely limited sample size of patients with ≥ 75 year, a meta-analysis of all tislelizumab RCTs to justify that efficacy of the overall population can be extrapolated to the group of elderly patients was provided. Information in patients ≥ 75 years of age is very limited also in other studies with small sample sizes and small number of events. Overall, the analyses do not exclude inconsistencies in the treatment effect across age, but at the same time do not raise any signal towards systematically poorer effect in elderly so far.

## 2.4.4. Conclusions on the clinical efficacy

Study 312 demonstrated statistically significant superiority in OS and PFS for the addition of tislelizumab to standard 1L chemotherapy in patients with ES-SCLC. OS KM curves showed a delayed treatment effect with an initial crossing due to higher incidences of early deaths in Arm T+C than in Arm P+C within the first three months after randomization; however, the median OS difference of 2 months and the sustained higher OS rate in Arm T+C with long follow-up indicate a clinically relevant improvement for those patients who benefit from the immunochemotherapy combination.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical safety

## Introduction

Data from all tislelizumab-treated patients in the completed pivotal Study BGB-A317-312 (hereinafter referred to as Study 312) are the primary source of data supporting the safety of tislelizumab in combination with etoposide and platinum-based chemotherapy as the first-line treatment in adult patients with ES-SCLC.

The primary safety data are from the end-of-study analysis of Study 312 (data cut-off date of 29 December 2023), which, compared to the final analysis ( data cut-off date of 19 April 2023) provides an additional 8.3 months of minimum follow-up time.

The safety profile of tislelizumab is complemented by the integrated safety data from four studies in which tislelizumab in combination with chemotherapy was administered to patients with untreated NSCLC or SCLC ( 1L lung cancer pool ) and by the pooled safety data from nine monotherapy studies ( tislelizumab monotherapy pool ),

## Table 42 Safety Analysis Populations

| Analysis set                          |    N | Definition                                                                                                                                           | Purpose                                                                                                                                          |
|---------------------------------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Study 312                             |  456 | All randomised patients from Study 312 who received ≥ 1 dose of study treatment                                                                      | Primary source of safety data for the intended indication                                                                                        |
| 1L lung cancer pool                   |  741 | Patients with untreated NSCLC or SCLC who received tislelizumab 200 mg Q3W plus chemotherapy in Studies 312, 307, 304, and 206                       | Reference population for the known safety profile of tislelizumab plus platinum-based chemotherapy in the 1L lung cancer setting                 |
| Tislelizumab monotherapy pool         | 1952 | Patients with various tumour types who received tislelizumab monotherapy at 200 mg Q3W in Studies 001, 102, 203, 204, 208, 209, 301, 302, and 303    | Reference population for the known safety profile of tislelizumab monotherapy For ADR determination and presentation of tislelizumab monotherapy |
| Tislelizumab combination therapy pool | 1950 | Patients with various tumour types who received tislelizumab 200 mg Q3W plus chemotherapy in Studies 205, 206, 304, 305, 306, 307, 309, 312, and 315 | For ADR determination and presentation of tislelizumab plus chemotherapy                                                                         |

Table 43 Studies in the 1L Lung Cancer Pool Providing Supporting Safety Data

|                                     | 206                                  | 304                                | 307                             | 312                          |
|-------------------------------------|--------------------------------------|------------------------------------|---------------------------------|------------------------------|
| Phase                               | 2                                    | 3                                  | 3                               | 3                            |
| Disease type                        | Advanced or metastatic NSCLC or SCLC | Stage IIIB or IV nonsquamous NSCLC | Stage IIIB or IV squamous NSCLC | Previously untreated ES-SCLC |
| Patients in Safety Analysis Set (N) | 54                                   | 222                                | 238                             | 227                          |
| Data cut-off date                   | 31-Dec-2019 (completed)              | 26-Apr-2023 (completed)            | 28-Apr-2023 (completed)         | 29-Dec-2023 (completed)      |

<div style=\"page-break-after: always\"></div>

Table 44 Studies in the Tislelizumab Monotherapy Pool Providing Supporting Safety Data

|                                     | 001                     | 102                     | 203                                    | 204                                                            | 208                                  |
|-------------------------------------|-------------------------|-------------------------|----------------------------------------|----------------------------------------------------------------|--------------------------------------|
| Phase                               | 1                       | 1/2                     | 2                                      | 2                                                              | 2                                    |
| Disease type                        | Solid tumours           | Solid tumours           | R/R cHL                                | UC                                                             | Previously treated, unresectable HCC |
| Patients in Safety Analysis Set (N) | 13                      | 300                     | 70                                     | 113                                                            | 249                                  |
| Data cut-off date                   | 12-Aug-2020 (completed) | 31-May-2020 (completed) | 02-Nov-2020 (completed)                | 11-Mar-2021 (completed)                                        | 06-Jul-2022 (completed)              |
|                                     | 209                     | 301                     | 302                                    | 303                                                            |                                      |
| Phase                               | 2                       | 3                       | 3                                      | 3                                                              |                                      |
| Disease type                        | Solid tumours           | Unresectable HCC        | Advanced unresectable/ metastatic OSCC | Locally advanced or metastatic NSCLC (squamous or nonsquamous) |                                      |
| Patients in Safety Analysis Set (N) | 80                      | 338 in tislelizumab arm | 255 in tislelizumab arm                | 534 in tislelizumab arm                                        |                                      |
| Data cut-off date                   | 08-Jul-2021 (ongoing)   | 14-Dec-2022 (completed) | 28-Dec-2022 (completed)                | 18-Jan-2024 (completed)                                        |                                      |

## Table 45 Studies in the Tislelizumab Combination Therapy Pool for ADR Determination Including Pivotal Study 312

|                                             | 205                                                                                   | 206                                                        | 304                                     | 305                                                                                                  | 306                                                                                                                             |
|---------------------------------------------|---------------------------------------------------------------------------------------|------------------------------------------------------------|-----------------------------------------|------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|
| Phase                                       | 2                                                                                     | 2                                                          | 3                                       | 3                                                                                                    | 3                                                                                                                               |
| Disease type                                | Inoperable, locally advanced or metastatic OSCC, GC/GEJ adenocarcinoma                | Locally advanced or metastatic NSCLC or SCLC               | Stage IIIB or IV nonsquamous NSCLC      | Locally advanced unresectable or metastatic GC/GEJ adenocarcinoma                                    | Unresectable, locally advanced recurrent or metastatic OSCC                                                                     |
| Chemotherapy                                | Oxaliplatin plus capecitabine for GC/GEJ adenocarcinoma; cisplatin plus 5 FU for OSCC | Platinum- containing doublet chemotherapy as per histology | Cisplatin or carboplatin and pemetrexed | Fluoropyrimidine- (capecitabine or 5-FU) and platinum- (oxaliplatin or cisplatin) based chemotherapy | Platinum- containing chemotherapy doublet (cisplatin or oxaliplatin) with fluoropyrimidine (capecitabine or 5-FU) or paclitaxel |
| Safety Analysis Set (N) in tislelizumab arm | 30 (15 GC/GEJ and 15 OSCC)                                                            | 54                                                         | 222                                     | 498                                                                                                  | 324                                                                                                                             |
| Data cut-off date                           | 31-Mar-2019 (completed)                                                               | 31-Dec-2019 (completed)                                    | 26-Apr-2023 (completed)                 | 28-Feb-2023 (ongoing)                                                                                | 28-Feb-2022 (ongoing)                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                                             | 307                                                                      | 309                         | 312                                     | 315                                                       |
|---------------------------------------------|--------------------------------------------------------------------------|-----------------------------|-----------------------------------------|-----------------------------------------------------------|
| Phase                                       | 3                                                                        | 3                           | 3                                       | 3                                                         |
| Disease type                                | Untreated Stage IIIB or IV squamous NSCLC                                | Recurrent or metastatic NPC | Untreated extensive- stage SCLC         | Resectable Stage II or IIIA NSCLC                         |
| Chemotherapy                                | T+PC: Paclitaxel and carboplatin; T+nPC: Nab- paclitaxel and carboplatin | Gemcitabine and cisplatin   | Cisplatin or carboplatin plus etoposide | Platinum-containing doublet chemotherapy as per histology |
| Safety Analysis Set (N) in tislelizumab arm | 238                                                                      | 131                         | 227                                     | 226                                                       |
| Data cut-off date                           | 28-Apr-2023 (completed)                                                  | 08-Dec-2023 (completed)     | 29-Dec-2023 (completed)                 | 21-Aug-2023 (ongoing)                                     |

## Patient exposure

Exposure to tislelizumab / placebo in Arms T+C and P+C (Study 312), in the 1L lung cancer pool, and in the tislelizumab monotherapy pool (Safety Analysis Set), respectively, is summarised in Table 46 ; exposure to chemotherapy in Study 312 and in the 1L lung cancer pool is summarised in Table 47 .

Table 46 Summary of Treatment Exposure to Tislelizumab / Placebo (Safety Analysis Set)

|                                      | Study 312                             | Study 312                            | Tislelizumab                                    |                                      |
|--------------------------------------|---------------------------------------|--------------------------------------|-------------------------------------------------|--------------------------------------|
|                                      | Tislelizumab + Chemotherapy (N = 227) | Placebo + Chemotherapy (N = 229)     | Combination Therapy in 1L Lung Cancer (N = 741) | Tislelizumab Monotherapy (N = 1952)  |
| Duration of Exposure (Months)        | Duration of Exposure (Months)         | Duration of Exposure (Months)        | Duration of Exposure (Months)                   | Duration of Exposure (Months)        |
| Mean (SD)                            | 9.51 (11.577)                         | -                                    | 12.75 (13.224)                                  | 9.78 (12.386)                        |
| Median                               | 4.47                                  | -                                    | 7.36                                            | 4.14                                 |
| Min, Max                             | 0.2, 53.3                             | -                                    | 0.2, 53.9                                       | 0.2, 63.2                            |
| Duration of Exposure (Months), n (%) | Duration of Exposure (Months), n (%)  | Duration of Exposure (Months), n (%) | Duration of Exposure (Months), n (%)            | Duration of Exposure (Months), n (%) |
| < 3                                  | 43 (18.9)                             | -                                    | 129 (17.4)                                      | 789 (40.4)                           |
| 3 to < 6                             | 103 (45.4)                            | -                                    | 194 (26.2)                                      | 368 (18.9)                           |
| 6 to < 9                             | 24 (10.6)                             | -                                    | 102 (13.8)                                      | 222 (11.4)                           |
| 9 to < 12                            | 11 (4.8)                              | -                                    | 79 (10.7)                                       | 90 (4.6)                             |
| 12 to < 18                           | 14 (6.2)                              | -                                    | 71 (9.6)                                        | 127 (6.5)                            |
| 18 to < 24                           | 4 (1.8)                               | -                                    | 38 (5.1)                                        | 87 (4.5)                             |
| ≥ 24                                 | 28 (12.3)                             | -                                    | 128 (17.3)                                      | 269 (13.8)                           |
| Duration of Exposure (Weeks)         | Duration of Exposure (Weeks)          | Duration of Exposure (Weeks)         | Duration of Exposure (Weeks)                    | Duration of Exposure (Weeks)         |
| Mean (SD)                            | 41.33 (50.339)                        | 23.76 (19.725)                       | -                                               | -                                    |
| Median                               | 19.43                                 | 19.14                                | -                                               | -                                    |
| Q1, Q3                               | 15.43, 41.14                          | 17.29, 25.71                         | -                                               | -                                    |
| Min, Max                             | 0.7, 231.7                            | 3.0, 156.6                           | -                                               | -                                    |
| Number of Cycles Received            | Number of Cycles Received             | Number of Cycles Received            | Number of Cycles Received                       | Number of Cycles Received            |
| Mean (SD)                            | 12.7 (15.48)                          | 7.3 (5.88)                           | 16.7 (17.30)                                    | 13.5 (16.96)                         |
| Median                               | 6.0                                   | 6.0                                  | 10.0                                            | 6.0                                  |
| Q1, Q3                               | 5.0, 13.0                             | 5.0, 8.0                             | -                                               | -                                    |

<div style=\"page-break-after: always\"></div>

|                                   | Study 312                             | Study 312                         |                                                              |                                     |
|-----------------------------------|---------------------------------------|-----------------------------------|--------------------------------------------------------------|-------------------------------------|
|                                   | Tislelizumab + Chemotherapy (N = 227) | Placebo + Chemotherapy (N = 229)  | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) | Tislelizumab Monotherapy (N = 1952) |
| Min, Max                          | 1, 69                                 | 1, 50                             | 1, 77                                                        | 1, 88                               |
| Number of Cycles Received, n (%)  | Number of Cycles Received, n (%)      | Number of Cycles Received, n (%)  | Number of Cycles Received, n (%)                             | Number of Cycles Received, n (%)    |
| 1                                 | 9 (4.0)                               | 11 (4.8)                          | -                                                            | -                                   |
| 2                                 | 17 (7.5)                              | 10 (4.4)                          | -                                                            | -                                   |
| 3                                 | 12 (5.3)                              | 7 (3.1)                           | -                                                            | -                                   |
| 4                                 | 17 (7.5)                              | 13 (5.7)                          | -                                                            | -                                   |
| 5-8                               | 93 ( 41.0 )                           | 142 ( 62.0 )                      | -                                                            | -                                   |
| 9-16                              | 35 (15.4)                             | 36 (15.7)                         | -                                                            | -                                   |
| >16                               | 44 ( 19.4 )                           | 10 ( 4.4 )                        | -                                                            | -                                   |
| Cumulative Dose Administered (mg) | Cumulative Dose Administered (mg)     | Cumulative Dose Administered (mg) | Cumulative Dose Administered (mg)                            | Cumulative Dose Administered (mg)   |
| Mean (SD)                         | 2547.6 (3097.38)                      | 1461.14 (1176.868)                | 3340.9 (3461.66)                                             | 2706.1 (3389.94)                    |
| Median                            | 1200.0                                | 1200.0                            | 2000.0                                                       | 1200.0                              |
| Q1, Q3                            | 1000.00, 2600.00                      | 1000.00, 1600.00                  | -                                                            | -                                   |
| Min, Max                          | 200, 13800                            | 200.0, 10000.0                    | 200, 15400                                                   | 200, 17600                          |
| Actual Dose Intensity (mg/week)   | Actual Dose Intensity (mg/week)       | Actual Dose Intensity (mg/week)   | Actual Dose Intensity (mg/week)                              | Actual Dose Intensity (mg/week)     |
| Mean (SD)                         | 61.64 (5.920)                         | -                                 | 61.05 (5.949)                                                | 64.57 (4.439)                       |
| Median                            | 63.19                                 | -                                 | 62.69                                                        | 66.67                               |
| Min, Max                          | 34.6, 68.3                            | -                                 | 26.8, 71.8                                                   | 30.8, 71.8                          |
| Actual Dose Intensity (mg/cycle)  | Actual Dose Intensity (mg/cycle)      | Actual Dose Intensity (mg/cycle)  | Actual Dose Intensity (mg/cycle)                             | Actual Dose Intensity (mg/cycle)    |
| Mean (SD)                         | 184.93 (17.759)                       | 186.80 (14.751)                   | -                                                            | -                                   |
| Median                            | 189.58                                | 190.91                            | -                                                            | -                                   |
| Q1, Q3                            | 180.65, 198.17                        | 180.65, 196.88                    | -                                                            | -                                   |
| Min, Max                          | 103.7, 204.9                          | 116.1, 206.6                      | -                                                            | -                                   |
| Relative Dose Intensity (%)       | Relative Dose Intensity (%)           | Relative Dose Intensity (%)       | Relative Dose Intensity (%)                                  | Relative Dose Intensity (%)         |
| Mean (SD)                         | 92.46 (8.879)                         | 93.40 (7.375)                     | 91.58 (8.924)                                                | 96.94 (6.549)                       |
| Median                            | 94.79                                 | 95.45                             | 94.03                                                        | 100.00                              |
| Q1, Q3                            | 90.32, 99.09                          | 90.32, 98.44                      | -                                                            | -                                   |
| Min, Max                          | 51.9, 102.4                           | 58.1, 103.3                       | 40.3, 107.7                                                  | 46.2, 107.7                         |

<div style=\"page-break-after: always\"></div>

Table 47 Summary of Treatment Exposure to Chemotherapy (Safety Analysis Set)

|                               | Study 312                             | Study 312                        |                                                              |
|-------------------------------|---------------------------------------|----------------------------------|--------------------------------------------------------------|
|                               | Tislelizumab + Chemotherapy (N = 227) | Placebo + Chemotherapy (N = 229) | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) |
| Duration of Exposure (Months) | Duration of Exposure (Months)         | Duration of Exposure (Months)    | Duration of Exposure (Months)                                |
| Mean (SD)                     | 2.77 (0.721)                          | 2.80 (0.704)                     | 5.64 (7.521)                                                 |
| Median                        | 2.86                                  | 2.89                             | 3.22                                                         |
| Q1, Q3                        | 2.76, 3.06                            | 2.76, 3.06                       | 2.79, 4.76                                                   |
| Min, Max                      | 0.2, 4.6                              | 0.7, 5.6                         | 0.2, 52.6                                                    |
| Number of Cycles Received     | Number of Cycles Received             | Number of Cycles Received        | Number of Cycles Received                                    |
| Mean (SD)                     | 3.7 (0.83)                            | 3.7 (0.78)                       | 7.4 (9.91)                                                   |
| Median                        | 4.0                                   | 4.0                              | 4.0                                                          |
| Q1, Q3                        | 4.0, 4.0                              | 4.0, 4.0                         | 4.0, 6.0                                                     |
| Min, Max                      | 1, 4                                  | 1, 4                             | 1, 69                                                        |
| Relative Dose Intensity (%)   | Relative Dose Intensity (%)           | Relative Dose Intensity (%)      | Relative Dose Intensity (%)                                  |
| Mean (SD)                     | 88.20 (11.866)                        | 87.89 (12.922)                   | 87.97 (11.274)                                               |
| Median                        | 90.18                                 | 90.15                            | 91.50                                                        |
| Q1, Q3                        | 80.53, 97.99                          | 80.41, 97.85                     | 80.52, 98.61                                                 |
| Min, Max                      | 48.0, 109.0                           | 47.0, 110.2                      | 36.6, 112.2                                                  |

## Adverse events

All TEAEs discussed in the following sections are treatment-emergent unless otherwise specified. Adverse events were coded using the Medical Dictionary for Regulatory Activities (MedDRA) terminology. All AE data were analyzed according to MedDRA Version 26.0 for AEs and for ADRs.

Since different studies have different TEAE definitions, a harmonized TEAE definition was used for analysis of safety parameters for the safety pools as well as the pivotal Study 312.

A treatment-emergent AE (TEAE) is defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study treatment up to 30 days after the last dose of study treatment or initiation of new anticancer therapy, whichever occurred first. TEAEs also included all imAEs identified as per a programmatic algorithmic approach, recorded up to 90 days after the last dose of the study treatment regardless of whether or not the patient started a new anticancer therapy. It should be noted that this differs from the Study 312 CSR analyses where imAEs starting beyond the 30-day time window after the last dose of study treatment were not considered as a TEAE.

As long as an AE met the criteria from the TEAE definition above, a same AE, defined as any consecutive records with the same Preferred Term (PT) was considered as a TEAE until its last record, even if it worsened outside of the treatment emergent period.

Safety data were summarized by number and percentage of patients having at least one TEAE, having at least one TEAE in each primary System Organ Class (SOC) and for each preferred term using MedDRA coding. A patient with multiple occurrences of a TEAE was counted only once in the respective TEAE category. A patient with multiple CTCAE grades for the same PT was summarized under the maximum CTCAE grade recorded for the event. TEAE with missing CTCAE grade were included in the 'All grades' column of the summary tables

## Adverse events summary

Owing to a harmonisation of the TEAE definition used in different studies and to a recalculation of TEAE incidence rates for the different safety pools, the safety data presented in this Assessment Report were

<div style=\"page-break-after: always\"></div>

principally extracted from the Summary of Clinical Safety, not from the (Final) Clinical Study Report of Study 312.

Table 48 Overview of Treatment-Emergent Adverse Events (including related TEAEs) (Safety Analysis Set)

|                                                                      | Study 312                                   | Study 312                              |                                                                    |                                           |
|----------------------------------------------------------------------|---------------------------------------------|----------------------------------------|--------------------------------------------------------------------|-------------------------------------------|
|                                                                      | Tislelizumab + Chemotherapy (N = 227) n (%) | Placebo + Chemotherapy (N = 229) n (%) | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) n (%) | Tislelizumab Monotherapy (N = 1952) n (%) |
| Patients With Any TEAE                                               | 226 (99.6)                                  | 228 (99.6)                             | 739 (99.7)                                                         | 1886 (96.6)                               |
| Treatment-Related                                                    | 226 (99.6)                                  | 228 (99.6)                             | 738 (99.6)                                                         | 1472 (75.4)                               |
| Related to Tislelizumab/Placebo                                      | 166 (73.1)                                  | 133 (58.1)                             | 617 (83.3)                                                         | 1472 (75.4)                               |
| Related to Any Component of Chemotherapies                           | 226 (99.6)                                  | 228 (99.6)                             | 735 (99.2)                                                         | NA                                        |
| ≥ Grade 3                                                            | 202 (89.0)                                  | 206 (90.0)                             | 619 (83.5)                                                         | 916 (46.9)                                |
| Treatment-Related                                                    | 194 (85.5)                                  | 198 (86.5)                             | 582 (78.5)                                                         | 364 (18.6)                                |
| Related to Tislelizumab/Placebo                                      | 61 (26.9)                                   | 38 (16.6)                              | 249 (33.6)                                                         | 364 (18.6)                                |
| Related to Any Component of Chemotherapies                           | 186 (81.9)                                  | 195 (85.2)                             | 559 (75.4)                                                         | NA                                        |
| Serious                                                              | 96 (42.3)                                   | 70 (30.6)                              | 323 (43.6)                                                         | 683 (35.0)                                |
| Treatment-Related                                                    | 72 (31.7)                                   | 42 (18.3)                              | 209 (28.2)                                                         | 241 (12.3)                                |
| Related to Tislelizumab/Placebo                                      | 46 (20.3)                                   | 17 (7.4)                               | 149 (20.1)                                                         | 241 (12.3)                                |
| Related to Any Component of Chemotherapies                           | 47 (20.7)                                   | 38 (16.6)                              | 135 (18.2)                                                         | NA                                        |
| Leading to Death                                                     | 14 (6.2)                                    | 4 (1.7)                                | 42 (5.7)                                                           | 150 (7.7)                                 |
| Treatment-Related                                                    | 8 (3.5)                                     | 0 (0.0)                                | 17 (2.3)                                                           | 21 (1.1)                                  |
| Related to Tislelizumab/Placebo                                      | 7 (3.1)                                     | 0 (0.0)                                | 16 (2.2)                                                           | 21 (1.1)                                  |
| Related to Any Component of Chemotherapies                           | 6 (2.6)                                     | 0 (0.0)                                | 10 (1.3)                                                           | NA                                        |
| Leading to Treatment Discontinuation                                 | 33 (14.5)                                   | 7 (3.1)                                | 192 (25.9)                                                         | 253 (13.0)                                |
| Treatment-Related                                                    | 27 (11.9)                                   | 4 (1.7)                                | 167 (22.5)                                                         | 118 (6.0)                                 |
| Leading to Tislelizumab/Placebo Discontinuation                      | 29 (12.8)                                   | 6 (2.6)                                | 115 (15.5)                                                         | 253 (13.0)                                |
| Leading to Any Component of Chemotherapies Discontinuation           | 16 (7.0)                                    | 5 (2.2)                                | 139 (18.8)                                                         | NA                                        |
| Leading to Treatment Modification                                    | 155 (68.3)                                  | 153 (66.8)                             | 538 (72.6)                                                         | 582 (29.8)                                |
| Treatment-Related                                                    | 144 (63.4)                                  | 145 (63.3)                             | 515 (69.5)                                                         | 350 (17.9)                                |
| Leading to Treatment Modification of Tislelizumab/Placebo            | 109 (48.0)                                  | 101 (44.1)                             | 439 (59.2)                                                         | 582 (29.8)                                |
| Leading to Treatment Modification of Any Component of Chemotherapies | 132 (58.1)                                  | 138 (60.3)                             | 485 (65.5)                                                         | NA                                        |
| Immune-Mediated TEAE                                                 | 91 (40.1)                                   | 42 (18.3)                              | 339 (45.7)                                                         | 659 (33.8)                                |
| Immune- Mediated TEAE ≥ Grade 3                                      | 25 (11.0)                                   | 1 (0.4)                                | 77 (10.4)                                                          | 105 (5.4)                                 |
| Infusion-Related Reaction                                            | 16 (7.0)                                    | 10 (4.4)                               | 45 (6.1)                                                           | 58 (3.0)                                  |
| Infusion-Related Reaction ≥ Grade 3                                  | 1 (0.4)                                     | 1 (0.4)                                | 3 (0.4)                                                            | 2 (0.1)                                   |

Source: ADSL, ADAE.

Abbreviations: 1L, first-line; TEAE, treatment-emergent adverse event; AE, adverse event; NA, not applicable; TEAE, treatment-emergent adverse event.

Adverse events were Graded for severity using CTCAE (v5.0 for studies 209, 304, 307, and 312, v4.03 for studies 001, 102, 203, 204, 206, 208, 301, 302, and 303).

Treatment-related TEAEs include those events considered by the investigator to be related or with missing assessment of the causal relationship.

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                               | Study 312                                                                                                                                                     | Study 312                                                                                                                                                     |                                                                                                                                                               |                                                                                                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                               | Tislelizumab + Chemotherapy (N = 227) n (%)                                                                                                                   | Placebo + Chemotherapy (N = 229) n (%)                                                                                                                        | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) n (%)                                                                                            | Tislelizumab Monotherapy (N = 1952) n (%)                                                                                                                     |
| Immune-mediated AEs were identified based on BeiGene standard process as defined in Immune-Mediated Adverse Event Identification Charter v1.2, imAE CCQ v2.4. | Immune-mediated AEs were identified based on BeiGene standard process as defined in Immune-Mediated Adverse Event Identification Charter v1.2, imAE CCQ v2.4. | Immune-mediated AEs were identified based on BeiGene standard process as defined in Immune-Mediated Adverse Event Identification Charter v1.2, imAE CCQ v2.4. | Immune-mediated AEs were identified based on BeiGene standard process as defined in Immune-Mediated Adverse Event Identification Charter v1.2, imAE CCQ v2.4. | Immune-mediated AEs were identified based on BeiGene standard process as defined in Immune-Mediated Adverse Event Identification Charter v1.2, imAE CCQ v2.4. |

## Exposure-adjusted analysis

In Study 312, the mean exposure to tislelizumab was longer than that to placebo, therefore exposureadjusted event rates (EAERs) were provided. However, as EAERs are associated with a number of methodological limitations, this Assessment Report is based on the 'naïve' rates of TEAEs.

Table 49 Overall Summary of Exposure-adjusted Event Rate of Treatment-Emergent Adverse Events (Safety Analysis Set)

|                                                                             | Study312                                                  | Study312                                            |                                                                                  |                                                        |
|-----------------------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------|----------------------------------------------------------------------------------|--------------------------------------------------------|
|                                                                             | Tislelizumab + Chemotherapy (N = 227) Event (EAER) 95% CI | Placebo + Chemotherapy (N =229) Event (EAER) 95% CI | Tislelizumab Combination Therapy in IL Lumg Cancer (N = 741) Event (EAER) 95% CI | Tislelizumab Monotherapy (N =1952) Event (EAER) 95% CI |
| Total Exposure Time (Person-Months)                                         | 2160.85                                                   | 1252.30                                             | 9623.43                                                                          | 19103.51                                               |
| All TEAE                                                                    | 5422 (250.92) (244.3, 257.7)                              | 4480 (357.74) (347.3, 368.4)                        | 22993 (238.93) (235.8, 242.0)                                                    | 21465 (112.36) (110.9, 113.9)                          |
| Treatment-Related                                                           | 3788 (175.30) (169.8, 181.0)                              | 3378 (269.74) (260.7, 279.0)                        | 17484 (181.68) (179.0, 184.4)                                                    | 8814 (46.14) (45.2, 47.1)                              |
| Tislelizumab/Placebo-Related                                                | 1188 (54.98) (51.9, 58.2)                                 | 744 (59.41) (55.2, 63.8)                            | 7065 (73.41) (71.7, 75.1)                                                        | 8814 (46.14) (45.2, 47.1)                              |
| Chemotherapy-Related                                                        | 3091 (143.05) (138.0, 148.2)                              | 3163 (252.57) (243.8, 261.5)                        | 14817 (153.97) (151.5, 156.5)                                                    | NA                                                     |
| >=Grade 3 TEAE                                                              | 721 (33.37) (31.0, 35.9)                                  | 713 (56.94) (52.8, 61.3)                            | 2498 (25.96) (24.9, 27.0)                                                        | 2023 (10.59) (10.1, 11.1)                              |
| Treatment-Related                                                           | 599 (27.72) (25.5, 30.0)                                  | 605 (48.31) (44.5, 52.3)                            | 2130 (22.13) (21.2, 23.1)                                                        | 589 (3.08) (2.8, 3.3)                                  |
| Tislelizumab/Placebo-Related                                                | 124 (5.74) (4.8, 6.8)                                     | 86 (6.87) (5.5, 8.5)                                | 644 (6.69) (6.2, 7.2)                                                            | 589 (3.08) (2.8, 3.3)                                  |
| Chemotherapy-Related                                                        | 546 (25.27) (23.2, 27.5)                                  | 599 (47.83) (44.1, 51.8)                            | 1964 (20.41) (19.5, 21.3)                                                        | NA                                                     |
| Serious TEAE                                                                | 169 (7.82) (6.7, 9.1)                                     | 103 (8.22) (6.7, 10.0)                              | 555 (5.77) (5.3, 6.3)                                                            | 1064 (5.57) (5.2, 5.9)                                 |
| >=Grade 3 TEAE                                                              | 144 (6.66) (5.6, 7.8)                                     | 89 (7.11) (5.7, 8.7)                                | 411 (4.27) (3.9, 4.7)                                                            | 792 (4.15) (3.9, 4.4)                                  |
| Treatment-Related                                                           | 122 (5.65) (4.7, 6.7)                                     | 62 (4.95) (3.8, 6.3)                                | 342 (3.55) (3.2, 4.0)                                                            | 318 (1.66) (1.5, 1.9)                                  |
| Tislelizumab/Placebo-Related Chemotherapy-Related                           | 62 (2.87) (2.2, 3.7) 83 (3.84) (3.1, 4.8)                 | 20 (1.60) (1.0, 2.5) 56 (4.47) (3.4, 5.8)           | 216 (2.24) (2.0, 2.6) 211 (2.19) (1.9, 2.5)                                      | 318 (1.66) (1.5, 1.9) NA                               |
| TEAE Leading toDeath                                                        | 15 (0.69) (0.4, 1.1)                                      | 4 (0.32) (0.1, 0.8)                                 | 45 (0.47) (0.3, 0.6)                                                             | 159 (0.83) (0.7, 1.0)                                  |
| Treatment-Related                                                           | 8 (0.37) (0.2, 0.7)                                       | 0 (0.00) (0.0, 0.0)                                 | 19 (0.20) (0.1, 0.3)                                                             | 23 (0.12) (0.1, 0.2)                                   |
| Chemotherapy-Related                                                        | 6 (0.28) (0.1, 0.6)                                       | 0 (0.00) (0.0, 0.0)                                 | 10 (0.10) (0.0, 0.2)                                                             | 23 (0.12) (0.1, 0.2) NA                                |
| Tislelizumab/Placebo-Related                                                | 7 (0.32) (0.1, 0.7)                                       | 0 (0.00) (0.0,0.0)                                  | 18 (0.19) (0.1, 0.3)                                                             |                                                        |
| TEAE Leading to Treatment                                                   | 34 (1.57) (1.1, 2.2)                                      | 7 (0.56) (0.2, 1.2)                                 | 285 (2.96) (2.6, 3.3)                                                            | 277 (1.45) (1.3, 1.6)                                  |
| Discontinuation                                                             |                                                           |                                                     |                                                                                  | 128 (0.67) (0.6, 0.8)                                  |
| Treatment-Related                                                           | 28 (1.30) (0.9, 1.9) 29 (1.34) (0.9, 1.9)                 | 4 (0.32) (0.1, 0.8) 6 (0.48) (0.2, 1.0)             | 243 (2.53) (2.2, 2.9) 148 (1.54) (1.3, 1.8)                                      | 277 (1.45) (1.3, 1.6)                                  |
| LeadingtoTreatmentDiscontinuation of Tislelizumab/Placebo Treatment-Related |                                                           |                                                     |                                                                                  | 128 (0.67) (0.6, 0.8)                                  |
| Leading toTreatment Discontinuation                                         | 23 (1.06) (0.7, 1.6) 17 (0.79) (0.5, 1.3)                 | 3 (0.24) (0.0, 0.7) 5 (0.40) (0.1, 0.9)             | 112 (1.16) (1.0, 1.4) 201 (2.09) (1.8, 2.4)                                      | NA                                                     |
| of Chemotherapy Treatment-Related                                           | 12 (0.56) (0.3, 1.0)                                      | 2 (0.16) (0.0, 0.6)                                 | 179 (1.86) (1.6, 2.2)                                                            | 0 (0.00) (0.0, 0.0)                                    |
| TEAE Leading to Treatment Modification                                      | 390 (18.05) (16.3, 19.9)                                  | 343 (27.39) (24.6, 30.4)                            | 2137 (22.21) (21.3, 23.2)                                                        | 1210 (6.33) (6.0, 6.7)                                 |
| Treatment-Related                                                           | 347 (16.06) (14.4, 17.8)                                  | 311 (24.83) (22.2, 27.8)                            |                                                                                  | 655 (3.43) (3.2, 3.7)                                  |
| LeadingtoTreatmentModification of Tislelizumab/Placebo                      | 254 (11.75) (10.4, 13.3)                                  | 194 (15.49) (13.4, 17.8)                            | 1937 (20.13) (19.2, 21.0) 1338 (13.90) (13.2, 14.7)                              | 1210 (6.33) (6.0, 6.7)                                 |
| Treatment-Related                                                           | 216 (10.00) (8.7, 11.4)                                   | 173 (13.81) (11.8, 16.0)                            | 1162 (12.07) (11.4, 12.8)                                                        | 655 (3.43) (3.2, 3.7)                                  |
| Leading toTreatment Modification of                                         | 285 (13.19) (11.7, 14.8)                                  | 291 (23.24) (20.6, 26.1)                            | 1694 (17.60) (16.8, 18.5)                                                        | NA                                                     |
| Chemotherapy Treatment-Related                                              | 267 (12.36) (10.9, 13.9)                                  | 271 (21.64) (19.1, 24.4)                            | 1592 (16.54) (15.7, 17.4)                                                        | 0 (0.00) (0.0, 0.0)                                    |

Immune-MediatedAE &gt;=Grade 3

Infusion-RelatedReactions &gt;=Grade 3

<div style=\"page-break-after: always\"></div>

## Most common adverse events

The most common TEAEs by Preferred Term (incidence rate ≥ 10% in Arm T+C) are presented in Table 50 .

Table 50 TreatmentEmergent Adverse Events with Incidence Rate ≥ 10% in Arm T+C by Preferred Term (Safety Analysis Set)

|                                        | Study 312                                   | Study 312                              |                                                                    |                                           |
|----------------------------------------|---------------------------------------------|----------------------------------------|--------------------------------------------------------------------|-------------------------------------------|
| Preferred Term                         | Tislelizumab + Chemotherapy (N = 227) n (%) | Placebo + Chemotherapy (N = 229) n (%) | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) n (%) | Tislelizumab Monotherapy (N = 1952) n (%) |
| Patients With Any TEAE                 | 226 (99.6)                                  | 228 (99.6)                             | 739 (99.7)                                                         | 1886 (96.6)                               |
| Anaemia                                | 193 (85.0)                                  | 194 (84.7)                             | 641 (86.5)                                                         | 511 (26.2)                                |
| Alopecia                               | 180 (79.3)                                  | 182 (79.5)                             | 375 (50.6)                                                         | 11 (0.6)                                  |
| Neutropenia                            | 156 (68.7)                                  | 161 (70.3)                             | 352 (47.5)                                                         | 31 (1.6)                                  |
| White blood cell count decreased       | 127 (55.9)                                  | 148 (64.6)                             | 464 (62.6)                                                         | 160 (8.2)                                 |
| Thrombocytopenia                       | 113 (49.8)                                  | 119 (52.0)                             | 278 (37.5)                                                         | 68 (3.5)                                  |
| Nausea                                 | 101 (44.5)                                  | 100 (43.7)                             | 315 (42.5)                                                         | 196 (10.0)                                |
| Decreased appetite                     | 89 (39.2)                                   | 86 (37.6)                              | 304 (41.0)                                                         | 290 (14.9)                                |
| Constipation                           | 84 (37.0)                                   | 58 (25.3)                              | 229 (30.9)                                                         | 227 (11.6)                                |
| Leukopenia                             | 75 (33.0)                                   | 56 (24.5)                              | 273 (36.8)                                                         | 63 (3.2)                                  |
| Alanine aminotransferase increased     | 67 (29.5)                                   | 46 (20.1)                              | 308 (41.6)                                                         | 430 (22.0)                                |
| Aspartate aminotransferase increased   | 52 (22.9)                                   | 35 (15.3)                              | 275 (37.1)                                                         | 482 (24.7)                                |
| Neutrophil count decreased             | 51 (22.5)                                   | 57 (24.9)                              | 392 (52.9)                                                         | 113 (5.8)                                 |
| Platelet count decreased               | 33 (14.5)                                   | 36 (15.7)                              | 279 (37.7)                                                         | 157 (8.0)                                 |
| Rash                                   | 33 (14.5)                                   | 20 (8.7)                               | 135 (18.2)                                                         | 201 (10.3)                                |
| Pyrexia                                | 32 (14.1)                                   | 17 (7.4)                               | 139 (18.8)                                                         | 311 (15.9)                                |
| Hyperuricaemia                         | 31 (13.7)                                   | 22 (9.6)                               | 81 (10.9)                                                          | 88 (4.5)                                  |
| Hypothyroidism                         | 32 (14.1)                                   | 9 (3.9)                                | 103 (13.9)                                                         | 251 (12.9)                                |
| Fatigue                                | 29 (12.8)                                   | 14 (6.1)                               | 53 (7.2)                                                           | 182 (9.3)                                 |
| Hyperglycaemia                         | 29 (12.8)                                   | 23 (10.0)                              | 104 (14.0)                                                         | 142 (7.3)                                 |
| Malaise                                | 29 (12.8)                                   | 31 (13.5)                              | 119 (16.1)                                                         | 113 (5.8)                                 |
| Gamma-glutamyltransferase increased    | 27 (11.9)                                   | 21 (9.2)                               | 102 (13.8)                                                         | 178 (9.1)                                 |
| Blood creatine phosphokinase increased | 26 (11.5)                                   | 6 (2.6)                                | 87 (11.7)                                                          | 128 (6.6)                                 |
| Dyspnoea                               | 26 (11.5)                                   | 27 (11.8)                              | 95 (12.8)                                                          | 136 (7.0)                                 |
| Pain in extremity                      | 26 (11.5)                                   | 19 (8.3)                               | 115 (15.5)                                                         | 76 (3.9)                                  |
| Lymphocyte count decreased             | 25 (11.0)                                   | 28 (12.2)                              | 95 (12.8)                                                          | 66 (3.4)                                  |
| Dizziness                              | 24 (10.6)                                   | 19 (8.3)                               | 80 (10.8)                                                          | 76 (3.9)                                  |
| Haemoptysis                            | 24 (10.6)                                   | 29 (12.7)                              | 90 (12.1)                                                          | 95 (4.9)                                  |
| Weight decreased                       | 24 (10.6)                                   | 12 (5.2)                               | 94 (12.7)                                                          | 289 (14.8)                                |
| Headache                               | 23 (10.1)                                   | 11 (4.8)                               | 49 (6.6)                                                           | 73 (3.7)                                  |

The most common TEAEs suspected by the Investigator to be causally related to any component of study treatment by Preferred Term are presented in Table 51 .

176 (8.14) (7.0,9.4) 28 (1.30) (0.9, 1.9)

19 (0.88) (0.5, 1.4) 1 (0.05)(0.0.0.3)

54 (4.31) (3.2,5.6) 1 (0.08) (0.0, 0.4)

13 (1.04) (0.6, 1.8) 1 (0.08) (0.0.0.4)

686 (7.13) (6.6, 7.7)

102 (1.06) (0.9, 1.3)

65 (0.68) (0.5, 0.9) 3 (0.03)(0.0.0.1)

1148 (6.01) (5.7,6.4) 116 (0.61) (0.5, 0.7)

77 (0.40) (0.3, 0.5)

2 (0.01) (0.0.0.0)

<div style=\"page-break-after: always\"></div>

Table 51 Treatment-Related Treatment-Emergent Adverse Events by System Organ Class with Incidence Rate ≥ 5% and by Preferred Term (Safety Analysis Set)

|                                                              | Study 312           | Study 312           |                          |                     |
|--------------------------------------------------------------|---------------------|---------------------|--------------------------|---------------------|
|                                                              |                     |                     | Tislelizumab Combination |                     |
|                                                              | Tislelizumab +      | Placebo +           |                          | Tislelizumab        |
|                                                              | Chemotherapy        | Chemotherapy        | Therapy in 1L Lung       | Monotherapy         |
| SystemOrganClass                                             | (N =227)            | (N =229)            | Cancer (N =741)          | (N = 1952)          |
| PreferredTerm                                                |                     |                     |                          | n (%)               |
| PatientsWithAnyTreatmentRelatedTEAE                          | n (%) 226 (99.6)    | n (%) 228 (99.6)    | n (%) 738 (99.6)         | 1472 (75.4)         |
| Blood and lymphatic system disorders                         | 209 (92.1)          | 214 (93.4)          | 668 (90.1)               | 282 (14.4)          |
| Anaemia                                                      | 174 (76.7)          | 180 (78.6)          | 598 (80.7)               | 204 (10.5)          |
| Neutropenia                                                  | 156 (68.7)          | 161 (70.3)          | 352 (47.5)               | 23 (1.2)            |
| Thrombocytopenia                                             | 112 (49.3)          | 119 (52.0)          | 276 (37.2)               | 36 (1.8)            |
| Leukopenia                                                   | 75 (33.0)           | 56 (24.5)           | 272 (36.7)               | 46 (2.4)            |
| Skin and subcutaneous tissue disorders                       | 183 (80.6)          |                     |                          | 398 (20.4)          |
|                                                              |                     | 185 (80.8)          | 452 (61.0)               | 7 (0.4)             |
| Alopecia                                                     | 178 (78.4)          | 182 (79.5)          | 370 (49.9) 124 (16.7)    | 163 (8.4)           |
| Rash                                                         | 28 (12.3)           | 19 (8.3)            | 46 (6.2)                 | 159 (8.1)           |
| Pruritus                                                     | 14 (6.2)            | 6 (2.6)             |                          |                     |
| Investigations                                               | 179 (78.9)          | 174 (76.0)          | 644 (86.9)               | 820 (42.0)          |
| Whitebloodcellcountdecreased                                 | 126 (55.5)          | 148 (64.6)          | 461 (62.2)               | 117 (6.0)           |
| Alanineaminotransferaseincreased                             | 60 (26.4)           | 40 (17.5)           | 285 (38.5)               | 304 (15.6)          |
| Neutrophil count decreased                                   | 51 (22.5)           | 57 (24.9)           | 388 (52.4)               | 77 (3.9)            |
| Aspartate aminotransferase increased                         | 44 (19.4)           | 31 (13.5)           | 251 (33.9)               | 334 (17.1)          |
| Platelet count decreased                                     | 32 (14.1)           | 36 (15.7)           | 274 (37.0)               | 84 (4.3)            |
| Lymphocyte count decreased                                   | 23 (10.1)           | 23 (10.0)           | 84 (11.3)                | 35 (1.8)            |
| Gastrointestinal disorders                                   | 144 (63.4)          | 118 (51.5)          | 452 (61.0)               | 320 (16.4)          |
| Nausea                                                       | 95 (41.9)           | 94 (41.0)           | 295 (39.8)               | 85 (4.4)            |
| Constipation Vomiting                                        | 52 (22.9) 50 (22.0) | 27 (11.8) 48 (21.0) | 125 (16.9) 167 (22.5)    | 32 (1.6)            |
|                                                              |                     |                     |                          | 52 (2.7)            |
| Metabolism and nutrition disorders                           | 126 (55.5)          | 109 (47.6)          | 428 (57.8)               | 326 (16.7)          |
| Decreased appetite                                           | 72 (31.7)           | 76 (33.2)           | 265 (35.8)               | 114 (5.8)           |
| Hypoalbuminaemia                                             | 24 (10.6)           | 17 (7.4)            | 79 (10.7)                | 39 (2.0)            |
| Hyponatraemia                                                | 24 (10.6)           | 14 (6.1)            | 73 (9.9)                 | 34 (1.7)            |
| Hyperglycaemia                                               | 20 (8.8)            | 11 (4.8)            | 66 (8.9)                 | 52 (2.7)            |
| Hypokalaemia                                                 | 16 (7.0)            |                     | 56 (7.6)                 | 27 (1.4)            |
| Hyperuricaemia                                               | 12 (5.3)            | 7 (3.1) 10 (4.4)    | 44 (5.9)                 | 37 (1.9)            |
| General disorders and administration site conditions         | 78 (34.4) 27 (11.9) | 56 (24.5) 24 (10.5) | 322 (43.5) 106 (14.3)    | 425 (21.8) 76 (3.9) |
| Malaise Fatigue                                              | 23 (10.1)           | 12 (5.2)            | 47 (6.3)                 | 105 (5.4)           |
| Asthenia                                                     | 14 (6.2)            | 13 (5.7)            | 119 (16.1)               | 117 (6.0)           |
| Pyrexia                                                      | 14 (6.2)            | 8 (3.5)             | 61 (8.2)                 | 132 (6.8)           |
| Endocrine disorders Hypothyroidism                           | 44 (19.4)           | 11 (4.8)            | 134 (18.1)               | 314 (16.1)          |
|                                                              | 32 (14.1)           | 9 (3.9)             | 101 (13.6)               | 235 (12.0)          |
| Hyperthyroidism                                              | 14 (6.2)            | 2 (0.9)             | 39 (5.3)                 | 82 (4.2)            |
|                                                              |                     | 0 (0.0)             | 2 (0.3)                  | 2 (0.1)             |
| Hypophysitis Respiratory, thoracic and mediastinal disorders | 2 (0.9) 31 (13.7)   | 24 (10.5)           | 141 (19.0)               | 178 (9.1)           |
| Hiccups                                                      | 10 (4.4) 9 (4.0)    | 9 (3.9) 3 (1.3)     | 18 (2.4) 53 (7.2)        | 1 (0.1) 52 (2.7)    |
| Pneumonitis                                                  |                     |                     |                          |                     |
|                                                              |                     | 3 (1.3)             | 15 (2.0)                 | 38 (1.9)            |
| Cough                                                        | 4 (1.8)             |                     | 25 (3.4)                 | 22 (1.1)            |
| Dyspnoea                                                     | 4 (1.8)             | 1 (0.4)             |                          |                     |
| Immune-mediated lung disease                                 | 3 (1.3)             | 1 (0.4)             | 13 (1.8)                 | 21 (1.1)            |
| Nervous system disorders Dizziness                           | 25 (11.0)           | 20 (8.7)            | 145 (19.6) 36 (4.9)      | 74 (3.8) 17 (0.9)   |
| Hypoaesthesia                                                | 12 (5.3)            | 7 (3.1)             |                          |                     |
|                                                              | 4 (1.8)             | 2 (0.9)             | 47 (6.3)                 | 9 (0.5)             |
| Headache                                                     | 3 (1.3)             | 4 (1.7)             | 7 (0.9)                  | 15 (0.8)            |
| Musculoskeletal and connective tissue disorders              | 21 (9.3)            | 14 (6.1)            | 149 (20.1)               | 152 (7.8)           |
| Arthralgia                                                   | 11 (4.8)            | 3 (1.3)             | 61 (8.2)                 | 59 (3.0)            |
| Pain in extremity                                            | 6 (2.6)             | 4 (1.7)             | 64 (8.6)                 | 17 (0.9)            |
| Muscular weakness Mvositis                                   | 3 (1.3)             | 1 (0.4)             | 15 (2.0)                 | 8 (0.4)             |
|                                                              | 3 (1.3)             | 1 (0.4)             | 5 (0.7)                  | 13 (0.7)            |
| Cardiac disorders                                            | 20 (8.8)            | 8 (3.5)             | 80 (10.8)                | 66 (3.4)            |
| Sinus tachycardia                                            | 6 (2.6)             | 0 (0.0)             | 14 (1.9)                 | 4 (0.2)             |
|                                                              |                     | 0 (0.0)             | 6 (0.8)                  | 3 (0.2)             |
| Immune-mediated myocarditis                                  | 4 (1.8)             | 0 (0.0)             |                          |                     |
| Palpitations                                                 | 3 (1.3)             |                     | 13 (1.8)                 | 7 (0.4)             |

<div style=\"page-break-after: always\"></div>

|                                | Study312                                  | Study312                             |                                                                |                                          |
|--------------------------------|-------------------------------------------|--------------------------------------|----------------------------------------------------------------|------------------------------------------|
| SystemOrganClass PreferredTerm | Tislelizumab+ Chemotherapy (N =227) n (%) | Placebo + Chemotherapy (N=229) n (%) | Tislelizumab Combination TherapyinILLung Cancer' (N=741) n (%) | Tislelizumab Monotherapy (N =1952) n (%) |
| Infectionsandinfestations      | 14 (6.2)                                  | 10 (4.4)                             | 75 (10.1)                                                      | 113 (5.8)                                |
| Upperrespiratorytractinfection | 5 (2.2)                                   | 0 (0.0)                              | 16 (2.2)                                                       | 14 (0.7)                                 |
| Herpes zoster                  | 2 (0.9)                                   | 0 (0.0)                              | 6 (0.8)                                                        | 8 (0.4)                                  |
| Pneumonia                      | 2 (0.9)                                   | 4 (1.7)                              | 22 (3.0)                                                       | 36 (1.8)                                 |
| Psychiatric disorders          | 13 (5.7)                                  | 7 (3.1)                              | 29 (3.9)                                                       | 21 (1.1)                                 |
| Insomnia                       | 11 (4.8)                                  | 5 (2.2)                              | 21 (2.8)                                                       | 20 (1.0)                                 |
| Agitation                      | 1 (0.4)                                   | 0 (0.0)                              | 3 (0.4)                                                        | 0 (0.0)                                  |
| Sitophobia                     | 1 (0.4)                                   | 0 (0.0)                              | 2 (0.3)                                                        | 0 (0.0)                                  |

## Severe adverse events

Severe (≥ CTCAE Grade 3) TEAEs by System Organ Class and the most common severe TEAEs by Preferred Term (incidence rate ≥ 2% in Arm T+C) are presented below.

Table 52 TreatmentEmergent Adverse Events ≥ Grade 3 by System Organ Class (Safety Analysis Set)

|                                                      | Study 312                                   | Study 312                              |                                                                    |                                           |
|------------------------------------------------------|---------------------------------------------|----------------------------------------|--------------------------------------------------------------------|-------------------------------------------|
|                                                      | Tislelizumab + Chemotherapy (N = 227) n (%) | Placebo + Chemotherapy (N = 229) n (%) | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) n (%) | Tislelizumab Monotherapy (N = 1952) n (%) |
| Primary System Organ Class                           |                                             |                                        |                                                                    |                                           |
| Patients With Any TEAE                               | 202 (89.0)                                  | 206 (90.0)                             | 619 (83.5)                                                         | 916 (46.9)                                |
| Blood and lymphatic system disorders                 | 154 (67.8)                                  | 153 (66.8)                             | 380 (51.3)                                                         | 125 (6.4)                                 |
| Investigations                                       | 84 (37.0)                                   | 90 (39.3)                              | 351 (47.4)                                                         | 282 (14.4)                                |
| Metabolism and nutrition disorders                   | 48 (21.1)                                   | 33 (14.4)                              | 98 (13.2)                                                          | 178 (9.1)                                 |
| Infections and infestations                          | 14 (6.2)                                    | 10 (4.4)                               | 68 (9.2)                                                           | 156 (8.0)                                 |
| General disorders and administration site conditions | 13 (5.7)                                    | 1 (0.4)                                | 32 (4.3)                                                           | 99 (5.1)                                  |
| Respiratory, thoracic and mediastinal disorders      | 12 (5.3)                                    | 8 (3.5)                                | 58 (7.8)                                                           | 113 (5.8)                                 |
| Gastrointestinal disorders                           | 11 (4.8)                                    | 6 (2.6)                                | 31 (4.2)                                                           | 165 (8.5)                                 |
| Nervous system disorders                             | 10 (4.4)                                    | 5 (2.2)                                | 26 (3.5)                                                           | 53 (2.7)                                  |
| Vascular disorders                                   | 10 (4.4)                                    | 12 (5.2)                               | 15 (2.0)                                                           | 56 (2.9)                                  |
| Skin and subcutaneous tissue disorders               | 8 (3.5)                                     | 4 (1.7)                                | 23 (3.1)                                                           | 31 (1.6)                                  |
| Cardiac disorders                                    | 5 (2.2)                                     | 7 (3.1)                                | 14 (1.9)                                                           | 32 (1.6)                                  |
| Musculoskeletal and connective tissue disorders      | 3 (1.3)                                     | 4 (1.7)                                | 14 (1.9)                                                           | 39 (2.0)                                  |
| Endocrine disorders                                  | 2 (0.9)                                     | 0 (0.0)                                | 4 (0.5)                                                            | 7 (0.4)                                   |

<div style=\"page-break-after: always\"></div>

|                                                                          | Study 312                                   | Study 312                              |                                                                    |                                           |
|--------------------------------------------------------------------------|---------------------------------------------|----------------------------------------|--------------------------------------------------------------------|-------------------------------------------|
|                                                                          | Tislelizumab + Chemotherapy (N = 227) n (%) | Placebo + Chemotherapy (N = 229) n (%) | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) n (%) | Tislelizumab Monotherapy (N = 1952) n (%) |
| Primary System Organ Class                                               |                                             |                                        |                                                                    |                                           |
| Hepatobiliary disorders                                                  | 2 (0.9)                                     | 1 (0.4)                                | 14 (1.9)                                                           | 75 (3.8)                                  |
| Injury, poisoning and procedural complications                           | 2 (0.9)                                     | 3 (1.3)                                | 10 (1.3)                                                           | 28 (1.4)                                  |
| Ear and labyrinth disorders                                              | 1 (0.4)                                     | 0 (0.0)                                | 1 (0.1)                                                            | 3 (0.2)                                   |
| Neoplasms benign, malignant and unspecified (including cysts and polyps) | 1 (0.4)                                     | 6 (2.6)                                | 6 (0.8)                                                            | 37 (1.9)                                  |
| Renal and urinary disorders                                              | 1 (0.4)                                     | 1 (0.4)                                | 7 (0.9)                                                            | 24 (1.2)                                  |
| Eye disorders                                                            | 0 (0.0)                                     | 0 (0.0)                                | 2 (0.3)                                                            | 9 (0.5)                                   |
| Immune system disorders                                                  | 0 (0.0)                                     | 0 (0.0)                                | 1 (0.1)                                                            | 2 (0.1)                                   |
| Product issues                                                           | 0 (0.0)                                     | 0 (0.0)                                | 0 (0.0)                                                            | 1 (0.1)                                   |
| Psychiatric disorders                                                    | 0 (0.0)                                     | 0 (0.0)                                | 4 (0.5)                                                            | 3 (0.2)                                   |
| Reproductive system and breast disorders                                 | 0 (0.0)                                     | 0 (0.0)                                | 1 (0.1)                                                            | 1 (0.1)                                   |

## Table 53 TreatmentEmergent Adverse Events ≥ Grade 3 with Incidence Rate ≥ 2% in Arm T+C by Preferred Term (Safety Analysis Set)

|                                     | Study 312                                   | Study 312                              |                                                                    |                                           |
|-------------------------------------|---------------------------------------------|----------------------------------------|--------------------------------------------------------------------|-------------------------------------------|
| Preferred Term                      | Tislelizumab + Chemotherapy (N = 227) n (%) | Placebo + Chemotherapy (N = 229) n (%) | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) n (%) | Tislelizumab Monotherapy (N = 1952) n (%) |
| Patients With Any TEAE ≥ Grade 3    | 202 (89.0)                                  | 206 (90.0)                             | 619 (83.5)                                                         | 916 (46.9)                                |
| Neutropenia                         | 128 (56.4)                                  | 125 (54.6)                             | 257 (34.7)                                                         | 10 (0.5)                                  |
| White blood cell count decreased    | 54 (23.8)                                   | 63 (27.5)                              | 152 (20.5)                                                         | 10 (0.5)                                  |
| Thrombocytopenia                    | 44 (19.4)                                   | 58 (25.3)                              | 98 (13.2)                                                          | 6 (0.3)                                   |
| Anaemia                             | 40 (17.6)                                   | 42 (18.3)                              | 122 (16.5)                                                         | 92 (4.7)                                  |
| Neutrophil count decreased          | 33 (14.5)                                   | 49 (21.4)                              | 234 (31.6)                                                         | 18 (0.9)                                  |
| Leukopenia                          | 27 (11.9)                                   | 24 (10.5)                              | 101 (13.6)                                                         | 4 (0.2)                                   |
| Hyponatraemia                       | 25 (11.0)                                   | 19 (8.3)                               | 36 (4.9)                                                           | 53 (2.7)                                  |
| Hypokalaemia                        | 15 (6.6)                                    | 4 (1.7)                                | 24 (3.2)                                                           | 36 (1.8)                                  |
| Hypertension                        | 9 (4.0)                                     | 10 (4.4)                               | 12 (1.6)                                                           | 43 (2.2)                                  |
| Platelet count decreased            | 8 (3.5)                                     | 8 (3.5)                                | 59 (8.0)                                                           | 16 (0.8)                                  |
| Lymphocyte count decreased          | 7 (3.1)                                     | 10 (4.4)                               | 59 (8.0)                                                           | 16 (0.8)                                  |
| Gamma-glutamyltransferase increased | 5 (2.2)                                     | 1 (0.4)                                | 16 (2.2)                                                           | 60 (3.1)                                  |
| Hypochloraemia                      | 5 (2.2)                                     | 1 (0.4)                                | 7 (0.9)                                                            | 4 (0.2)                                   |
| Pneumonia                           | 5 (2.2)                                     | 6 (2.6)                                | 34 (4.6)                                                           | 77 (3.9)                                  |
| Rash                                | 5 (2.2)                                     | 0 (0.0)                                | 15 (2.0)                                                           | 12 (0.6)                                  |
| Febrile neutropenia                 | 4 (1.8)                                     | 8 (3.5)                                | 16 (2.2)                                                           | 0 (0.0)                                   |

<div style=\"page-break-after: always\"></div>

## Table 54 Treatment-Related TreatmentEmergent Adverse Events ≥ Grade 3 by System Organ Class with Incidence Rate ≥ 5% and by Preferred Term (Safety Analysis Set)

|                                                  | Study 312                                  | Study 312                             |                                                                    |                                          |
|--------------------------------------------------|--------------------------------------------|---------------------------------------|--------------------------------------------------------------------|------------------------------------------|
| SystemOrgan Class PreferredTerm                  | Tislelizumab+ Chemotherapy (N = 227) n (%) | Placebo+ Chemotherapy (N = 229) n (%) | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) n (%) | Tislelizumab Monotherapy (N =1952) n (%) |
| PatientsWithAny Treatment-Related TEAE >=Grade 3 | 194 (85.5)                                 | 198 (86.5)                            | 582 (78.5)                                                         | 364 (18.6)                               |
| Blood and lymphaticsystem disorders              | 153 (67.4)                                 | 152 (66.4)                            | 373 (50.3)                                                         | 41 (2.1)                                 |
| Neutropenia                                      | 128 (56.4)                                 | 125 (54.6)                            | 257 (34.7)                                                         | 7 (0.4)                                  |
| Thrombocytopenia                                 | 44 (19.4)                                  | 58 (25.3)                             | 98 (13.2)                                                          | 3 (0.2)                                  |
| Anaemia                                          | 38 (16.7)                                  | 39 (17.0)                             | 110 (14.8)                                                         | 27 (1.4)                                 |
| Leukopenia                                       | 26 (11.5)                                  | 24 (10.5)                             | 100 (13.5)                                                         | 3 (0.2)                                  |
| Investigations                                   | 82 (36.1)                                  | 89 (38.9)                             | 340 (45.9)                                                         | 135 (6.9)                                |
| Whiteblood cellcount decreased                   | 54 (23.8)                                  | 63 (27.5)                             | 150 (20.2)                                                         | 4 (0.2)                                  |
| Neutrophilcountdecreased                         | 33 (14.5)                                  | 49 (21.4)                             | 234 (31.6)                                                         | 9 (0.5)                                  |
| Platelet count decreased                         | 8 (3.5)                                    | 8 (3.5)                               | 58 (7.8)                                                           | 5 (0.3)                                  |
| Lymphocytecount decreased                        | 7 (3.1)                                    | 8 (3.5)                               | 18 (2.4)                                                           | 10 (0.5)                                 |
| Metabolism andnutrition disorders                | 17 (7.5)                                   | 6 (2.6)                               | 41 (5.5)                                                           | 36 (1.8)                                 |
| Hypokalaemia                                     | 5 (2.2)                                    | 0 (0.0)                               | 9 (1.2)                                                            | 6 (0.3)                                  |
| Hyponatraemia                                    | 4 (1.8)                                    | 3 (1.3)                               | 11 (1.5)                                                           | 9 (0.5)                                  |
| Hyperglycaemia                                   | 3 (1.3)                                    | 2 (0.9)                               | 4 (0.5)                                                            | 7 (0.4)                                  |

## Serious adverse event/deaths/other significant events

## Serious adverse events

## Table 55 Serious TreatmentEmergent Adverse Events with Incidence Rate ≥ 1% in Arm T+C by Preferred Term (Safety Analysis Set)

|                                      | Study 312                                   | Study 312                              |                                                                    |                                           |
|--------------------------------------|---------------------------------------------|----------------------------------------|--------------------------------------------------------------------|-------------------------------------------|
| Preferred Term                       | Tislelizumab + Chemotherapy (N = 227) n (%) | Placebo + Chemotherapy (N = 229) n (%) | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) n (%) | Tislelizumab Monotherapy (N = 1952) n (%) |
| Patients With Any Serious TEAE       | 96 (42.3)                                   | 70 (30.6)                              | 323 (43.6)                                                         | 683 (35.0)                                |
| Thrombocytopenia                     | 17 (7.5)                                    | 18 (7.9)                               | 29 (3.9)                                                           | 2 (0.1)                                   |
| Neutropenia                          | 16 (7.0)                                    | 9 (3.9)                                | 19 (2.6)                                                           | 1 (0.1)                                   |
| Hyponatraemia                        | 5 (2.2)                                     | 1 (0.4)                                | 7 (0.9)                                                            | 8 (0.4)                                   |
| Neutrophil count decreased           | 5 (2.2)                                     | 3 (1.3)                                | 16 (2.2)                                                           | 0 (0.0)                                   |
| Platelet count decreased             | 5 (2.2)                                     | 5 (2.2)                                | 15 (2.0)                                                           | 4 (0.2)                                   |
| Pneumonitis                          | 5 (2.2)                                     | 0 (0.0)                                | 34 (4.6)                                                           | 25 (1.3)                                  |
| White blood cell count decreased     | 5 (2.2)                                     | 3 (1.3)                                | 7 (0.9)                                                            | 0 (0.0)                                   |
| Alanine aminotransferase increased   | 4 (1.8)                                     | 0 (0.0)                                | 8 (1.1)                                                            | 12 (0.6)                                  |
| Pneumonia                            | 4 (1.8)                                     | 5 (2.2)                                | 39 (5.3)                                                           | 85 (4.4)                                  |
| Febrile neutropenia                  | 3 (1.3)                                     | 5 (2.2)                                | 10 (1.3)                                                           | 0 (0.0)                                   |
| Aspartate aminotransferase increased | 3 (1.3)                                     | 0 (0.0)                                | 8 (1.1)                                                            | 15 (0.8)                                  |
| Anaemia                              | 3 (1.3)                                     | 4 (1.7)                                | 10 (1.3)                                                           | 6 (0.3)                                   |
| Ileus                                | 3 (1.3)                                     | 1 (0.4)                                | 3 (0.4)                                                            | 2 (0.1)                                   |
| Immune-mediated myocarditis          | 3 (1.3)                                     | 0 (0.0)                                | 5 (0.7)                                                            | 3 (0.2)                                   |
| Leukopenia                           | 3 (1.3)                                     | 1 (0.4)                                | 7 (0.9)                                                            | 0 (0.0)                                   |
| Haemoptysis                          | 2 (0.9)                                     | 5 (2.2)                                | 14 (1.9)                                                           | 13 (0.7)                                  |

<div style=\"page-break-after: always\"></div>

## Table 56 Serious Treatment-Emergent Adverse Events by System Organ Class (Safety Analysis Set)

|                                                                         | Study 312                                   | Study 312                              |                                                                    |                                           |
|-------------------------------------------------------------------------|---------------------------------------------|----------------------------------------|--------------------------------------------------------------------|-------------------------------------------|
|                                                                         | Tislelizumab + Chemotherapy (N = 227) n (%) | Placebo + Chemotherapy (N = 229) n (%) | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) n (%) | Tislelizumab Monotherapy (N = 1952) n (%) |
| Primary System Organ Class                                              |                                             |                                        |                                                                    |                                           |
| Patients With Any TEAE                                                  | 96 (42.3)                                   | 70 (30.6)                              | 323 (43.6)                                                         | 683 (35.0)                                |
| Blood and lymphatic system disorders                                    | 28 (12.3)                                   | 28 (12.2)                              | 64 (8.6)                                                           | 15 (0.8)                                  |
| Investigations                                                          | 17 (7.5)                                    | 6 (2.6)                                | 46 (6.2)                                                           | 33 (1.7)                                  |
| Metabolism and nutrition disorders                                      | 15 (6.6)                                    | 4 (1.7)                                | 30 (4.0)                                                           | 53 (2.7)                                  |
| Respiratory, thoracic and mediastinal disorders                         | 14 (6.2)                                    | 10 (4.4)                               | 84 (11.3)                                                          | 138 (7.1)                                 |
| Gastrointestinal disorders                                              | 11 (4.8)                                    | 5 (2.2)                                | 35 (4.7)                                                           | 142 (7.3)                                 |
| General disorders and administration site conditions                    | 9 (4.0)                                     | 1 (0.4)                                | 32 (4.3)                                                           | 81 (4.1)                                  |
| Infections and infestations                                             | 9 (4.0)                                     | 9 (3.9)                                | 59 (8.0)                                                           | 142 (7.3)                                 |
| Nervous system disorders                                                | 8 (3.5)                                     | 4 (1.7)                                | 24 (3.2)                                                           | 50 (2.6)                                  |
| Cardiac disorders                                                       | 7 (3.1)                                     | 5 (2.2)                                | 18 (2.4)                                                           | 34 (1.7)                                  |
| Endocrine disorders                                                     | 3 (1.3)                                     | 0 (0.0)                                | 5 (0.7)                                                            | 8 (0.4)                                   |
| Hepatobiliary disorders                                                 | 2 (0.9)                                     | 0 (0.0)                                | 12 (1.6)                                                           | 65 (3.3)                                  |
| Injury, poisoning and procedural complications                          | 2 (0.9)                                     | 2 (0.9)                                | 12 (1.6)                                                           | 29 (1.5)                                  |
| Musculoskeletal and connective tissue disorders                         | 2 (0.9)                                     | 3 (1.3)                                | 9 (1.2)                                                            | 31 (1.6)                                  |
| Neoplasms benign, malignant and unspecified (including cysts and polyps | 2 (0.9)                                     | 4 (1.7)                                | 5 (0.7)                                                            | 33 (1.7)                                  |
| Skin and subcutaneous tissue disorders                                  | 2 (0.9)                                     | 0 (0.0)                                | 7 (0.9)                                                            | 14 (0.7)                                  |
| Ear and labyrinth disorders                                             | 1 (0.4)                                     | 0 (0.0)                                | 1 (0.1)                                                            | 1 (0.1)                                   |
| Renal and urinary disorders                                             | 1 (0.4)                                     | 0 (0.0)                                | 7 (0.9)                                                            | 23 (1.2)                                  |
| Eye disorders                                                           | 0 (0.0)                                     | 0 (0.0)                                | 3 (0.4)                                                            | 6 (0.3)                                   |
| Immune system disorders                                                 | 0 (0.0)                                     | 0 (0.0)                                | 0 (0.0)                                                            | 3 (0.2)                                   |
| Product issues                                                          | 0 (0.0)                                     | 0 (0.0)                                | 0 (0.0)                                                            | 1 (0.1)                                   |
| Psychiatric disorders                                                   | 0 (0.0)                                     | 0 (0.0)                                | 4 (0.5)                                                            | 2 (0.1)                                   |
| Reproductive system and breast disorders                                | 0 (0.0)                                     | 0 (0.0)                                | 1 (0.1)                                                            | 1 (0.1)                                   |
| Surgical and medical procedures                                         | 0 (0.0)                                     | 0 (0.0)                                | 0 (0.0)                                                            | 1 (0.1)                                   |
| Vascular disorders                                                      | 0 (0.0)                                     | 4 (1.7)                                | 2 (0.3)                                                            | 12 (0.6)                                  |

<div style=\"page-break-after: always\"></div>

Table 57 Serious Treatment-Related Treatment-Emergent Adverse Events by System Organ Class with Incidence Rate ≥ 2% and by Preferred Term (Safety Analysis Set)

|                                                      | Study 312                                 | Study 312                              |                                                                    |                                          |
|------------------------------------------------------|-------------------------------------------|----------------------------------------|--------------------------------------------------------------------|------------------------------------------|
| System Organ Class PreferredTerm                     | Tislelizumab + Chemotherapy (N=227) n (%) | Placebo + Chemotherapy (N = 229) n (%) | Tislelizumab Combination Therapy in IL Lung Cancer (N = 741) n (%) | Tislelizumab Monotherapy (N =1952) n (%) |
| Patients With Any Serious, Treatment-Related TEAE    | 72 (31.7)                                 | 42 (18.3)                              | 209 (28.2)                                                         | 241 (12.3)                               |
| Blood andlymphaticsystem disorders                   | 28 (12.3)                                 | 28 (12.2)                              | 62 (8.4)                                                           | 8 (0.4)                                  |
| Thrombocytopenia                                     | 17 (7.5)                                  | 18 (7.9)                               | 29 (3.9)                                                           | 1 (0.1)                                  |
| Neutropenia                                          | 16 (7.0)                                  | 9 (3.9)                                | 19 (2.6)                                                           | 1 (0.1)                                  |
| Anaemia                                              | 3 (1.3)                                   | 4 (1.7)                                | 9 (1.2)                                                            | 3 (0.2)                                  |
| Febrile neutropenia                                  | 3 (1.3)                                   | 5 (2.2)                                | 10 (1.3)                                                           | 0 (0.0)                                  |
| Leukopenia                                           | 3 (1.3)                                   | 1 (0.4)                                | 7 (0.9)                                                            | 0 (0.0)                                  |
| Investigations                                       | 17 (7.5)                                  | 6 (2.6)                                | 46 (6.2)                                                           | 24 (1.2)                                 |
| Neutrophil count decreased                           | 5 (2.2)                                   | 3 (1.3)                                | 16 (2.2)                                                           | 0 (0.0)                                  |
| Platelet count decreased                             | 5 (2.2)                                   | 5 (2.2)                                | 15 (2.0)                                                           | 4 (0.2)                                  |
| Whitebloodcellcountdecreased                         | 5 (2.2)                                   | 3 (1.3)                                | 7 (0.9)                                                            | 0 (0.0)                                  |
| Alanine aminotransferaseincreased                    | 4 (1.8)                                   | 0 (0.0)                                | 8 (1.1)                                                            | 10 (0.5)                                 |
| Aspartate aminotransferaseincreased                  | 3 (1.3)                                   | 0 (0.0)                                | 8 (1.1)                                                            | 11 (0.6)                                 |
| Respiratory,thoracicandmediastinaldisorders          | 8 (3.5)                                   | 3 (1.3)                                | 46 (6.2)                                                           | 66 (3.4)                                 |
| Pneumonitis                                          | 4 (1.8)                                   | 0 (0.0)                                | 30 (4.0)                                                           | 24 (1.2)                                 |
| Asthma                                               | 1 (0.4)                                   | 0 (0.0)                                | 1 (0.1)                                                            | 0 (0.0)                                  |
| Immune-mediated lung disease                         | 1 (0.4)                                   | 1 (0.4)                                | 5 (0.7)                                                            | 15 (0.8)                                 |
| Interstitial lung disease                            | 1 (0.4)                                   | 1 (0.4)                                | 6 (0.8)                                                            | 11 (0.6)                                 |
| Respiratory failure                                  | 1 (0.4)                                   | 0 (0.0)                                | 1 (0.1)                                                            | 1 (0.1)                                  |
| Metabolism andnutritiondisorders                     | 7 (3.1)                                   | 1 (0.4)                                | 19 (2.6)                                                           | 19 (1.0)                                 |
| Diabetes mellitus                                    | 2 (0.9)                                   | 0 (0.0)                                | 3 (0.4)                                                            | 0 (0.0)                                  |
| Hyperglycaemia                                       | 2 (0.9)                                   | 1 (0.4)                                | 2 (0.3)                                                            | 4 (0.2)                                  |
| Type 1 diabetes mellitus                             | 2 (0.9)                                   | 0 (0.0)                                | 4 (0.5)                                                            | 3 (0.2)                                  |
| Diabetic ketosis                                     | 1 (0.4)                                   | 0 (0.0)                                | 1 (0.1)                                                            | 0 (0.0)                                  |
| Gastrointestinaldisorders                            | 6 (2.6)                                   | 1 (0.4)                                | 19 (2.6)                                                           | 28 (1.4)                                 |
| Diamhoea                                             | 2 (0.9)                                   | 0 (0.0)                                | 3 (0.4)                                                            | 5 (0.3)                                  |
| Ileus                                                | 2 (0.9)                                   | 0 (0.0)                                | 2 (0.3)                                                            | 0 (0.0)                                  |
| Abdominaldistension                                  | 1 (0.4)                                   | 0 (0.0)                                | 1 (0.1)                                                            | 1 (0.1)                                  |
| Gastrointestinal haemomhage                          | 1 (0.4)                                   | 0 (0.0)                                | 1 (0.1)                                                            | 0 (0.0)                                  |
| Cardiac disorders                                    | 5 (2.2)                                   | 0 (0.0)                                | 12 (1.6)                                                           | 14 (0.7)                                 |
| Immune-mediated myocarditis                          | 3 (1.3)                                   | 0 (0.0)                                | 5 (0.7)                                                            | 3 (0.2)                                  |
| Autoimmunemyocarditis                                | 1 (0.4)                                   | 0 (0.0)                                | 1 (0.1)                                                            | 1 (0.1)                                  |
| Cardiac failure acute                                | 1 (0.4)                                   | 0 (0.0)                                | 1 (0.1)                                                            | 0 (0.0)                                  |
| Paloitations                                         | 1 (0.4)                                   | 0(0.0)                                 | 1 (0.1)                                                            | 1 (0.1)                                  |
| General disorders and administration site conditions | 5 (2.2)                                   | 0 (0.0)                                | 14 (1.9)                                                           | 14 (0.7)                                 |
| Fatigue                                              | 2 (0.9)                                   | 0 (0.0)                                | 3 (0.4)                                                            | 2 (0.1)                                  |
| Asthenia                                             | 1 (0.4)                                   | 0 (0.0)                                | 1 (0.1)                                                            | 2 (0.1)                                  |
| Death                                                | 1 (0.4)                                   | 0 (0.0)                                | 2 (0.3)                                                            | 2 (0.1)                                  |
| Malaise                                              | 1 (0.4)                                   | 0 (0.0)                                | 2 (0.3)                                                            | 2 (0.1)                                  |

## Deaths

## Table 58 Summary of All Deaths (Safety Analysis Set)

|                        | Study 312                                   | Study 312                              |                                                                    |                                           |
|------------------------|---------------------------------------------|----------------------------------------|--------------------------------------------------------------------|-------------------------------------------|
| Category               | Tislelizumab + Chemotherapy (N = 227) n (%) | Placebo + Chemotherapy (N = 229) n (%) | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) n (%) | Tislelizumab Monotherapy (N = 1952) n (%) |
| Total Number of Deaths | 175 (77.1)                                  | 196 (85.6)                             | 506 (68.3)                                                         | 1412 (72.3)                               |
| Cause of Death         |                                             |                                        |                                                                    |                                           |
| Disease Under Study    | 157 (69.2)                                  | 188 (82.1)                             | 357 (48.2)                                                         | 1181 (60.5)                               |
| Adverse Event          | 8 (3.5)                                     | 0 (0.0)                                | 30 (4.0)                                                           | 87 (4.5)                                  |
| Concurrent Illness     | 0 (0.0)                                     | 0 (0.0)                                | 0 (0.0)                                                            | 9 (0.5)                                   |

<div style=\"page-break-after: always\"></div>

|                                                    | Study 312                                   | Study 312                              |                                                                    |                                           |
|----------------------------------------------------|---------------------------------------------|----------------------------------------|--------------------------------------------------------------------|-------------------------------------------|
| Category                                           | Tislelizumab + Chemotherapy (N = 227) n (%) | Placebo + Chemotherapy (N = 229) n (%) | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) n (%) | Tislelizumab Monotherapy (N = 1952) n (%) |
| Indeterminate                                      | 0 (0.0)                                     | 0 (0.0)                                | 78 (10.5)                                                          | 49 (2.5)                                  |
| Unknown                                            | 0 (0.0)                                     | 0 (0.0)                                | 0 (0.0)                                                            | 13 (0.7)                                  |
| Other                                              | 10 (4.4)                                    | 8 (3.5)                                | 41 (5.5)                                                           | 73 (3.7)                                  |
| Death Within 30 Days After Last Dose of Study Drug | 12 (5.3)                                    | 6 (2.6)                                | 28 (3.8)                                                           | 140 (7.2)                                 |
| Cause of Death                                     |                                             |                                        |                                                                    |                                           |
| Disease Under Study                                | 7 (3.1)                                     | 6 (2.6)                                | 11 (1.5)                                                           | 78 (4.0)                                  |
| Adverse Event                                      | 5 (2.2)                                     | 0 (0.0)                                | 16 (2.2)                                                           | 58 (3.0)                                  |
| Concurrent Illness                                 | 0 (0.0)                                     | 0 (0.0)                                | 0 (0.0)                                                            | 1 (0.1)                                   |
| Indeterminate                                      | 0 (0.0)                                     | 0 (0.0)                                | 1 (0.1)                                                            | 2 (0.1)                                   |
| Other                                              | 0 (0.0)                                     | 0 (0.0)                                | 0 (0.0)                                                            | 1 (0.1)                                   |
| Death > 30 Days After Last Dose of Study Drug      | 163 (71.8)                                  | 190 (83.0)                             | 478 (64.5)                                                         | 1272 (65.2)                               |
| Cause of Death                                     |                                             |                                        |                                                                    |                                           |
| Disease Under Study                                | 150 (66.1)                                  | 182 (79.5)                             | 346 (46.7)                                                         | 1103 (56.5)                               |
| Adverse Event                                      | 3 (1.3)                                     | 0 (0.0)                                | 14 (1.9)                                                           | 29 (1.5)                                  |
| Concurrent Illness                                 | 0 (0.0)                                     | 0 (0.0)                                | 0 (0.0)                                                            | 8 (0.4)                                   |
| Indeterminate                                      | 0 (0.0)                                     | 0 (0.0)                                | 77 (10.4)                                                          | 47 (2.4)                                  |
| Unknown                                            | 0 (0.0)                                     | 0 (0.0)                                | 0 (0.0)                                                            | 13 (0.7)                                  |
| Other                                              | 10 (4.4)                                    | 8 (3.5)                                | 41 (5.5)                                                           | 72 (3.7)                                  |

Abbreviation: 1L, first-line.

Death reasons 'Progression of disease' and 'Disease progression' were reported under 'Disease Under Study'.

Deaths with complete missing death dates were only counted in total number of deaths.

(data cut-off 29 December 2023)

TEAEs leading to death (incidence rate ≥ 0.4%) are presented in Table 59 . The total number of fatalities in Study 312 (14 patients in Arm T+C and 4 patients in Arm P+C) includes both the patients for whom the primary cause of death was the disease under study (2+2+1+1=6 patients in Arm T+C versus 1 patient in Arm P+C; Table 59 ) and the patients for whom the primary cause of death was a TEAEs (8 patients in Arm T+C versus 0 patients in Arm P+C; Table 58 ); as per the protocol, signs and symptoms of disease progression had to be reported as a TEAE.

Table 59 TreatmentEmergent Adverse Events Leading to Death With Incidence Rate ≥ 0.4% by Preferred Term (Safety Analysis Set)*

|                                         | Study 312                                   | Study 312                              |                                                                    |                                           |
|-----------------------------------------|---------------------------------------------|----------------------------------------|--------------------------------------------------------------------|-------------------------------------------|
| Preferred Term                          | Tislelizumab + Chemotherapy (N = 227) n (%) | Placebo + Chemotherapy (N = 229) n (%) | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) n (%) | Tislelizumab Monotherapy (N = 1952) n (%) |
| Patients With Any TEAE Leading to Death | 14 (6.2)                                    | 4 (1.7)                                | 42 (5.7)                                                           | 150 (7.7)                                 |
| Death                                   | 2 (0.9)                                     | 0 (0.0)                                | 6 (0.8)                                                            | 18 (0.9)                                  |
| Depressed level of consciousness        | 2 (0.9)                                     | 0 (0.0)                                | 2 (0.3)                                                            | 1 (0.1)                                   |
| Multiple organ dysfunction syndrome     | 1 (0.4)                                     | 0 (0.0)                                | 1 (0.1)                                                            | 11 (0.6)                                  |
| Respiratory failure                     | 1 (0.4)                                     | 1 (0.4)                                | 3 (0.4)                                                            | 10 (0.5)                                  |
| General physical health deterioration   | 0 (0.0)                                     | 0 (0.0)                                | 0 (0.0)                                                            | 10 (0.5)                                  |

<div style=\"page-break-after: always\"></div>

|                                                                                                                               | Study 312                                                                                                                     | Study 312                                                                                                                     |                                                                                                                               |                                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| Preferred Term                                                                                                                | Tislelizumab + Chemotherapy (N = 227) n (%)                                                                                   | Placebo + Chemotherapy (N = 229) n (%)                                                                                        | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) n (%)                                                            | Tislelizumab Monotherapy (N = 1952) n (%)                                                                                     |
| Hepatic failure                                                                                                               | 0 (0.0)                                                                                                                       | 0 (0.0)                                                                                                                       | 1 (0.1)                                                                                                                       | 12 (0.6)                                                                                                                      |
| Pneumonia                                                                                                                     | 0 (0.0)                                                                                                                       | 0 (0.0)                                                                                                                       | 3 (0.4)                                                                                                                       | 12 (0.6)                                                                                                                      |
| Upper gastrointestinal haemorrhage                                                                                            | 0 (0.0)                                                                                                                       | 0 (0.0)                                                                                                                       | 0 (0.0)                                                                                                                       | 9 (0.5)                                                                                                                       |
| * TEAES Grade 5 are due to complications of the disease under study. Incidence rates per Preferred Term ≥ 0.5% in any column. | * TEAES Grade 5 are due to complications of the disease under study. Incidence rates per Preferred Term ≥ 0.5% in any column. | * TEAES Grade 5 are due to complications of the disease under study. Incidence rates per Preferred Term ≥ 0.5% in any column. | * TEAES Grade 5 are due to complications of the disease under study. Incidence rates per Preferred Term ≥ 0.5% in any column. | * TEAES Grade 5 are due to complications of the disease under study. Incidence rates per Preferred Term ≥ 0.5% in any column. |

## Adverse events of special interest (AESIs)

AESIs include immune-mediated TEAEs (imTEAEs) and infusion-related reactions (IRRs).

## Immune-mediated treatment-emergent adverse events

Immune-mediated TEAEs imTEAEs comprise TEAEs occurring from the date of the first dose of study treatment to 90 days after the last dose of study treatment, regardless of whether the patient started a new anticancer therapy.

An overview of imTEAEs is presented in Table 60. imTEAEs by category are described in Table 61. A summary of imTEAEs occurring in patients in Arm T+C of Study 312 by category (incidence rate ≥ 1%) and  differentiated  by  severity,  modification  /  discontinuation  of  study  treatment,  use  of  supportive medications (corticosteroids, immunosuppressants, and hormone replacement), and recovery status is presented in Table 62.

## Table 60 Overview of Immune-Mediated Treatment-Emergent Adverse Events (Safety Analysis Set)

|                                                                    | Study 312                                   | Study 312                              |                                                                    |                                           |
|--------------------------------------------------------------------|---------------------------------------------|----------------------------------------|--------------------------------------------------------------------|-------------------------------------------|
|                                                                    | Tislelizumab + Chemotherapy (N = 227) n (%) | Placebo + Chemotherapy (N = 229) n (%) | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) n (%) | Tislelizumab Monotherapy (N = 1952) n (%) |
| Patients With Any Immune-Mediated Treatment-Emergent Adverse Event | 91 (40.1)                                   | 42 (18.3)                              | 339 (45.7)                                                         | 659 (33.8)                                |
| ≥ Grade 3                                                          | 25 (11.0)                                   | 1 (0.4)                                | 77 (10.4)                                                          | 105 (5.4)                                 |
| Leading to Death                                                   | 1 (0.4)                                     | 0 (0.0)                                | 7 (0.9)                                                            | 2 (0.1)                                   |
| Serious                                                            | 22 (9.7)                                    | 3 (1.3)                                | 82 (11.1)                                                          | 113 (5.8)                                 |
| Leading to Treatment Discontinuation                               | 13 (5.7)                                    | 2 (0.9)                                | 61 (8.2)                                                           | 66 (3.4)                                  |
| Leading to Treatment Discontinuation of Tislelizumab/Placebo       | 13 (5.7)                                    | 2 (0.9)                                | 56 (7.6)                                                           | 66 (3.4)                                  |
| Leading to Treatment Modification                                  | 25 (11.0)                                   | 6 (2.6)                                | 108 (14.6)                                                         | 144 (7.4)                                 |
| Leading to Treatment Modification of Tislelizumab/Placebo          | 24 (10.6)                                   | 5 (2.2)                                | 100 (13.5)                                                         | 144 (7.4)                                 |
| Treated With Systemic Corticosteroids                              | 25 (11.0)                                   | 3 (1.3)                                | 113 (15.2)                                                         | 183 (9.4)                                 |
| Treated With Other Immunosuppressant                               | 2 (0.9)                                     | 0 (0.0)                                | 10 (1.3)                                                           | 11 (0.6)                                  |
| Treated With Hormone Therapy                                       | 35 (15.4)                                   | 4 (1.7)                                | 92 (12.4)                                                          | 199 (10.2)                                |

<div style=\"page-break-after: always\"></div>

Table 61 Immune-Mediated Treatment-Emergent Adverse Events by Category (Safety Analysis Set)

|                                                          | Study 312                                   | Study 312                              |                                                                    |                                           |
|----------------------------------------------------------|---------------------------------------------|----------------------------------------|--------------------------------------------------------------------|-------------------------------------------|
| Category                                                 | Tislelizumab + Chemotherapy (N = 227) n (%) | Placebo + Chemotherapy (N = 229) n (%) | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) n (%) | Tislelizumab Monotherapy (N = 1952) n (%) |
| Patients With Any Immune-Mediated TEAE                   | 91 (40.1)                                   | 42 (18.3)                              | 339 (45.7)                                                         | 659 (33.8)                                |
| Immune-mediated skin adverse reaction                    | 38 (16.7)                                   | 20 (8.7)                               | 151 (20.4)                                                         | 247 (12.7)                                |
| Immune-mediated endocrinopathies (hypothyroidism)        | 37 (16.3)                                   | 11 (4.8)                               | 121 (16.3)                                                         | 269 (13.8)                                |
| Immune-mediated pneumonitis                              | 17 (7.5)                                    | 7 (3.1)                                | 81 (10.9)                                                          | 101 (5.2)                                 |
| Immune-mediated endocrinopathies (hyperthyroidism)       | 15 (6.6)                                    | 6 (2.6)                                | 59 (8.0)                                                           | 100 (5.1)                                 |
| Immune-mediated endocrinopathies (diabetes mellitus)     | 9 (4.0)                                     | 0 (0.0)                                | 15 (2.0)                                                           | 12 (0.6)                                  |
| Immune-mediated myocarditis/pericarditis                 | 5 (2.2)                                     | 0 (0.0)                                | 14 (1.9)                                                           | 15 (0.8)                                  |
| Immune-mediated hepatitis                                | 4 (1.8)                                     | 0 (0.0)                                | 9 (1.2)                                                            | 23 (1.2)                                  |
| Immune-mediated myositis/rhabdomyolysis                  | 3 (1.3)                                     | 1 (0.4)                                | 6 (0.8)                                                            | 16 (0.8)                                  |
| Immune-mediated colitis                                  | 2 (0.9)                                     | 0 (0.0)                                | 7 (0.9)                                                            | 11 (0.6)                                  |
| Immune-mediated endocrinopathies (hypophysitis)          | 2 (0.9)                                     | 0 (0.0)                                | 4 (0.5)                                                            | 5 (0.3)                                   |
| Immune-mediated endocrinopathies (thyroiditis)           | 2 (0.9)                                     | 0 (0.0)                                | 5 (0.7)                                                            | 21 (1.1)                                  |
| Immune-mediated endocrinopathies (adrenal insufficiency) | 1 (0.4)                                     | 0 (0.0)                                | 3 (0.4)                                                            | 10 (0.5)                                  |
| Other immune-mediated reactions (CNS)                    | 1 (0.4)                                     | 1 (0.4)                                | 3 (0.4)                                                            | 1 (0.1)                                   |
| Other immune-mediated reactions (blood dyscrasias)       | 1 (0.4)                                     | 0 (0.0)                                | 2 (0.3)                                                            | 0 (0.0)                                   |
| Other immune-mediated reactions (pancreatitis)           | 1 (0.4)                                     | 0 (0.0)                                | 1 (0.1)                                                            | 5 (0.3)                                   |
| Immune-mediated nephritis and renal dysfunction          | 0 (0.0)                                     | 0 (0.0)                                | 4 (0.5)                                                            | 4 (0.2)                                   |
| Other immune-mediated reactions (musculoskeletal)        | 0 (0.0)                                     | 0 (0.0)                                | 4 (0.5)                                                            | 17 (0.9)                                  |
| Other immune-mediated reactions (ocular)                 | 0 (0.0)                                     | 0 (0.0)                                | 0 (0.0)                                                            | 2 (0.1)                                   |
| Other immune-mediated reactions (other)                  | 0 (0.0)                                     | 0 (0.0)                                | 2 (0.3)                                                            | 1 (0.1)                                   |

<div style=\"page-break-after: always\"></div>

Table 62 Summary of Immune-Mediated TreatmentEmergent Adverse Events in Occurring in ≥ 1% of Patients in Arm T+C of Study 312 by Category

| Study 312                                                                                                                                              | Study 312                                                                                                                                              | Study 312                                                                                                                                              | Study 312                                                                                                                                              | Study 312                                                                                                                                              | Study 312                                                                                                                                              | Study 312                                                                                                                                              | Study 312                                                                                                                                              | Study 312                                                                                                                                              | Study 312                                                                                                                                              | Study 312                                                                                                                                              | Study 312                                                                                                                                              | Study 312                                                                                                                                              |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        | Led to Discon- tinued Treatment                                                                                                                        | Corticosteroids                                                                                                                                        | Corticosteroids                                                                                                                                        | Corticosteroids                                                                                                                                        | Immune- suppres-                                                                                                                                       | Hormone replace- ment                                                                                                                                  | Patients                                                                                                                                               | Median (months)                                                                                                                                        | Median (months)                                                                                                                                        | Median (months)                                                                                                                                        |
|                                                                                                                                                        |                                                                                                                                                        | Led to Modified                                                                                                                                        |                                                                                                                                                        | Treated / High-dose                                                                                                                                    | Median                                                                                                                                                 | Median                                                                                                                                                 |                                                                                                                                                        |                                                                                                                                                        | recovered                                                                                                                                              | Time to first                                                                                                                                          | Dura- tion of events                                                                                                                                   | Duration of resolved                                                                                                                                   |
| imTEAE                                                                                                                                                 | Total /                                                                                                                                                | Treat-                                                                                                                                                 |                                                                                                                                                        |                                                                                                                                                        | Initial dose                                                                                                                                           | Duration                                                                                                                                               |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |
| Category /                                                                                                                                             | ≥ G3                                                                                                                                                   | ment                                                                                                                                                   |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        | sants                                                                                                                                                  | n (%)                                                                                                                                                  |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |
|                                                                                                                                                        | n (%)                                                                                                                                                  | n (%)                                                                                                                                                  | n (%)                                                                                                                                                  | n (%)                                                                                                                                                  | (mg/day)                                                                                                                                               |                                                                                                                                                        | n (%)                                                                                                                                                  |                                                                                                                                                        | n (%)                                                                                                                                                  | onset                                                                                                                                                  |                                                                                                                                                        | events                                                                                                                                                 |
| Dataset                                                                                                                                                |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        | (months)                                                                                                                                               |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |                                                                                                                                                        |
| Skin adverse reaction Arm T+C 38 (16.7) / 8 (3.5) 7 (3.1) 3 (1.3) 9 (23.7)/6 (15.8) 50.000 0.789 1 (2.6) -- 26 (68.4) 3.220 1.708 0.756 Hypothyroidism | Skin adverse reaction Arm T+C 38 (16.7) / 8 (3.5) 7 (3.1) 3 (1.3) 9 (23.7)/6 (15.8) 50.000 0.789 1 (2.6) -- 26 (68.4) 3.220 1.708 0.756 Hypothyroidism | Skin adverse reaction Arm T+C 38 (16.7) / 8 (3.5) 7 (3.1) 3 (1.3) 9 (23.7)/6 (15.8) 50.000 0.789 1 (2.6) -- 26 (68.4) 3.220 1.708 0.756 Hypothyroidism | Skin adverse reaction Arm T+C 38 (16.7) / 8 (3.5) 7 (3.1) 3 (1.3) 9 (23.7)/6 (15.8) 50.000 0.789 1 (2.6) -- 26 (68.4) 3.220 1.708 0.756 Hypothyroidism | Skin adverse reaction Arm T+C 38 (16.7) / 8 (3.5) 7 (3.1) 3 (1.3) 9 (23.7)/6 (15.8) 50.000 0.789 1 (2.6) -- 26 (68.4) 3.220 1.708 0.756 Hypothyroidism | Skin adverse reaction Arm T+C 38 (16.7) / 8 (3.5) 7 (3.1) 3 (1.3) 9 (23.7)/6 (15.8) 50.000 0.789 1 (2.6) -- 26 (68.4) 3.220 1.708 0.756 Hypothyroidism | Skin adverse reaction Arm T+C 38 (16.7) / 8 (3.5) 7 (3.1) 3 (1.3) 9 (23.7)/6 (15.8) 50.000 0.789 1 (2.6) -- 26 (68.4) 3.220 1.708 0.756 Hypothyroidism | Skin adverse reaction Arm T+C 38 (16.7) / 8 (3.5) 7 (3.1) 3 (1.3) 9 (23.7)/6 (15.8) 50.000 0.789 1 (2.6) -- 26 (68.4) 3.220 1.708 0.756 Hypothyroidism | Skin adverse reaction Arm T+C 38 (16.7) / 8 (3.5) 7 (3.1) 3 (1.3) 9 (23.7)/6 (15.8) 50.000 0.789 1 (2.6) -- 26 (68.4) 3.220 1.708 0.756 Hypothyroidism | Skin adverse reaction Arm T+C 38 (16.7) / 8 (3.5) 7 (3.1) 3 (1.3) 9 (23.7)/6 (15.8) 50.000 0.789 1 (2.6) -- 26 (68.4) 3.220 1.708 0.756 Hypothyroidism | Skin adverse reaction Arm T+C 38 (16.7) / 8 (3.5) 7 (3.1) 3 (1.3) 9 (23.7)/6 (15.8) 50.000 0.789 1 (2.6) -- 26 (68.4) 3.220 1.708 0.756 Hypothyroidism | Skin adverse reaction Arm T+C 38 (16.7) / 8 (3.5) 7 (3.1) 3 (1.3) 9 (23.7)/6 (15.8) 50.000 0.789 1 (2.6) -- 26 (68.4) 3.220 1.708 0.756 Hypothyroidism | Skin adverse reaction Arm T+C 38 (16.7) / 8 (3.5) 7 (3.1) 3 (1.3) 9 (23.7)/6 (15.8) 50.000 0.789 1 (2.6) -- 26 (68.4) 3.220 1.708 0.756 Hypothyroidism |
| Arm T+C                                                                                                                                                | 37 (16.3) / 1 (0.4)                                                                                                                                    | 3 (1.3)                                                                                                                                                | 0 (0.0)                                                                                                                                                | 1 (2.7) / 0 (0.0)                                                                                                                                      | 33.333                                                                                                                                                 | 0.033                                                                                                                                                  | 0 (0.0)                                                                                                                                                | 25 (67.6)                                                                                                                                              | 17 (45.9)                                                                                                                                              | 4.337                                                                                                                                                  | 2.333                                                                                                                                                  | 2.037                                                                                                                                                  |
| Pneumonitis                                                                                                                                            | Pneumonitis                                                                                                                                            | Pneumonitis                                                                                                                                            | Pneumonitis                                                                                                                                            | Pneumonitis                                                                                                                                            | Pneumonitis                                                                                                                                            | Pneumonitis                                                                                                                                            | Pneumonitis                                                                                                                                            | Pneumonitis                                                                                                                                            | Pneumonitis                                                                                                                                            | Pneumonitis                                                                                                                                            | Pneumonitis                                                                                                                                            | Pneumonitis                                                                                                                                            |
| Arm T+C                                                                                                                                                | 17 (7.5) / 5 (2.2)                                                                                                                                     | 6 (2.6)                                                                                                                                                | 2 (0.9)                                                                                                                                                | 6 (35.3) / 5 (29.4)                                                                                                                                    | 85.000                                                                                                                                                 | 0.559                                                                                                                                                  | 1 (5.9)                                                                                                                                                | --                                                                                                                                                     | 5 (29.4)                                                                                                                                               | 4.830                                                                                                                                                  | NR                                                                                                                                                     | 4.501                                                                                                                                                  |
| Hyperthyroidism                                                                                                                                        | Hyperthyroidism                                                                                                                                        | Hyperthyroidism                                                                                                                                        | Hyperthyroidism                                                                                                                                        | Hyperthyroidism                                                                                                                                        | Hyperthyroidism                                                                                                                                        | Hyperthyroidism                                                                                                                                        | Hyperthyroidism                                                                                                                                        | Hyperthyroidism                                                                                                                                        | Hyperthyroidism                                                                                                                                        | Hyperthyroidism                                                                                                                                        | Hyperthyroidism                                                                                                                                        | Hyperthyroidism                                                                                                                                        |
| Arm T+C                                                                                                                                                | 15 (6.6) / 0 (0.0)                                                                                                                                     | 0 (0.0)                                                                                                                                                | 0 (0.0)                                                                                                                                                | 0 (0.0) / 0 (0.0)                                                                                                                                      | --                                                                                                                                                     | --                                                                                                                                                     | 0 (0.0)                                                                                                                                                | 0 (0.0)                                                                                                                                                | 10 (66.7)                                                                                                                                              | 3.450                                                                                                                                                  | 2.234                                                                                                                                                  | 2.103                                                                                                                                                  |
| Diabetes Mellitus                                                                                                                                      | Diabetes Mellitus                                                                                                                                      | Diabetes Mellitus                                                                                                                                      | Diabetes Mellitus                                                                                                                                      | Diabetes Mellitus                                                                                                                                      | Diabetes Mellitus                                                                                                                                      | Diabetes Mellitus                                                                                                                                      | Diabetes Mellitus                                                                                                                                      | Diabetes Mellitus                                                                                                                                      | Diabetes Mellitus                                                                                                                                      | Diabetes Mellitus                                                                                                                                      | Diabetes Mellitus                                                                                                                                      | Diabetes Mellitus                                                                                                                                      |
| Arm T+C                                                                                                                                                | 9 (4.0) / 6 (2.6)                                                                                                                                      | 3 (1.3)                                                                                                                                                | 0 (0.0)                                                                                                                                                | --                                                                                                                                                     | --                                                                                                                                                     | --                                                                                                                                                     | 0 (0.0)                                                                                                                                                | 8 (88.9)                                                                                                                                               | 1 (11.1)                                                                                                                                               | 4.205                                                                                                                                                  | NR                                                                                                                                                     | 0.411                                                                                                                                                  |
| Myocarditis/Pericarditis                                                                                                                               | Myocarditis/Pericarditis                                                                                                                               | Myocarditis/Pericarditis                                                                                                                               | Myocarditis/Pericarditis                                                                                                                               | Myocarditis/Pericarditis                                                                                                                               | Myocarditis/Pericarditis                                                                                                                               | Myocarditis/Pericarditis                                                                                                                               | Myocarditis/Pericarditis                                                                                                                               | Myocarditis/Pericarditis                                                                                                                               | Myocarditis/Pericarditis                                                                                                                               | Myocarditis/Pericarditis                                                                                                                               | Myocarditis/Pericarditis                                                                                                                               | Myocarditis/Pericarditis                                                                                                                               |
| Arm T+C                                                                                                                                                | 5 (2.2) / 1 (0.4)                                                                                                                                      | 1 (0.4)                                                                                                                                                | 4 (1.8)                                                                                                                                                | 5 (100.0) / 5 (100.0)                                                                                                                                  | 132.500                                                                                                                                                | 1.314                                                                                                                                                  | 0 (0.0)                                                                                                                                                | --                                                                                                                                                     | 3 (60.0)                                                                                                                                               | 1.413                                                                                                                                                  | 3.417                                                                                                                                                  | 1.018                                                                                                                                                  |
| Hepatitis                                                                                                                                              | Hepatitis                                                                                                                                              | Hepatitis                                                                                                                                              | Hepatitis                                                                                                                                              | Hepatitis                                                                                                                                              | Hepatitis                                                                                                                                              | Hepatitis                                                                                                                                              | Hepatitis                                                                                                                                              | Hepatitis                                                                                                                                              | Hepatitis                                                                                                                                              | Hepatitis                                                                                                                                              | Hepatitis                                                                                                                                              | Hepatitis                                                                                                                                              |
| Arm T+C                                                                                                                                                | 4 (1.8) / 2 (0.9)                                                                                                                                      | 1 (0.4)                                                                                                                                                | 1 (0.4)                                                                                                                                                | 3 (75.0) / 2 (50.0)                                                                                                                                    | 157.500                                                                                                                                                | 0.821                                                                                                                                                  | 0 (0.0)                                                                                                                                                | --                                                                                                                                                     | 2 (50.0)                                                                                                                                               | 1.561                                                                                                                                                  | 1.741                                                                                                                                                  | 1.150                                                                                                                                                  |
| Myositis/Rhabdomyolysis                                                                                                                                | Myositis/Rhabdomyolysis                                                                                                                                | Myositis/Rhabdomyolysis                                                                                                                                | Myositis/Rhabdomyolysis                                                                                                                                | Myositis/Rhabdomyolysis                                                                                                                                | Myositis/Rhabdomyolysis                                                                                                                                | Myositis/Rhabdomyolysis                                                                                                                                | Myositis/Rhabdomyolysis                                                                                                                                | Myositis/Rhabdomyolysis                                                                                                                                | Myositis/Rhabdomyolysis                                                                                                                                | Myositis/Rhabdomyolysis                                                                                                                                | Myositis/Rhabdomyolysis                                                                                                                                | Myositis/Rhabdomyolysis                                                                                                                                |
| Arm T+C                                                                                                                                                | 3 (1.3) / 0 (0.0)                                                                                                                                      | 2 (0.9)                                                                                                                                                | 0 (0.0)                                                                                                                                                | 1 (33.3) / 1 (33.3)                                                                                                                                    | 50.000                                                                                                                                                 | 2.563                                                                                                                                                  | 0 (0.0)                                                                                                                                                | --                                                                                                                                                     | 2 (66.7)                                                                                                                                               | 1.413                                                                                                                                                  | 1.577                                                                                                                                                  | 0.953                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

## Infusion-related reactions

Table 63 Overview of Infusion-Related Reactions (Safety Analysis Set)

|                                                              | Study 312                                   | Study 312                              | Tislelizumab Combination Therapy in 1L Cancer (N = 741)   | Tislelizumab                 |
|--------------------------------------------------------------|---------------------------------------------|----------------------------------------|-----------------------------------------------------------|------------------------------|
|                                                              | Tislelizumab + Chemotherapy (N = 227) n (%) | Placebo + Chemotherapy (N = 229) n (%) | Lung n (%)                                                | Monotherapy (N = 1952) n (%) |
| Patients With Any Event                                      | 16 (7.0)                                    | 10 (4.4)                               | 45 (6.1)                                                  | 58 (3.0)                     |
| ≥Grade 3                                                     | 1 (0.4)                                     | 1 (0.4)                                | 3 (0.4)                                                   | 2 (0.1)                      |
| Leading to Death                                             | 0 (0.0)                                     | 0 (0.0)                                | 0 (0.0)                                                   | 0 (0.0)                      |
| Serious TEAEs                                                | 0 (0.0)                                     | 0 (0.0)                                | 1 (0.1)                                                   | 2 (0.1)                      |
| Leading to Treatment Discontinuation of Tislelizumab/Placebo | 0 (0.0)                                     | 0 (0.0)                                | 0 (0.0)                                                   | 1 (0.1)                      |
| Leading to Treatment Modification of Tislelizumab/Placebo    | 2 (0.9)                                     | 0 (0.0)                                | 4 (0.5)                                                   | 4 (0.2)                      |
| Leading to Dose Delay/Interruption of Tislelizumab/Placebo   | 1 (0.4)                                     | 0 (0.0)                                | 2 (0.3)                                                   | 2 (0.1)                      |
| Treated With Systemic Corticosteroids                        | 2 (0.9)                                     | 3 (1.3)                                | 8 (1.1)                                                   | 12 (0.6)                     |
| Treated With High Dose Systemic Corticosteroids              | 1 (0.4)                                     | 0 (0.0)                                | 6 (0.8)                                                   | 5 (0.3)                      |

## Adverse drug reactions

ADRs by System Organ Class, Group Term, and Frequency Category are presented in Table 64 (ADRs for Study 312, tislelizumab monotherapy and tislelizumab combination therapy are shown side by side).

Data used for the determination of ADR and presented in section 4.8 of the SmPC comes from the pooled data of 1,952 patients across multiple tumour types for the monotherapy and 1,950 patients for the combination with chemotherapy. The data are presented below.

<div style=\"page-break-after: always\"></div>

## Table 64 Adverse Drug Reactions by System Organ Class, Group Term and Frequency Category (Safety Analysis Set)

|                                      | Study 312                            | Study 312                            | Study 312                            | Placebo + Chemotherapy Tislelizumab Therapy   | Placebo + Chemotherapy Tislelizumab Therapy   | Placebo + Chemotherapy Tislelizumab Therapy   |                                      |                                      |                                      |                                      |                                      |                                      |
|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| System Organ Class Group Term        | (N = 227) All Grades n (%)           | Grade 3-4 n (%)                      | Frequency Category (All Grades)      | (N = 229) All Grades n (%)                    | Grade 3-4 n (%)                               | Frequency Category (All Grades)               | (N = 1950) All Grades n (%)          | Grade 3-4 n (%)                      | Frequency Category (All Grades)      | (N = 1952) All Grades n (%)          | Grade 3-4 n (%)                      | Frequency Category (All Grades)      |
| Infections and infestations          | Infections and infestations          | Infections and infestations          | Infections and infestations          | Infections and infestations                   | Infections and infestations                   | Infections and infestations                   | Infections and infestations          | Infections and infestations          | Infections and infestations          | Infections and infestations          | Infections and infestations          | Infections and infestations          |
| Pneumonia 1                          | 9 (4.0)                              | 5 (2.2)                              | Common                               | 16 (7.0)                                      | 6 (2.6)                                       | Common                                        | 227 (11.6)                           | 78 (4.0)                             | Very Common                          | 186 (9.5)                            | 70 (3.6)                             | Common                               |
| Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders          | Blood and lymphatic system disorders          | Blood and lymphatic system disorders          | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders | Blood and lymphatic system disorders |
| Anaemia 2                            | 195 (85.9)40                         | (17.6)                               | Very Common194                       | (84.7)                                        | 42 (18.3)                                     | Very Common1311                               | (67.2)                               | 282 (14.5)                           | Very Common                          | 541 (27.7)                           | 94 (4.8)                             | Very Common                          |
| Thrombocytopenia 3                   | 144 (63.4)51                         | (22.5)                               | Very Common153                       | (66.8)                                        | 66 (28.8)                                     | Very Common949                                | (48.7)                               | 275 (14.1)                           | Very Common                          | 212 (10.9)                           | 21 (1.1)                             | Very Common                          |
| Neutropenia 4                        | 207 (91.2)161                        | (70.9)                               | Very Common218                       | (95.2)                                        | 174 (76.0)                                    | Very Common1397                               | (71.6)                               | 882 (45.2)                           | Very Common                          | 136 (7.0)                            | 28 (1.4)                             | Common                               |
| Lymphopenia 5                        | 27 (11.9)                            | 9 (4.0)                              | Very Common32                        | (14.0)                                        | 13 (5.7)                                      | Very Common200                                | (10.3)                               | 61 (3.1)                             | Very Common                          | 88 (4.5)                             | 25 (1.3)                             | Common                               |
| Immune system disorders              | Immune system disorders              | Immune system disorders              | Immune system disorders              | Immune system disorders                       | Immune system disorders                       | Immune system disorders                       | Immune system disorders              | Immune system disorders              | Immune system disorders              | Immune system disorders              | Immune system disorders              | Immune system disorders              |
| Sjogren's syndrome                   | 0 (0.0)                              | 0 (0.0)                              | -                                    | 0 (0.0)                                       | 0 (0.0)                                       | -                                             | 2 (0.1)                              | 0 (0.0)                              | Uncommon                             | 0 (0.0)                              | 0 (0.0)                              | -                                    |
| Endocrine disorders                  | Endocrine disorders                  | Endocrine disorders                  | Endocrine disorders                  | Endocrine disorders                           | Endocrine disorders                           | Endocrine disorders                           | Endocrine disorders                  | Endocrine disorders                  | Endocrine disorders                  | Endocrine disorders                  | Endocrine disorders                  | Endocrine disorders                  |
| Hypothyroidism 6                     | 37 (16.3)                            | 1 (0.4)                              | Very Common11                        | (4.8)                                         | 0 (0.0)                                       | Common                                        | 311 (15.9)                           | 5 (0.3)                              | Very Common                          | 276 (14.1)                           | 2 (0.1)                              | Very Common                          |
| Hyperthyroidism 7                    | 24 (10.6)                            | 0 (0.0)                              | Very Common8                         | (3.5)                                         | 0 (0.0)                                       | Common                                        | 152 (7.8)                            | 1 (0.1)                              | Common                               | 128 (6.6)                            | 0 (0.0)                              | Common                               |
| Thyroiditis 8                        | 2 (0.9)                              | 0 (0.0)                              | Uncommon                             | 0 (0.0)                                       | 0 (0.0)                                       | -                                             | 14 (0.7)                             | 1 (0.1)                              | Uncommon                             | 21 (1.1)                             | 0 (0.0)                              | Common                               |
| Adrenal insufficiency 9              | 1 (0.4)                              | 1 (0.4)                              | Uncommon                             | 0 (0.0)                                       | 0 (0.0)                                       | -                                             | 17 (0.9)                             | 9 (0.5)                              | Uncommon                             | 11 (0.6)                             | 5 (0.3)                              | Uncommon                             |
| Hypophysitis 10                      | 2 (0.9)                              | 0 (0.0)                              | Uncommon                             | 0 (0.0)                                       | 0 (0.0)                                       | -                                             | 9 (0.5)                              | 1 (0.1)                              | Uncommon                             | 3 (0.2)                              | 0 (0.0)                              | Uncommon                             |
| Metabolism and nutrition disorders   | Metabolism and nutrition disorders   | Metabolism and nutrition disorders   | Metabolism and nutrition disorders   | Metabolism and nutrition disorders            | Metabolism and nutrition disorders            | Metabolism and nutrition disorders            | Metabolism and nutrition disorders   | Metabolism and nutrition disorders   | Metabolism and nutrition disorders   | Metabolism and nutrition disorders   | Metabolism and nutrition disorders   | Metabolism and nutrition disorders   |
| Hyperglycaemia 11                    | 31 (13.7)                            | 3 (1.3)                              | Very Common26                        | (11.4)                                        | 4 (1.7)                                       | Very Common204                                | (10.5)                               | 18 (0.9)                             | Very Common                          | 186 (9.5)                            | 30 (1.5)                             | Common                               |
| Hyponatraemia 12                     | 59 (26.0)                            | 25 (11.0)                            | Very Common56                        | (24.5)                                        | 19 (8.3)                                      | Very Common364                                | (18.7)                               | 90 (4.6)                             | Very Common                          | 182 (9.3)                            | 56 (2.9)                             | Common                               |
| Hypokalaemia 13                      | 39 (17.2)                            | 15 (6.6)                             | Very Common19                        | (8.3)                                         | 4 (1.7)                                       | Common                                        | 334 (17.1)                           | 88 (4.5)                             | Very Common                          | 158 (8.1)                            | 36 (1.8)                             | Common                               |
| Diabetes mellitus 14                 | 9 (4.0)                              | 6 (2.6)                              | Common                               | 0 (0.0)                                       | 0 (0.0)                                       | -                                             | 32 (1.6)                             | 20 (1.0)                             | Common                               | 19 (1.0)                             | 7 (0.4)                              | Uncommon                             |
| Nervous system disorders             | Nervous system disorders             | Nervous system disorders             | Nervous system disorders             | Nervous system disorders                      | Nervous system disorders                      | Nervous system disorders                      | Nervous system disorders             | Nervous system disorders             | Nervous system disorders             | Nervous system disorders             | Nervous system disorders             | Nervous system disorders             |
| Guillain-Barre syndrome 0            | (0.0)                                | 0 (0.0)                              | -                                    | 0 (0.0)                                       | 0 (0.0)                                       | -                                             | 1 (0.1)                              | 1 (0.1)                              | Rare                                 | 1 (0.1)                              | 1 (0.1)                              | Rare                                 |
| Encephalitis 15                      | 0 (0.0)                              | 0 (0.0)                              | -                                    | 1 (0.4)                                       | 1 (0.4)                                       | Uncommon                                      | 1 (0.1)                              | 1 (0.1)                              | Rare                                 | 0 (0.0)                              | 0 (0.0)                              | -                                    |
| Myasthenia Gravis                    | 0 (0.0)                              | 0 (0.0)                              | -                                    | 0 (0.0)                                       | 0 (0.0)                                       | -                                             | 1 (0.1)                              | 1 (0.1)                              | Rare                                 | 0 (0.0)                              | 0 (0.0)                              | -                                    |
| Eye disorders                        |                                      |                                      |                                      |                                               |                                               |                                               |                                      |                                      |                                      |                                      |                                      |                                      |

<div style=\"page-break-after: always\"></div>

|                                                 | Study 312                                       | Study 312                                       | Study 312                                       | Placebo + Chemotherapy Tislelizumab             | Placebo + Chemotherapy Tislelizumab             | Placebo + Chemotherapy Tislelizumab             |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| System Organ Class                              | (N = 227) All Grades                            | Grade 3-4 Frequency                             | Grade 3-4 Frequency                             | (N = 229)                                       | (N = 229)                                       | Frequency (All                                  | Therapy (N = 1950)                              | Therapy (N = 1950)                              | Frequency Category (All                         | (N = 1952) All Grades                           | (N = 1952) All Grades                           | Frequency Category (All Grades)                 |
| Group Term                                      | n (%)                                           | n (%)                                           | Category (All Grades)                           | All Grades n (%)                                | Grade 3-4 n (%)                                 | Category Grades)                                | All Grades n (%)                                | Grade 3-4 n (%)                                 | Grades)                                         | n (%)                                           | Grade 3-4 n (%)                                 |                                                 |
| Uveitis 16                                      | 0 (0.0)                                         | 0 (0.0)                                         | -                                               | 0 (0.0)                                         | 0 (0.0)                                         | -                                               | 3 (0.2)                                         | 1 (0.1)                                         | Uncommon                                        | 5 (0.3)                                         | 0 (0.0)                                         | Uncommon                                        |
| Cardiac disorders                               |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| Myocarditis 17                                  | 5 (2.2)                                         | 0 (0.0)                                         | Common                                          | 0 (0.0)                                         | 0 (0.0)                                         | -                                               | 23 (1.2)                                        | 4 (0.2)                                         | Common                                          | 14 (0.7)                                        | 4 (0.2)                                         | Uncommon                                        |
| Pericarditis                                    | 0 (0.0)                                         | 0 (0.0)                                         | -                                               | 0 (0.0)                                         | 0 (0.0)                                         |                                                 | 1 (0.1)                                         | 1 (0.1)                                         | Rare                                            | 2 (0.1)                                         | 0 (0.0)                                         | Uncommon                                        |
| Vascular disorders                              |                                                 |                                                 |                                                 |                                                 |                                                 | -                                               |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| Hypertension 18                                 | (11.5) 9                                        | (4.0)                                           | Very Common19                                   | (8.3)                                           | 10 (4.4)                                        | Common                                          | 115 (5.9)                                       | 37 (1.9)                                        | Common                                          | 117 (6.0)                                       | 47 (2.4)                                        | Common                                          |
| 26 Respiratory, thoracic and mediastinal        |                                                 | disorders                                       |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| Cough                                           | 37 (16.3)                                       | 0 (0.0)                                         | Very Common28                                   | (12.2)                                          | 1 (0.4)                                         | Very Common293                                  | (15.0)                                          | 5 (0.3)                                         | Very Common                                     | 298 (15.3)                                      | 5 (0.3)                                         | Very Common                                     |
| Dyspnoea                                        | 26 (11.5)                                       | 3 (1.3)                                         | Very Common27                                   | (11.8)                                          | 1 (0.4)                                         | Very Common180                                  | (9.2)                                           | 13 (0.7)                                        | Common                                          | 136 (7.0)                                       | 21 (1.1)                                        | Common                                          |
| Pneumonitis 19                                  | 17 (7.5)                                        | 5 (2.2)                                         | Common                                          | 7 (3.1)                                         | 0 (0.0)                                         | Common                                          | 151 (7.7)                                       | 37 (1.9)                                        | Common                                          | 101 (5.2)                                       | 33 (1.7)                                        | Common                                          |
| Gastrointestinal disorders                      |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| Diarrhoea 20                                    | 37 (16.3)                                       | 3 (1.3)                                         | Very Common31                                   | (13.5)                                          | 2 (0.9)                                         | Very Common395                                  | (20.3)                                          | 35 (1.8)                                        | Very Common                                     | 197 (10.1)                                      | 13 (0.7)                                        | Very Common                                     |
| Nausea                                          | 101 (44.5)1                                     | (0.4)                                           | Very Common100                                  | (43.7)                                          | 1 (0.4)                                         | Very Common844                                  | (43.3)                                          | 28 (1.4)                                        | Very Common                                     | 196 (10.0)                                      | 4 (0.2)                                         | Very Common                                     |
| Stomatitis 21                                   | 11 (4.8)                                        | 0 (0.0)                                         | Common                                          | 4 (1.7)                                         | 0 (0.0)                                         | Common                                          | 181 (9.3)                                       | 22 (1.1)                                        | Common                                          | 64 (3.3)                                        | 6 (0.3)                                         | Common                                          |
| Pancreatitis 22                                 | 4 (1.8)                                         | 1 (0.4)                                         | Common                                          | 1 (0.4)                                         | 0 (0.0)                                         | Uncommon                                        | 54 (2.8)                                        | 19 (1.0)                                        | Common                                          | 18 (0.9)                                        | 13 (0.7)                                        | Uncommon                                        |
| Colitis 23                                      | 2 (0.9)                                         | 0 (0.0)                                         | Uncommon                                        | 0 (0.0)                                         | 0 (0.0)                                         | -                                               | 20 (1.0)                                        | 8 (0.4)                                         | Common                                          | 14 (0.7)                                        | 4 (0.2)                                         | Uncommon                                        |
| Hepatobiliary disorders                         |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| Hepatitis 24                                    | 4 (1.8)                                         | 2 (0.9)                                         | Common                                          | 2 (0.9)                                         | 1 (0.4)                                         | Uncommon                                        | 73 (3.7)                                        | 33 (1.7)                                        | Common                                          | 54 (2.8)                                        | 28 (1.4)                                        | Common                                          |
| Skin and subcutaneous tissue disorders          | Skin and subcutaneous tissue disorders          | Skin and subcutaneous tissue disorders          | Skin and subcutaneous tissue disorders          | Skin and subcutaneous tissue disorders          | Skin and subcutaneous tissue disorders          |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |                                                 |
| Rash 25                                         | 45 (19.8)                                       | 8 (3.5)                                         | Very Common21                                   | (9.2)                                           | 0 (0.0)                                         | Common                                          | 418 (21.4)                                      | 57 (2.9)                                        | Very Common                                     | 319 (16.3)                                      | 26 (1.3)                                        | Very Common                                     |
| Pruritus                                        | 15 (6.6)                                        | 0 (0.0)                                         | Common                                          | 6 (2.6)                                         | 0 (0.0)                                         | Common                                          | 198 (10.2)                                      | 3 (0.2)                                         | Very Common                                     | 215 (11.0)                                      | 1 (0.1)                                         | Very Common                                     |
| Vitiligo 26                                     | 0 (0.0)                                         | 0 (0.0)                                         | -                                               | 0 (0.0)                                         | 0 (0.0)                                         | -                                               | 6 (0.3)                                         | 0 (0.0)                                         | Uncommon                                        | 13 (0.7)                                        | 0 (0.0)                                         | Uncommon                                        |
| Erythema multiforme                             | 0 (0.0)                                         | 0 (0.0)                                         | -                                               | 0 (0.0)                                         | 0 (0.0)                                         | -                                               | 1 (0.1)                                         | 0 (0.0)                                         | Rare                                            | 3 (0.2)                                         | 1 (0.1)                                         | Uncommon                                        |
| Stevens-Johnson syndrome                        | 0 (0.0)                                         | 0 (0.0)                                         | -                                               | 0 (0.0)                                         | 0 (0.0)                                         | -                                               | 0 (0.0)                                         | 0 (0.0)                                         | -                                               | 1 (0.1)                                         | 1 (0.1)                                         | Rare                                            |
| Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders |
| Arthralgia                                      | 34 (15.0) 0                                     | (0.0)                                           | Very Common18                                   | (7.9)                                           | 0 (0.0)                                         | Common                                          | 227 (11.6)                                      | 3 (0.2)                                         | Very Common                                     | 180 (9.2)                                       | 4 (0.2)                                         | Common                                          |

<div style=\"page-break-after: always\"></div>

|                                                      | Study 312                                            | Study 312                                            | Study 312                                            |                                                      |                                                      |                                                      |                                                      |                                                      |                                                      |                                                      |                                                      |                                                      |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                      | Tislelizumab + Chemotherapy (N = 227)                | Tislelizumab + Chemotherapy (N = 227)                | Tislelizumab + Chemotherapy (N = 227)                | Placebo + Chemotherapy (N = 229)                     | Placebo + Chemotherapy (N = 229)                     | Placebo + Chemotherapy (N = 229)                     | Tislelizumab Combination Therapy (N = 1950)          | Tislelizumab Combination Therapy (N = 1950)          | Tislelizumab Combination Therapy (N = 1950)          | Tislelizumab Monotherapy (N = 1952)                  | Tislelizumab Monotherapy (N = 1952)                  | Tislelizumab Monotherapy (N = 1952)                  |
| System Organ Class Group Term                        | All Grades n (%)                                     | Grade 3-4 n (%)                                      | Frequency Category (All Grades)                      | All Grades n (%)                                     | Grade 3-4 n (%)                                      | Frequency Category (All Grades)                      | All Grades n (%)                                     | Grade 3-4 n (%)                                      | Frequency Category (All Grades)                      | All Grades n (%)                                     | Grade 3-4 n (%)                                      | Frequency Category (All Grades)                      |
| Myalgia                                              | 3 (1.3)                                              | 0 (0.0)                                              | Common                                               | 3 (1.3)                                              | 0 (0.0)                                              | Common                                               | 80 (4.1)                                             | 3 (0.2)                                              | Common                                               | 35 (1.8)                                             | 0 (0.0)                                              | Common                                               |
| Arthritis27                                          | 0 (0.0)                                              | 0 (0.0)                                              | -                                                    | 0 (0.0)                                              | 0 (0.0)                                              | -                                                    | 21 (1.1)                                             | 4 (0.2)                                              | Common                                               | 18 (0.9)                                             | 2 (0.1)                                              | Uncommon                                             |
| Myositis28                                           | 3 (1.3)                                              | 0 (0.0)                                              | Common                                               | 1 (0.4)                                              | 0 (0.0)                                              | Uncommon                                             | 14 (0.7)                                             | 4 (0.2)                                              | Uncommon                                             | 16 (0.8)                                             | 5 (0.3)                                              | Uncommon                                             |
| Renal and urinary disorders                          | Renal and urinary disorders                          | Renal and urinary disorders                          | Renal and urinary disorders                          | Renal and urinary disorders                          | Renal and urinary disorders                          | Renal and urinary disorders                          | Renal and urinary disorders                          | Renal and urinary disorders                          | Renal and urinary disorders                          | Renal and urinary disorders                          | Renal and urinary disorders                          | Renal and urinary disorders                          |
| Nephritis29                                          | 0 (0.0)                                              | 0 (0.0)                                              | -                                                    | 0 (0.0)                                              | 0 (0.0)                                              | -                                                    | 8 (0.4)                                              | 4 (0.2)                                              | Uncommon                                             | 4 (0.2)                                              | 1 (0.1)                                              | Uncommon                                             |
| General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions |
| Fatigue30                                            | 75 (33.0)                                            | 8 (3.5)                                              | Very Common60                                        | (26.2)                                               | 0 (0.0)                                              | Very Common796                                       | (40.8)                                               | 81 (4.2)                                             | Very Common                                          | 481 (24.6)                                           | 41 (2.1)                                             | Very Common                                          |
| Pyrexia31                                            | 32 (14.1)                                            | 0 (0.0)                                              | Very Common17                                        | (7.4)                                                | 0 (0.0)                                              | Common                                               | 360 (18.5)                                           | 11 (0.6)                                             | Very Common                                          | 314 (16.1)                                           | 7 (0.4)                                              | Very Common                                          |
| Decreased appetite                                   | 89 (39.2)                                            | 1 (0.4)                                              | Very Common86                                        | (37.6)                                               | 1 (0.4)                                              | Very Common782                                       | (40.1)                                               | 51 (2.6)                                             | Very Common                                          | 290 (14.9)                                           | 16 (0.8)                                             | Very Common                                          |
| Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       | Investigations                                       |
| Aspartate aminotransferase increased                 | 52 (22.9)                                            | 3 (1.3)                                              | Very Common35                                        | (15.3)                                               | 0 (0.0)                                              | Very Common590                                       | (30.3)                                               | 42 (2.2)                                             | Very Common                                          | 482 (24.7)                                           | 72 (3.7)                                             | Very Common                                          |
| Alanine aminotransferase increased                   | 67 (29.5)                                            | 3 (1.3)                                              | Very Common46                                        | (20.1)                                               | 1 (0.4)                                              | Very Common597                                       | (30.6)                                               | 41 (2.1)                                             | Very Common                                          | 430 (22.0)                                           | 37 (1.9)                                             | Very Common                                          |
| Blood bilirubin increased32                          | 24 (10.6)                                            | 0 (0.0)                                              | Very Common11                                        | (4.8)                                                | 1 (0.4)                                              | Common                                               | 271 (13.9)                                           | 18 (0.9)                                             | Very Common                                          | 303 (15.5)                                           | 54 (2.8)                                             | Very Common                                          |
| Blood alkaline phosphatase increased                 | 13 (5.7)                                             | 1 (0.4)                                              | Common                                               | 11 (4.8)                                             | 0 (0.0)                                              | Common                                               | 132 (6.8)                                            | 5 (0.3)                                              | Common                                               | 165 (8.5)                                            | 26 (1.3)                                             | Common                                               |
| Blood creatinine increased                           | 19 (8.4)                                             | 3 (1.3)                                              | Common                                               | 14 (6.1)                                             | 0 (0.0)                                              | Common                                               | 214 (11.0)                                           | 7 (0.4)                                              | Very Common                                          | 104 (5.3)                                            | 4 (0.2)                                              | Common                                               |
| Injury, poisoning and procedural complications       | Injury, poisoning and procedural complications       | Injury, poisoning and procedural complications       | Injury, poisoning and procedural complications       | Injury, poisoning and procedural complications       | Injury, poisoning and procedural complications       | Injury, poisoning and procedural complications       | Injury, poisoning and procedural complications       | Injury, poisoning and procedural complications       | Injury, poisoning and procedural complications       | Injury, poisoning and procedural complications       | Injury, poisoning and procedural complications       | Injury, poisoning and procedural complications       |
| Infusion related reaction33                          | 16 (7.0)                                             | 1 (0.4)                                              | Common                                               | 10 (4.4)                                             | 1 (0.4)                                              | Common                                               | 123 (6.3)                                            | 12 (0.6)                                             | Common                                               | 58 (3.0)                                             | 2 (0.1)                                              | Common                                               |

Patients with multiple events for a given Group Term and System Organ Class were counted only once at the worst grade for the Group Term and System Organ Class, respectively. Frequency category was based on the following convention: very common (&gt;=1/10); common (&gt;=1/100 to &lt;1/10); uncommon (&gt;=1/1,000 to &lt;1/100); rare (&gt;=1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000).

## Adverse events were classified based on MedDRA 26.1.

Adverse events were graded for severity using CTCAE (v5.0 for studies 209, 304, 305, 307, 309, 312, and 315, v4.03 for studies 001, 102, 203, 204, 205, 206, 208, 301, 302, 303, and 306). System Organ Classes were sorted by Internationally Agreed Order.

Within each System Organ Class, events were ranked by the decreasing frequency of Group Term in the 'All Grades' of monotherapy.

1. Pneumonia included reports of Bronchopulmonary aspergillosis, Candida pneumonia, Lower respiratory tract infection, Lower respiratory tract infection bacterial, Pneumocystis jirovecii pneumonia, Pneumonia, Pneumonia bacterial, Pneumonia fungal, Pneumonia mycoplasmal, Pneumonia staphylococcal, and Pneumonia viral.

<div style=\"page-break-after: always\"></div>

| Study 312                     | Study 312                             | Study 312                             | Study 312              | Study 312              | Study 312              | Study 312                                   | Study 312                                   | Study 312                                   | Study 312               | Study 312    | Study 312                  | Study 312                       | Study 312              | Study 312   | Study 312   | Study 312   | Study 312   | Study 312   |
|-------------------------------|---------------------------------------|---------------------------------------|------------------------|------------------------|------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|-------------------------|--------------|----------------------------|---------------------------------|------------------------|-------------|-------------|-------------|-------------|-------------|
|                               | Tislelizumab + Chemotherapy (N = 227) | Tislelizumab + Chemotherapy (N = 227) | Placebo + Chemotherapy | Placebo + Chemotherapy | Placebo + Chemotherapy | Tislelizumab Combination Therapy (N = 1950) | Tislelizumab Combination Therapy (N = 1950) | Tislelizumab Combination Therapy (N = 1950) | Tislelizumab            | Tislelizumab | Monotherapy (N = 1952)     | Monotherapy (N = 1952)          | Monotherapy (N = 1952) |             |             |             |             |             |
| System Organ Class Group Term | All Grades n (%)                      | Grade 3-4 n (%)                       |                        | All Grades n (%)       | Grade n (%)            | Frequency Category (All Grades)             | All Grades n (%)                            | Grade 3-4 n (%)                             | Frequency Category (All | Grades)      | Grades (%) Grade 3-4 n (%) | Frequency Category (All Grades) |                        |             |             |             |             |             |

2. Anaemia included reports of Anaemia and Haemoglobin decreased.
3. Thrombocytopenia included reports of Immune thrombocytopenia, Platelet count decreased, and Thrombocytopenia.
4. Neutropenia included reports of Neutropenia and Neutrophil count decreased.
5. Lymphopenia included reports of Lymphocyte count decreased, Lymphocyte percentage decreased, and Lymphopenia.
6. Hypothyroidism included reports of Anti-thyroid antibody increased, Central hypothyroidism, Hypothyroidism, Immune-mediated hypothyroidism, Primary hypothyroidism, Thyroid hormones decreased, Thyroxine decreased, Thyroxine free decreased, Tri-iodothyronine decreased, and Tri-iodothyronine free decreased.
7. Hyperthyroidism included reports of Blood thyroid stimulating hormone decreased, Hyperthyroidism, Immune-mediated hyperthyroidism, Thyroxine free increased, Thyroxine increased, Triiodothyronine free increased, and Tri-iodothyronine increased.
8. Thyroiditis included reports of Autoimmune thyroiditis, Immune-mediated thyroiditis, Silent thyroiditis, Thyroiditis, and Thyroiditis subacute.
9. Adrenal insufficiency included reports of Addison's disease, Adrenal insufficiency, Glucocorticoid deficiency, Immune-mediated adrenal insufficiency, Primary adrenal insufficiency, and Secondary adrenocortical insufficiency.
10. Hypophysitis included reports of Hypophysitis and Hypopituitarism.
11. Hyperglycaemia included reports of Blood glucose increased and Hyperglycaemia.
12. Hyponatraemia included reports of Blood sodium decreased and Hyponatraemia.
13. Hypokalaemia included reports of Blood potassium decreased and Hypokalaemia.
14. Diabetes mellitus included reports of Diabetes mellitus, Diabetic ketoacidosis, Diabetic ketosis, Ketoacidosis, Latent autoimmune diabetes in adults, and Type 1 diabetes mellitus.
15. Encephalitis included reports of Encephalitis and Immune-mediated encephalitis.
16. Uveitis included reports of Chorioretinitis, Iridocyclitis, Iritis, and Uveitis.
17. Myocarditis included reports of Autoimmune myocarditis, Immune-mediated myocarditis, and Myocarditis.
18. Hypertension included reports of Blood pressure increased, Essential hypertension, and Hypertension.
19. Pneumonitis included reports of Immune-mediated lung disease, Interstitial lung disease, Organising pneumonia, and Pneumonitis.
20. Diarrhoea included reports of Diarrhoea and Frequent bowel movements.
21. Stomatitis included reports of Aphthous ulcer, Mouth ulceration, Oral mucosa erosion, and Stomatitis.
22. Pancreatitis included reports of Amylase increased, Lipase increased, Pancreatitis, and Pancreatitis acute.
23. Colitis included reports of Autoimmune colitis, Colitis, Colitis ulcerative, and Immune-mediated enterocolitis.
24. Hepatitis included reports of Autoimmune hepatitis, Drug-induced liver injury, Hepatic function abnormal, Hepatitis, Hepatotoxicity, Immune-mediated hepatitis, and Liver injury.
25. Rash included reports of Acute febrile neutrophilic dermatosis, Autoimmune dermatitis, Dermatitis, Dermatitis acneiform, Dermatitis allergic, Dermatitis exfoliative, Drug eruption, Eczema, Erythema, Erythema nodosum, Hand dermatitis, Immune-mediated dermatitis, Lichenoid keratosis, Pemphigoid, Psoriasis, Rash, Rash erythematous, Rash follicular, Rash macular, Rash maculopapular, Rash papular, Rash pruritic, Rash pustular, Skin exfoliation, and Urticaria.
26. Vitiligo included reports of Leukoderma, Skin depigmentation, Skin hypopigmentation, and Vitiligo.
27. Arthritis included reports of Arthritis, Immune-mediated arthritis, and Polyarthritis.
28. Myositis included reports of Immune-mediated myositis, Myositis, and Rhabdomyolysis.
29. Nephritis included reports of Focal segmental glomerulosclerosis, Glomerulonephritis membranous, Immune-mediated nephritis, Immune-mediated renal disorder, Nephritis, and Tubulointerstitial nephritis.
30. Fatigue included reports of Asthenia, Fatigue, Lethargy, Malaise, and Physical deconditioning.
31. Pyrexia included reports of Body temperature increased and Pyrexia.
32. Blood bilirubin increased included reports of Bilirubin conjugated increased, Blood bilirubin increased, Blood bilirubin unconjugated increased, and Hyperbilirubinaemia.
33. Infusion related reaction included reports of Anaphylactic reaction, Chills, Corneal oedema, Dermatitis allergic, Drug eruption, Drug hypersensitivity, Face oedema, Gingival Swelling, Hypersensitivity, Infusion Related Reaction, Laryngeal Obstruction, Laryngeal Oedema, Lip Oedema, Lip Swelling, Mouth Swelling, Pruritus Allergic, Rash, Rash erythematous, Rash macular, Rash pruritic, Rhinitis allergic, Swelling face, Tongue oedema, Type-1 hypersensitivity, and Urticaria.

## The characteristics of imADRs for tislelizumab are summarised below by category.

<div style=\"page-break-after: always\"></div>

Table 65 Summary of Immune-Mediated ADRs in Patients Treated With Tislelizumab Monotherapy

|                                 |                                 |                           | Led to n (1.9)                  | Corticosteroids           | Corticosteroids       | Corticosteroids   | Corticosteroids   | Immuno-              | Hormone           | Patient Median (months)   | Patient Median (months)   | Patient Median (months)   | Patient Median (months)   |
|---------------------------------|---------------------------------|---------------------------|---------------------------------|---------------------------|-----------------------|-------------------|-------------------|----------------------|-------------------|---------------------------|---------------------------|---------------------------|---------------------------|
|                                 |                                 | Total / ≥ Gr 3 Led        | to Discon- tinued Treatment (%) | Treated / High-dose n (%) |                       | Median            | Median            | n                    | Replace- ment (%) | s Recov- ered n (%)       | Time to First Onset       | Dura- tion of Event       | Duration Resolved Event   |
|                                 |                                 | n (%)                     | Modified Treat- ment n (%)      |                           |                       | Initial Dose      | Duration          | suppres- sants n (%) |                   |                           |                           |                           |                           |
| imADR Category                  | imADR Category                  |                           |                                 |                           |                       | (mg/day)          | (months)          |                      |                   |                           |                           |                           |                           |
| Pneumonitis                     | Pneumonitis                     | 100 (5.1) / 34 (1.7) 37   | 36 (1.8)                        | 69 (69.0) / 63 (63.0)     | 63.750                | 1.643             | 2 (2.0)           | --                   | 47 (47.0)         |                           | 4.123                     | 6.275                     | 2.793                     |
| Hepatitis                       | Hepatitis                       | 23 (1.2) / 18 (0.9) 15    | (0.8) 5 (0.3)                   | 18 (78.3) / 17 (73.9)     |                       | 100.000           | 2.168 2           | (8.7)                | --                | 14 (60.9)                 | 0.723                     | 2.103                     | 1.084                     |
| Skin Adverse Reaction           | Skin Adverse Reaction           | 246 (12.6) / 22 (1.1)     | 25 (1.3) 2 (0.1)                | 37 (15.0) / 13 (5.3)      |                       | 30.000            | 0.690             | 1 (0.4)              | --                | 177 (72.0)                | 1.544                     | 2.004                     | 1.068                     |
| Colitis                         | Colitis                         | 11 (0.6) / 4 (0.2) 8      | (0.4) 2 (0.1)                   |                           | 11 (100.0) / 6 (54.5) | 30.000            | 0.936             | 0 (0.0)              | --                | 9 (81.8)                  | 6.045                     | 1.380                     | 0.920                     |
| Myositis/Rhabdo myolysis        | Myositis/Rhabdo myolysis        | 16 (0.8) /5 (0.3) 9       | (0.5)                           | 4 (0.2)                   | 9 (56.3) / 8 (50.0)   | 75.000            | 1.478             | 1 (6.3)              | --                | 12 (75.0)                 | 1.511                     | 1.413                     | 1.248                     |
| roidism                         | roidism                         | 269 (13.8) / 2 (0.1)      | 12 (0.6)                        | 2 (0.1)                   | 2 (0.7) / (0.0)       | 10.000            | 1.938             | 0 (0.0)              | 174 (64.7)        | 98 (36.4)                 | 4.008                     | 7.524                     | 2.070                     |
| Hyperthy- roidism               |                                 | 100 (5.1) / 0 (0.0) 5     | (0.3) 1 (0.1)                   | 3 (3.0) / 1 (1.0)         | 30.000                |                   | 0.854             | 0 (0.0)              | 11 (11.0)         | 77 (77.0)                 | 2.070                     | 2.070                     | 1.413                     |
| Thyroiditis                     |                                 | 21 (1.1) / 0 (0.0) 4      | (0.2) 0 (0.0)                   | 2 (9.5) / 0 (0.0)         | 22.500                | 1.446             |                   | 0 (0.0)              | 14 (66.7)         | 8 (38.1)                  | 2.037                     | 5.552                     | 1.971                     |
| Endocrinopathies                | Adrenal Insuffi- ciency         | 10 (0.5) / 5 (0.3) 8      | (0.4) 0 (0.0)                   | 10 (100.0) / 2 (20.0)     | 25.000                | NR                |                   | 0 (0.0)              | --                | 3 (30.0)                  | 10.283                    | NR                        | 1.938                     |
| Hypophy- sitis                  |                                 | 5 (0.3) / 0 (0.0) 0 (0.0) | 0 (0.0)                         | 4 (80.0) / 0 (0.0)        | 12.500                | NR                | 0 (0.0)           |                      | --                | 1 (20.0)                  | 9.002                     | NR                        | 2.300                     |
| Diabetes Mellitus               | Diabetes Mellitus               | 12 (0.6) / 6 (0.3)        | 3 (0.2) 3 (0.2)                 | 0 (0.0) / 0 (0.0)         |                       | --                | --                | 0 (0.0)              | 10 (83.3)         | 1 (8.3)                   | 6.489                     | NR                        | 0.723                     |
| Nephritis and Renal Dysfunction | Nephritis and Renal Dysfunction | 4 (0.2) / 1 (0.1) 2       | (0.1) 1 (0.1)                   | 3 (75.0) / 3 (75.0)       |                       | 90.000            | NR                | 1 (25.0)             | --                | 2 (50.0)                  | 1.544                     | NR                        | 0.296                     |
| Myocarditis/Peri- carditis      | Myocarditis/Peri- carditis      | 15 (0.8) / 4 (0.2)        | 8 (0.4) 7                       | (0.4)                     | 10 (66.7) / 9 (60.0)  | 75.000            | 0.936             | 1 (6.7)              | --                | 9 (60.0)                  | 1.577                     | 5.060                     | 1.183                     |
| immune- mediated                | Ocular                          | 2 (0.1) / 0 (0.0) 1 5 / 5 | (0.1) 0 (0.0) (0.3)             | 0 (0.0) / 0 (0.0)         | --                    |                   | -- 0              | 0 (0.0)              | --                | 1 (50.0)                  | 1.413                     | NR                        | 0.723                     |
|                                 | Pancreati- tis                  | (0.3) 5 (0.3)             | 0 (0.0)                         | 2 (40.0) / 1 (20.0)       | 33.333                | 0.230             |                   | (0.0)                | --                | 5 (100.0)                 | 9.068                     | 0.608                     | 0.608                     |
| Other                           | Central Nervous System          | 1 (0.1) / 1 (0.1) 0 (0.0) | 0 (0.0)                         | 0 (0.0) / 0 (0.0)         | --                    |                   | --                | 1 (100.0)            | --                | 1 (100.0)                 | 4.271                     | 1.971                     | 1.971                     |

<div style=\"page-break-after: always\"></div>

|                   |                      |                                   | Led to Discon- tinued   | Corticosteroids           | Corticosteroids              | Corticosteroids   |                              | Hormone Replace-   | Patient Median (months)   | Patient Median (months)   | Patient Median (months)   | Patient Median (months)    |
|-------------------|----------------------|-----------------------------------|-------------------------|---------------------------|------------------------------|-------------------|------------------------------|--------------------|---------------------------|---------------------------|---------------------------|----------------------------|
| imADR Category    | Total / ≥ Gr 3 n (%) | Led to Modified Treat- ment n (%) | Treatment n (%)         | Treated / High-dose n (%) | Median Initial Dose (mg/day) | Duration (months) | Immuno- suppres- sants n (%) | ment n (%)         | s Recov- ered n (%)       | Time to First Onset       | Dura- tion of Event       | Duration of Resolved Event |
| Musculo- skeletal | 15 (0.8) / 2 (0.1)   | 2 (0.1)                           | 2 (0.1)                 | 10 (66.7) / 4 (26.7)      | 22.500                       | 1.478             | 1 (6.7)                      | --                 | 6 (40.0)                  | 3.023                     | NR                        | 1.380                      |

<div style=\"page-break-after: always\"></div>

## Laboratory findings

## Immunogenicity

For information on the immunogenicity of tislelizumab, see section pharmacokinetics

## Haematology

## Table 66 Summary of Laboratory Abnormalities Worsened from Baseline: Haematology (Safety Analysis Set)

| Study 312            | Study 312        | Study 312                             | Study 312                             | Study 312                        | Study 312                        |                                                                      |                                                                      |                                     |                                     |
|----------------------|------------------|---------------------------------------|---------------------------------------|----------------------------------|----------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|-------------------------------------|-------------------------------------|
|                      |                  | Tislelizumab + Chemotherapy (N = 227) | Tislelizumab + Chemotherapy (N = 227) | Placebo + Chemotherapy (N = 229) | Placebo + Chemotherapy (N = 229) | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) n (%) n | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) n (%) n | Tislelizumab Monotherapy (N = 1952) | Tislelizumab Monotherapy (N = 1952) |
| Parameter            | Direction- ality | All Grades n/M (%)                    | Grade 3 - 4 n/M (%)                   | All Grades n/M (%)               | Grade 3 - 4 n/M (%)              | All Grades n/M (%)                                                   | Grade 3 - 4 n/M (%)                                                  | All Grades n/M (%)                  | Grade 3 - 4 n/M (%)                 |
| Haemoglobin (g/L)    | High             | 5/225 (2.2)                           | 0/225 (0.0)                           | 2/226 (0.9)                      | 0/226 (0.0)                      | 20/736 (2.7)                                                         | 0/736 (0.0)                                                          | 86/1914 (4.5)                       | 2/1914 (0.1)                        |
| Haemoglobin (g/L)    | Low              | 201/225 (89.3)                        | 39/225 (17.3)                         | 204/226 (90.3)                   | 40/226 (17.7)                    | 676/736 (91.8)                                                       | 125/736 (17.0)                                                       | 752/1914 (39.3)                     | 85/1914 (4.4)                       |
| Leukocytes (10^9/L)  | Low              | 206/225 (91.6)                        | 89/225 (39.6)                         | 215/226 (95.1)                   | 95/226 (42.0)                    | 660/736 (89.7)                                                       | 255/736 (34.6)                                                       | 321/1914 (16.8)                     | 18/1914 (0.9)                       |
| Lymphocytes (10^9/L) | High             | NA                                    | NA                                    | NA                               | NA                               | 4/52 (7.7)                                                           | 0/52 (0.0)                                                           | 40/1890 (2.1)                       | 3/1890 (0.2)                        |
| Lymphocytes (10^9/L) | Low              | NA                                    | NA                                    | NA                               | NA                               | 33/52 (63.5)                                                         | 5/52 (9.6)                                                           | 776/1890 (41.1)                     | 169/1890 (8.9)                      |
| Neutrophils (10^9/L) | Low              | 213/225 (94.7)                        | 165/225 (73.3)                        | 220/224 (98.2)                   | 177/224 (79.0)                   | 673/734 (91.7)                                                       | 479/734 (65.3)                                                       | 258/1891 (13.6)                     | 39/1891 (2.1)                       |
| Platelets (10^9/L)   | Low              | 152/225 (67.6)                        | 52/225 (23.1)                         | 167/226 (73.9)                   | 66/226 (29.2)                    | 528/736 (71.7)                                                       | 153/736 (20.8)                                                       | 315/1914 (16.5)                     | 24/1914 (1.3)                       |

Abbreviations: 1L, first-line; NA, not applicable.

n is the number of patients for whom the Grade worsened from baseline in the 'All Grades' or 'Grades 3-4' category.

M is the number of patients treated with any dose of the study drug and with baseline and any postbaseline assessment.

Percentages were calculated based on M.

Laboratory results were Graded using CTCAE (v5.0 for studies 206, 209, 304, 307, and 312, v4.03 for studies 001, 102, 203, 204, 208, 301, 302, and 303).

Laboratory results were reported up to 30 days of the last dose of study treatment.

## Clinical chemistry

## Table 67 Summary of Laboratory Abnormalities Worsened from Baseline: Serum Chemistry (Safety Analysis Set)

| Study 312                       | Study 312        | Study 312                             | Study 312                             | Study 312                    | Study 312              |                                                              |                                                              |                          |                           |
|---------------------------------|------------------|---------------------------------------|---------------------------------------|------------------------------|------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------|---------------------------|
|                                 |                  | Tislelizumab + Chemotherapy (N = 227) | Tislelizumab + Chemotherapy (N = 227) | Placebo + Chemotherapy       | Placebo + Chemotherapy | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) | Tislelizumab Monotherapy | Tislelizumab Monotherapy  |
| Parameter                       | Direc- tionality | All Grades n/M (%)                    | Grade 3 - 4 n/M (%)                   | (N = 229) All Grades n/M (%) | Grade 3 - 4 n/M (%)    | All Grades n/M (%)                                           | Grade 3 - 4 n/M (%)                                          | (N = All Grades n/M (%)  | 1952) Grade 3 - 4 n/M (%) |
| Alanine Aminotransferase (IU/L) | High             | 72/222 (32.4)                         | 5/222 (2.3)                           | 56/224 (25.0)                | 1/224 (0.4)            | 358/733 (48.8)                                               | 25/733 (3.4)                                                 | 628/1911 (32.9)          | 49/1911 (2.6)             |
| Albumin (g/L)                   | Low              | 85/222 (38.3)                         | 0/222 (0.0)                           | 69/224 (30.8)                | 1/224 (0.4)            | 336/733 (45.8)                                               | 2/733 (0.3)                                                  | 639/1911 (33.4)          | 6/1911 (0.3)              |
| Alkaline Phosphatase (IU/L)     | High             | 75/222 (33.8)                         | 2/222 (0.9)                           | 50/224 (22.3)                | 0/224 (0.0)            | 250/732 (34.2)                                               | 6/732 (0.8)                                                  | 610/1910 (31.9)          | 52/1910 (2.7)             |

<div style=\"page-break-after: always\"></div>

| Study 312                        | Study 312        | Study 312                             | Study 312                             | Study 312              | Study 312              |                                                              |                                                              |                                     |                                     |
|----------------------------------|------------------|---------------------------------------|---------------------------------------|------------------------|------------------------|--------------------------------------------------------------|--------------------------------------------------------------|-------------------------------------|-------------------------------------|
|                                  |                  | Tislelizumab + Chemotherapy (N = 227) | Tislelizumab + Chemotherapy (N = 227) | Placebo + Chemotherapy | Placebo + Chemotherapy | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) | Tislelizumab Monotherapy (N = 1952) | Tislelizumab Monotherapy (N = 1952) |
| Parameter                        | Direc- tionality | All Grades n/M (%)                    | Grade 3 - 4 n/M (%)                   | All Grades n/M (%)     | Grade 3 - 4 n/M (%)    | All Grades n/M (%)                                           | Grade 3 - 4 n/M (%)                                          | All Grades n/M (%)                  | Grade 3 - 4 n/M (%)                 |
| Aspartate Aminotransferase (U/L) | High             | 60/222 (27.0)                         | 6/222 (2.7)                           | 49/224 (21.9)          | 0/224 (0.0)            | 339/733 (46.2)                                               | 15/733 (2.0)                                                 | 708/1911 (37.0)                     | 92/1911 (4.8)                       |
| Bilirubin (umol/L)               | High             | 35/222 (15.8)                         | 3/222 (1.4)                           | 13/225 (5.8)           | 1/225 (0.4)            | 182/733 (24.8)                                               | 13/733 (1.8)                                                 | 452/1910 (23.7)                     | 54/1910 (2.8)                       |
| Creatine Kinase (ukat/L)         | High             | 55/220 (25.0)                         | 6/220 (2.7)                           | 17/224 (7.6)           | 2/224 (0.9)            | 167/678 (24.6)                                               | 16/678 (2.4)                                                 | 259/1254 (20.7)                     | 24/1254 (1.9)                       |
| Creatinine (umol/L)              | High             | 27/222 (12.2)                         | 3/222 (1.4)                           | 24/224 (10.7)          | 1/224 (0.4)            | 134/733 (18.3)                                               | 16/733 (2.2)                                                 | 253/1911 (13.2)                     | 23/1911 (1.2)                       |
| Glucose (mmol/L)                 | High             | 92/221 (41.6)                         | 0/221 (0.0)                           | 73/224 (32.6)          | 0/224 (0.0)            | 359/730 (49.2)                                               | 0/730 (0.0)                                                  | 865/1905 (45.4)                     | 83/1905 (4.4)                       |
| Glucose (mmol/L)                 | Low              | 21/221 (9.5)                          | 2/221 (0.9)                           | 6/224 (2.7)            | 1/224 (0.4)            | 98/730 (13.4)                                                | 4/730 (0.5)                                                  | 208/1905 (10.9)                     | 9/1905 (0.5)                        |
| Potassium (mmol/L)               | High             | 12/224 (5.4)                          | 0/224 (0.0)                           | 14/224 (6.3)           | 2/224 (0.9)            | 68/735 (9.3)                                                 | 10/735 (1.4)                                                 | 191/1906 (10.0)                     | 17/1906 (0.9)                       |
| Potassium (mmol/L)               | Low              | 51/224 (22.8)                         | 15/224 (6.7)                          | 33/224 (14.7)          | 8/224 (3.6)            | 207/735 (28.2)                                               | 50/735 (6.8)                                                 | 296/1906 (15.5)                     | 55/1906 (2.9)                       |
| Sodium (mmol/L)                  | High             | 11/224 (4.9)                          | 1/224 (0.4)                           | 3/223 (1.3)            | 0/223 (0.0)            | 56/735 (7.6)                                                 | 2/735 (0.3)                                                  | 131/1906 (6.9)                      | 2/1906 (0.1)                        |
| Sodium (mmol/L)                  | Low              | 85/224 (37.9)                         | 31/224 (13.8)                         | 89/223 (39.9)          | 29/223 (13.0)          | 388/735 (52.8)                                               | 90/735 (12.2)                                                | 662/1906 (34.7)                     | 123/1906 (6.5)                      |

Abbreviation: 1L, first-line.

n is the number of patients for whom the Grade worsened from baseline in the 'All Grades' or 'Grades 3-4' category.

M is the number of patients treated with any dose of the study drug and with baseline and any postbaseline assessment. Percentages were calculated based on M.

Laboratory results were Graded using CTCAE (v5.0 for studies 206, 209, 304, 307, and 312, v4.03 for studies 001, 102, 203, 204, 208, 301, 302, and 303).

Laboratory results were reported up to 30 days of the last dose of study treatment.

## Hepatic laboratory tests

Basic information on the impact of treatment on hepatic laboratory values is included in the table above.

## Thyroid panel

Table 68 Summary of Thyroid Laboratory Tests (Safety Analysis Set)

|                                   | Study312                                | Study312                              |                                                             |                                            |
|-----------------------------------|-----------------------------------------|---------------------------------------|-------------------------------------------------------------|--------------------------------------------|
| LaboratoryParameter               | Tislelizumab+ Chemotherapy (N= 227) (%) | Placebo+ Chemotherapy (N=229) m/I (%) | Tislelizumab CombinationTherapy inILLungCancer (N=741) (%)/ | Tislelizumab Monotherapy (N =1952) n/I (%) |
| Post-baselineTSH>ULNandT4<LLN     | 26/204 (12.7)                           | 5/212 (2.4)                           | 86/677 (12.7)                                               | 216/1577 (13.7)                            |
| BaselineTSHandT4withinnormalrange | 19/204 (9.3)                            | 1/212 (0.5)                           | 59/677 (8.7)                                                | 128/1577 (8.1)                             |
| Post-baselineTSH<LLNandT4>ULN     | 10/204 (4.9)                            | 0/212 (0.0)                           | 36/677 (5.3)                                                | 102/1577 (6.5)                             |
| BaselineTSHandT4withinnormalrange | 9/204 (4.4)                             | 0/212 (0.0)                           | 29/677 (4.3)                                                | 81/1577 (5.1)                              |

Source:ADSL,ADLBSI.

Abbreviations:1L,first-line;TSH,thyroidstimulatinghomoneT4,thyroxine;LLN,1owerlimitofnormal;ULN,upperlimitofnommal

nisthenumberofpatientswiththeworstpostbaselinevalue andbaselinevalue.

Misthenumberofpatientstreatedwithanydoseof thestudydrugandwithbaselineandanypostbaselineassessment.PercentageswerecalculatedbasedonM Postbaselineliverlaboratory abnormalitiesweresummarizeduntil30days afterthelastdoseofstudydrug.

unblind/bgb\\_a317/filing\\_sclc312/sclc312\\_2024\\_scs\\_eu/dev/pgm/tlfs/t-1b-th.sas11JUL202406:44t-2-7-4-7-3-1b-th.rtf

## Safety in special populations

Study 312 was carried out in an exclusively Chinese population. The following baseline variables were used to define subgroups:

<div style=\"page-break-after: always\"></div>

- Age (&lt; 65, 65 -&lt; 75, ≥ 75 years)
- Sex (female versus male)
- Hepatic impairment (normal versus impaired)
- Renal impairment (normal versus impaired)
- ECOG Performance Status (0 versus 1)
- Smoking status (smoked versus never smoked)

<div style=\"page-break-after: always\"></div>

Table 69 Subgroup Analysis: Overview of Treatment-Emergent Adverse Events by Age Group (Safety Analysis Set)

|                                      | Study 312                   | Study 312                   | Study 312                   | Study 312                   | Study 312            | Study 312            | Study 312            | Study 312            |
|--------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|----------------------|----------------------|----------------------|----------------------|
|                                      | Tislelizumab + Chemotherapy | Tislelizumab + Chemotherapy | Tislelizumab + Chemotherapy | Tislelizumab + Chemotherapy | Placebo+Chemotherapy | Placebo+Chemotherapy | Placebo+Chemotherapy | Placebo+Chemotherapy |
|                                      | $9 > (N=138) n (%)          | 65-<75 (N=81) n (%)         | >=75 (N=8) n (%)            | All (N=227) n (%)           | <65 (N=148) n (%)    | 65-<75 (N=78) n (%)  | >=75 (N=3) n (%)     | All (N=229) n (%)    |
| PatientsWith AnyTEAE                 | 137 (99.3)                  | 81 (100.0)                  | 8 (100.0)                   | 226 (99.6)                  | 147 (99.3)           | 78 (100.0)           | 3 (100.0)            | 228 (99.6)           |
| >=Grade 3                            | 119 (86.2)                  | 75 (92.6)                   | 8 (100.0)                   | 202 (89.0)                  | 130 (87.8)           | 73 (93.6)            | 3 (100.0)            | 206 (90.0)           |
| Serious                              | 60 (43.5)                   | 32 (39.5)                   | 4 (50.0)                    | 96 (42.3)                   | 48 (32.4)            | 21 (26.9)            | 1 (33.3)             | 70 (30.6)            |
| Leading to Death                     | 11 (8.0)                    | 3 (3.7)                     | 0(0.0)                      | 14 (6.2)                    | 2 (1.4)              | 1 (1.3)              | 1 (33.3)             | 4 (1.7)              |
| Leading to Treatment                 | 17 (12.3)                   | 16 (19.8)                   | 0 (0.0)                     | 33 (14.5)                   | 4 (2.7)              | 2 (2.6)              | 1 (33.3)             | 7 (3.1)              |
| Discontinuation Leading to Treatment | 95 (68.8)                   | 55 (67.9)                   | 5 (62.5)                    | 155 (68.3)                  | 98 (66.2)            | 54 (69.2)            | 1 (33.3)             | 153 (66.8)           |
| Modification Immune-Mediated AE      | 60 (43.5)                   | 28 (34.6)                   | 3 (37.5)                    | 91 (40.1)                   | 30 (20.3)            | 12 (15.4)            | 0 (0.0)              | 42 (18.3)            |
| Immune-Mediated AE>= Grade 3         | 13 (9.4)                    | 11 (13.6)                   | 1 (12.5)                    | 25 (11.0)                   | 1 (0.7)              | 0 (0.0)              | 0 (0.0)              | 1 (0.4)              |
| Infusion-Related Reaction            | 5 (3.6)                     | 11 (13.6)                   | 0 (0.0)                     | 16 (7.0)                    | 6 (4.1)              | 4 (5.1)              | 0 (0.0)              | 10 (4.4)             |
| Infusion-Related Reaction >= Grade 3 | 0 (0.0)                     | 1 (1.2)                     | 0 (0.0)                     | 1 (0.4)                     | 0 (0.0)              | 1 (1.3)              | 0 (0.0)              | 1 (0.4)              |

<div style=\"page-break-after: always\"></div>

Table 70 Subgroup Analysis: Overview of Treatment-Emergent Adverse Events by Sex (Safety Analysis Set)

|                                      | Study 312                 | Study 312                 | Study 312                 | Study 312             | Study 312             | Study 312             |
|--------------------------------------|---------------------------|---------------------------|---------------------------|-----------------------|-----------------------|-----------------------|
|                                      | Tislelizumab+Chemotherapy | Tislelizumab+Chemotherapy | Tislelizumab+Chemotherapy | Placebo +Chemotherapy | Placebo +Chemotherapy | Placebo +Chemotherapy |
|                                      | Female (N=41)             | Male (N=186)              | All (N=227)               | Female (N=44)         | Male                  | All (N=229)           |
|                                      |                           |                           |                           |                       | (N=185)               |                       |
|                                      | n (%)                     | n (%)                     | (%)                       | n (%)                 | n (%)                 | n (%)                 |
| Patients With Any TEAE               | 41 (100.0)                | 185 (99.5)                | 226 (99.6)                | 44 (100.0)            | 184 (99.5)            | 228 (99.6)            |
| >=Grade 3                            | 37 (90.2)                 | 165 (88.7)                | 202 (89.0)                | 41 (93.2)             | 165 (89.2)            | 206 (90.0)            |
| Serious                              | 22 (53.7)                 | 74 (39.8)                 | 96 (42.3)                 | 12 (27.3)             | 58 (31.4)             | 70 (30.6)             |
| Leading to Death                     | 3 (7.3)                   | 11 (5.9)                  | 14 (6.2)                  | 0 (0.0)               | 4 (2.2)               | 4 (1.7)               |
| Leading to Treatment Discontinuation | 11 (26.8)                 | 22 (11.8)                 | 33 (14.5)                 | 0 (0.0)               | 7 (3.8)               | 7 (3.1)               |
| Leading to Treatment Modification    | 29 (70.7)                 | 126 (67.7)                | 155 (68.3)                | 36 (81.8)             | 117 (63.2)            | 153 (66.8)            |
| Immune-Mediated AE                   | 24 (58.5)                 | 67 (36.0)                 | 91 (40.1)                 | 6 (13.6)              | 36 (19.5)             | 42 (18.3)             |
| Immune-Mediated AE>=Grade 3          | 6 (14.6)                  | 19 (10.2)                 | 25 (11.0)                 | 0 (0.0)               | 1 (0.5)               | 1 (0.4)               |
| Infusion-Related Reaction            | 3 (7.3)                   | 13 (7.0)                  | 16 (7.0)                  | 2 (4.5)               | 8 (4.3)               | 10 (4.4)              |
| Infusion-Related Reaction >=Grade 3  | 0 (0.0)                   | 1 (0.5)                   | 1 (0.4)                   | 0 (0.0)               | 1 (0.5)               | 1 (0.4)               |

<div style=\"page-break-after: always\"></div>

## Safety related to drug-drug interactions and other interactions

No  new  information  on  drug  interactions  for  tislelizumab  has  been  generated  in  support  of  this application.

## Discontinuation due to adverse events

## Table 71 Treatment-Emergent Adverse Events Leading to Treatment Discontinuation With Incidence Rate ≥ 1% by Preferred Term (Safety Analysis Set)

|                                                             | Study 312                                   | Study 312                              |                                                                    |                                           |
|-------------------------------------------------------------|---------------------------------------------|----------------------------------------|--------------------------------------------------------------------|-------------------------------------------|
| Preferred Term                                              | Tislelizumab + Chemotherapy (N = 227) n (%) | Placebo + Chemotherapy (N = 229) n (%) | Tislelizumab Combination Therapy in 1L Lung Cancer (N = 741) n (%) | Tislelizumab Monotherapy (N = 1952) n (%) |
| Patients With Any TEAE Leading to Treatment Discontinuation | 33 (14.5)                                   | 7 (3.1)                                | 192 (25.9)                                                         | 253 (13.0)                                |
| Immune-mediated myocarditis                                 | 3 (1.3)                                     | 0 (0.0)                                | 5 (0.7)                                                            | 2 (0.1)                                   |
| Blood creatinine increased                                  | 2 (0.9)                                     | 0 (0.0)                                | 16 (2.2)                                                           | 1 (0.1)                                   |
| Neutrophil count decreased                                  | 1 (0.4)                                     | 0 (0.0)                                | 9 (1.2)                                                            | 0 (0.0)                                   |
| Platelet count decreased                                    | 1 (0.4)                                     | 0 (0.0)                                | 8 (1.1)                                                            | 3 (0.2)                                   |
| Pneumonitis                                                 | 1 (0.4)                                     | 0 (0.0)                                | 20 (2.7)                                                           | 16 (0.8)                                  |
| Thrombocytopenia                                            | 1 (0.4)                                     | 1 (0.4)                                | 17 (2.3)                                                           | 1 (0.1)                                   |
| Anaemia                                                     | 0 (0.0)                                     | 0 (0.0)                                | 29 (3.9)                                                           | 1 (0.1)                                   |
| Pneumonia                                                   | 0 (0.0)                                     | 0 (0.0)                                | 7 (0.9)                                                            | 19 (1.0)                                  |

Table 72 Treatment-Related Treatment-Emergent Adverse Events Leading to Treatment Discontinuation by System Organ Class (with Incidence Rate ≥ 1%) and Preferred Term (Safety Analysis Set)

|                                                         | Study 312                                  | Study 312                             |
|---------------------------------------------------------|--------------------------------------------|---------------------------------------|
| System Organ Class PreferredTerm                        | Tislelizumab + Chemotherapy (N =227) n (%) | Placebo + Chemotherapy (N =229) n (%) |
| PatientsWithAnyTreatment-RelatedTEAE LeadingtoTreatment | 27 (11.9)                                  | 4 (1.7)                               |
| Discontinuation                                         |                                            |                                       |
| Cardiac disorders                                       | 5 (2.2)                                    | 0 (0.0)                               |
| Immune-mediated myocarditis                             | 3 (1.3)                                    | 0 (0.0)                               |
| Autoimmunemyocarditis                                   | 1 (0.4)                                    | 0 (0.0)                               |
| Cardiac failure acute                                   | 1 (0.4)                                    | 0 (0.0)                               |
| Investigations                                          | 5 (2.2)                                    | 0 (0.0)                               |
| Blood creatimine increased                              | 2 (0.9)                                    | 0 (0.0)                               |
| Aspartate aminotransferase increased                    | 1 (0.4)                                    | 0 (0.0)                               |
| Neutrophil count decreased                              | 1 (0.4)                                    | 0 (0.0)                               |
| Platelet count decreased                                | 1 (0.4)                                    | 0 (0.0)                               |
| Troponin T increased                                    | 1 (0.4)                                    | 0 (0.0)                               |
| Respiratory, thoracic and mediastinal disorders         | 4 (1.8)                                    | 1 (0.4)                               |
| Asthma                                                  | 1 (0.4)                                    | 0 (0.0)                               |
| Immune-mediated lung disease                            | 1 (0.4)                                    | 0 (0.0)                               |
| Pneumonitis                                             | 1 (0.4)                                    | 0 (0.0)                               |
| Respiratory failure                                     | 1 (0.4)                                    | 0 (0.0)                               |
| Blood and lymphatic system disorders                    | 3 (1.3)                                    | 1 (0.4)                               |
| Febrile neutropenia                                     | 1 (0.4)                                    | 0 (0.0)                               |
| Immune-mediated pancytopenia                            | 1 (0.4)                                    | 0 (0.0)                               |
| Thrombocytopenia                                        | 1 (0.4)                                    | 1 (0.4)                               |

<div style=\"page-break-after: always\"></div>

| Skin and subcutaneous tissue disorders   | 3 (1.3)   | 0 (0.0)   |
|------------------------------------------|-----------|-----------|
| Immune-mediated dermatitis               | 1 (0.4)   | 0 (0.0)   |
| Psoriasis                                | 1 (0.4)   | 0 (0.0)   |
| Rash                                     | 1 (0.4)   | 0 (0.0)   |

## Post marketing experience

Tislelizumab has received marketing authorization in several countries/regions, mainly including China, the United States, EU, United Kingdom, Switzerland, and Australia for various indications. The first marketing authorization for tislelizumab was granted in China on 26-Dec-2019. The first approval in the EU was for tislelizumab as monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior platinum-based chemotherapy on 13-Sep-2023.

As of 25 June 2024, there is a cumulative total exposure of approximately 266,073 person-years (3,192,876 person-months) based on the treatment cycle of Q3W.

The safety profile of tislelizumab including post-marketing safety data is summarized in the PBRER. During the reporting interval of the first 6-month PBRER (26 December 2023 through 25 June 2024), Immune-mediated cystitis was identified as safety signal and confirmed as an ADR. In addition, two actions were taken for safety reasons in the post-marketing setting during the reporting interval:

- 'Stevens-Johnson syndrome (SJS)' and 'Toxic epidermal necrolysis (TEN)' were included as ADRs in the sections 'Adverse drug reactions' and 'Warnings and precautions' of the SmPC (approval of Type II variation on 21 March 2024).
- The signals 'Coeliac disease' and 'Pancreatic failure' were implemented in the SmPC (approval of grouped Type IA variation on 16 May 2024).

Overall, these safety updates have not resulted in significant changes of the benefit/risk profile of tislelizumab.

## 2.5.1. Discussion on clinical safety

The safety data supporting the application for extension of indication for tislelizumab in combination with etoposide and platinum-based chemotherapy as a first-line treatment for adult patients with ESSCLC were collected in the pivotal Study 312 ). The primary safety data are from the end-of-study analysis (with a data cut-off date of 29 December 2023), providing an additional 8.3 months of minimum follow-up time compared to the final analysis (with a data cut-off date of 19 April 2023). Safety data from the 1L lung cancer pool and from the tislelizumab monotherapy pool are provided for context and are presented side by side with the safety data from Study 312 in most tables. However, the safety data from these pools are only discussed in individual instances due to very disparate patient populations. Safety data from the tislelizumab combination therapy pool (1950 patients)) are used for the selection of adverse drug reactions.

In Study 312, the median duration of exposure to tislelizumab / placebo (19.43 weeks in Arm T+C versus 19.14 weeks in Arm P+C) 1 , the median number of cycles received (6.0 cycles in both treatment arms) 2 , and the median relative dose intensity (RDI) (94.79% versus 95.45%) were similar in both treatment arms. A higher proportion of patients in Arm T+C received &gt; 16 cycles of study treatment

1  Mean duration of exposure to tislelizumab: 41.33 (Standard Deviation (SD) 50.339) weeks and to placebo 23.76 (SD

19.725) weeks)

2  Mean number of cycles received: 12.7 (SD 15.48) cycles in Arm T+C versus 7.3 (SD 5.88) cycles in Arm P+C

<div style=\"page-break-after: always\"></div>

than in Arm P+C (19.4% versus 4.4%). Similar exposures to chemotherapy were observed in both treatment arms (median duration of exposure 2.86 months in Arm T+C versus 2.89 months in Arm P+C 3 ; median number of cycles received 4.0 in both treatment arms). Likewise, the median RDI was comparable in both treatment arms (90.18% versus 90.15%). Hence, the addition of tislelizumab to a standard chemotherapy regimen did not negatively affect the study participants' ability to receive chemotherapy.

Almost all patients in both treatment arms of Study 312 (≥ 99%) experienced ≥ 1 TEAE. The incidence rates of the most common TEAEs by Preferred Term were generally comparable in both treatment arms; the most commonly reported events were (incidence rate ≥ 30% in either arm): Anaemia (85.0% in Arm T+C versus 84.7% in Arm P+C), Alopecia (79.3% versus 79.5%), Neutropenia (68.7% versus 70.3%), White blood cell count decreased (55.9% versus 64.6%), Thrombocytopenia (49.8% versus 52.0%), Nausea (44.5% versus 43.7%), Decreased Appetite (39.2% versus 37.6%), Constipation (37.0% versus 25.3%), and Leukopenia (33.0% versus 24.5%). A higher incidence rate in Arm T+C compared to Arm P+C (incidence rate ≥ 20% in both treatment arms, difference ≥ 5%) was reported for the Preferred Terms of Constipation, Leukopenia, and Alanine aminotransferase increased. Higher incidence rates in Arm T+C compared to Arm P+C (difference ≥ 10%) were also reported for the System Organ Classes of General disorders and administration site conditions (53.7% versus 43.2%) and Endocrine disorders (19.4% versus 4.8%). All events are in line with the known safety profiles of tislelizumab and the chemotherapy components, respectively, while the difference in incidence rates highlights the additive toxicity of tislelizumab in combination with chemotherapy.

The overall incidence rates of severe TEAEs (CTCAE ≥ Grade 3) in both treatment arms of Study 312 were similar (89.0% in Arm T+C versus 90.0% in Arm P+C). The incidence rates of the most common severe TEAEs by Preferred Term were generally comparable in both treatment arms; the most com monly reported severe events were (incidence rate ≥ 10% in either arm): Neutropenia (56.4% versus 54.6%), White blood cell count decreased (23.8% versus 27.5%), Thrombocytopenia (19.4% versus 25.3%), Anaemia (17.6% versus 18.3%), Neutrophil count decreased (14.5% versus 21.4%), and Leukopenia (11.9% versus 10.5%). Severe TEAEs by Preferred Term with a higher incidence rate in Arm T+C than in Arm P+C (difference ≥ 2%) were Rash (2.2% versus 0.0%), Hyponatraemia (11.0% versus 8.3%), and Hypokalaemia (6.6% versus 1.7%). A higher incidence rate of severe events in Arm T+C compared to Arm P+C (difference ≥ 5%) was reported for the System Organ Classes Metabolism and nutrition disorders (21.1% versus 14.4%) and General disorders and administration site conditions (5.7% versus 0.4%).

The overall incidence rate of serious TEAEs was higher by more than 10% in Arm T+C compared to Arm P+C of Study 312 (42.3% versus 30.6%). The incidence rates of the most common serious TEAEs by Preferred Term in Arms T+C and P+C were mostly comparable in both treatment arms (incidence rate ≥ 2% in either arm): Thrombocytopenia (7.5% versus 7.9%), Neutropenia (7.0% versus 3.9%), Hyponatraemia (2.2% versus 0.4%), Neutrophil count decreased (2.2% versus 1.3%), Platelet count decreased (2.2% versus 2.2%), Pneumonitis (2.2% versus 0.0%), White blood cell count decreased (2.2% versus 1.3%), Pneumonia (1.8% versus 2.2%), Febrile neutropenia (1.3% versus 2.2%), and Haemoptysis (0.9% versus 2.2%). This collection of serious events reflects both the dominant toxicities of the chemotherapy components and tislelizumab and / or the symptoms of the disease under study. The distribution of the remaining serious TEAEs by Preferred Term was sporadic across different System Organ Classes. However, it appears that the small differences across Preferred Terms added up to a tangible detriment for Arm T+C compared with Arm P+C. Neutropenia and Pneumonitis were the only serious TEAEs by Preferred Term with a higher incidence rate (difference ≥ 2%) in Arm

3  Mean duration of exposure to chemotherapy: 2.77 (SD 0.721) months in Arm T+C versus 2.80 (SD 0.704) months in Arm P+C

<div style=\"page-break-after: always\"></div>

T+C compared to Arm P+C. Pneumonitis is both associated with the disease under study and with tislelizumab. Neutropenia is a known ADR of carboplatin, etoposide, and tislelizumab, which may have contributed to the additive toxicity of the combination. A higher incidence rate of serious events in Arm T+C compared to Arm P+C (difference ≥ 5%) was reported for one System Organ Class only, Metabolism and nutrition disorders (6.6% versus 1.7%).

As observed in previous studies evaluating tislelizumab in combination with chemotherapy in other indications, the incidence rates of serious TEAEs were generally higher in Arm T+C than in Arm P+C in Study 312. However, no unexpected safety signals were observed with the combination under consideration.

Most deaths occurred &gt; 30 days after the patients' last dose of study treatment (71.8% versus 83.0%); for these deaths, disease under study was the primary cause in both treatment arms (66.1% versus 79.5%). The incidence rates of any TEAEs leading to death were 6.2% ( 14 patients ) in Arm T+C and 1.7% (4 patients) in Arm P+C. TEAEs leading to death were reported in eight patients in Study 312, all from Arm T+C (Preferred Terms of Thrombocytopenia, Cardiac failure acute, Gastrointestinal haemorrhage, Subileus, Autoimmune myocarditis, Febrile neutropenia, Death (death of unknown cause, two fatalities with very limited information for medical assessments). Per the protocol, signs and symptoms of disease progression needed to be reported as a TEAE; as a result, the disease under study was the primary cause of death in another six patients in Arm T+C (Preferred Terms of Death (two fatalities), Depressed level of consciousness (two fatalities), Multiple organ dysfunction syndrome, Respiratory failure. Thus, fatal events were spread across different System Organ Classes with low incidence rates of each Preferred Term (&lt; 1% in either arm). The events leading to death were consistent with the known safety profiles of the study treatment and / or the underlying disease, and / or comorbidities. For a discussion of the higher rates of early deaths in Arm T+C versus Arm P+C, please see discussion on clinical efficacy.

TEAEs assessed as causally related to tislelizumab / placebo were experienced by 73.1% of patients in Arm T+C and by 58.1% of patients in Arm P+C of Study 312. Furthermore, 99.6% of patients experi enced ≥ 1 TEAE related to any component of chemotherapy in both treatment arms. TEAEs Grade ≥ 3 related to tislelizumab / placebo were reported at a higher incidence rate in Arm T+C than in Arm P+C (26.9% in Arm T+C versus 16.6% in Arm P+C). Most TEAEs Grade ≥ 3 related to any component of chemotherapy showed comparable incidence rates in both treatment arms (81.9% versus 85.2%). By contrast, the incidence rate of serious TEAEs related to tislelizumab / placebo was higher in Arm T+C than in Arm P+C (20.3% versus 7.4%). The incidence rate of serious TEAEs related to any component of chemotherapy was slightly higher in Arm T+C compared to Arm P+C (20.7% versus 16.6%). TEAEs leading to death assessed as causally related to tislelizumab / placebo occurred at higher incidence rates in Arm T+C than in Arm P+C (3.1% versus 0.0%). Similarly, TEAEs leading to death assessed as causally related to any component of chemotherapy occurred at higher incidence rates in Arm T+C than in Arm P+C (2.6% versus 0.0%). TEAEs leading to discontinuation of tislelizumab / placebo were observed at considerably higher incidence rates in Arm T+C than in Arm P+C (12.8% versus 2.6%); those leading to discontinuation of any component of chemotherapy also occurred at higher incidence rates in Arm T+C than in Arm P+C (7.0% versus 2.2%).

In line with the immune-modulatory mechanism of action of tislelizumab, immune-mediated TEAEs were reported more commonly in Arm T+C than in Arm P+C of Study 312 (40.1% in Arm T+C versus 18.3% Arm P+C). The same applies for all other categories of imTEAEs (imTEAEs Grade ≥ 3, serious imTEAEs, imTEAEs leading to dose modification / discontinuation of treatment); one patient in Arm T+C (0.4%, autoimmune myocarditis) and no patient in Arm P+C died due to imTEAEs. The most commonly reported imTEAEs by imTEAE cat egory in Arms T+C and P+C (incidence rate ≥ 5% in either arm) were immune-mediated skin adverse reactions (16.7% versus 8.7%), immune-mediated endocrinopathies (hypothyroidism; 16.3% versus 4.8%, hyperthyroidism; 6.6% versus 2.6%) and immune-

<div style=\"page-break-after: always\"></div>

mediated pneumonitis (7.5% versus 3.1%). A substantial proportion of patients in Arm T+C did not recover from their imTEAEs despite supportive treatment, in particular patients with hypothyroidism (patients recovered: 45.9% in Arm T+C versus 54.5% in Arm P+C), pneumonitis (patients recovered: 29.4% versus 57.1%), and diabetes mellitus (patients recovered: 11.1% versus not applicable).

The incidence rates of infusion-related reactions were relatively low in both treatment arms of Study 312 (7.0% in Arm T+C and 4.4% in Arm P+C), with no serious events reported.

Laboratory findings in Study 312 reflect the known toxicity profiles of tislelizumab and the chemotherapy components. Decreases in haematological parameters were high but similar in both treatment arms, indicating that they were largely driven by the chemotherapy components. Abnormalities in terms of clinical chemistry were more common in Arm T+C than in Arm P+C, suggesting that these were principally associated with tislelizumab. Increases in liver enzymes (in particular AST) and abnormalities in the thyroid panel consistent with hypo- and hyperthyroidism in Arm T+C were most likely due to the immune-mediated effects of tislelizumab on the liver and the thyroid gland, respectively.

The proportions of female patients and the proportions of patients ≥ 75 years of age in both treatment arms of Study 312 were small (18.1% in Arm T+C versus 19.2% in Arm P+C), and 3.5% versus 1.3% respectively). Similar trends in the incidence rates of TEAE categories were observed across the subgroups and the overall study population in both treatment arms. Any numerical differences observed were not considered to be clinically meaningful given the limited sample sizes of some of the subgroups and the small number of events that led to these differences.

Only Chinese patients were enrolled in Study 312. The extrapolation of the safety data observed in the Chinese patient population enrolled in Study 312 to a European patient population can be considered acceptable, as no clinically meaningful differences attributable to ethnic background were identified in other global studies with tislelizumab across various indications.

In Study 312, the incidence rate of TEAEs leading to discontinuation of any component of study treatment was higher in Arm T+C than in Arm P+C (14.5% in Arm T+C versus 3.1% in Arm P+C). Generally, this shift was not driven by specific Preferred Terms; however, several TEAEs leading to treatment discontinuation were immune-mediated. Most events reflected the known safety profiles of the study treatments or complications of the disease under study: Immune-mediated myocarditis (1.3% versus 0.0%), Blood creatinine increased (0.9% versus 0.0%), Neutrophil count decreased (0.4% versus 0.0%), Platelet count decreased (0.4% versus 0.0%), Pneumonitis (0.4% versus 0.0%), and Thrombocytopenia (0.4% versus 0.4%). The only TEAE leading to treatment discontinuation with a difference in incidence rate ≥ 1% between the two treatment arms was Immune -mediated myocarditis.

TEAEs leading to dose modification of tislelizumab / placebo were reported in 48.0% of patients in Arm T+C and in 44.1%% of patients in Arm P+C; those leading to dose modification of any component of chemotherapy were reported in 58.1% of patients in Arm T+C and in 65.5% of patients in Arm P+C.

For the presentation of Adverse Drug Reactions (ADRs) in the SmPC, the safety of tislelizumab as monotherapy and in combination therapy have been revised and are now based on the pooled data of 1,952 patients and 1950 patents respectively across multiple tumour types, which is endorsed.

No clinically relevant differences were noted between imADRs when tislelizumab was administered as a monotherapy or as a combination therapy. Section 4.8 of the SmPC has been updated with the revised frequencies for the ADR, but no new ADR were added to the table in section 4.8.

<div style=\"page-break-after: always\"></div>

In order to comply with the Annex to the European commission guideline on 'Excipients in the labelling and package leaflet of medicinal products from human use'' (SANTE-2017-11668) Rev.4, a warning, to inform about the risk of allergic reactions due to the excipient polysorbate 20, was included in section 4.4 of the SmPC. It was also clarified in section 4.4 of the SmPC that Tevimbra is to be diluted in sodium chloride 9 mg/mL (0.9%) solution for infusion and that it should be taken into consideration for patients on a controlled sodium diet.

## 2.5.2. Conclusions on clinical safety

Overall, the safety profile observed for tislelizumab in combination with etoposide and platinum-based chemotherapy in adult patients with ES-SCLC in the first-line setting was consistent with the existing safety profile of tislelizumab (mainly imTEAEs) and the known safety profiles of the chemotherapy components (mainly haematologic and gastrointestinal toxicity), and the expected additive toxicity of tislelizumab when given in combination with chemotherapy. There are no new safety signals for tislelizumab when used in this combination regimen.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted/was requested to submit an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 4.0 is acceptable:

The CHMP endorsed the Risk Management Plan version 4.0 with the following content:

## Safety concerns

| Summary of Safety Concerns   | Summary of Safety Concerns              |
|------------------------------|-----------------------------------------|
| Important Identified Risks   | Immune-mediated adverse reactions       |
| Important Potential Risks    | Reproductive and developmental toxicity |
| Missing Information          | None                                    |

## Pharmacovigilance plan

None.

<div style=\"page-break-after: always\"></div>

Risk minimisation measures

| Safety Concern                          | Risk Minimisation Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Pharmacovigilance Activities                                                                                                                                             |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks              | Important Identified Risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Important Identified Risks                                                                                                                                               |
| Immune- Mediated Adverse Reactions      | Routine Risk Minimisation Measures: SmPC Section 4.2 where guidelines for withholding or permanent discontinuation of treatment are provided. SmPC Section 4.4 where advice is provided regarding monitoring and management of immune-mediated adverse reactions. SmPC Section 4.8 where the adverse drug reactions of immune-mediated adverse reactions are listed. PL Section 2 and PL Section 4 where guidance on how to early identify signs and symptoms and seek medical attention is included. Additional Risk Minimisation Measures: Patient card Legal Status: Restricted medical prescription                       | Routine Pharmacovigilance Activities Beyond Adverse Reactions Reporting and Signal Detection: Targeted follow-up checklist Additional Pharmacovigilance Activities: None |
| Important Potential Risks               | Important Potential Risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Important Potential Risks                                                                                                                                                |
| Reproductive and Developmental Toxicity | Routine Risk Minimisation Measures: SmPC Section 4.6 where advice is provided regarding the need for women of childbearing potential to avoid getting pregnant for lactating women to avoid breastfeeding infants while taking tislelizumab, and that women of childbearing potential should use effective contraception during treatment with tislelizumab and for 4 months after the last dose. SmPC Section 5.3. PL Section 2 where guidance on how to early identify signs and symptoms and seek medical attention is included. Additional Risk Minimisation Measures: None Legal Status: Restricted medical prescription | Routine Pharmacovigilance Activities Beyond Adverse Reactions Reporting and Signal Detection: None Additional Pharmacovigilance Activities: None                         |
| Missing Information                     | Missing Information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Missing Information                                                                                                                                                      |
| None                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                          |

Abbreviations: PL, Product Label; SmPC, Summary of Product Characteristics.

## 2.7. Update of the Product information

As a consequence of this new indication, sections 2, 4.1, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The MAH also took the opportunity to make editorial changes to the SmPC, Annex II and Package Leaflet.

<div style=\"page-break-after: always\"></div>

Please refer to Annex 2 which includes all agreed changes to the Product Information.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

The full user testing was performed as part of the marketing authorisation for the treatment of NSCLC and a bridging was conducted to cover the second-line treatment OSCC. The current changes in the package leaflet are minor related to the extension of the indication 'a type of lung cancer called extensive-stage small cell lung cancer'.

In section 1 'What Tevimbra is and what it is used for' a revised wording was included to add the new indication in patient-friendly terms. In addition, section 2 'What you need to know before you are given Tevimbra' was amended in order to implement the warning statement in the context of the excipient polysorbate 20 according to the statement published in the annex of the excipients guideline together with the inclusion of a statement for the dilution step of the concentration and the resulting higher intake of sodium. The section 4 'Possible side effects' contains an update of new side effects and frequencies for the proposed new indication.

There are no further proposed changes to the content of the package leaflet. In particular the key messages for the safe use of the medicinal product are not impacted. Furthermore, the design, layout and format of the package leaflet will be maintained and the readability will not be affected negatively.

Therefore, the justification for not performing a consultation with target patient groups is considered acceptable

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The approved indication is:

Tevimbra, in combination with etoposide and platinum chemotherapy, is indicated for the first-line treatment of adult patients with extensive-stage SCLC.

SCLC accounts for approximately 13% of all lung cancer cases. It is an aggressive, poorly differentiated, and high-grade neuroendocrine carcinoma. The majority of patients (approximately 70%) are diagnosed with extensive-stage disease and have a poor prognosis, with a median OS of approximately 8 to 13 months and an expected 2-year survival rate of only 5% (Johal et al 2021; Socinski et al 2009).

## 3.1.2. Available therapies and unmet medical need

Standard of care 1L treatment for patients with untreated ES-SCLC was platinum plus etoposide for decades. Despite the high initial response rates after chemotherapy, almost all patients with ES-SCLC would relapse or experience disease progression with a PFS of 5-6 months ( Demedts et al 2010; Noda et al 2002; Rossi et al 2012; Rudin et al 2008; Schmittel et al 2011; Zugazagoitia and Paz-Ares 2022, ESMO guideline 2021).

<div style=\"page-break-after: always\"></div>

Recently, the addition of PD-L1 inhibitors to the standard platinum-etoposide backbone, with continuation of immunotherapy as maintenance, has become the new standard of care in first-line therapy (ESMO 2021). Atezolizumab was the first checkpoint inhibitor receiving an approval for the 1L treatment of ES-SCLC in the EU in September 2019 (based on Study IMpower133; EMEA/H/C/004143/II/0018), followed by durvalumab in August 2020 (based on the CASPIAN study; EMEA/H/C/004771/II/0014/G). In February 2025, serplulimab, a PD-1 inhibitor received a marketing authorisation in 1L ES-SCLC (based on study ASTRUM-005; EMEA/H/C/006170/0000).

## 3.1.3. Main clinical studies

The pivotal double-blind Study 312 randomized 457 patients with ES-SCLC in a 1:1 ratio to receive a 1L treatment of tislelizumab plus chemotherapy (T+C) versus placebo plus chemotherapy (P+C). Tislelizumab (200 mg/kg IV Q3W) or placebo were continued as maintenance treatment until disease progression or unacceptable toxicity. Randomization was stratified by ECOG PS (0 versus 1), investigator-chosen chemotherapy (cisplatin versus carboplatin) and brain metastasis (yes versus no). The primary endpoint was OS. Efficacy results were provided from the final analysis (data cutoff date: 19 April 2023). Updated results upon Last Patient Last visit (data cutoff date: 29-December 2023) were presented for descriptive purpose.

## 3.2. Favourable effects

Study 312 demonstrated a statistically significant improvement in OS with tislelizumab plus chemotherapy over placebo plus chemotherapy (median OS: 15.5 months versus 13.5 months; stratified HR = 0.75 [95% CI: 0.61, 0.93]; 1-sided stratified p = 0.0040) at the FA (median survival follow-up of 31.2 months in Arm T+C). Updated OS results showed a sustained benefit with additional follow-up (DCO 29 Dec 2023).

The study also demonstrated a statistically significant improvement in the secondary endpoint PFS (median PFS: 4.7 months for T+C versus 4.3 months for P+C; stratified HR: 0.64 [95% CI: 0.52 to 0.78]; 1sided stratified p &lt; 0.0001).

## 3.3. Uncertainties and limitations about favourable effects

Study 312 recruited patients only outside the EU (in China only). Exploratory analyses were provided to support the applicability of Chinese Study 312 data to the EU patient population. Although these analyses need to be interpreted with caution, they did not indicate plausible signals to suggest a differential treatment effect. In conclusion, the effects of tislelizumab demonstrated in Study 312 also apply for European patients.

Number of elderly patients with ≥ 75 years and for patients with brain metastasis are too limited to draw conclusions on a potentially different treatment effect in these subgroups. This is reflected in section 5.1 of the SmPC.

## 3.4. Unfavourable effects

The overall incidence rate of serious TEAEs was higher by more than 10% in Arm T+C compared to Arm P+C of Study 312 (42.3% versus 30.6%). The incidence rates of the most common serious TEAEs by Preferred Term in Arms T+C and P+C were mostly comparable in both treatment arms (incidence rate ≥ 2% in either arm): Thrombocytopenia, Neutropenia, Hyponatraemia, Neutrophil count decreased, Platelet count decreased, Pneumonitis, White blood cell count decreased, Pneumonia,

<div style=\"page-break-after: always\"></div>

Febrile neutropenia, and Haemoptysis. Neutropenia and Pneumonitis were the only serious TEAEs by Preferred Term with a differ ence ≥ 2% in incidence rates in Arm T+C compared to Arm P+C. It appears, however, that small differences across Preferred Terms added up to a substantial detriment for Arm T+C compared with Arm P+C.

Immune-mediated TEAEs were reported more commonly in Arm T+C than in Arm P+C of Study 312 (40.1% versus 18.3%). The same applies for all other categories of imTEAEs (imTEAEs Grade ≥ 3, serious imTEAEs, imTEAEs leading to dose modification / discontinuation of treatment / death). The most commonly reported imTEAEs by imTEAE category in Arms T+C and P+C (incidence rate ≥ 5% in either arm) were immune-mediated skin adverse reactions, immune-mediated endocrinopathies (hypothyroidism), immune-mediated pneumonitis, and immune-mediated endocrinopathies (hyperthyroidism). A substantial proportion of patients (&gt; 50%) in Arm T+C did not recover from their imTEAEs despite supportive treatment.

In Study 312, the incidence rate of TEAEs leading to discontinuation of any component of study treatment was higher in Arm T+C than in Arm P+C (14.5% versus 3.1%). Generally, this shift was not driven by specific Preferred Terms; notwithstanding, several TEAEs leading to treatment discontinuation were immune-mediated. The only TEAE leading to treatment discontinuation with a difference in incidence rate ≥ 1% between the two treatment arms was Immune -mediated myocarditis.

The incidence rates of death due to TEAEs was numerically higher in Arm T+C compared with Arm P+C (3.5% versus none). However, there were no new safety signals identified.

## 3.5. Uncertainties and limitations about unfavourable effects

Uncertainty is associated with the low proportions of female patients (18.1% in Arm T+C) and of patients aged ≥ 75 years (3.5% in Arm T+C) in Study 312; however, no patterns in terms of safety outcomes were observed in these subgroups that would suggest a distinct toxicity profile.

Only Chinese patients were enrolled in this study; notwithstanding, the extrapolation of the safety data observed in the Chinese patient population enrolled in Study 312 to a European patient population can be considered acceptable, as no clinically meaningful differences attributable to ethnic background were identified in other global studies with tislelizumab across various indications.

## 3.6. Effects Table

Effects Table for Tevimbra in combination with platinum and etoposide for 1L treatment of ES-SCLC (FA; data cut-off: 19 Apr 2023)

| Effect             | Short description                                                                          | Unit                        | Treatment         | Control           | Uncertainties / Strength of evidence                                                                                                                                           |
|--------------------|--------------------------------------------------------------------------------------------|-----------------------------|-------------------|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Favourable Effects | Favourable Effects                                                                         | Favourable Effects          | N=227             | N=230             | N=230                                                                                                                                                                          |
| OS                 | time from randomization date to the date of death due to any cause                         | months (95% CI)             | 15.5 (13.5, 17.1) | 13.5 (12.1, 14.9) | mature OS data with sustained benefit with longer follow-up (median survival follow-up of 39.8 months in Arm T+C at DCO of 29 Dec 2023);                                       |
| OS                 | time from randomization date to the date of death due to any cause                         | HR (95% CI)                 | 0.75 (0.61, 0.93) | 0.75 (0.61, 0.93) | mature OS data with sustained benefit with longer follow-up (median survival follow-up of 39.8 months in Arm T+C at DCO of 29 Dec 2023);                                       |
| PFS                | time from the randomization date to disease progression or death, whichever occurred first | months (95% CI) HR (95% CI) | 4.7 (4.3, 5.5)    | 4.3 (4.2, 4.4)    | general consistent results across subgroups; however, PD-L1 subgroup analyses non-reliable; early crossing of OS curves due to higher rate of deaths in the first three months |
| PFS                | time from the randomization date to disease progression or death, whichever occurred first |                             | 0.64 (0.52, 0.78) | 0.64 (0.52, 0.78) | general consistent results across subgroups; however, PD-L1 subgroup analyses non-reliable; early crossing of OS curves due to higher rate of deaths in the first three months |

<div style=\"page-break-after: always\"></div>

| Effect               | Short description    | Unit   | Treatment   | Control   | Uncertainties / Strength of evidence   |
|----------------------|----------------------|--------|-------------|-----------|----------------------------------------|
| Unfavourable Effects | Unfavourable Effects |        | N=227       | N=229     |                                        |
| Serious              | All causality        | %      | 42.3        | 30.6      |                                        |
| TEAEs                | related              | %      | 31.7        | 18.3      |                                        |
| Deaths               | Due to TEAEs         | %      | 3.5         | 0.0       |                                        |
| TEAEs                | All causality        | %      | 14.5        | 3.1       |                                        |
| leading to DC        | Treatment-related    | %      | 11.9        | 1.7       |                                        |
| im                   | All causality        | %      | 40.1        | 18.3      |                                        |
| TEAEs                | ≥ Grade 3            | %      | 11.0        | 0.4       |                                        |

Abbreviations: 1L=First-line, CI=Confidence Interval, DC= discontinuation, DCO= data cut-off, HR= Hazard Ratio, im=immune-mediated, PD-1=Programmed Death Protein 1, PFS=Progression-Free Survival, OS=Overall Survival, SCS=Summary of Clinical Safety, TEAE=Treatment-emergent adverse event.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Study 312 demonstrated statistically significant superiority in OS and PFS with the addition of tislelizumab to standard 1L chemotherapy in patients with ES-SCLC. OS KM curves showed a delayed treatment effect with an initial crossing due to higher incidences of early deaths in Arm T+C compared to the Arm P+C within the first three months after randomization; however, the median OS difference of 2 months and the sustained higher OS rate in Arm T+C with long follow-up establish a clinically relevant improvement for those patients who benefit from the immunochemotherapy combination.

Higher incidence rates of serious TEAEs, imTEAEs, and TEAEs leading to discontinuation have been observed for tislelizumab in combination with etoposide and platinum-based chemotherapy compared to placebo in combination with etoposide and platinum-based chemotherapy. However, additional toxicity would be expected for immunochemotherapy, and no new safety signals were identified for tislelizumab when used in this combination.

## 3.7.2. Balance of benefits and risks

The improvement in overall survival in patients with 1L ES-SCLC outweighs the additional toxicity of tislelizumab in the combination with standard chemotherapy.

## 3.7.3. Additional considerations on the benefit-risk balance

N/A

## 3.8. Conclusions

The overall B/R of tislelizumab in combination with etoposide and platinum chemotherapy for the 1L treatment of ES-SCLC is positive

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of indication to include first-line treatment of adult patients with extensive-stage Small Cell Lung Cancer (SCLC) for Tevimbra in combination with etoposide and platinum chemotherapy based on final results from study BGB-A317-312; a phase 3, randomized, double-blind, placebo-controlled study of platinum plus etoposide with or without tislelizumab in patients with untreated extensive-stage small cell lung cancer. As a consequence, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The MAH also took the opportunity to make further changes to the SmPC, Annex II and Package Leaflet (editorial and in line with the SmPC guideline). The supportive studies BGB-A317-309 and BGB-A317-315 are provided for the purpose of updating the safety data package as well as updated data (latest CSR versions with new data cut-off) from the monotherapy pool (tislelizumab used at 200mg Q3W) consisting of the studies 001, 102, 203, 204, 208, 209, 301, 302, and 303 and from the combination with chemotherapy pool consisting of the studies 205, 206, 304, 305, 306, 307 and 312.

Version 4.0 of the RMP has also been agreed.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I, II and IIIB and to the Risk Management Plan are recommended.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk management plan (RMP)

The Marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

In addition, an updated RMP should be submitted:

At the request of the European Medicines Agency; whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

<div style=\"page-break-after: always\"></div>

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that tislelizumab is not similar to serplulimab within the meaning of Article 3 of Commission Regulation (EC) No. 847/200.